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Summary 
Chronic obstructive pulmonary disease (COPD) is a common lung disorder that encompasses 
chronic bronchitis and emphysema. It is characterised by irreversible airflow limitation with 
progressive worsening and has complications of respiratory failure and cor pulmonale. It is a 
major cause of morbidity. In Australia, 10.2% of individuals aged 40 years or older suffer 
from Stage 2 or higher of COPD. Globally, COPD is an increasing public health problem. It 
was the fifth leading cause of death worldwide in 2002 and is projected to be the third leading 
cause of death by 2030.  
The main causes of COPD are cigarette smoking and inhalation of noxious particles or gases. 
The pathogenesis of COPD is not fully understood but it involves chronic inflammation, 
oxidative stress, protease/anti-protease imbalance, abnormal apoptosis and immune responses.  
Clinically, COPD symptoms include chronic cough, sputum production, shortness of breath or 
dyspnea and chest tightness. It can be divided into remission/stable phase and exacerbation 
phase. Exacerbations of COPD involve episodes of deterioration of symptoms, which are 
mainly triggered by respiratory viruses and bacteria. Exacerbations are major causes of 
morbidity, hospitalization and mortality and strongly affect health-related quality of life 
(HRQoL), and thus represent a significant proportion of costs associated with COPD. 
The pharmacotherapy for stable COPD, as recommended by Global Initiative for Chronic 
Obstructive Lung Disease (GOLD), includes bronchodilators (β2-agonists, anti-cholinergics 
and methylxanthines) and inhalation of corticosteroids. However, these are associated with a 
range of unwanted side effects and do not provide long-term relief for COPD. During the 
exacerbation phase, pharmacotherapies and other support are commonly effective in 
managing the symptoms. 
Internationally, the increasing use of complementary and alternative therapies including 
Chinese herbal medicine (CHM) has generated broad interest from the World Health 
Organisation (WHO), academia, governments, healthcare professionals and the community. 
Recent advancements in the understanding of the pharmacological actions of Chinese herbs 
and formulae, such as their anti-inflammation actions and effects on immune function, may 
contribute to clinical decision making in increasing the use of CHM for the management of 
COPD.  
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A number of randomised controlled trials (RCTs) have evaluated the benefits of oral CHM 
formulae and herbal extracts for stable COPD over the last two decades. Furthermore, a 
number of reviews of clinical studies on herbal medicines for COPD have been conducted but 
these only included small numbers of studies and did not adequately represent non-English 
studies such as those conducted in China.  
CHMs have a long history of use for chronic lung disorders, including conditions similar to 
chronic bronchitis and emphysema. In China, CHMs are frequently used in the management 
of COPD and are used in conjunction with conventional pharmacotherapy. Clinical studies 
suggest CHMs appear to have benefits for treating COPD. Moreover, experimental studies 
indicate certain CHMs have pharmacological actions relevant to COPD. Therefore, at least 
some of the CHMs appear to have potential to assist in the management of COPD. 
The main objectives of this study were to: 1) evaluate the efficacy and safety of using oral 
CHM in treating patients with COPD based on systematic reviews (SRs) and meta-analysis of 
the results of RCTs and experimental studies; and 2) to determine which herbs and formulae 
show the greatest promise for further clinical research based on their history of use in the 
classical literature, analysis of results from RCTs and the findings of experimental studies. 
This thesis consists of the following main components: 1. Reviews of the current conceptions 
and the current treatment of COPD in Conventional medicine and Chinese medicine; 2. 
Analysis of the traditional classification of COPD-like disorders in Classical Chinese 
medicine books (i.e. written up until 1911); 3. Identification of the main formulae and 
individual herbs used for COPD-like disorders over the span of the Classical Chinese 
medicine literature; 4. Systematic searches of RCTs on CHM for COPD; meta-analyses of 
results from RCTs for each main outcome measure; and analyses of the usage of herbal 
formulae and individual herbs in the RCTs; and 5. Identification of the likely mechanisms of 
action of the shortlisted herbs. 
To address objective 1, SRs were conducted guided by the Cochrane Handbook for 
Systematic Reviews of Interventions. English and Chinese databases were searched, 101 RCTs 
for CHM in stable COPD were selected and three SRs were conducted. Overall, the findings 
of these three SRs supported the use of oral CHM in:  
 the improvement and prevention of decline of FEV1% predicted of stable COPD 
patients for CHM plus routine pharmacotherapy (RP) compared with RP (MD 5.12; 
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95% CI 3.56 to 6.68) in 20 studies; for CHM alone versus RP (MD 8.79; 95% CI 4.66 
to 12.92) in 8 studies; and for CHM versus placebo (MD 7.46; 95% CI 3.72 to 11.20);  
 improving QoL when CHM plus RP was compared with RP using St. George 
Respiratory Questionnaire (SGRQ) (MD -5.15; 95% CI -7.26,  -3.05) or using Cai’s 
QoLQ (MD -0.25; 95% CI -0.37, -0.13);  
 reduction of COPD exacerbation frequency when CHM plus RP was compared with 
RP (MD -1.40; 95% CI -2.34, -0.46);  
 improving exercise tolerance capacity as tested by 6-minute walk distance (6MWD) 
when CHM plus RP was compared with RP (MD 41.39; 95% CI 28.69, 54.10); and  
 relief of a range of symptoms in favour of the CHMs versus the control groups. 
CHM as an adjunct therapy for COPD patients appeared to be well tolerated. However, there 
were insufficient data for meta-analyses to determine the effectiveness of CHM when 
compared with placebo. 
In addition, certain CHMs appear to have had the effects of lowering the levels of TNF- α and 
IL-8 in sputum and serum, and regulating the levels of T lymphocyte subsets as well as 
immunoglobulins such as IgA and IgG. Experimental studies provided supporting evidence 
for the actions of a number of the formulae and herbs used in the RCTs. 
To address Objective 2, based on results from the RCTs and the classical Chinese medicine 
literature, a number of formulae were identified as promising: Liu Jun Zi Tang ‘Six 
Gentleman Decoction’, Bu Fei Tang ‘Tonify the Lungs Decoction’  and Shen Ge San 
‘Ginseng and Gecko Powder’ etc. The following herbs were found to be frequently used for 
COPD: Ren shen (Panax ginseng), Dang shen (Codonopsis pilosula), Huang qi (Astragalus 
membranaceus), Bai zhu (Atractylodes macrocephala), Fu ling (Poria cocos), Mai dong 
(Ophiopogon japonicus), Wu wei zi (Schisandra chinensis), Dan shen (Salvia miltiorrhiza) 
and Tao ren (Prunus persica). Moreover, experimental studies found that certain of these 
herbs and formulae have anti-inflammatory actions and may improve immune functions 
through the regulation of the levels of cytokines and T lymphocyte subsets.  
In conclusion, this study comprehensively and systematically analysed modern RCTs and 
classical Chinese medicine interventions for COPD. Employing a range of methods of 
analysis, this study demonstrates that certain CHMs are potentially effective for the 
symptomatic management of COPD and appear to be safe adjunct therapies for adult patients 
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with stable COPD. Nevertheless, further studies are needed to determine the therapeutic 
benefits. Such studies should address methodological weaknesses identified in the relevant 
reviews such as randomisation, allocation concealment, blinding and sample sizes, and would 
preferably be conducted in a multi-centre setting. Once efficacy of specific individual herbs or 
formulae is confirmed, further studies to elucidate the mechanisms of action of these herbs or 
formulae such as anti-inflammatory effect need to be undertaken to facilitate more informed 
clinical decision making for effective use of CHMs for COPD. 
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1 Chapter One: General Introduction 
1.1. Background  
Chronic obstructive pulmonary disease (COPD) is a common lung disorder characterised by 
progressive worsening and irreversible airflow limitation, and is a major cause of morbidity 
and mortality worldwide (1, 2). Because of the increasing prevalence of COPD and its 
substantial economic and social burden, greater awareness initiatives and worldwide research 
studies have been conducted in an attempt to improve the management and prevention of this 
global health problem. 
1.1.1 Definition of COPD 
1.1.1.1 Development of COPD 
The concept of COPD has evolved over a 200-year history. Its primary components include 
chronic bronchitis and emphysema (3).  
The clinical understanding of chronic bronchitis, first referred to as a disabling disease 
characterised by chronic cough and mucus hypersecretion, was traced to Badham in 1814 (4). 
The earliest description of emphysema was termed ‘voluminous’ by Bonet in 1679 (5) and 
‘turgid’ by Morgagni in 1769 (6). In 1821, the term emphysema was used by Laënnec to 
describe a hyperinflated lung (7). The spirometer was invented by Hutchinson in 1846 (8). 
After 100 years, in 1962, the American Thoracic Society (ATS) defined chronic bronchitis as 
chronic cough lasting at least three months per year for more than two years and described 
emphysema anatomically as enlarged alveolar spaces and loss of alveolar walls. The term 
‘COPD’ was used by Briscoe in a discussion at the 9th Aspen Emphysema Conference in 1965 
(3). These established concepts of COPD and its components alongside 50 years of research 
form the foundation of the definitions of COPD in the 21
st
 century.  
1.1.1.2 Modern definition of COPD 
COPD is defined as a chronic lung disease characterised by irreversible airflow limitation, 
according to the GOLD (9), the ATS and European Respiratory Society (ERS) guidelines (10). 
The airflow limitation in COPD is progressive and also associated with an abnormal 
inflammatory response of the lungs which is in response to noxious particles and/or gases 
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with the primary cause being cigarette smoking (11). COPD also produces significant 
systemic consequences which can contribute to the increased severity of the condition. The 
components of COPD include chronic bronchitis and emphysema. The former is defined by 
the presence of chronic or recurrent cough and sputum production that persists on most days 
for a minimum of three months per year for at least two consecutive years, which is not 
attributed to other pulmonary or cardiac causes. Emphysema is defined anatomically by 
permanent, destructive enlargement of airspaces distal to the terminal bronchioles in the 
absence of obvious fibrosis (12).  
1.1.2 International variations of COPD prevalence 
The prevalence of COPD is increasing in association with the ageing population (13). Studies 
estimating the prevalence of COPD are variable worldwide, based on the severity of COPD 
by GOLD and ATS/ERS criteria that categorise patients into four stages by Spirometric 
assessment (tested after administration of an adequate dose of inhalation of a short-acting 
bronchodilator, on the premise of that the ratio of forced expiratory volume in one second 
(FEV1)/ forced vital capacity (FVC) is less than 70%): Stage 1 (FEV1≥80% predicted); Stage 
2 (FEV1 50 ≤ to <80% predicted); Stage 3 (FEV1 30 ≤ to < 50% predicted); Stage 4 (FEV1 
<30% predicted) (9, 10).  
The prevalence of COPD at Stage 1 or higher was 13.9% in the general population in 
individuals aged 18 years and older as reported by the Third National Health and Nutrition 
Examination Survey in 2007 (14). In individuals aged 40 years and older, the prevalence of 
COPD at Stage 2 or higher was 10.2% in Australia (15), 8.2% in China (16), 5.8% in 
Germany (17), 10% in The Netherlands (18), 10.7% in Austria (19), 8.2% in Canada (20), 
7.7% in Korea (21) and >8.4% in New Zealand (22).  
1.1.2.1 Geographic and racial factors 
According to an international survey, there were differences in the prevalence of COPD 
among different geographic regions. Compared to the Americas, Europe and the Pacific, the 
prevalence of COPD was higher in Southeast Asia and Latin America (13, 23). In addition, 
the prevalence of COPD also varies among different regions of the same country, as reported 
by the 2008 National Health Survey (Figure 1.1) in Australia (24) and as reported by Zhong et 
al. in 2007 in China (Figure 1.2) (16).  
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Figure 1. 1 The prevalence of COPD among the different states in Australia 
 
 
 
 
 
 
 
Figure 1. 2 The prevalence of COPD among the different provinces in China 
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A study conducted by Chamberlain at el. suggested that COPD was not associated with racial 
factors, as whites and blacks had the same trend of increasing COPD-related mortality in the 
US (25).  
1.1.2.2 Age and gender factors 
COPD is typically diagnosed in middle-aged or elderly people, although it may occur early in 
life, with a family history of asthma and respiratory infections in childhood being the other 
important determinants of COPD (26). In some healthy young adults, lung function 
performance may predict airflow obstruction 20 years later (9). 
COPD was more common in men; however, because of increased tobacco use in high-income 
countries and increased exposure to indoor air pollution (such as biomass fuels used for 
cooking and heating) in low-income countries in women, this disease now affects men and 
women almost equally (27). In Australia, since women aged 20−29 years have higher 
smoking rates than any other sub-group of the population, the prevalence of COPD in women 
is likely to increase in the coming decades (28). 
1.1.3 Risk factors for COPD 
The risk factors for COPD are related to the interaction between genetic factors and various 
environmental factors. The main contributory risk factors are genetic factors, cigarette smoke, 
occupational exposure and indoor and outdoor air pollutants. 
1.1.3.1 Tobacco smoking (active and passive smoking) 
Tobacco smoking, including cigarette, pipe, cigar and other types of tobacco use, as well as 
environmental tobacco smoke is a major cause and the most important risk factor for COPD 
worldwide, as approximately 10−15% of all smokers have been reported to develop COPD 
(29). According to estimates of the World Health Organization (WHO), 73% and 40% of 
mortality due to COPD is associated with smoking in high-income countries and low and 
middle-income countries, respectively (30). The risk of developing COPD was also 
significantly increased in current and former smokers in the United Kingdom (UK) (31). 
Therefore, smoking prevention initiatives should be given the highest priority to reduce the 
incidence of COPD.  
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1.1.3.2 Genetic factors 
Although smoking is closely related to COPD incidence, not all smokers develop COPD in 
their lifetime, and approximately 10% of COPD sufferers (32) have never smoked. These 
findings imply that genetic factors may be involved in the development of COPD (33). Stoller 
and Aboussouan found that alpha1-antitrypsin deficiency is a genetic disorder that confers 
susceptibility to COPD (34). 
1.1.3.3 Occupational exposure  
Approximately 15% of COPD cases may be attributable to workplace exposure according to a 
systematic epidemiological review (35), which found a strong association between increased 
COPD risk and exposure to dusts and chemicals (vapours, irritants and fumes) (36). The latest 
study suggested that increased occupational diesel exhaust exposure was also associated with 
increased COPD risk (37). 
1.1.3.4 Indoor air pollution  
Exposure to indoor air pollutants is also associated with COPD development. For example, 
cooking or heating using biomass fuels, performing domestic work using cleaner fuels in 
badly ventilated buildings in rural areas and inhalation of smoke in homes are important risk 
factors for COPD (38, 39). 
1.1.3.5 Outdoor air pollution  
Exposure to outdoor air pollution has been demonstrated to confer the highest relative risk 
associated with mortality following chronic respiratory disease (40). A large multi-city study 
of elderly subjects hospitalised for COPD (41) also found that exposure to outdoor air 
pollution had a significant long-term effect on mortality rates. 
1.1.4 Co-morbidity in COPD patients 
Th pulmonary inflammation in COPD is often associated with systemic inflammation. 
Consequently, COPD may be linked or co-exist with some other disorders. It is estimated that 
approximately two-thirds of patients with COPD have one or two co-morbidities (13). The 
main co-morbidities include cardiovascular (myocardial infarction, stroke, high blood 
pressure, pulmonary hypertension (PH), cor pulmonale, tachyarrhythmia) (42-45), other 
respiratory (pulmonary embolism)(46), endocrine (obesity, type 2 diabetes mellitus) (47-49), 
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gastroenterological (gastric ulcer and gastro-oesophageal reflux disease) (50), osteoarticular 
(Osteoporosis) and psychiatric disorders (depression, anxiety) (51, 52), malignant tumours 
(lung cancer) (53) and anemia (approximately 29%, and presents as low levels of 
haemoglobin (<11 g/dL)) (54).  
In addition, co-morbid conditions may result in impaired functional capacity, worsening 
dyspnoea, reduced HRQoLand increased mortality (55). Therefore, it is important to also 
consider the frequent association of co-morbidities when treating COPD.  
1.1.5 Impact of COPD 
1.1.5.1 Morbidity and mortality of COPD  
According to the Global Burden of Disease Project conducted by the WHO, COPD was the 
fifth leading cause of death worldwide in 2002 and is projected to be the third leading cause 
of death by 2030 (27). Based on WHO estimates, 80 million people worldwide have moderate 
to severe COPD, and more than 3 million people died from COPD in 2005, which accounted 
for 5% of all deaths globally. Therefore, COPD is becoming a growing health and economic 
burden throughout the world.  
1.1.5.2 Burden of COPD 
The total burden of COPD involves both the economic and social aspects. The economic 
burden is estimated by the overall costs of COPD, including both direct and indirect costs. 
Direct costs are those related to the detection, treatment, prevention and rehabilitation for 
COPD, while indirect costs refer to those related to the morbidity and mortality caused by 
COPD. The annual combination of direct and indirect costs of COPD has been estimated to 
$8.9 billion in Australia (15), $23.9 billion in the US (50) and nearly £1.5 billion in the UK 
(56). 
From a patient’s perspective, COPD has a profound effect on quality of life (57). 
1.1.6 Management of COPD 
COPD is a preventable and treatable disease. Treatment strategies mainly include managing 
stable COPD and its exacerbations, as no cure has been found to date (9). It is generally 
understood that current pharmacotherapy approaches do not prevent the progression of COPD 
or improve lung function (9). Furthermore, pharmacotherapeutic drugs have been associated 
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with significant adverse events such as potential cardiac rhythm disturbances, oropharyngeal 
candidiasis, dryness of the mouth, nausea and heartburn, headache and insomnia, skin 
bruising, and precipitate the risk of pneumonia and cardiovascular diseases (58). Since there is 
no cure for COPD, symptom management, quality of life improvement and reducing 
exacerbations have become the primary treatment objectives, particularly in stable COPD (58). 
1.1.7 Complementary and alternative medicine (Chinese medicine) 
Complementary and alternative medicine (CAM) approaches have been used increasingly in 
patients with chronic disease (59). Chinese herbal medicin (CHM) has been used for over 
3,000 in China and has been gaining acceptance in developed countries (60, 61). CHM, as the 
main component of traditional Chinese medicine (TCM), is used by 14% of adults with 
chronic pulmonary conditions; specifically, ginseng is used by 23% of herbal medicine 
consumers in the US (62). CHM has been shown to be effective for chronic diseases such as 
irritable bowel syndrome, type 2 diabetes mellitus and COPD (63-65).  
Numerous studies regarding CHM for COPD have been conducted in China and other 
countries since 1990. Some studies demonstrated that CHM formulae were effective for 
relieving symptoms, improving lung ventilation function and quality of life in patients with 
COPD (66, 67). It has also been suggested that CHM could be potentially effective for COPD 
treatment in terms of immunomodulation, anti-inflammation, oxidant−antioxidant balance, 
promotion of hemorheology and prevention of hypoxia-induced PH (68-73). However, 
conclusive evidence of the effectiveness and safety of CHM for COPD is lacking.  
1.2. Study rationale 
1.2.1 COPD is a significant global health problem  
The prevalence of COPD is expected to increase because of increased smoking in both high-
income and low-income countries worldwide. COPD is predicted to become the third leading 
cause of death worldwide by 2030 because of its high rates of morbidity and mortality (74, 
75). COPD is an important economic burden associated with globally increasing direct and 
indirect costs (30). In Australia, COPD is the third leading cause of disease burden (76) and 
an important public health problem. 
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1.2.2 Limitations of pharmacotherapy and associated side effects 
Current medical approaches include the long- or short-acting, inhaled or oral bronchodilators 
(beta2-agonists and anticholinergics) and inhaled corticosteroids used independently or in 
combination. They are recommended as the first-line treatment of patients with COPD. 
Methylxanthines (theophylline, etc.) have been used as the third-line therapy. These medical 
approaches can prevent symptoms or reduce their severity, although they not inhibit the 
decline of lung function. Thus, the effectiveness of the recommended medical approaches are 
limited and are associated with side effects such as easy bruising, dry mouth and minor 
cardiovascular events (77). In addition, if the consideration of cost is also included, high 
expense is a barrier to the use of inhaled bronchodilators (9). 
1.2.3 Promising results from CHM studies 
CHMs have a long history of use for chronic lung disorders, including conditions similar to 
chronic bronchitis and emphysema. In China, CHMs are frequently used in the management 
of COPD and are used in conjunction with pharmaceutical management (78). There is 
increasing scientific evidence of the efficacy of CHM for the treatment of stable COPD. A 
preliminary study suggested that a single herb, ginseng extract, was effective in improving 
lifelong function of patients with moderate COPD (79), while other investigators have 
reported effectiveness using other herbal formulae (69, 80). Nevertheless, these data have yet 
to be critically reviewed, and many clinical trials to date suffer from poor methodological 
design quality. Thus, a critical review and more stringently designed randomised, controlled 
clinical trials are needed to delineate which single herbs or formulae may produce the best 
efficacy for the treatment of stable COPD. 
1.2.4 Potential benefit for COPD 
More than 10% of adults aged ≥40 years have COPD, and the prevalence of this disease is 
increasing worldwide. With growing causes of morbidity, mortality and hospitalisation in both 
developing and developed countries, COPD is a global burden and a major public health 
concern. COPD has no cure; therefore, it is critical to consider new approaches for preventing 
disease progression, particularly in earlier stages of COPD. This study will create a profile of 
the efficacy and safety of CHM for the treatment of COPD based on a systematic analysis of 
the contemporary literature and the results of clinical trials, and an analysis of the classical 
literature to provide scientific assessment of the available evidence for herbs and herbal 
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formulae best suited for COPD treatment. 
1.3. Aims and objectives  
This study aims to evaluate the efficacy and safety of oral CHM formulae for the treatment of 
patients with stable COPD through systematic reviews (SRs) of the modern literature, 
analysis of the results of RCTs and the findig of experimental studies. In addition, this study 
will identify which herbs and formulae are most frequently used to treat patients with stable 
COPD in clinical trials and which have histories of use for disorders analogous to COPD in 
the classical Chinese herbal literature. Another major objective of this study is to determine 
the specific types of herbs and formulae most likely to be beneficial in the treatment of COPD 
by analysis of both the modern and classical literature in order to provide directions for future 
clinical and experimental research.  
1.4. Research questions 
The research questions targeted by this study are as follows: 
1. In COPD patients, based on RCT evidence, do CHMs: 
–  improve Lung function? 
–  improve of Quality of life? 
–  reduce of COPD exacerbation frequency? 
–  alleviate symptoms? 
–  provide good clinical tolerance? 
2. Which CHMs appear the most effective for the management of stable COPD based on 
the RCT evidence? 
3. Which CHMs (formulae and individual herbs) have the most consistent histories of 
use in the classical Chinese medical literature for disorders analogous to COPD? 
4. Based on all sources of evidence, which are the most promising herbs or formulae for 
ongoing research into the clinical management of COPD? 
1.5. Thesis outline 
This thesis consists of the following main components:  
1. Reviews of the current conceptions, and the current treatment of COPD in Conventional 
medicine and CM; and 
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2. Analysis of the traditional classification of COPD-like disorders in Classical Chinese 
medicine books (i.e. written up until 1911); and 
3. Identification of the main formulae and individual herbs used for COPD-like disorders over 
the span of the Classical Chinese medicine literature; and 
4. Systematic searches of randomised controlled trails (RCTs) on CHM for COPD; meta-
analyses of results from RCTs for each main outcome measure; and analyses of the usage of 
herbal formulae and individual herbs in the RCTs; and 
5. Identification of the likely mechanisms of action of the shortlisted herbs. 
The following flow diagram illustrates the overall study design (Figure 1.3).  
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Figure 1. 3 Overview of the study design 
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1.5.1 Analysis of Chinese classical literature relevant to COPD 
This analysis will be completed through a search of terms relating to COPD through ‘Zhong 
Hua Yi Dian’ (Encyclopaedia of TCM). It will determine which herbs and formulae were 
frequently used in treating combinations of symptoms which are likely to have been 
associated with COPD.  
1.5.2 Analyses of the modern literature and clinical trial results  
The analyses of the results of the modern randomised clinical trials (RCTs) will be conducted 
according to an evidence-based medicine approach as defined by Resenberg (81). According 
to its potential for bias, evidence can be classified into five levels, as shown in Appendix 1. 
Level 1 includes SRs of RCTs, which can include a meta-analysis and a more precise estimate 
of treatment effect (82). A large number of clinical trials have investigated the use of CHM for 
COPD over the past few decades. Therefore, three SRs were conducted in this study 
according to the methods or the Cochrane airway group (83). The three SRs are ‘oral ginseng 
formulae for stable COPD’ (84), SR2 ‘oral CHM for the improvement quality of life in stable 
COPD’ (85) both in Chapter 6 and SR3 ‘oral CHM for treatment of stable COPD’ in Chapter 
7.  
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2 Chapter Two: Review of western medicine-based literature 
concerning chronic obstructive pulmonary disease  
2.1 Introduction  
This chapter focuses on the advanced knowledge accumulated by a review of western 
medicine-based literature concerning chronic obstructive pulmonary disease (COPD), 
including diagnosis, classification, differential diagnosis, pathogenesis and management of 
stable COPD.  
2.2 Diagnosis of COPD 
COPD includes the co-existence of two conditions: chronic bronchitis and emphysema. 
Therefore, diagnosis should include both of these conditions. 
2.2.1 Symptoms of COPD 
Individuals that meet the following criteria should be considered for a diagnosis of COPD: 
 Age over 35 years; 
 History of exposure to risk factors such as cigarette smoking; and 
 Presence of persistent, progressive symptoms involving chronic cough (the cough may 
initially be intermittent and present only early in the morning, and it may later progress to 
daily occurrence, often throughout the day. It may or may not be unproductive), chronic 
sputum production, shortness of breath and dyspnoea (hallmark); these symptoms may be 
accompanied by wheezing and chest tightness. 
2.2.2 Physical signs of COPD 
The physical signs of COPD include the following:  
 Tachypnoea (rapid breathing rate);  
 Wheezing sounds or crackles in the lungs as heard by a stethoscope;  
 Duration of exhalation longer than that of inhalation; enlargement of the chest, 
particularly the anteroposterior diameter (hyperaeration);  
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 Active use of the neck muscles to aid in breathing (three depressions sign); breathing 
through pursed lips;  
 Increased anteroposterior to lateral diameter ratio of the chest (barrel chest); 
 Bluish colour of the skin and lips (cyanosis, referred to as blue bloaters), most commonly 
seen in patients with advanced COPD with chronic primary bronchitis rather than 
emphysema; 
 Pink colour of the face, most commonly seen in patients suffering from emphysema in 
whom exhalation is particularly laborious (referred to as pink puffers). 
2.2.3 Spirometry in COPD 
The diagnosis of COPD is confirmed by spirometry breathing tests. Spirometry measures the 
FEV1, which is the greatest volume of air that can be exhaled in the first second of a large 
breath. Spirometry also measures the FVC, which is the greatest volume of air that can be 
completely exhaled after a large breath. Normally, at least 70% FVC is exhaled in the first 
second (FEV1/FVC >70%). A below-normal FEV1/FVC ratio is necessary for COPD 
diagnosis. More specifically, the GOLDcriteria for COPD diagnosis also requires that values 
should be measured after the intake of a bronchodilator (9). The FEV1 (measured after 
bronchodilator intake) is expressed as a percentage of a predicted normal value based on an 
individual’s age, gender, height and weight. Furthermore, spirometry can aid in determining 
the severity of COPD (9).  
2.2.4 Diagnostic imaging and other tests for COPD  
Diagnostic imaging for COPD includes radiological imaging, computed tomography (CT) and 
magnetic resonance imaging (MRI). 
2.2.4.1 Chest X-ray 
Chest X-ray examination displays a black and white image of the lungs and heart for 
assessment of the airways, parenchyma and vasculature. Although COPD cannot be 
diagnosed by chest X-ray alone, it may be useful for diagnosing advanced emphysema or for 
identifying and ruling out alternative diagnoses of diseases with symptoms mimicking those 
of COPD exacerbations, such as lung cancer, heart failure, pneumonia or tuberculosis (TB). 
Abnormal findings on chest X-rays of COPD patients may show the following: 
 Flattening of the diaphragm; 
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 Increased anteroposterior diameter of the chest; 
 A long narrow heart; and/or 
 Abnormal air collection within the lung (focal bullae) (86).  
2.2.4.2 Computed tomography  
In contrast to the chest X-ray, CT has been used in this field for fewer years. Emphasis is on 
structural imaging of the lung parenchyma and airways and differential diagnosis of lung 
disease. In particular, high-resolution CT (HRCT) has been shown to correlate well with 
pathology and is currently the best method for sensitive, non-invasive assessment of 
pathological changes in the lung (87). Using modern multi-slice CT (MSCT) technology, the 
entire lung can be displayed in a high-resolution mode, creating thin slices ≤1 mm during a 
single breath hold (3D-HRCT). Therefore, MSCT enables a more straightforward assessment 
of the distribution of emphysema (88). 
2.2.4.3 Magnetic resonance imaging 
MRI of the lung involves a unique combination of structural and functional assessment (such 
as perfusion, ventilation and respiratory dynamics) within a single imaging study. It is 
routinely used in clinical practice for diagnosing pulmonary hypertension, airway diseases, 
cystic fibrosis, lung cancer and other disease states. Although the role of MRI in phenotyping 
COPD has yet to be determined, it is highly useful in assessing COPD (89). 
2.2.5 Arterial blood gas measurement 
Arterial blood gas analysis is the gold standard method for obtaining information regarding 
oxygenation, ventilation and acid base status of the body (90). Blood is drawn from an artery, 
usually one in the wrist and blood gases are measured to determine the amount of oxygen 
dissolved in the arterial blood at partial pressure (PaO2), the percentage of haemoglobin 
saturated with oxygen (PO2 sat), the amount of carbon dioxide dissolved in arterial blood at 
partial pressure (PaCO2) and the amount of acid in the blood (normal pH, 7.35−7.45). 
With regard to advanced COPD, arterial blood gases should be measured in stable patients 
with FEV1 <50% predicted. The results of blood gas measurement in COPD patients often 
show a normal or decreased PaO2, increased PaCO2, respiratory acidosis or clinical signs that 
suggest respiratory failure or right heart failure (58). 
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2.2.6 Alpha1-antitrypsin deficiency screening 
Patients who develop COPD at a young age (<45 years) or have a family history of COPD 
may have co-existing alpha1-antitrypsin deficiency (i.e. <15%−20% of the normal value) (34). 
2.3 Classification of COPD severity  
The severity of COPD is classified into four stages as per spirometry performed after 
bronchodilator intake. This classification scheme of the severity of COPD differs according to 
the current COPD guidelines of different countries, which are summarized in Table 2. 1. 
Table 2. 1 Severity of COPD by spirometry results 
Classification  
of COPD 
Severity 
FEV1 value (FEV1/FVC ratio <70%) 
GOLD COPD-X 
(Australia) 
NICE 
(UK) 
CSRD 2002 CSRD 2007 
Stage I Mild 
FEV1 ≥80% 
Predicted 
FEV1 
60%−80% 
Predicted 
≥80% 
Predicted 
FEV1 ≥80% 
Predicted 
FEV1 ≥80% 
Predicted 
Stage II Moderate 
50%−80% 
Predicted 
40%−59% 
Predicted 
50%−79% 
Predicted 
IIA: <80% FEV1 
≥50% 
<80% 
FEV1≥50% 
Stage III Severe 
30%−50% 
Predicted 
<40% 
Predicted 
30%−49% 
Predicted 
IIB: <50% FEV1 
≥30% 
<50% FEV1 
≥30% 
Stage IV Very severe 
<30% 
Predicted or 
<50% 
Predicted plus 
CRF 
 
<30% 
Predicted or 
<50% 
Predicted plus 
CRF 
III: < 30% 
Predicted or 
< 50% Predicted 
plus CRF 
<30% 
Predicted or 
<50% 
Predicted plus 
CRF 
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; CRF, chronic respiratory failure; 
GOLD: Global initiative for Chronic obstructive Lung Disease (9); COPD-X, Australian and New Zealand 
guidelines for the management of chronic obstructive pulmonary disease (58); NICE, National Institute for 
Health and Clinical Excellence-COPD guideline updated in 2010, CSRD, Chinese Society of Respiratory 
Disease (91, 92). 
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2.4 Stable COPD and COPD exacerbations 
COPD can be divided into two stages: stable disease and disease exacerbation. Exacerbations 
of COPD involve episodes of worsening of symptoms, which are mainly triggered by 
respiratory viruses and bacteria (93). They are a major cause of morbidity, hospitalization and 
mortality and strongly affect HRQoL(94). Exacerbations of COPD were categorized into 
three types by Anthonisen et al. in 1987: type 1 refers to COPD characterized by the major 
symptoms of worsened dyspnoea, increased sputum volume and sputum purulence; type 2 
refers to COPD characterized by only the latter two of the abovementioned symptoms; and 
type 3 refers to COPD characterized by only one of the abovementioned symptoms combined 
with coughing, wheezing or symptoms of an upper respiratory tract infection (95). Diagnosis 
of major exacerbation requires the occurrence of two new symptoms that persist for minimum 
of two days, one of which must be a major symptom such as increased dyspnoea, sputum 
volume or sputum purulence. Minor exacerbation symptoms include coughing, wheezing, 
sore throat, nasal discharge and/or fever (96). 
2.5 Differential diagnosis  
Other lung diseases such as asthma (in particular), bronchiectasis, TB, obliterative 
bronchiolitis, diffuse panbronchiolitis (DPB) and congestive heart failure (CHF) need to be 
distinguished from COPD. These differential diagnoses are discussed below and summarized 
in Appendix 2.   
2.5.1 Asthma 
Asthma is a chronic inflammatory disease of the airways characterized by airway hyper-
responsiveness leading to reversible airway obstruction, whereas airflow limitation is 
irreversible in COPD. Approximately 300 million people throughout the world are affected 
(97). The condition affects girls more than boys during early childhood, and this gender 
preponderance extends to adolescence. Asthma is the most common childhood disease and is 
the leading cause of childhood morbidity according to figures from school absences, hospital 
emergency departments and hospitalizations (98).  
The development of asthma is related to sensitization to aeroallergens (house dust mites, pet 
allergens, cockroaches and fungi), maternal diet during pregnancy and/or abnormal lactation, 
pollutants (especially tobacco smoke), microbes and their products and psychosocial factors. 
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Typical symptoms include recurrent episodes of wheezing, breathlessness, chest tightness and 
coughing, particularly at night or early in the morning. Asthma is classified into four types: 
intermittent, persistent-mild, persistent-moderate and persistent-severe. Some of the 
diagnostic tests for asthma include chest radiography or HRCT scanning. The most essential 
diagnostic component is spirometry, which is used to demonstrate the extent of obstruction 
and assess reversibility; however, this test is not suitable for elderly patients. The key 
parameter for the diagnosis of asthma is FEV1 of at least 12% after inhalation of a short-
acting β-adrenergic agonist bronchodilator. 
The pathogenic mechanism of asthma differs according to the age of the patient. Asthma with 
onset during childhood and adulthood (<40 years of age) is usually immunoglobin IgE-
mediated, and exacerbations are typically caused by exposure to allergens or by acute 
respiratory tract viral infections. Asthma that develops at middle age or later is generally not 
mediated by IgE. In the elderly, it often develops with a component of irreversible airway 
obstruction (99). Therefore, asthma and COPD are not easily distinguishable because these 
conditions tend to overlap and converge in elderly individuals, thus making diagnosis difficult 
in these patients.  
2.5.2 Bronchiectasis  
Bronchiectasis is a common condition that is a major cause of respiratory morbidity. It is 
characterized by abnormal dilatation of the bronchi and bronchioles caused by Haemophilus 
influenzae and Pseudomonas aeruginosa (100), resulting in airway restriction; in this respect, 
this condition is similar to COPD. Bronchiectasis is associated with many factors, but most 
patients have idiopathic disease or rhinosinusitis and occurs more frequently in adults than in 
children (101). Patients present with chronic cough with productive mucopurulent sputum and 
other symptoms such as dyspnoea and haemoptysis, rhinosinusitis, fatigue and bi-basal 
crackles. These symptoms persist for many years and are associated with respiratory function 
decline despite treatment. HRCT is the gold standard for diagnosis and severity assessment 
(102). Spirometry results typically show moderate airflow obstruction with a high prevalence 
of bronchial hyper-reactivity.  
There may be considerable overlap between bronchiectasis and COPD. Treatment regimens 
are still not well defined. Anti-inflammatory therapy and macrolides have been suggested for 
the treatment of bronchiectasis (103).  
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2.5.3 Tuberculosis  
Tuberculosis (TB) is characterized by blood-stained sputum, is caused by specific bacteria 
(usually Mycobacterium tuberculosis) and is infectious, whereas COPD does not have any of 
these features. The classic symptoms of TB include chronic cough with blood-stained sputum 
or haemoptysis, fever, night sweats and weight loss. TB is diagnosed by tests that include 
sputum mycobacterial load assessed by time to positivity in liquid culture, tuberculin skin 
testing and chest X-ray or scan showing radiological cavitation. Treatment for TB involves 
the use of antibiotics to eradicate bacteria, particularly in cases of Mycobacterium 
tuberculosis infection.  
2.5.4 Obliterative bronchiolitis 
Obliterative bronchiolitis (also called constrictive bronchiolitis or bronchiolitis obliterans) is 
an irreversible fibrotic respiratory disease of the small airway. Its characteristic features 
include fibrotic and destructive lesions in the bronchiolar submucosal layer, which develop 
external to the airway lumen but do not extend into the alveoli (104). The most common 
symptom is shortness of breath with or without cough, which occurs early in the disease 
course. Chest physical examination may be normal or show early inspiratory crackles or 
squeaks. The expiratory HRCT scan typically shows a mosaic pattern, which is a patchwork 
of high- and low-density regions resulting from air trapping. Similar to COPD, this condition 
displays irreversible airflow obstruction as indicated by decreased FEV1 or FEV1/FVC ratio 
according to pulmonary function test results (105). COPD is also an irreversible respiratory 
disease presenting with shortness of breath; however, unlike obliterative bronchiolitis, COPD-
mediated destruction extends deep into the alveoli and terminal bronchioles.  
2.5.5 Diffuse panbronchiolitis  
Diffuse panbronchiolitis (DPB) is an idiopathic inflammatory disease characterized by 
progressive, suppurative and obstructive airway disease (106). Prominent pathological 
changes seen in the respiratory bronchioles are unique to DPB (107). The inflammatory 
infiltrate destroys the bronchiolar epithelium and extends to the peribronchiolar spaces, 
although most of the alveoli are unaffected. Neutrophils and T lymphocytes, particularly 
CD8+ T cells, together with the cytokines IL-8 and macrophage inflammatory protein-1 are 
recognized to play important roles in the development of DPB (108). Symptoms (cough and 
sputum) typically occur between the second and fifth decades of life. Exertional dyspnoea 
usually follows. Physical examination reveals crackles, wheezes or both. The majority (80%) 
20 
 
of patients with DPB have a history of chronic paranasal sinusitis or suffer from persistent 
disease. In half of the untreated patients, sputum volume exceeds 50 mL per day, followed by 
progression to bronchiectasis, respiratory failure and eventually death (109). 
2.5.6 Congestive heart failure (CHF)  
Congestive heart failure (CHF) is a common condition with a higher prevalence in the elderly. 
CHF symptoms include dyspnoea, ankle or pulmonary oedema, fatigue and heart palpitations. 
It is associated with an average life expectancy of approximately three years after diagnosis, 
which is significantly less than that associated with many other serious illnesses such as 
cancer of the breast or colon (110). Although CHF shares a common symptom of dyspnoea 
with COPD, it is not difficult to distinguish between these diseases because of the obvious 
cardiac involvement of CHF. 
2.6 Pathological changes in COPD  
COPD is a mixture of disease manifestations such as bronchitis, small airway disease and 
emphysema. The presence of airway inflammation and remodelling are the most important 
features of COPD. These changes typically occur in the proximal airways (trachea and 
bronchi >2 mm internal diameter), peripheral airways (internal diameter <2 mm), lung 
parenchyma (respiratory bronchioles and alveoli) and pulmonary vasculature.  
The aetiology of COPD is attributed to exposure to cigarette smoke and other occupational or 
environmental noxious particles, which induce the inflammatory response in the small 
airways (peripheral airways) and lungs. This response results in increased numbers of 
inflammatory cells [macrophages, CD8+ (cytotoxic) T lymphocytes, neutrophils or 
eosinophils], leading to excessive mucus production in the airway lumen, goblet cell 
hyperplasia and sub-mucosal gland hypertrophy. The primary consequence of mucus hyper-
secretion is airway obstruction. Concurrently, inflammatory cell infiltration results in a cycle 
of airway wall injury, scarring and remodelling, leading to abnormal tissue alterations such as 
squamous metaplasia. Chronic inflammation is followed by scarring and remodelling that 
thickens the airway walls and results in narrowing of the airways (e.g. fibrosis). Consequently, 
these changes lead to airflow limitation. On the other hand, inflammation and damage to the 
lung parenchyma (respiratory bronchioles and alveoli) result in emphysema development. 
Inflammation associated with substantially increased numbers of macrophages, CD8+, T 
lymphocytes and other inflammatory cells ultimately cause destruction of the alveolar walls.  
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Furthermore, increased inflammatory cell infiltration in emphysema destroys the air space 
walls (e.g. fibrosis), causes apoptosis of epithelial and endothelial cells, decreases the surface 
area available for gaseous exchange of oxygen and carbon dioxide during breathing and 
reduces the elasticity of the lungs, which results in enlargement of the alveolar space and a 
loss of support for the airways in the lungs.  
Conventionally, there are three types of emphysema, namely centriacinar, panacinar and distal 
acinar. Distal acinar emphysema, however, is not associated with airflow limitations (111) 
and will not be discussed here. Centriacinar emphysema is most commonly observed in 
smokers, and it is characterized by regions of dilatation and destruction of respiratory 
bronchioles in the central area of the acinus. In contrast, panacinar emphysema involves the 
dilatation and destruction of the entire acinus, including the alveolar sacs as well as 
respiratory bronchioles, with the lower lobe dilated to a larger degree than the upper lobe. 
Deficiency of alpha1-antitrypsin and an early onset are commonly associated with panacinar 
emphysema. Both centriacinar and panacinar emphysema are characterized by alveolar 
destruction with loss of the capillary bed that is likely to collapse, causing further airflow 
limitation. Moreover, inflammatory cell immigration to the small airways, together with 
fibrosis and smooth muscle cell proliferation, result in a decreased diameter and increased 
airway resistance, leading to airflow limitation (112). 
Increased numbers of inflammatory cells also cause structural changes to the pulmonary 
vasculature, including intimal thickening, endothelial dysfunction in the pulmonary vessels, 
smooth muscle hypertrophy and inflammatory infiltration. These alterations inevitably lead to 
the development of PH (112). 
2.7 Pathogenesis of COPD  
Several extensively investigated physiological mechanisms contribute to the pathogenesis of 
COPD. These pathogenic mechanisms are described below, and they include specific 
mediators of chronic inflammation, oxidative stress, protease−anti-protease imbalance, 
apoptosis, autoimmune responses and neurogenic mechanisms (113). Deficiencies in repair 
and replacement of destroyed alveolar walls and tissue have also been proposed to be 
responsible for COPD.  
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2.7.1 Roles of chronic inflammation and inflammatory cells in the pathogenesis of 
COPD 
The hallmark of COPD is chronic immune inflammation, which involves a wide variety of 
inflammatory cells that release proteolytic enzymes and pro-inflammatory mediators into the 
lung. It has been demonstrated that the development of COPD is linked to an increased 
infiltration of inflammatory cells such as neutrophils, macrophages, T lymphocytes (CD4+ 
and CD8+ cells), B lymphocytes, eosinophils and epithelial cells into the lung and peripheral 
airways (114). This inflammatory response involves innate and adaptive immune responses of 
the lung and plays a key role in the pathogenesis of COPD. Important inflammatory mediators 
of COPD include chemokines such as interleukin-8 (IL-8) and pro-inflammatory cytokines 
such as tumour necrosis factor-α (TNF-α), IL-1β and IL-6. The function and activity of each 
inflammatory mediator is described individually in the following sections. COPD may worsen 
with the occurrence of exacerbations in patients infected with viruses or bacteria, resulting in 
severe decline of lung function (115, 116). Normally, innate immune responses are critical 
mediators of the host response in COPD patients and involve complex molecular and cellular 
systems. This innate immunity may progressively be compromised in COPD patients, leading 
to susceptibility to frequent exacerbations of the disease. Therefore, innate immune responses 
are partially responsible for maintaining inflammation and tissue destruction in COPD 
patients (117). 
2.7.1.1 Neutrophils 
Neutrophils are the predominant inflammatory cells in the conducting airway and are related 
to mucus hyper-secretion. The severity of COPD is correlated to increased numbers of 
neutrophils in the airway lumen, parenchyma, bronchial glands and sputum (118). Testing of 
sputum and bronchiolar and bronchoalveolar lavage samples from COPD patients revealed a 
direct correlation between neutrophil count and COPD severity, with neutrophils rising from 
30% to 70%. Of these, 15% neutrophils were present in the bronchoalveolar lavage fluid 
(BALF). Neutrophils can be destructive to the lung because they contain high levels of 
proteolytic enzymes such as serine proteinases, neutrophil elastase, proteinase-3 and cathepsin 
G. In addition, neutrophil elastase and cathepsin G are secretagogues that probably contribute 
to mucus hyper-secretion in both large and small airways in COPD patients (119).  
Myeloperoxidase (MPO) is stored in the primary granule and is the only enzyme in the body 
that produces hypochlorous acid, which effectively chlorinates tyrosine protein residues into 
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3-chlorotyrosine. Patients with stable COPD have been shown to have 3-chlorotyrosine in 
sputum, which is related to MPO activity. Therefore, MPO may play a role in the 
inflammatory process of COPD (120). Elevated human neutrophil lipocalin in the sputum of 
patients strongly correlated to decreased FEV1 and the degree of airway obstruction and 
emphysema. Neutrophil elastase is also increased in sputum and is directly related to the 
severity of emphysema and decreased lung function (121, 122). Neutrophil elastase can also 
degrade connective tissue components, activate serum proteins, inhibit ciliary activity and 
stimulate pro-inflammatory CXC chemokine ligand (CXCL)-8 and transform growth factor 
(TGF)-β synthesis, inactivate tissue inhibitors of MMPs and cleave cytokines (123). This 
proteolytic enzyme in combination with MMPs and cathepsins may also lead to emphysema 
and mucus hyper-secretion. 
2.7.1.2 Macrophages  
Macrophages are substantially increased throughout the respiratory airway, lumen, epithelium, 
lung parenchyma and pulmonary vasculature in COPD patients, and they are directly related 
to the severity of disease, obstruction of airway and degree of alveolar wall damage in 
emphysema (119). They also contribute to the adaptive immune response (124). Macrophages 
can produce an array of mediators to accomplish phagocytosis of inhaled particles and 
bacteria as well as clearance via the mucociliary escalator to keep the lungs healthy and free 
of infection (119). Cytokines are released by macrophages in the early immune response, 
including and IL-1β during the recurrence of COPD. Macrophages can also produce a variety 
of chemokines and other chemotactic mediators such as leukotriene B4 (LTB4), and they may 
be the source of elevated CXCL8, CXCL1 and LTB4 in the secretions of COPD patients 
Granulocyte–macrophage colony-stimulating factor (GM-CSF) is also released by 
macrophages and is increased in sputum obtained from patients with COPD exacerbations; 
this may enhance survival of neutrophils. Macrophages provide antioxidants and antioxidant 
enzymes such as glutathione catalase and superoxide dismutase, both of which dampen 
oxidative stress from exogenous (e.g. cigarette smoke) and endogenous (e.g. phagocytosis of 
bacteria) sources. Proteolytic enzymes produced by pulmonary macrophages include MMP1, 
MMP2, MMP9, MMP12 and MMP14, all of which are involved in emphysema (125). 
Cyclic adenosine monophosphate (cAMP) is a second messenger that is essential for relaying 
hormonal responses in many biological processes (126). Signalling of this molecule also 
directly controls inflammation by regulation of the immune response of leukocytes. Most 
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leukocytes express the exchange protein activated by cAMP-1 which links cAMP signalling 
to the inflammatory response (127). 
2.7.1.3 T lymphocytes 
T lymphocytes play a key role in the regulation of airway inflammation in COPD patients. T 
lymphocytes can damage the lung by directly or indirectly releasing inflammatory mediators 
such as interferon-gamma (IFN-γ) from activated CD4+ cells and TNF-α from CD8+ cells 
(128). Therefore, a hallmark of COPD is the infiltration of T cells that can cause further 
inflammation and emphysema (129). The T lymphocyte and its subsets play an important role 
in the pathogenesis of COPD (130). The relationship between the severity of COPD and the 
degree of lymphocytic infiltration into the lung has been demonstrated by Zhu et al (131).  
2.7.1.4 B Lymphocytes  
B lymphocytes (B cells) play a critical role in the humoral immune response and are an 
essential component of the adaptive immune system. B cells have been found in the lungs of 
COPD patients and are associated with inflammatory reaction-mediated development of 
COPD (132).  
2.7.1.5 Epithelial cells  
The role of epithelial cells and their interaction with the underlying cell layers in COPD is not 
well understood (133). Epithelial cells initiate and augment airway host defence mechanisms 
(134). They also participate in innate and adaptive immune responses and in mucosal 
inflammation. Epithelial cells produce antimicrobial host defence molecules, pro-
inflammatory cytokines and chemokines in response to activation via pathogen recognition 
receptors. They are also responsible for mucus production in both protective immune 
responses and allergic airway inflammatory diseases (134). 
2.7.2 Inflammatory mediators 
Inflammatory mediators are critical to the pathophysiology of COPD. Numerous inflammatory mediators, 
including chemokines, lipid mediators, cytokines, reactive oxygen species (ROS), reactive nitrogen species 
(RNS), inflammatory peptides and growth factors, are involved in the complex inflammatory process 
driving COPD pathogenesis (135). This review primarily discusses chemokines, cytokines, ROS and RNS. 
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2.7.2.1 Chemotactic factors: lipid mediators and LTB4 
Smokers susceptible to the development of COPD exhibit up-regulated LTB4 in their 
peripheral lungs (136). LTB4 is a pro-inflammatory mediator derived from membrane 
phospholipids by the sequential actions of cytosolic phospholipase A2, 5-lipoxygenase and 
leukotriene A4 hydrolase (137). It is produced from a variety of inflammatory cells, 
predominantly from macrophages and neutrophils. LTB4 is the most potent pro-inflammatory 
chemo-attractant (138). It promotes the recruitment of CD8+ T cells to the sites of 
inflammation (139). The activation of LTB4 is mediated by the BLT1 receptor, which is a 
high-affinity G protein-coupled cell surface receptor of LTB4 and is expressed predominantly 
in leukocytes (137). The inactivation of LTB4 is promoted by peroxisome proliferator-
activated receptor-αcells, a group of transcription factors that regulate the gene expression of 
enzymes associated with lipid homeostasis and control various types of inflammatory 
responses (140).  
2.7.2.2 Chemokines 
Chemokines regulate the movement of inflammatory and immune cells to the target organs 
(141). Among the chemokines, a CXC chemokine, is a potent chemotactic and paracrine 
regulator of neutrophils. The infiltration of activated neutrophils plays a central role in 
inflammation and oxidative injury of the lungs. 
Interleukin-8 (IL-8) 
IL-8 plays a critical role in the pathogenesis of COPD. It is secreted by various cells, 
including macrophages, neutrophils and airway epithelial cells (142). Other chemokines 
involved in the recruitment of inflammatory cells are growth-related oncogene-alpha cells, 
epithelial cell-derived neutrophil-activating peptide-78, monocyte chemo-attractant protein-1 
and macrophage inflammatory protein-1α (135). 
2.7.2.3 Cytokines  
Cytokines are extracellular signalling proteins produced by different cell types and are 
involved in cell–cell interactions (143). Cytokines associated with COPD include TNF-α, 
IFN-γ, IL-1β, IL-6, GM-CSF and IL-32. These cytokines play important roles in the 
pathogenesis of COPD and have recently attracted more interest in research investigations. 
Some of these cytokines are increased or activated in COPD and are associated with COPD 
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severity (144). Therefore, cytokine inhibitors may have beneficial effects against COPD (145). 
Tumour necrosis factor-α (TNF-α) 
TNF-α has a wide range of pro-inflammatory activities and plays an important role in 
mediating inflammation in COPD patients (146). It is produced from several cells, including 
monocytes/macrophages, T lymphocytes, mast cells and cells of the airway epithelium (143). 
TNF-α has multiple pro-inflammatory actions, including neutrophil degranulation 
accompanied by release of proteolytic enzymes, enhancement of intercellular adhesion 
molecule-1 expression and control of cellular migration and permeability. It also stimulates 
the secretion of GM-CSF, IL-6 and IL-8 and activates the nuclear transcription factor-κB 
(NF-κB), which activates the IL-8 gene in epithelial cells and macrophages. Therefore, TNF-α 
has a major role in the induction and maintenance of airway inflammation, so TNF-α 
inhibitors may be effective for treating COPD (147). 
IL-6 
IL-6 is a pleiotropic, pro-inflammatory and immunomodulatory cytokine secreted by 
monocytes, macrophages, T cells, B cells, fibroblasts, airway epithelial cells and endothelial 
cells. IL-6 is secreted from airway smooth muscle and is involved in the activation, 
proliferation and differentiation of T cells. It serves as a terminal differentiating factor for B 
cells and induces production of IgG, IgA and IgM (148). It appears to have an important role 
in COPD pathogenesis. Some studies report that high levels of IL-6 in serum or sputum 
samples are associated with impaired lung function or a more rapid decline in lung function. 
Furthermore, IL-6 is an important mediator of the acute phase response and can up-regulate 
C-reactive protein (CRP) at the transcriptional level. CRP has been associated with lung 
function in healthy individuals and/or lung function decline in smokers with COPD. In 
addition, IL-6 has recently been shown to contribute to the development of PH, a well-known 
complication of COPD that is associated with pulmonary artery remodelling triggered by 
alveolar hypoxia (149).  
IL-2 
The role of IL-2 in the inflammatory process is complex and involves both the pro-
inflammatory and regulatory components of the immune response (150). IL-2 is associated 
with signal transducer and activator of transcription 5, TGF- β, CD4 and CD25 (150, 151).  
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Other relevant cytokine markers include IL-32 (152), (153) which is related to progression of 
COPD and airflow obstruction (154) and IL-1β which is increased in airway secretions and is 
directly correlated with COPD severity (155). 
2.7.3 Oxidative stress 
Oxidative stress is an imbalance between oxidants and antioxidants, which can cause damage 
to the cellular structures of the lung. Therefore, it is critical in the pathogenesis of COPD 
(156). Oxidative stress is caused by increased exposure to oxidants contained in inhaled 
particles and cigarette smoke and those released from Reactive oxygen species (ROS) 
generated by inflammatory cells such as macrophages, neutrophils and eosinophils (157) as 
well as immune and epithelial cells of the airways. Oxidative stress also aggravates COPD by 
altering nuclear histone acetylation and deacetylation, resulting in increased gene expression 
of pro-inflammatory mediators in the lung (158). 
2.7.4 Protease−anti-protease imbalance 
Imbalances between proteases and anti-proteases also contribute to the development of 
emphysema. This balance may be disrupted by cigarette smoke or genetically related 
conditions such as alpha-1 antitrypsin deficiency, which increase the activity of inflammatory 
cells and cause imbalance between the two enzymes (159). For example, an increase in 
proteinases such as MMPs has been implicated in the development of emphysema (132, 133), 
in the degradation of collagen in the skin of smokers (134) and in age-related remodelling of 
vascular walls (135). 
2.7.5 Apoptosis in COPD 
The term apoptosis was first proposed by Kerr et al. in 1972 to describe the process of cell 
turnover in healthy adult tissues (160). It is a protective mechanism of cell death against the 
expression of heritable genotypic changes in cells associated with mutagenesis and 
carcinogenesis, which are commonly seen in embryonic development (161). Recent evidence 
suggests that apoptosis may be an important mechanism of COPD pathogenesis. The study by 
Segura–Valdez in 2000 demonstrated increased alveolar cell death in the endothelium and 
epithelium by employing the technique of in situ end labelling of fragmented 
deoxyribonucleic acid (DNA) in BALF from patients with COPD (162). In addition to 
endothelial and epithelial cell death, this process was also demonstrated in the alveolar 
parenchymal cells, thereby contributing to chronic lung damage. It was later found by 
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Yokohori in 2004 that there was an increase in cell proliferation in emphysematous lung tissue 
following apoptosis of the abovementioned cells (163). Therefore, it appears that in COPD 
patients, emphysema may be a dynamic repeated process of cell death and proliferation. 
2.7.6 Autoimmune responses 
Autoimmune responses, including innate and adaptive immune processes, have been 
implicated in the pathogenesis of COPD (164). COPD represents a pattern of overlapping 
diseases (165) such as asthma. Both COPD and asthma are obstructive airway diseases 
involving chronic inflammation of the respiratory tract, although the patterns of inflammatory 
cells and mediators between the two diseases are markedly different. These different 
inflammatory cell profiles result in distinct patterns of structural damages in the respective 
diseases (166). The unique inflammatory cell types and mediators are in turn determined by 
the involvement of different immune cells, which recruit and activate specific inflammatory 
cells and result in respiratory tract cell damage (166), thus implicating immune involvement 
in COPD pathogenesis.  
2.7.7 Reactive oxygen species (ROS) and Reactive nitrogen species (RNS) 
ROS include a variety of free oxygen radicals and derivatives of oxygen that contain paired 
electrons (167). They can be produced by enzymatic reactions or obtained from inhalation. 
When ROS react with nitric oxide, RNS can be formed. Both ROS and RNS cause oxidative 
damage to DNA, lipids, proteins and carbohydrates, leading to impaired cellular function and 
enhanced inflammatory reactions. Therefore, ROS and RNS may contribute to the 
pathogenesis of several lung diseases, including COPD (168). 
2.7.8 Neurogenic mechanisms in COPD pathogenesis 
Neurogenic mechanisms may also be important in COPD pathogenesis because neuropeptide 
substance P, vasoactive intestinal peptide and neuropeptide Y levels are elevated in the 
airways of COPD patients and smokers with normal lung function (169). 
The process of COPD pathogenesis, including the involvement of key inflammatory and 
immune cells, is shown in Figure 2.1. 
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Figure 2. 1 The pathogenesis of chronic obstructive pulmonary disease involves key 
inflammatory and immune cells. 
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2.8 Pathophysiology  
Several factors cause gaseous exchange abnormalities, airflow limitation, mucus hyper-
secretion and pulmonary hypertension PH (170). Therefore, these components contribute to 
the pathophysiology of COPD, including mucociliary dysfunction, airway inflammation and 
structural changes. 
2.8.1 Airflow limitation and air trapping 
The pathophysiology of COPD is mainly characterized by inflammation throughout the 
central and peripheral airways, lung parenchyma and pulmonary vasculature (171). 
Narrowing of the lumen in the peripheral airways and parenchymal destruction contributes to 
the loss of alveolar attachments around the peripheral airways and the lung parenchyma 
because of repeated cycles of inflammation and repair (172). Concomitantly, lesions in the 
peripheral airways and lung parenchyma result in chronic airflow limitation (111). This 
impediment of airflow causes progressive trapping of air during expiration with subsequent 
hyperinflation, which diminishes elastic recoil and decreases the inspiratory capacity. The end 
result is dyspnoea and decreased exercise tolerance (172). 
2.8.2 Gaseous exchange abnormalities 
Breathing involves the mouth or nose, the oropharynx, nasopharynx, larynx, bronchi, 
bronchioles and the alveoli in which gaseous exchange of oxygen and carbon dioxide takes 
place. Gaseous exchange is increasingly affected as COPD worsens, resulting in an imbalance 
in the ventilation-perfusion ratio (VA/Q) and ultimately causing arterial hypoxemia with or 
without hypercapnia (173). These biochemical parameters directly correlate to the severity of 
emphysema. As the disease progresses in severity, the ventilatory muscles are impaired, 
leading to decreased ventilation and carbon dioxide retention. The abnormalities in alveolar 
ventilation and a decreased pulmonary vascular bed further worsen the abnormalities in VA/Q 
(174). 
2.8.3 Mucus hyper-secretion 
One of the pathophysiological features of COPD is hypersecretion of mucus in the airway. 
This feature is related to the increase in the number of surface epithelial goblet cell 
hyperplasia and to the size of the submucosal glands (175). During central airway 
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inflammation caused by inhaled irritants, mucus production is increased and mucociliary 
clearance is impaired. In the end mucus glands are enlarged and the number of goblet cells 
increases leading to mucus hypersecretion. The impaired clearance will provide suitable viral 
and bacterial growth conditions and subsequent infections in the respiratory tract, which will 
damage the airway further. Ciliary cells will also be lost leading to further loss of mucus 
clearance and increase of exacerbation risk (170). A recent study showed that MUC5AC, is 
found to be the predominant mucin secreted by mucosal glands in the central airways in stable 
COPD patients (176). 
2.8.4 Pulmonary hypertension (PH) 
Another pathophysiological feature of COPD is the development of PH as a result of changes 
in the structure and function of pulmonary vessels. The pathogenic mechanism of PH involves 
pulmonary vascular remodelling and endothelial dysfunction (177). The process of pulmonary 
vascular remodelling involves the thickening of arterial walls and small and pre-capillary 
arteries. This thickening is associated with the proliferation of hyperplasic intimae of the 
pulmonary muscular arteries (178). Endothelial cells function to decrease vascular tone, 
regulate vessel adaptation to increased blood flow and modulate hypoxic vasoconstriction 
(177). Therefore, endothelial cell dysfunction may result in vasoconstriction due to 
endothelin-1 or angiotensin or vasodilatation due to nitric oxide (NO) or prostacyclin (179). 
Therefore, the development of PH can be attributed to the combination of pulmonary vascular 
remodelling, endothelial dysfunction and inflammatory cell infiltration, which impairs the 
ventilation−perfusion balance and ultimately leads to hypoxia (177).  
2.9 Management of stable COPD 
COPD is a chronic condition without a cure, and it can be divided into two stages: stable 
disease and exacerbation. Management during the stable stage focuses on improving lung 
function, health status and exercise tolerance, relieving symptoms and complications and 
decreasing the frequency and intensity of exacerbations to avoid disease progression and 
mortality.  
2.9.1 Routine pharmacotherapy for the treatment of stable COPD 
Routine pharmacotherapeutic approaches for the treatment of stable COPD include the use of 
bronchodilators and corticosteroids. 
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2.9.1.1 Bronchodilators  
Bronchodilators include β2-agonists, anti-cholinergics and methylxanthines. 
β2-agonists  
β2-agonists are commonly used for the treatment of stable COPD because they can relax the 
smooth muscles of the airway, dilate the trachea and relieve airway limitation by increasing 
the quantity of cAMP via their agonistic effects on β2-adrenergic receptors (180, 181). β2-
adrenoceptors are one of the three subgroups of β-adrenoreceptors, namely β1, β2 and β3, 
which are present in cardiac muscle, airway smooth muscle and adipose tissue, respectively. 
β2-adrenergic receptors are found not only in airway smooth muscle cells (around 30,000–
40,000 per cell) but also in several other types of cells, including lung epithelial and 
endothelial cells and mast cells. However, they are most abundant in the small airways, 
particularly the alveoli. Because the smaller airways of the alveoli are most affected in COPD 
patients, β2-agonists are commonly used for the management of stable COPD. There are two 
types of β2-agoinsts that differ with regard to their onset and duration of effects: short-acting 
β2-agonists (SABAs) and long-acting β2-agonists (LABAs). SABAs have rapid onset of 
effects within a few minutes, and their effects last for 4−6 hours, whereas LABAs have 
longer-lasting effects that last for at least 12 hours. Since the 1990s, LABAs such as 
formoterol and salmeterol have shown an acceptable safety index and are used for the 
treatment of COPD (182). However, like all agonists, they have side effects due to their 
inotropic and chronotropic properties, including increased incidence of arrhythmias and 
cardiomyopathy and worsening or induction of myocardial ischemia. Tremor is also a 
common adverse effect of β-agonists. Long-term use of β-agonists may lead to tolerance, poor 
disease control, sudden life-threatening exacerbations and asthma-related death (183).  
Anti-cholinergics  
The parasympathetic motor system regulates the bronchomotor tone through the mediation of 
muscarinic (M) and nicotinic receptors to cause constriction of bronchial muscles and release 
of mucus into the airway lumen. This parasympathetic bronchoconstrictive effect is mediated 
by the M1 and M3 receptors in the lung tissue (184), and this cholinergic effect is harmful for 
COPD patients. On the other hand, M2 receptors present in the postganglionic 
parasympathetic nerves in the lung tissue inhibit acetylcholine release from these nerve 
terminals (185). This anti-cholinergic effect is beneficial for COPD patients because it can 
inhibit M1 and M3 receptors and spare M2 receptors. Therefore, anti-cholinergics are used as 
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the first-line maintenance treatment for COPD. Two types of anticholinergic bronchodilators 
given primarily in the form of aerosol are used for COPD: short-acting drugs such as 
ipratopium bromide and oxitropium bromide and long-acting drugs such as tiotropium 
bromide (Spiriva).  
Tiotropium bromide is a long-acting anticholinergic bronchodilator that maintains 
bronchodilation for at least 24 hours, allowing once-daily administration. It reportedly 
improves lung function (particularly FEV1) and decreases the occurrence of exacerbation in 
COPD patients (186-188). Bateman et al. suggested that this drug may also have positive 
effects on inflammatory cells, airway remodelling, cough and mucus production (189). As a 
first-line treatment, it plays an important role in maintenance treatment for COPD. Potential 
adverse effects of anti-cholinergics include dry mouth and supraventricular tachycardia 
according to the results of a randomized, controlled trial (183).   
In addition to the use of long-acting β-agonists and anti-cholinergics, combinations of these 
two groups of medications, such as albuterol/ipratropium, have also been used for COPD 
treatment. However, the preliminary observed side effects of combined pharmacotherapy are 
similar to those of an individual drug alone. The potential of harmful synergistic effects 
warrants further investigation (190).  
Methylxanthines  
Methylxanthines such as aminophylline and theophyline are commonly used for the treatment 
of stable COPD (191) because of their properties of bronchoprotection, bronchodilation and 
immune modulation (192). Pharmacologically, methylxanthines are weak bronchodilators that 
relax the bronchial muscles, and they may also have anti-inflammatory properties. The 
proposed anti-inflammatory mechanism involves competitive antagonism of G-coupled 
adenosine A(1) and A(2) receptors and inhibition of phosphodiesterases (193). Theophylline 
improves lung function, PO2 and walking distance in COPD patients. However, because of its 
adverse effects, particularly nausea, its use for treatment of COPD is controversial (194).  
2.9.1.2 Glucocorticosteroids 
Inhaled glucocorticosteroids such as beclomthasone, budesonide, fluticasone and 
triamcinolone are also used for the treatment of COPD. Some glucocorticosteroid inhaler 
medications are combined with long-acting β2-agonists such as formoterol/budesonide and 
salmeterol/fluticasone. However, regular use of inhaled glucocorticosteroids does not modify 
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the long-term decline in FEV1 (195). On the other hand, oral glucocorticosteroids have been 
shown in two retrospective studies to have clinical effects on short-term changes in FEV1 
(196). However, severe side effects are associated with long-term systemic administration of 
glucocorticosteroids in addition to an increased risk of pneumonia; therefore, their benefit as 
oral medications is limited (197, 198). 
Glucocorticosteroids are the most effective anti-inflammatory therapy for numerous chronic 
inflammatory and immune diseases via the activation of anti-inflammatory genes and post-
transcriptional effects (199). This activation involves a complex mechanism in which 
glucocorticoids bind to glucocorticoid receptors in the cytoplasm, translocate to the nucleus 
and bind to glucocorticoid response elements and co-activator molecules. In COPD patients 
who smoke, histone deacetylase 2 activity is markedly impaired as a result of 
oxidative/nitrative stress; therefore, inflammation is resistant to the anti-inflammatory effects 
of corticosteroids (200). This may explain the lack of long-term effects of corticosteroid 
medications in COPD patients.  
2.9.1.3 Mucoactive medicines 
One of the pathological symptoms of COPD is hyper-secretion of mucus in the airway. 
Therefore, mucoactive medications are used to improve sputum expectoration and/or decrease 
mucus hyper-secretion. These medications include expectorants, mucoregulators, mucolytics 
and mucokinetics (201). Expectorants induce the removal of sputum through coughing. 
Mucolytics thin the mucus and decrease its viscosity. Mucokinetics mobilize cough and 
increase sputum expectoration while mucoregulators suppress chronic hyper-secretion of 
mucus (202). 
2.9.1.4 Phosphodiesterase type 4 inhibitors 
cAMP has a wide range of anti-inflammatory effects on numerous key effectors involved in 
COPD. Phosphodiesterase type 4 (PDE4) inhibitors increase the intracellular concentrations 
of cAMP by inhibiting the enzymatic breakdown of cyclic nucleotides cAMP and cyclic 
guanosine monophosphate (cGMP) to their respective 5-nucleotide monophosphates by 
phosphodiesterases (203). There are 11 categories of phosphodiesterases (203), of which 
PDE4 inhibitors are relevant to COPD. PDE4 is a group of pharmacologically distinct 
enzymes encoded by at least four distinct genes (PDEA, PDEB, PDEC, PDED) that are 
specific for cAMP (204). PDE4 inhibitors are used for the treatment of COPD; of these, 
inhibitors of p38 MAPK, NF-κB kinase and phosphoinositide 3 kinase (PI3K) -gamma and -
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delta have side effects, particularly nausea and other gastrointestinal effects. Therefore, 
delivery of this particular type of inhibitors via inhalation may be necessary (205). Other oral 
PDE4 inhibitors such as roflumilast represent a new class of drugs that have shown efficacy 
and acceptable tolerability in pre-clinical and short-term clinical studies involving COPD 
patients. Oral roflumilast for treatment of COPD has been demonstrated to improve lung 
function and decrease exacerbations in four studies that were published in the Lancet (206, 
207). The side effects of roflumilast were found to include intractable diarrhoea, acute 
pancreatitis, weight loss and psychiatric symptoms such as anxiety, depression and insomnia, 
as well as increasing risk of incidence of cancer (208).  
2.9.2 New therapeutic approaches for COPD  
Till date, COPD has been preventable and treatable but not curable. Current therapies cannot 
prevent disease progression or mortality, despite recent advances in the development of 
longer-acting inhaled β2-agonists and M antagonists (and combinations). These new drugs 
still fail to suppress chronic lung inflammation in COPD patients. Indacaterol, a new LABA, 
has been shown to be efficacious for the treatment of COPD and asthma (209-211). It is 
considered to be a potentially useful drug for combination therapy in the future (212, 213). 
However, some studies have shown that it has an adverse effect profile similar to that of other 
β2-agonists (214, 215).  
A different (and perhaps more promising) approach involves inhibition of the inflammatory 
and destructive process involved in the pathogenesis of COPD. Several mediator antagonists 
have proved disappointing. Thus far, the more promising drugs include CXCR2 antagonists 
that block the pulmonary recruitment of neutrophils and monocytes. Broad-spectrum anti-
inflammatory drugs may be more effective, and further investigations to clarify their 
mechanism of action are warranted.  
The most promising therapeutic strategy may still lie in the potent anti-inflammatory effects 
of corticosteroids. As mentioned above, in COPD patients who smoke, inflammation is 
resistant to the anti-inflammatory effects of corticosteroids because histone deacetylase 2 
activity is markedly impaired as a result of oxidative/nitrative stress. Therefore, the better 
approach may be to increase histone deacetylase 2 activity using theophylline-like drugs and 
PI3K-delta inhibitors and decrease oxidative/nitrative stress using more effective antioxidants 
and non-antibiotic macrolides (216). A recent clinical trial showed that oral iosmapimod, an 
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inhibitor of the signalling mediator p38 MAPK, significantly decreased plasma fibrinogen in 
COPD patients (217). 
It is evident that there have been little therapeutic advances in the treatment of COPD over the 
past few decades. The pathophysiology of COPD is multi-factorial, and successful treatment 
can be difficult to define. At present, the most quantitative endpoint is FEV1 using spirometry. 
Perhaps, the most suitable strategy for COPD treatment is the development of a biomarker 
that can be used as an endpoint measure for new pharmacotherapies (218).  
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3 Chapter Three: Chinese medicine for chronic obstructive 
pulmonary disease (COPD) 
3.1. Introduction 
This chapter will introduce the history of Chinese herbal medicine (CHM) and modern 
research related to COPD. It will also discuss Traditional Chinese medicine (TCM) theories 
and modern Chinese medicine (CM) research regarding the pathogenesis, treatment and CHM 
therapeutic mechanism for the treatment of COPD. Finally, evidence derived from clinical 
trials and animal experiments using CHM will be reviewed. 
3.2. Background of complementary and alternative medicine 
3.2.1. Definition of complementary and alternative medicine 
Complementary and Alternative Medicine (CAM) is defined by National Centre for CAM as 
‘a group of diverse medical and health care systems, practices and products that are not 
generally considered to be a part of conventional medicine’ (219). CAM consists of natural 
products including herbal medicines and dietary supplements, mind-body medicine 
(meditation, yoga etc) and manipulative and body-based practices (spinal manipulation and 
massage).  
When CAM is used together with conventional medicine it is termed ‘complementary 
medicine’, whereas the use of CAM in place of conventional medicine is referred to as 
‘alternative medicine’. The combination of CAM and conventional medicine for uses in 
which evidence of effectiveness and safety exists is referred to as ‘integrative medicine’, e.g. 
the integration of CM and western medicine.  
3.2.2. Prevalence of complementary and alternative medicine practice 
The use of CAM is developing rapidly within western countries and the connection with 
conventional health care services is expanding (220). The trend in the use of CAM has 
markedly increased over the last decade. For example, the use of CAM increased from 34% in 
1990 to 62% in 2002 in the US (221), from 20% in 1998 to 27% in 2002 in the UK (222) and 
from 20.3% in 1993 to 23.3% in 2000 in Australia (223). The prevalence of CAM practice in 
the general population was high in some countries: 60% in Australia in 2007 (224), 73% in 
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Germany in 2002 (225) and 76% in Japan in 2002 (226). Approximately 38% of adults used 
CHM in the US in 2007 (227). The prevalence of CAM practice in England was 28.3% in 
2008 (228). The overall prevalence of use of CAM in Ireland was 27% in 2002 (222). In 
Canada, the use of CAM was lower than other countries (12%) (229). CAM approaches are 
increasingly utilised by patients with chronic disease (59, 230), such as diabetes (231) and 
cancer (232, 233).  
3.3. Chinese herbal medicine  
Chinese herbal medicine (CHM) is derived from ancient China before the Christian era. It was 
developed and boomed during the 12th and 18th centuries, and was accepted and applied 
worldwide by 1970s. CHM has been modernised and industrialised over the past few decades. 
3.3.1. History of Chinese Herbal Medicine 
CM, also referred to as traditional CM (TCM), is a major health care system that has been 
used for more than 4,000 years in China before the introduction of western medicine. The 
theory of CM is derived from the ancient fundamental philosophy of Yin and Yang as well as 
the Five Phase Theory and developed gradually into a holistic system, which includes 
physiology, pathology, aetiology, a diagnostic system, treatment principles and treatment 
methods as well as disease prevention (234).  
Various CM therapies are used in an effort to promote health and treat disease. The most 
commonly used approaches are CHM and acupuncture. CHM is a crucial modality in TCM, 
which includes Chinese Materia Medica, herbal formulae and the applications of formulae as 
internal and external medicines. These formulations are a unique feature of CHM.  
CHM was invented by Emperor Shennong prior to the 17th century (BC) after risking his life 
by tasting numerous herbs. Initially, CHM began with the treatment of a symptom with single 
herb. The physical descriptions, properties and growing regions of the herbs were first 
described in the classical book of Shan Hai Jing-Xi Shan Jing (山海经西山经), published 
before the Xianqin (221 BC 先秦), while the CHM formulae were recorded in the oldest 
medical book, Prescriptions for Fifty-Two Diseases.  
Further progress of syndrome differentiation, treatment principles, principles of herbal 
formulation and examples of prescription preparation were summarised in The Yellow 
Emperor’s Classic of Internal Medicine (黄帝内经) published during the Spring and Autumn 
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period (770−746 BC春秋时代). This book provided the foundation for the development CM 
theories as well as TCM formulae. The first Chinese pharmacological book was entitled Shen 
Nong Ben Cao Jing and included 365 herbs categorised into three types (上,中,下三品) and 
was written by several physicians during the period of Qin-Han dynasty (221−220 BC). The 
first clinical medicine treatise, entitled Treatise on Cold-Attack and Miscellaneous Diseases 
(伤寒论 ), containing 314 formulae was written by an outstanding physician, Zhang 
Zhongjing in the Donghan (Eastern Han) dynasty (25 BC−220 AD东汉). 
After a few hundred years, formulae were further developed during the Tang and Song 
dynasties (618−1279). Typical works included the Bei Ji Qian Jin Yao Fang (备急千金要方) 
with 5,300 formulae written by Sun Simiao during the Tang dynasty (652), Tai Ping Sheng 
Hui Fang (太平圣惠方) with 16,834 formulae compiled by Wang Haiyin and issued in 992 
and Shen Ji Zong Lu (圣济总录) with 20,000 formulae organised by the government and 
compiled from 1111−1117. Corrections were made to Tai Ping Hui Min He Ji Ju Fang (太平
惠民和剂局方) by Chen Shiwen et al. in 1151, which comprised the first formula dictionary. 
The TCM formulae were improved during the Ming and Qing dynasty (1368−1911). For 
example, the well-known works such as Pu Ji Fang (普济方) with 61,739 formulae was 
written by Zhu Li and published in 1406, and Gu Jin Tu Shu Ji Cheng-Yi Bu Quan Lu (古今图
书集成-医部全录) was compiled by Jiang Tingxi et al. and published in 1726, which was the 
largest book of CM (235).  
3.3.2. Development of Chinese Herbal Medicine and modern research 
During the early 19th century, western medicine was introduced to China. Initially, western 
medicine was regarded as ‘witchcraft’ and not accepted by the Chinese. In 1859, the first 
hospital was established by John Glasgow Kerr who came to China from the United States 
and recruited students to learn western medicine (236). Gradually, the knowledge of western 
medicine spread across China and impacted CM. In 1918, a medical book, Yi Xue Zhong 
Zhong Can Xi Lu (医学衷中参西录) written by Zhang Xichun was published. This was 
the first book to integrate CM and western medicine.  
After 1950, several TCM tertiary colleges, CM academic institutes and hospitals specialising 
in CM were established in numerous capital cities in China. Over the past six decades under 
the auspices of the new government, these CM institutions undertook extensive research into 
the pharmacological and chemical properties of CM herbs and their active components by 
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employing modern scientific techniques and methodologies. These studies formalised the 
knowledge of CHM into a tertiary education system while evaluating and describing classical 
and modern CM formulae. As a result, CHM combined with western medicine have become 
the mainstream health care system for the Chinese population.  
CHM was introduced to the UK, Germany and France in the early 18th century. Some 
classical CHM books were translated to foreign languages. In 1970, CHM was approved by 
the WHO, and since then CHM has become accepted worldwide. Over the past decade, CHM 
has become more impactful with regard to global health, particularly playing a prominent role 
in the treatment of severe acute respiratory syndromes (SARS) (237). To date, industries in 
countries such as China, India, the US and Nigeria as well as WHO have heavily invested in 
research on CHM in an attempt to identify promising medicinal herbs and novel chemical 
compounds (238). It is anticipated that CHM will play an important role in global health in 
future. 
3.3.3. Chinese Herbal Medicine in treatment of diseases 
CHM is an important aspect of CAM practice (239). CHM is used not only in the treatment of 
acute diseases such as SARS (237), H1N1 influenza (240) and acute ischemic stroke (241), 
but also of chronic diseases such as diabetes (242), endometriosis (243), chronic kidney 
disease (244) and disordered breathing during sleep (245). Herbal medicines are used by 14% 
of adults with chronic pulmonary conditions; specifically, ginseng is used by 23% of herbal 
medicine consumers in the US (62) and 6% of the Victorian herb users (246).  
3.4. COPD in Chinese Medicine 
There is no specific mention of COPD in traditional CM. However, based on its clinical 
manifestations, there are some symptoms or diseases of pulmonary systems (Fei xi bing 
zheng-肺系病证) in CM, which are thought to be similar to COPD according to the Practice 
of Chinese Internal Medicine textbook (247). Categories of symptoms or diseases of 
pulmonary systems such as ‘cough’, ‘long-term cough’ (Jiu ke sou, 久咳嗽 ), ‘dyspnea’ 
(Chuan zheng, 喘证), ‘asthma with wheezing’ (哮证), ‘lung distension’ (Fei zhang, 肺胀), 
‘phlegm-fluid retention’ (Tan yin, 痰饮), ‘cough and dyspnea’ (Ke chuan 咳) and ‘lung 
obstruction’ (Fei bi, 肺痹) were first described in The Yellow Emperor’s Classic of Internal 
Medicine, published during the Spring and Autumn period (770−746 BC). These descriptions 
were next published in Jin Gui Yao Lue (金匮要略), which was written by Zhang Zhongjing 
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in Donghan (25−220 BC). Additional information regarding the pathogenesis of these 
symptoms was recorded in Zhu Bing Yuan Hou Lun (诸病源侯论) by Chao Yuanfang in the 
period of the Sui Dynasty (581-618 AD). During the past three decades, ‘cough’ (Ke sou), 
‘dyspnea’ (Chuan zheng), ‘asthma with wheezing’, ‘lung distension’ (Fei zhang) and ‘phlegm-
fluid retention’ (Tan yin) are commonly regarded as COPD because of their symptomatic 
similarity to the disease. However, ‘cough and dyspnoea’ (Ke chuan) and Fei bi are also 
associated with COPD but are not listed in Practice of Chinese Internal Medicine (248). 
3.4.1 Definitions of COPD-related terms in CM  
3.4.1.1 Jiu ke sou (Long-term cough) 
Cough is a symptom and condition of pulmonary disease. In CM, it is called Ke sou, which 
includes two words. Ke (咳) means audible cough without sputum, while Sou (嗽) is an 
inaudible cough with sputum. These conditions are difficult to distinguish and are generally 
regarded as a single condition. Based on the duration of cough, it is divided into acute cough 
and chronic cough. Chronic cough is referred to as Jiu ke sou (long-term cough) or Ji nian ke 
sou (cough for many years, 积年咳嗽) and is relevant to COPD. Therefore, the COPD-related 
condition involves a long-term cough in addition to impairment of the internal organs. The 
aetiology of cough can be classified into exopathic factors and internal impairment. Stable 
COPD is associated with internal impairment whereas exacerbation of COPD is because of 
exopathic factors (249). 
3.4.1.2 Chuan zheng (Dyspnea) 
Dyspnoea is referred to as Chuan zheng in CM, which is a feature of dyspnoeic respiration. 
The patient presents with an open mouth, flaring nostrils, lifted shoulders and failure to 
remain horizontal because of difficult breathing. It is the chief manifestation of pulmonary 
disease or a result of pathologic changes of other organs that affect the lung and may be 
present in a variety of disorders including COPD (248). 
3.4.1.3 Fei zhang (Lung distension) 
The TCM condition of lung distension (i.e. Fei zhang) may be regarded as a condition related 
to COPD. It is caused by prolonged unresolved cough or asthma with wheezing leading to 
impairment and deficiency of the lung, spleen and kidney with resultant impediment of qi 
flows. The condition is characterised by manifestations that include fullness and distension of 
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the chest, excessive phlegm and saliva production, coughing and wheezing. These symptoms 
are aggravated by physical activities. In serious cases, the complexion may be lack-lustre, lips 
and tongue cyanotic and face and limbs dropsy (248). The condition is typically chronic and 
difficult to cure.  
3.4.1.4 Tan yin (Phlegm-fluid retention) 
Tan yin is a pathological condition that results from retention of body fluids in different 
regions of the body because of abnormal circulation and transportation. The concept of Tanyin 
is defined in both a broad sense and a narrow sense. According to the chapter on ‘Treatment 
of Cough and Tan yin’ in the Essentials from the Golden Cabinet (Jin Gui Yao Lue, 金匮要略), 
the narrow sense of Tan yin refers to the common condition of phlegm-fluid retention, while 
the broad sense of Tan yin consists of four conditions depending on where the fluid 
accumulates in the body. One of them is caused by fluid retention in chest and lung, and is 
termed Zhi yin (thoracic fluid retention, 支饮). This condition is due to a deficiency of lung qi 
manifesting as difficulty in breathing, cough with wheezing, shortness of breath, the need to 
sit up to breathe more easily and the inability to lie flat while sleeping (248).  Based on its 
clinical description, this condition is also relevant to the western concept of COPD (248). 
3.4.2 Differentiation of COPD-related diseases from other similar respiratory 
conditions in TCM 
Based on the symptoms and key manifestations of COPD, it can be diagnosed as Jiu ke sou, Chuan 
zheng, Fei zhang and Tan yin in CM, as described above. However, there are several other TCM 
respiratory conditions that share common clinical manifestations with the above COPD conditions, 
and it is important to recognise their characteristic features and be able to differentiate them from 
similar COPD-related diseases. The following sections discuss the clinical features of respiratory 
diseases and their distinctions from similar but COPD-related diseases.  
3.4.2.1 Xiao zheng (Asthma with wheezing) 
Xiao zheng (哮证) is an acute cough condition characterised by laboured breathing with a 
whistling sound, cough with sputum and stuffiness in the chest. It is always accompanied with 
dyspnoea. It generally begins in childhood, and can be triggered by external wind-cold or 
wind-heat attacks, changes in weather or inappropriate lifestyle. The condition may last years 
or decades. It is clinically similar to the COPD-related condition of Chuan zheng. The 
hallmark feature of Chuan zheng is dyspnoeic respiration, which presents during the 
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developing stages of certain acute or chronic diseases. Chuan zheng is not an independent 
disease, while Xiao zheng is an independent disease. Apart from the commonly shared feature 
of dyspnoeic respiration, the patient exhibits a characteristic water gurgling sound in the 
throat during attacks. Therefore, the differentiation between the two conditions is that the 
COPD-related Chuan zheng involves rapidity and difficulty in breathing, whereas Xiao zheng 
is related to the respiratory gurgling sound (248). 
3.4.2.2 Fei yong (Bronchiectasis) 
In TCM, Fei yong (lung abscess, 肺痈) is described as a disease of the lung characterised by 
putrid accumulation due to internal heat attack on the lung; the heat remains unresolved and 
blocks the lung meridian, leading to formation and accumulation of pus in the lung. The 
characteristic clinical manifestations include fever, cough, pain in the chest, profuse sputum 
production with marked foul smell or coughing with blood. It is easy to misdiagnose this 
condition as the COPD-related phlegm-fluid retention condition of the Tan yin group since 
they share the common symptoms of cough, inability to lie flat and profuse sputum 
production. However, the development of cough in phlegm-fluid retention is slow compared 
to the rapid and acute cough development in Fei yong. Furthermore, in profuse sputum 
observed in phlegm-fluid retention is not thick or putrid, and there is no blood in the sputum. 
Also, heat involvement is substantially more severe in Fei Yong than in cough due to phlegm-
fluid retention (248). 
3.4.2.3 Fei wei (Lung atrophy) 
Fei wei (肺痿) is a condition of weakness of the lobes of the lung caused by long-term 
unresolved coughing and wheezing, which damages the lung qi and excessively consumes the 
body fluids. The key features include shortness of breath, coughing or spitting turbid saliva 
and repeated occurrences. Its pathogenesis is primarily caused by excessive dryness and heat 
in the lung, coldness and deficiency of lung qi. In lung yin deficiency, Fei wei presents with 
expectoration of white and turbid sputum or thick bloody sputum, similar to Fei yong. 
Therefore, it is necessary to distinguish this condition from Fei yong (bronchiectasis), and 
subsequently from the COPD-related condition of cough due to phlegm-fluid retention. The 
major differences between the two conditions are that Fei yong are caused by stagnant lung qi 
causing flow impediment, whereas Fei wei is due to deficiency of lung qi causing weakness in 
flow. Fei yong is an excess yang condition of rapid onset, with thick, putrid and foul sputum, 
while Fei wei is a deficiency of yin condition of slow onset, with turbid sputum that is not 
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foul. Furthermore, patients suffering from Fei yong generally have a normal body weight 
whereas those with Fei wei are emaciated because of the prolonged nature of the disease. In 
modern CM, Fei wei may refer to Idiopathic pulmonary fibrosis (248).  
3.4.2.4 Fei lao (Tuberculosis) 
Fei lao (lung consumption, 肺痨) is caused by Mycobacterium tuberculosis infection in the 
lung, and is an infectious and chronic degenerative disease. In TCM, Fei lao has a root 
deficiency of yin, and during its course of disease progression often results in damage of the 
five zang organs. The common presentations include cough, coughing up blood, tidal fever, 
night sweat, pain in the chest and emaciation. Fei lao can mimic other respiratory diseases, 
particularly Fei yong and the COPD-related Fei zhang and critical discrimination is necessary 
to differentiate Fei lao from them.  
Fei yong usually involves presentations of high fever, aversion to cold, cough and pain in the 
chest, as well as coughing or throwing up profuse amounts of yellowish-green, thick sputum 
that may be laden with blood. Its pathogenesis is attributed to heat toxins, and can be easily 
distinguished from the chronically progressive nature of the yin deficiency disease of Fei lao 
(248).  
Fei zhang is regarded as a COPD-related condition and is characterised by four key features, 
namely, cough, expectoration of sputum, wheezing and oedema. When wheezing is presented 
with dyspnoea, it typically is the consequence of the worsening of prolonged cough, or Xiao 
zheng. This is different from the yin deficiency of Fei lao.  
3.4.3 Aetiology of COPD-related conditions  
Since COPD is a long-term condition related to a group of diseases including cough, asthma-
related wheezing, dyspnoea, lung distension and phlegm-fluid retention; therefore, the 
aetiology and pathogenesis of COPD in CM is a complex process. In CM, an acute attack of 
COPD (i.e. exacerbation COPD) is related to the invasion of external pathogens, while stable 
COPD is thought to be associated with internal pathogens. The causes of COPD depend on 
which particular disease it is related to. Nevertheless, the causes can be generalised into two 
types, namely, the exopathic causes and internal impairment. 
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3.4.3.1 Exopathic causes 
The exopathic causes of COPD are also called predisposing causes. They mainly include 
invasion by exopathogens, improper diet, emotional disturbances and stress.  
 Invasion by exopathogenic wind involves cold, heat and dryness when the organism fails 
to adapt to sudden climatic changes, or inhalation of pollen, smoke and dust and irritating 
smells, which may induce cough, asthma with wheezing, dyspnoea, lung distension or 
excessive fluid retention in the chest and hypochondrium.  
 Improper diet consisting of partiality for a particular kind of food, excessive intake of 
greasy, sweet, or pungent food, mutton or fish or excessive alcohol consumption may 
induce asthma-related wheezing, dyspnoea and excessive fluid retention in the chest and 
hypochondrium. 
 Emotional disturbances or drastic variation of the seven emotions may obstruct the ascent 
and descent of qi, and the stagnation of lung qi may further enliven the endopathic 
induction of asthma with wheezing and dyspnoea.  
 Stress may consume and injure the qi of the spleen, kidney and lung, which enlivens 
internally latent pathogens and leads to asthma with wheezing and dyspnoea and 
excessive fluid retention in the chest and hypochondrium. 
However, invasion by an exopathogen results in an acute condition or acute attack during the 
chronic illness process. Thus, it will not be considered relevant to the chronic illness during 
the remission period (248).  
3.4.3.2 Internal impairment 
Internal impairment as the cause of COPD is related to impairment of the lung, spleen and 
kidney, which includes spontaneous pulmonary diseases such as the phlegm retention in the 
lung, stagnation of lung qi because of phlegm produced by spleen dampness or by failure of 
the impaired kidney to receive qi. These processes induce cough, asthma with wheezing, 
dyspnoea, lung distension and excessive fluid retention in the chest and hypochondrium. 
Therefore, internal impairment of the viscera and bowel (Zang-fu) function is a key cause of 
COPD during the remission period (248).  
3.4.4 Physiology and pathology of COPD-related conditions 
In CM, COPD involves the lung, spleen and kidney; functional failure in any of these organs 
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will affect the others. The physiological relationship between the lung, spleen and kidney 
determines the interrelation of their shared pathology. 
3.4.4.1 Physiology and pathology of the lung  
In CM, the lung (Fei, 肺) is responsible for performing respiration, dominating dispersion, 
depuration and descending of qi, as well as regulating both qi activity and the metabolism of 
body fluids. When the lung is impaired by a pathogen, it will lead to the conversion of body 
fluid into phlegm stored in the lung, and further dysfunction of lung will damage its normal 
function of dispersing and descending of qi. This process results in adverse flow of qi and 
presents as symptoms such as cough, sputum production, difficulty in breathing and chest 
tightness (234).  
3.4.4.2 Physiology and pathology of the spleen 
The spleen (Pi, 脾) is the central organ involved in the secretion of saliva and production of qi, 
and is called the ‘foundation of postnatal existence’. It is responsible for the transportation 
and transformation of food and fluids to the lung and heart, where qi and blood are formed, 
respectively, with assistance of Yuan qi from the kidney. In addition, it controls the flow of 
blood to the muscles and limbs and raises qi. The spleen is impaired by improper diet, which 
includes indulgence in greasy, cold, uncooked/raw or pungent food, or excessive alcohol 
consumption; these dietary factors result in deficiency of spleen qi and dysfunction of the 
spleen with respect to transportation and transformation. Consequently, fluid may be 
accumulated to form dampness and phlegm or the spleen may fail to govern the blood (234).  
3.4.4.3 Physiology and pathology of the kidney 
The kidney (Shen, 肾) functions to store the essence that is the foundation of life activities 
and all physiological activities of the human body, dominates the reception of qi and regulates 
body fluids to maintain normal metabolism. If the kidney is deficient in qi, it is unlikely to 
maintain normal inspiration and to grasp qi, leading to shortness of breath and dyspnoea (234).  
3.4.4.4 The relationship between the lung, spleen and kidney 
Based on Five Phase Theory, the relationship between the lung (metal), spleen (earth) and 
kidney (water) is such that the lung is generated by the spleen and the kidney is generated by 
the lung. On the other hand, the interaction between the spleen and kidney is one in which 
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spleen overpowers the kidney. The main function of these relationships manifests by way of 
the formation of qi and water metabolism. The lung controls the qi and respiration, the kidney 
controls inspiration and the grasping of qi, while the spleen is the source of formation of qi 
and controls the raising of qi (234).  
3.4.5 Pathogenesis of COPD-related conditions  
COPD is closely related to ‘cough’, ‘dyspnoea’, ‘asthma with wheezing’, ‘fluid retention’ and 
‘lung distension’. The causative factors of these symptoms or diseases are numerous and are 
briefly explained as follows. 
The pathogeneses of cough and chronic cough are invasion by exopathogens and internal 
impairment due to disorders of the viscera and bowel (Zang-fu) function. This disease is 
associated with the lung and other organs, particularly in the chronic cough condition. This 
was described in the classical work of Za Bing Yuan Liu Xi Chu (杂病源流犀烛) written by 
Shen Jinao which states ‘If lung is not impaired, it would not present cough, if spleen is not 
impaired, it would not present prolonged cough, if kidney is not impaired and fire is not in 
excess, the cough is not serious’. Chronic cough in the remissive stage is regarded as mainly 
relevant to internal impairment, which is due to deficiency of lung qi or lung yin as a result of 
spontaneous pulmonary disease, phlegm produced from spleen dampness, transformed fire 
from stagnated liver qi or failure of the kidney to receive qi.  
Asthma with wheezing is a paroxysmal disease. Its pathogenesis is due to internal impairment 
of the spleen and kidney resulting in retention of phlegm in lung. The leading endopathic 
cause of asthma with wheezing is complicated by a syndrome interwoven with deficiency and 
excess. At the acute attack stage, it is regarded as a syndrome of excess in superficiality with 
either cold-phlegm or heat-phlegm, whereas during remission it is a deficiency syndrome of 
the lung, spleen and kidney. Deficient lung qi with lowered resistance leads to failure of the 
dispersing function of the superficies and accumulation of phlegm in the lung. Deficiency of 
spleen qi leads to failure of transportation and further deficiency of the middle qi and 
accumulation of phlegm and dampness in the body. Deficiency of kidney yang or yin leads to 
failure of respiration and controlling reception of qi. 
The pathogenesis of dyspnoea is similar to asthma with wheezing. In general, dyspnoea is 
derived from the disorder of qi in its normal function of ascending and descending, ingoing 
and outgoing. The occurrence of dyspnoea is largely governed by the lung and kidney, with 
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the lung controlling qi movement and the kidney being the root of qi. Dyspnoea is also 
classified into two types: excess and deficiency. The former originates from the lung and the 
latter from the kidney.  
The pathogenesis of excessive fluid retention in the chest and hypochondrium is due to cold-
fluid retention in the lung and deficiency of yang in the spleen and kidney. Chronic fluid 
retention occurs in the spleen and kidney, causing them to fail in their warming and 
transforming functions, resulting in suffusion of water.  
Lung distension results from chronic cough and dyspnoea with recurrent episodes, which are 
primarily due to deficiencies of the lung, spleen and kidney. These deficiencies result in 
abnormal water metabolism and cause fluid retention, qi deficiency, qi stagnation and phlegm 
and stasis intertexture (247).  
3.4.6 Syndromes and treatment of COPD-related conditions  
The above COPD-related conditions and their respective syndromes and treatments are 
summarised according to references (247, 250) in  Appendix 3.  
3.5. Advanced research progress for COPD in TCM 
For past two decades, along with increasing incidences of COPD in China, TCM has also 
made significant advances in its understanding of COPD in the areas of disease definition, 
syndrome differentiation, pathogenesis, treatment, experimental research and clinical trials.  
3.5.1 Disease definition  
In 2009, lung distension (Fei zhang) was matched along with COPD by the ‘definition of 
Chinese medicine dominant entities’ addressed by the State of Administration of TCM of the 
People’s Republic of China (251). 
3.5.2 Syndrome differentiation  
COPD diagnosis is complex, involving syndrome differentiation based on the concepts of 
exterior impairment, interior impairment, deficiency syndrome and excessive syndrome, 
regardless of whether it is diagnosed as cough, dyspnoea, lung distension or fluid retention. 
To date, there is no standardised syndrome differentiation method for COPD alone. According 
to a review of the current research of CM approaches for COPD treatment during the non-
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attack period, deficiency syndrome is regarded as the principal condition. Deficiency 
syndrome primarily involves qi deficiencies of the lung, spleen and kidney, deficiency of yang 
of the kidney and yin deficiency of the lung and kidney. However, yin deficiency is only a 
minor presentation. At different phases of COPD development, the presenting symptoms may 
be either deficiency in the functions of the lung, the lung and spleen, the lung and kidney, or 
all of these. Otherwise, the excess syndromes of phlegm and/or blood stasis should be 
considered. The presentation of prolonged sputum production in the morning is due to phlegm 
produced by the spleen that is stored in lung. The manifestation of blood stasis always 
manifests as chest tightness, shortness of breath and purplish lips and nails. Symptoms of each 
syndrome are as follows: 
 Deficiency of lung qi: cough with shortness of breath, clear sputum, fatigue and aversion 
to talking, weak and low voice, intolerance of wind, spontaneous perspiration, pale 
tongue with thin and whitish fur, and weak and feeble pulse. 
 Deficiency of qi of the lung and spleen with phlegm and dampness: cough with profuse 
thin sputum production, easy expectoration, sensation of stuffiness and fullness in the 
chest or dyspnoea with rumbling of sputum in the throat, pale tongue with white and 
greasy fur, and slippery pulse. 
 Deficiency of qi of the lung and kidney: shortness of breath or dyspnoea, exhaling more 
than inhaling, interrupted respiration that becomes more serious with movement, 
spontaneous perspiration, listlessness, low voice, lassitude in the loins and knees, pale 
tongue with white fur, and deep and feeble pulse. 
 Deficiency of yin of the lung and kidney: cough with dyspnoea, low volume of sticky 
sputum (sometimes blood streaked), dry mouth and throat, dysphoria with feverish 
sensation in the chest, palms and soles, lassitude in the loins and knees, emaciation, red 
tongue with little fur, and rapid pulse (252).  
3.5.3 Pathogenesis of COPD in Chinese Medicine 
Pathogenesis of COPD is characterised by deficiency, phlegm production and blood stasis. 
Deficiency refers to vital qi deficiency and impairment that primarily involves the lung, 
spleen and kidney, and is an important internal factor responsible for COPD occurrence, 
phlegm production and blood stasis (253). Sputum production is one of the primary symptoms 
of COPD. Therefore, phlegm not only results from pathological conditions but is also a 
pathogenic factor resulting in COPD. Blood stasis is caused by qi stagnancy or qi deficiency 
(254).  
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3.5.3.1 Deficiencies of the lung, spleen and kidney 
COPD is a long-term condition with recurrent attacks and a protracted disease course that 
leads to the consumption of the vital qi inside the body. First, COPD is caused by a prolonged 
illness consisting of cough and dyspnoea leading to impairment of lung qi. Thus, deficiency 
of lung qi essentially causes the development of COPD. In addition, according to the CM Five 
Phase Theory, the spleen is the mother of the lung, i.e. the lung (metal) is generated by the 
spleen (earth). Prolonged deficiency of lung qi eventually leads to impairment of the spleen 
and stomach and further causes deficiency of spleen qi, i.e. ‘Child’s illness involving the 
Mother’. Deficiency of spleen qi plays a key role in the progress of COPD. On the other hand, 
kidney (water) is generated by the lung (metal); thus, prolonged deficiency of lung qi 
eventually affects the kidney by depletion of kidney qi and failure to breathe qi into the kidney. 
Therefore, deficiency of kidney qi is the consequence of gradual aggravation of COPD. The 
lung, spleen and kidney affect and interact with each other during the development of COPD 
(255).  
3.5.3.2 Phlegm-fluid retention 
Phlegm is the accumulation product of pathological change of the internal organs as a result 
of an internal pathogenic factor. Deficiencies of the lung, spleen and kidney lead to failure of 
fluid metabolism. Deficiency of lung qi results in the loss of the capability of the lung to 
distribute body fluids, with subsequent accumulation of phlegm-dampness in the lung and the 
presentation of sputum production. Deficiency of spleen qi inhibits it from performing its 
function of transportation and transformation, which leads to abnormal stagnancy and fluid 
retention in the lung. Thus, it is said in the classic that the ‘lung is a utensil for storage of 
phlegm and the spleen is a source of forming phlegm’. Deficiency of the kidney (particularly 
kidney yang) leads to its inability to control body fluids, maintain normal metabolism and 
maintain warmth. The loss of the function of transforming fluid will result in the abnormal 
conversion of fluid to sputum and cough.  
On the other hand, abnormal distribution of body fluids due to dysfunction of the lung, spleen 
and kidney produces phlegm and dampness, which are regarded as an internal injury that 
further leads to stagnation of phlegm in lung and obstruction of lung qi, causing failure of the 
descending function of the lung and presenting as cough, sputum and dyspnoea. In addition, 
phlegm is an interior pathogenic factor, which may also be evoked by exterior pathogenic 
factors with accompanying heat, dampness or cold syndrome. Stagnation of phlegm as fluid 
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retention is a perennial condition in the progression of COPD. It is distributed through qi, 
spreading throughout the body, thereby swelling the body or filling the upper orifices and 
resulting in severe conditions such as disturbance of consciousness. Therefore, phlegm is 
regarded as an important factor for exacerbation of COPD in CM. However, the onus lies 
mainly with the spleen, because if the spleen is proficient at transportation, transformation is 
ensured. Then, Tan yin can be moved and stagnation can be avoided.  
The lung is the utensil for storage of phlegm, while the spleen is the source of phlegm 
production. Consequently, lung deficiency indicates that phlegm cannot be transformed easily, 
while spleen deficiency suggests that dampness is not transported. Thus, phlegm ascends 
leading to cough with wheezing, and dampness descends and accumulates resulting in oedema 
of the lower limbs. Therefore, both oedema and wheezing are the consequence of the failure 
of normal movement of ascending and descending qi and loss of qi’s ability to move freely. If 
both the spleen and lung are treated simultaneously, normal transportation and transformation 
of phlegm and dampness will be assured (253). 
3.5.3.3 Blood stasis 
Blood stasis is also a consequence of pathological changes in COPD. The blood vessels 
converge in the lung, and the lung is responsible for the coordination of functional activities. 
Since circulation of blood depends on qi’s function of promoting and warming, abnormal flow 
of the lung qi will cause abnormal blood flow to the heart. Deficiency of lung qi or deficiency 
of the spleen and kidney (particularly involving heart yang) weakens the function of qi’s 
promoting and warming the blood circulation and results in poor circulation or further 
formation of blood stasis. In addition, stagnation of phlegm in the lung affects the lung’s 
function of ascending and descending and qi movement, thus inhibiting the movement of qi 
and causing blood stasis. If altered circulation or stagnation of blood occurs in the blood 
vessels of the lung, lung qi will be inhibited or impaired, leading to the dysfunction of qi 
dispersal; this process results in failure of the lung to distribute fluid throughout the body and 
subsequently dampness turns into phlegm. Therefore, blood and phlegm can affect each other 
during the development of COPD (256).  
In summary, deficiency syndromes are the primary cause of the development of COPD 
whereas phlegm and blood stasis are involved in excessive syndromes that are the secondary 
cause. Therefore, the combination of the primary cause of deficiency and the secondary cause 
of excess is the fundamental cause of the development of COPD. The presence of these 
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factors and their interactions can lead to a cycle of repeated onset and protracted course of 
COPD.  
3.5.4 Treatment of COPD 
Based on the differentiation of the syndromes of chronic cough, asthma with wheezing, 
dyspnoea, lung distension and excessive fluid retention in the chest and hypochondrium, the 
prescription of herbal medicine targets the symptom pattern (i.e. syndrome). Thus, the 
establishment of the treatment principles of COPD is based on the following differentiation of 
syndromes common in COPD, which include replenishing and restoring the lung qi, 
replenishing the lung and invigorating the spleen, replenishing the lung and tonifying the 
kidney, replenishing the lung, invigorating the spleen and tonifying the kidney and 
moisturizing the lung and nourishing the kidney. Formulae and herbal preparations:  
 Replenishing and restoring the lung qi: Bu Fei Tang includes Ren shen, Huang qi, Shu di 
huang, Wu wei zi, Zi wan, Sang bai pi; 
 Replenishing the lung and invigorating the spleen: Liu Jun Zi Tang includes Ren shen, Fu 
ling, Bai zhu, Chen pi, Ban xia (Zhi), Gan cao (Zhi); 
 Replenishing the lung and tonifying the kidney: Shen Ge San includes Ren shen, Ge jie; 
 Replenishing the lung, invigorating the spleen and tonifying the kidney: Bu Fei Fang & 
Liu Jun Zi Fang & Shen Ge San;  
 Moisturizing the lung and nourishing kidney: Bai He Gu Jin Tang includes Sheng di 
huang, Shu di huang, Mai dong, Bei mu, Bai he, Dang gui, Shao yao, Gan cao, Xuan shen, 
Jie geng (248).  
3.5.5 Clinical trial research  
Early research studies of COPD were conducted in the 1960s and were largely based on 
clinical observations of CHM in the treatment for COPD. Randomised clinical trials (RCTs) 
were applied only in the 1990s (257, 258). Until then, COPD patients were identified as 
having chronic bronchitis, emphysema or chronic asthmatic bronchitis; it was not until the 
late 1990s that the concept of COPD was introduced and patients were identified according to 
the Guideline of Diagnosis and Management for COPD which was issued by the Chinese 
Society of Respiratory Diseases (CSRD) in 1997 (259). The RCTs evaluated the effectiveness 
of CHM in treatment of stable COPD patients (260-262) and those in the acute stage of 
exacerbation (263-265). These trials involved various treatment interventions that included 
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CHM by oral, inhalation and injection administrations, fumigation-washing therapy, 
acupuncture and acupressure, Qigong, Taiji as well as co-intervention strategies such as oral 
administration of CHM combined with acupuncture or acupressure. Results from numerous 
trials for stable COPD patients indicated that CHM not only relieved symptoms but also 
improved HRQoLstatus, decelerated the decline of lung function, reduced the incidence of 
acute exacerbations and hospitalisations and improved nutrition status (266). In Chapters 6 
and 7, we will focus on the assessment of the trials that evaluated the effectiveness and safety 
of oral CHM in the treatment of patients with stable COPD, through SRsand meta-analyses. 
These trials and animal experiments have revealed certain biochemical and immunological 
mechanisms of CHM in the treatment COPD and this knowledge is described in the following 
sections. 
3.5.6 Research in animal models 
In past decade, approximately 90 reports have been published regarding animal models of 
COPD. Studies using CHM formulae in a rat COPD model focused on establishing different 
syndromes and determining the mechanism of action of CHM in the treatment of COPD. 
Common syndromes in a murine COPD model involved cold-fluid retention in the lung, 
phlegm-heat retention in the lung, lung qi deficiency with stable COPD and deficiency of the 
lung, spleen and kidney (267). Studies of the mechanism of action of CHM focused on the 
effects of CHM formulae or extracts of single herb on airway structure remodelling, 
inflammatory cells and mediators, genetic factors, vasculature endothelial function and effects 
on lung function (268). 
3.5.7 Research on the therapeutic mechanism of CHM for COPD 
Based on results of this literature review of clinical trials and animal experimental research, 
the therapeutic mechanism of CHM for treating COPD is summarised according to the 
following aspects: 
 Immunoregulation,  
 Balance of oxidants and antioxidants,  
 Improvement of blood rheology, 
 Prevention of pulmonary hypertension, 
 Improvement of respiratory muscle function, anti-inflammatory, antibacterial and 
bronchodilator action as well as mucous clearance.  
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3.5.7.1 Immunoregulation 
The ability of CHM to improve immunoregulatory functions of cellular and humoral 
immunity has been demonstrated by the effects of inflammatory mediators, the level of 
immunoglobulins (Ig) and regulation of T lymphocyte subsets (269).  
Reduced levels of released inflammatory mediators  
COPD is characterised by chronic inflammation of the airway, pulmonary parenchyma and 
pulmonary vasculature, with impairment of pulmonary structure by inflammatory mediators 
such as leukotrienes, tumour necrosis factor-alpha (TNF-α) and interleukin (IL)-8. 
Significantly reduced serum levels of TNF-α and IL-8 have been found in clinical trials (270-
272) and experimental research studies (273, 274). Therefore, CHM may have effects on 
cytokine activities and prevent the inflammatory response in COPD patients.  
Enhanced Ig levels  
The serum levels of IgA, IgM and IgG were decreased in patients with COPD relative to 
healthy subjects (275). CHM has been demonstrated to significantly enhance the levels of IgA, 
IgG and IgM in patients with COPD compared to controls after Sheng Mai Injection (276). 
Therefore, CHM may potentially improve immune-related defences in patients suffering from 
COPD.  
Regulation of T lymphocytes 
COPD patients have reduced levels of T lymphocytes including CD3+, CD4+ and 
CD4+/CD8+ subsets, B cells and natural killer cells compared to healthy subjects, thus 
implying impairment of cellular immunity function in COPD (277). It was reported that CHM 
regulated the level of CD3+, CD4+, CD4+/CD8+ and CD8+ T cells in a study that used a 
formula containing Ren shen, Fu ling, Bai zhu and Ci wu jia and Shan zhu yu etc. and a 
separate study that used a formula containing Ren shen, Huang qi, Shan yao, Fang feng, Mai 
dong, Wei jin, Dan shen, Tao ren, Guo lou and Bei mu (275, 278). Therefore, CHM may 
improve the immunodeficiency of patients with COPD. 
3.5.7.2 Regulation of oxidant-antioxidant balance 
Because of excessive secretion of TNF-α and IL-8 in patients with COPD leading to 
neutrophil aggregation in the small airway and accumulation of oxygen radicals, these oxygen 
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radicals may attack the endothelial cell membrane and mitochondrial membrane in the airway; 
this process causes lipid peroxidation leading to impairment and apoptosis of cells. Dang shen 
(Salvia miltiorrhiza) injection was found to increase the plasma level of human glutathione 
peroxidase (GSH-Px) and catalase and decrease lipid peroxidation, which indicated that 
Salvia miltiorrhiza could markedly attenuate lipid peroxide (LPO) reactions and adjust the 
antioxidant imbalance in patients with chronic cor pulmonale (279).  
3.5.7.3 Improvement of blood rheology 
In patients with COPD or cor pulmonale, recurrent infection, hypoxemia and carbon dioxide 
retention lead to increased haematocrit (Hct) blood and plasma viscosity and fibrinogen, 
thereby resulting in hyperviscosity syndrome and forming micro-thrombi in the lung. In 
COPD patients treated with CHM formulae by either oral or inhaled administration, including 
Zao jiao and Da zao in one study and Ma huang (Zhi), Xing ren, Gan cao, Huang qi and Chi 
shao in another (280, 281), CHM treatment decreased Hct, fibrinogen, blood viscosity and 
shear rate. 
3.5.7.4 Prevention of pulmonary hypertension 
As a result of long-term hypoxemia leading to increased aggregative index of red blood cell 
and blood viscosity that further cause blood stasis and dysfunction of lung tissue 
microcirculation, complications of pulmonary hypertension and cor pulmonale are common. 
Although the prevalence of pulmonary hypertension in patients with mild and moderate 
COPD is not known, studies have reported a high prevalence of pulmonary hypertension, 
which ranges from 30−70% in patients with advanced COPD and hypoxemia. Patients with 
COPD and hypoxemia had severely elevated pulmonary pressure and pulmonary vascular 
resistance (PVR) that lead to right heart ventricle dysfunction.  
Vasodilator therapy may be effective in decreasing both pulmonary hypertension and 
systemic blood pressure, although this may also worsen hypoxemia. Studies have 
demonstrated that CHM may be potentially effective in selectively reducing pulmonary 
hypertension while not affecting the systemic blood pressure or worsening hypoxemia. In 
addition, pulmonary hypertension by hypoxemia is recognised to correlate with disturbances 
of blood coagulation and humoral factors. Therefore, maintaining balance of the ratio of 
tissue-type plasminogen activator (tPA)/PA inhibitor (PAI) and prostaglandin I2 
(PGI2)/thromboxane A (TXA2) as well as that of endothelin and Nitric oxide (NO) is critical 
for relief of pulmonary hypertension. CHM formulae or single extracts have been 
56 
 
demonstrated to have possible effects on pulmonary hypertension through different 
mechanisms described in the following sections.  
Decreased mean pulmonary arterial pressure and pulmonary vascular resistance  
Decreased mean pulmonary arterial pressure and PVR were found in studies using injection of 
extracts of single herbs such as Dang gui, Dan shen and Huang qi in the treatment of patients 
with stable COPD and pulmonary hypertension (PH) (282, 283). In addition, decreased mPAP 
was also found in studies using oral administration of CHM formulae by comparing pre- and 
post-treatment data. For example, Zhang (2001) used CHM formulae that included Ren shen, 
Huang qi, Lu jiao jiao, Ge jie powder, Fa ban xia, Mu li, Ting li zi, Fu ling, Gu zhi, Chuan 
xiong and Shui zhi for the treatment of patients with stable COPD and pulmonary 
hypertension (284), while Sun Zikai (2001) used CHM formulae that included Xie bai, Ting li 
zi, Huang qin, Gua lou pi, Sang bai pi, Zhi ma huang, Fang feng, Dan shen, She gan, Xing ren 
and Gan cao in the treatment of patients with COPD exacerbations and PH (285). 
Enhancement of type plasminogen activator (tPA) / PA inhibitor (PAI) ratio 
The tPA protein is involved in the breakdown of blood clots and is found in endothelial cells. 
PAI is the inhibitor of activators of plasminogen and fibrinolysis. PAI1 is a serine protease 
inhibitor protein and is a main inhibitor of the PA. It was reported that a CHM formula Qing 
Ning Oral Liquid including Huang qi, Bai zhu, Fang feng, Dan shen and Chuan xiong may 
increase tPA activity and decrease PAI activity in senile COPD patients treated for PH. 
Meanwhile, it has been implied that PH is potentially correlated with tPA activity and PAI 
activity (286).  
Prostaglandin I2/Thromboxane A2 balance  
Humoral factors play an important role in pulmonary vasoconstriction. Pulmonary 
vasoconstriction or vasodilatation depends on the ratio of vasoconstrictors/vasodilators. PGI2 
is a vasodilator, and causes increases in cAMP in blood platelet cells and suppresses their 
aggregation, whereas TXA2 is a vasoconstrictor that stimulates activation of new platelets and 
increases platelet aggregation. Imbalances in the ratio of PGI2/TXA2 lead to hypertension. 
Extracts of Mao dong qing leaf administered as a Dihydroxyacetophenone injection were 
found to reduce the level of plasma atrial natriuretic peptide (ANP), cGMP and blood 
viscosity, enhance the level of cAMP/cGMP and regulate the balance of the PGI2/TXA2 ratio 
in patients with stable COPD (287). A Xie Bai capsule consisting of Xie bai, Gua lou, Ban xia 
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and Huang lian etc. was found to have similar functions in the treatment of patients with 
COPD and PH (288). 
Nitric oxide (NO) and Endothelin balance  
Endothelin (ET) is a protein that constricts blood vessels and raises blood pressure. NO is 
recognised as an important endothelium-derived vasodilator that plays a major role in 
maintaining vascular tone in normal pulmonary vasculature (289). Increased ET and 
decreased NO lead to strongly constricted pulmonary vasculature and PH. Wu found that a 
CHM formula containing Di huang (Shu), Dang shen, Huang qi, Fu ling, Bai zhu, Ling zhi, 
Tu si zi, Du zhong, Xing ren (Bei), Su zi, Dan shen and Dang gui decreased the level of serum 
ET and increased serum NO levels in patients with stable COPD (290), while ET1 was 
decreased in a study using Dang gui injection in patients with COPD and PH (283). 
3.5.7.5 Improvement of respiratory muscle function 
In COPD patients, because of increased lung volume, malnutrition, increased airway 
resistance, hypoxaemia, hypercapnia and respiratory acidosis that cause structural changes of 
the respiratory muscle and reduction of respiratory function, there is increased energy demand 
of the respiratory muscle. Conversely, respiratory muscle fatigue is one of causes of leading 
worsening hypercapnia and respiratory failure that finally form a vicious cycle, thereby 
accelerating the reduction of exercise tolerance and quality of life. Studies on the effect of 
Shen Mai Injection have indicated that it may improve diaphragmatic function in COPD 
patients with respiratory failure and diaphragm fatigue (291); it may also improve respiratory 
muscle strength and respiratory muscle endurance in COPD patients (292). Shen Mai 
Injection has been demonstrated to improve adaptability of the diaphragm muscles and further 
improve the relaxation and contractility function of fatigued diaphragm muscles in a rat 
experimental model (293).  
The results found in randomised clinical trials for the effects of CHMs in stable COPD will be 
analysed and discussed in chapters six and seven and the results of experimental studies of 
specific CHM will be discussed in Chapter 8. 
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4 Chapter Four: Methods for analysing the classical literature 
and modern clinical trials 
This chapter is divided into two parts: 1) methods used for analysing the classical literature 
(4.1) and 2) methods used for systematically reviewing and analysing contemporary clinical 
trials (4.2).  
All books relevant to CM written up to 1911 belong to classical literature, whereas books 
written after 1911 belong to modern literature (294). The classical literature was analysed 
based on searches of the Encyclopaedia of Traditional Chinese Medicine, which comprises 
about 1,000 classical books, while the modern literature analysis focused on the contemporary 
clinical trial literature published during the 1970s and later.  
The methods used for the classical literature included the following: search strategies; 
selection of search terms; establishing selection criteria (both inclusion and exclusion criteria); 
developing coding and rating systems based on the selection criteria; procedures for data 
extraction and data entry for both formulae and herbs; and procedures for data analysis using 
SPSS.  
The analyses of the modern literature included SRs and meta-analyses based on evidence-
based medicine. The methods for the SRs included the following: search strategies, including 
identifying search terms and databases for searching; establishing criteria for considering 
these studies, including identifying the types of patients, studies, interventions and outcome 
measures; assessments of risk of bias and methodological quality of included studies; data 
collection and data analysis using Review Manager (5.1.0); and data interpretation. In 
addition, analyses are conducted of the frequency of usage of herbal formulae and individual 
herbs. 
4.1 Methodology for searching the classical literature 
In general, searches of the classical literature tend to be more productive for diseases for 
which clearly identifiable classical terms exist or for conditions that can be identified based 
on the kinds of signs and symptoms that are frequently recorded in the classical literature. In 
these cases, the classical terms for each of the signs and symptoms can be identified and used 
as primary search terms. In the case of COPD, because it is a modern disease category, it 
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modern designation, Fei zhang, and the major clinical symptoms of COPD formed the basis 
of the search terms.  
The search procedure used an electronic database: Zhong Hua Yi Dian (ZHYD: Encyclopaedia 
of Traditional Chinese Medicine) (295). The ZHYD is a large series of electronic books on 
compact disk. It is a comprehensive collection of classical Chinese medical books that was 
issued by the Hunan electronic and audio-visual publishing house. The latest version of ZHYD 
contains 1,000 ancient and pre-modern Chinese medical books in more than 10,000 volumes 
and 0.4 billion words. It is the most ambitious collection of Chinese electronic books that has 
been accumulated to date and includes the major Chinese ancient works, many of which are 
from rare manuscripts and are the only existing copies. These books cover the period from 
ancient times up to the period of the Republic of China (1911-1948). Relevant results from 
searches were entered into Excel spreadsheets. Inclusion and exclusion criteria were applied 
to the extracted data. Finally, the data were rated for their relevance to COPD and analyzed by 
SPSS (version 19). 
4.1.1 Search terms and search strategy  
The search strategies included the following:  
 Search for and identify suitable search terms;  
 Establish inclusion and exclusion criteria for selecting suitable data; and  
 Develop criteria for classifying, coding and rating data. 
4.1.1.1 Search methods for identifying search terms 
As discussed in Chapter 3, there are no disease names that correspond exactly to COPD 
within traditional Chinese medicine, either in modern texts or in the classical literature. 
However, disorders similar to the contemporary concept of COPD may have been classified 
under other disease names in the classical literature.  
Discussions of terms used for disorders analogous to COPD appear in books on Chinese 
internal medicine and in modern literature reviews of the classical literature. Thus, it was 
necessary search these sources to identify suitable search terms. The approach used was to 
locate the sections on disorders similar to COPD in the following sources: TCM books issued 
in past decades; classical books; journal articles; and CM dictionaries. Terms relevant to 
COPD were defined based on the symptoms and signs that are typical of COPD; for example, 
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chronic cough, dyspnoea and sputum.  
The methods used to identify search terms involved the following steps. The results for each 
of these steps are discussed in detail below. 
Step 1: Search books on Chinese medicine, including general books and specialist books on 
respiratory diseases, to identify disease names used in the traditional literature that 
are relevant to COPD and to ensure that a wide range of possible terms are 
considered. 
Step 2: Use CM dictionaries to identify terms related to COPD. 
Step 3: Search the journal databases CNKI and CQVIP for any articles on the origin of COPD, 
its names during the classical period or how it was treated in pre-modern China.  
Step 4: Categorize the classical terms into the following: those that appear to be good matches 
with the modern terms for COPD and could be considered as search terms; classical 
terms that are not clear or do not match with COPD; terms whose scopes of meaning 
are too broad to be considered as useful search terms. 
Step 5: Conduct ZHYD searches to determine the number of results for each term and examine 
example references to determine if they are good matches to the disease.  
4.1.1.2 Method for identifying and selecting search terms for the classical literature 
Searches were conducted of relevant books in the Library at Guangdong Provincial Hospital 
of Chinese Medicine or Beijing University of TCM, books in Xin Hua Book store in Beijing, 
China and books and dictionaries held at RMIT University in Melbourne.  
Step 1: Book Searches  
A workshop was held at Guangdong Provincial Chinese Medicine Hospital from October 7-14, 
2010 that focused on methods used for analysis of the classical CM literature. More than ten 
books were located in the library at Guangdong Provincial Chinese Medicine Hospital. These 
included books on Chinese internal medicine, clinical Chinese internal medicine and specialty 
books on respiratory diseases, which contained chapters on COPD and/or pulmonary diseases 
associated with COPD and listed in Appendix 4.  
The TCM disease names commonly related to COPD in these chapters were Ke sou (咳嗽), 
Chuan zheng (喘证) and Fei zhang (肺胀). Ke sou was further divided into Bao ke (暴咳) and 
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Jiu ke (久咳) in two books written by Wu and Zhu (296, 297). The former term refers to a 
suddenly occurring violent cough of short duration and the latter term refers to a long-term 
cough. In addition, syndrome names like Tan ke (痰咳) and Tan sou (痰嗽) were described in 
the book written by Wang in 2009 (248). The term Zhi yin (支饮) was also found in the book 
by Wu (296), but it was not classified under pulmonary diseases. Fei zhang was mentioned in 
all of the books (Appendix 4).  
Step 2: Dictionary Searches  
The words pertaining to major symptoms, syndromes and disease names for COPD and 
related disorders were looked up in dictionaries, including Zhong Yi Da Ci Dian (中医大辞
典), Jian Ming Zhong Yi Ci Dian (简明中医辞典) and Xin Pian Jian Ming Zhong Yi Ci Dian 
(新编简明中医辞). These terms are listed in (Table 4. 1). The TCM disease names associated 
with COPD found in these dictionaries included the following: Ke sou; Chuan zheng; and 
Chuan sou (喘嗽). The syndrome names included the following: Ke ni (咳逆) Chuan man (喘
满); Chuan tan (喘痰); Fei zhang; Tan ke (痰咳); Tan sou (痰嗽); Tan chuan (痰喘); Tan yin 
ke sou (痰饮咳嗽); Tan yin chuan ji (痰饮喘急); and Tan yu sou (痰瘀嗽) (Table 4.1).  
Table 4. 1 Traditional disease names related to COPD found in dictionaries 
First Author, 
date 
Dictionary name (in 
English) 
Dictionary name (in 
Chinese) 
Disease names relevant to 
COPD 
Li, 2004 
Concise Chinese Medicine 
Dictionary 
简明中医辞典 (修订本) 
Ke sou, Chuan zheng,  
Fei zhang 
Li, 2005 
Great Dictionary of Chinese 
Medicine 
中医大辞典 
Ke sou, Chuan zheng,  
Fei zhang, Tan yin 
Yan, 2007 
New Concise Dictionary of 
Chinese Medicine 
新编简明中医辞典 
Ke sou, Chuan zheng,  
Fei zhang 
 
Step 3: Journal Database Searches  
As discussed in Chapter 4, 102 articles were included in the systematic review based on 
searches of several journal databases, including CNKI, CQVIP and Wanfang. COPD was 
considered to belong to the Chinese medicine category of Chuan zheng (including Jiu chuan 
久喘 and Xu chuan 虚喘) in 57 articles, to the category of Fei zhang in 57 articles, to the 
category of Ke sou (including Jiu ke and Ke sou by internal impairment, 内伤咳嗽) in 35 
articles, to the category of Tan yin in 15 articles and to Xiao zheng (哮证) in 12 articles.  
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In addition, the terms Ke chuan (咳喘), Duan qi (短气) and Xu lao (虚劳) were reported in 
one article each. Chuan zheng and Fei zhang were simultaneously mentioned in 52 articles, 
while the three terms Ke sou, Chuan zheng and Fei zhang were all mentioned in 28 articles. 
Step 4 Categorization of the classical terms 
Cough is one of the most common symptoms not only for COPD, but also for other lung and 
non-lung diseases. Thus, it is not a symptom unique to COPD. Cough in and of itself does not 
lead to a diagnosis of COPD, even if it is chronic. A positive diagnosis of COPD is made 
when cough also presents with terminal bronchiectasis (i.e. emphysema as a result of partial 
blockage of terminal bronchioles).  
Similarly, wheezing is a syndrome that can be observed in many different diseases, such as 
cardiac or renal insufficiency, both of which may present with breathing difficulties. Tan Yin, 
a by-product of a disturbance in water metabolism, can stagnate in any Zang fu (viscera and 
bowels) organs causing various types of disease. In Chinese medicine, the condition of Tan 
yin is not classified within the category of pulmonary diseases. Also, the three presentations 
of Cough, Wheezing and Tan yin described above actually encompass a wide range of 
medical conditions.  
The important issue was how to differentially identify the circumstances when these terms 
were relevant to the diagnosis of COPD. Identifying conditions that were likely to have been 
COPD was based on the age of the patient, descriptions of the symptoms and their onset 
(whether the condition was acute or chronic) and other aspects (see details below).  
Step 5 Search procedures for ZHYD 
When the ZHYD is opened, two separate window panes are displayed to the left and right of 
the interface. These interact with each other as the user navigates through the different 
sections of the CD-ROM. The pane on the left-hand side shows the outline of the dictionary 
and a catalogue of books. The pane on the right-hand side shows the contents of relevant 
works. There are five functions on the top of the right pane that include the search field and 
buttons for book search, headings search, content search and results exchange.  
The following figures show the procedure for searching the ZHYD using a particular search 
term. In Figure 4.1, Ke sou was entered into the search field, the categories/headings (Mu lu) 
search was selected and 839 hits were found for this term in the categories/headings in the 
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books (shown in red text). 
 
Select the ‘Heading search’ 
button 
 
Figure 4. 1 Search procedure for the ZHYD using Ke sou as the search term and showing the initial results 
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After this, the ‘show results’ button is selected to display all of the book headings in which 
results were found in the left-hand pane (see Figure 4.2).  
 
Figure 4. 2 Search procedure for the ZHYD using Ke sou as the search term, showing the book headings 
that contain results (left pane) 
Select the ‘show results’ button 
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By selecting the arrow key at the right bottom corner, one can scroll down to see all of the 
contents in the book that are shown under each heading displayed in the right-hand pane (see 
Figure 4.3). 
 
Select the arrow 
 
Figure 4. 3 Search procedure for the ZHYD using Ke sou as the search term, showing the book contents in 
the right pane for each heading in results left pane. 
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Results of trial searches of the ZHYD for search term selection 
Trial searches of the ZHYD were conducted for each candidate search term to determine its 
utility and specificity (see Table 4.2). For example, the terms Tan yin (phlegm, sputum) and 
Ke sou (cough) were entered into the ZHYD. Both search terms were found to be too broad. 
There were 297 results found in a headings search for Tan yin. These included a wide variety 
of conditions that involved Tan yin as a symptom or as part of the aetiology. Similarly, there 
were 839 results found when searching the term Ke sou, which involved many kinds of Ke 
sou (cough) with numerous instances of children with Ke sou. Some of these results referred 
to long-term or many years cough that were described as Jiu ke sou, Jinian kesou (积年咳嗽), 
Yuannian kesou (远年咳嗽 ) or Tanyin kesou. Thus, these more specific terms were 
considered to be more suitable as search terms for COPD. 
Table 4. 2 Results from heading searches and content searches for candidate search terms 
Search terms Heading search Content search 
Ke sou (cough) 839 10,830 
Jiu ke sou (long-term cough) 11 94 
Jiu ke (chronic cough) 21 609 
Jiu sou (chronic sputum) 39 1083 
Chuan zheng (dyspnoea) 20 72 
Chuan sou (dyspnoea and sputum 46 1845 
Ke chuan (cough and dyspnoea) 13 629 
Fei zhang (lung distension) 13 656 
Zhi yin (Thoracic fluid retention) 8 520 
Tan yin (phlegm-fluid retention) 297 4318 
Tanyin kesou 
(phlegm-fluid retention causing cough) 
25 84 
 
4.1.1.3 Finalisation of search terms 
Based on the steps discussed above, the following list of search terms was identified: Jiu ke; 
Jiu sou; Ke chuan; Chuan sou; Chuan zheng; Fei zhang; Zhi yin; and Tan yin ke sou. The 
majority of these search terms are disease names in Chinese medicine, in addition to some 
syndrome names that are related to cough and dyspnoea. Zhi yin also belongs to the category 
of Tan yin with a presentation of either cough, dyspnoea, sputum or chest tightness. 
According to respiratory experts’ opinions on the correlation between terms used in CM and 
COPD, the term Zhi yin was suggested by Guangdong Provincial Hospital as a suitable search 
term. 
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4.1.1.4 Establishing selection criteria based on clinical features 
Based on the results of the trial searches, it was evident that each search term could find many 
references that were irrelevant to COPD because all examples of the term were included in the 
ZHYD search results. Therefore, it was important to establish criteria for identifying irrelevant 
references. Also, the remaining references could include examples that were more or less clear 
examples of COPD; thus, a method for distinguishing these was also needed.  
Based on the diagnostic features of COPD, inclusion and exclusion criteria were established 
to assist in identifying relevant references resulting from the searches.  
Inclusion criteria  
The key clinical features for a positive diagnosis of COPD are as follows: 1) patients older 
than 18 years of age of either gender; 2) long-time or perennial cough accompanied by 
sputum production or shortness of breath or dyspnoea; and 3) chronic condition. Therefore, 
classical references that included these three features were considered as the mostly likely to 
refer to COPD. In addition, treatments were limited to 4) oral preparations, such as an herbal 
decoction or a pill. 
Exclusion criteria 
References that mentioned the following features were considered as exclusion criteria: 1) 
exacerbation or acute condition; 2) hard breathing diagnosed as Xiao zheng (asthma) or Hou 
chuan (齁喘) in Chinese medicine; 3) haemoptysis or purulent sputum with abnormal smell 
that was diagnosed as Fei yong (肺痈), Fei lao (肺痨), Fei wei or a similar symptom in 
Chinese medicine; 3) children or pregnant or postpartum women; 4) intervention with 
acupuncture or moxibustion, acupressure, steaming and inhaling; 5) dietary interventions or 
use of special foods, such as animal organs. Also, instances of references duplicated in the 
same book were excluded.  
4.1.1.5 Scoring the inclusion and exclusion criteria for COPD 
Based on the trial searches using candidate search terms it was evident that there was no 
disease name that always directly corresponded to COPD in the classical works of Chinese 
medicine. Therefore, to select references from the classical literature that more or less closely 
corresponded to COPD, a scoring procedure for the above COPD diagnostic features was 
established. 
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The key symptoms of cough, sputum, dyspnoea and chest tightness are not only associated 
with COPD, but are also present in other respiratory diseases. In addition, disorders involving 
children, women or haemoptysis needed to be identified and scored. 
Scoring of the key symptoms included the following:  
 Dyspnoea was scored from 0 to 4: ‘0’ was no mention of dyspnoea and ‘4’ was severe 
dyspnoea;  
 Cough was scored from 0 to 3: ‘0’ was no mention of cough and ‘3’ was chronic or long 
term cough;  
 Sputum was scored the same way as Cough;  
 Chest tightness was scored from 0 to 2: ‘0’ was no mention of chest tightness and ‘2’ was 
chest tightness.  
The details of the scoring system are shown in Table 4.3.  
Table 4. 3 Key symptoms of COPD: Numerical scores and meanings 
Symptom 0 1 2 3 4 
Dyspnoea No mention No Yes Worse with exercise Severe dyspnoea 
Cough No mention No Yes Chronic or long time cough NS 
Sputum No mention No Yes Chronic sputum  
Chest tightness No mention No Yes NS NS 
 
In addition, children and women (pregnant and post partum) needed to be identified and 
excluded. The scoring for children and women was from 0 to 2, with ‘0’ as no mention, ‘1’ for 
children and ‘2’ for women (pregnant and post partum). 
Normally, haemoptysis is not relevant to COPD, so this condition should be excluded. This 
was scored the same way as chest tightness. Also, acute injury or acute lung diseases should 
be excluded. Acute conditions were scored from 0 to 2. The scoring systems for these 
exclusions are listed in Table 4.4. 
Table 4. 4 Exclusions: Numerical scores and meanings 
Exclusions 0 1 2 
Children/women No mention Yes children Yes women 
Haemoptysis No mention No Yes 
Acute condition No mention No, chronic disorders Yes 
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To integrate all of the factors described above, plus any other information that was consistent 
with a diagnosis of COPD, a global score was also used. The global score was from 0 to 4: ‘0’ 
indicated that no relevant information was provided, ‘1’ was not COPD, and ‘4’ was likely 
COPD (see Table 4.5). 
Table 4. 5 Global scoring system for items in classical works: Numerical scores and meanings 
Score 0 1 2 3 4 
Meaning of score 
No 
information 
Not COPD 
Possible 
COPD 
Possible 
complication of COPD 
Likely COPD 
 
4.1.1.6 Search procedure for identifying references in the ZHYD CD 
Each search term (i.e., Jiu ke, Jiu sou, Chuan zheng, Tanyin kesou, Ke chuan, Chuan sou, Fei 
zhang and Zhi yin) was searched for separately in the ZHYD using the headings search. For 
each search, one term was entered into the search field, ‘headings search’ was chosen, the 
number of hits was recorded and the ‘show results’ button was used to show a catalogue of the 
results in the left-side pane. When each item from the left pane was chosen, the catalogued 
content of the book section appeared in the right pane.  
When the reference included an herbal formula, all of the content in the right-hand pane for 
each item along with the formulae was copied into an Excel spreadsheet. Results that were 
simply a title, had content that was not related to formulae or were duplicated items were not 
copied. A content search was not used because the results found in trial content searches were 
too broad and consisted of a great deal of content that was irrelevant to the use of herbal 
formulae. For example, Ke sou located 839 items through ‘headings search’ and more than 
10,000 items using ‘content search’. Thus, it was impractical to use ‘content search’ for each 
of the search terms. 
4.1.2 Data entry into Excel spreadsheets 
The content of each item that was relevant to the oral administration of herbal formulae was 
copied to a single line in an Excel spreadsheet that had been set up for data extraction. Each 
spreadsheet included the following columns: search term; book; symptoms described; formula 
name; and formula ingredients and preparation. When the reference included more than one 
herbal formula, each was listed on a separate line in the spreadsheet so that each line 
contained one herbal formula associated with the search term. 
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Columns for the inclusion and exclusion criteria and global scores were also established as 
follows: key symptoms - dyspnoea in column 1 (C1), cough in C2, sputum in C3, chest 
tightness in C4 and haemoptysis in C7. Each of these was assessed using the COPD rating 
scales discussed above and these scores were entered in the spreadsheet. In addition, children 
and pregnant or post partum women were identified in C5 and acute conditions were 
identified in C6. The ‘global scores’ were coded in Excel in C8. Each formula and each herb 
was assigned a code number in Excel. 
4.1.3 Data entry into SPSS  
The Excel data were entered into SPSS (Version 19) as numerical values with each column in 
Excel becoming a variable in SPSS. Each herb in each formula comprised a single line of data, 
which was referred to as an ‘herb entry’ (HE). Each herb entry included the identity of the 
herb as a numerical code based on its Chinese name, the name of the formula and book from 
which it was derived, the search term used to locate the entry and the categorization scores 
(i.e. inclusion/exclusion criteria scores and global score). The HE formed the main unit of 
analysis because the ultimate aim was to locate individual herbs for further research. 
4.1.4 Data analysis with SPSS 
Any duplication due to repetition of the same formula for the same indications within the 
same book or repetition of the book under a different name or section in the ZHYD was 
identified. These were excluded from further analysis. Baseline data for the key variables 
were calculated after excluding duplicated citations. 
At the next stage, based on the exclusion criteria, formulae identified as unlikely to be COPD 
were excluded (e.g. disorders of children, acute conditions). Total frequencies of formulae and 
individual herbs were calculated. Frequencies were also calculated according to the four 
principal COPD symptoms. To conduct this analysis, these variables were recoded as 
dichotomous outcomes. The aim was to determine whether there were variations in the herbs 
used according to each symptom.  
Subsequently, the entries were grouped based on combinations of the four principal COPD 
symptoms; first in pairs, then in groups of three, and finally the citations that combined all 
four symptoms were identified. These were considered the groups most likely to have referred 
to conditions consistent with the modern concept of COPD. For these citations, formula and 
herb frequencies were calculated and individual citations were examined. 
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Independent of the hierarchical analysis and after excluding duplications, the citations were 
grouped based on the global rating scores. The aim here was to identify citations that were 
more or less likely to have referred to COPD based on the rater reading the item and 
allocating a value, rather than the step-wise procedure outlined above.  
Frequencies were calculated for herbs identified according to the sub-groups identified by the 
global rating procedure. The results were compared with those obtained using the hierarchical 
procedure. 
4.2 Methodology used for the systematic reviews (SRs) and analyses of 
clinical trials 
SRs were performed to identify randomized clinical trials (RCTs) that had used oral CHM 
formulae or extracts of single herbs to treat patients with stable COPD. The review methods 
included identifying studies for consideration, search methods, establishing criteria for the 
inclusion and exclusion of studies, assessments of risk of bias and methodological quality of 
the included studies, and data extraction and analyses of the outcomes and herbal treatments 
used. 
4.2.1 Criteria for considering studies 
The following selection criteria were established to identify the types of studies, patients’ 
characteristics, interventions and outcome measures (shown in Tablew 4.6). 
Table 4. 6 Summary of the study selection criteria 
 Inclusion criteria Exclusion criteria 
Study design Parallel RCT Not RCTs or Quasi-randomized trials 
Intervention 
Oral administration of CHM formulae or 
single herbs in any form 
 Inhalation, intravenous, injection, 
plaster or steaming 
 CHM used in combination with 
acupuncture or acupressure 
Patients 
 Older than 18 years of age 
 Either gender and any ethnic origin 
 Diagnosed with COPD in the stable 
stage 
 Younger than 18 years of age 
 COPD exacerbations 
 Other lung disease 
Outcome measures At least one outcome measure for COPD 
None of the defined outcome measures 
reported 
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4.2.1.1 Types of studies  
Randomized, parallel, controlled clinical trials were included regardless of whether or not 
they were blinded. Quasi-randomized trials and controlled clinical trials without 
randomization were excluded. 
4.2.1.2 Study subject characteristics 
Male and female patients, older than 18 years of age, of any ethnic origin, and who had a 
diagnosis of stable COPD were included. Stable COPD fulfilled any of the following 
diagnostic criteria: 1. Guidelines of the global strategy for the diagnosis, management and 
prevention of COPD by the Global initiative for COPD (GOLD) (9); 2. ATS and the 
European Respiratory Society (298); 3. COPD-X Plan issued by the Australian Lung 
Foundation and the Australian and New Zealand Thoracic Society (58); or 4. Guidelines for 
the diagnosis and management of COPD issued by the CSRD (91, 92).  
Patients were diagnosed as having stable COPD. Stable COPD was defined as no current 
infection, no disease exacerbation and no use of antibiotics prior to study entry. Patients in the 
severe stage of COPD, but without respiratory failure, pulmonary hypertension or cor 
pulmonale were also included. Patients with significant lung diseases other than COPD, such 
as a diagnosis of asthma, chronic bronchitis, cystic fibrosis, bronchiectasis, or respiratory 
failure, pulmonary hypertension and cor pulmonale were excluded. 
4.2.1.3 Types of interventions 
The interventions reviewed were all oral administrations of herbal medicines, including single 
herbs (or extracts of single herbs), multi-herb formulations, Chinese proprietary medicines or 
preparations involving decoctions, oral liquids, tablets, capsules, pills, granules or syrups. 
Any CHM administrations through inhalation, intravenous injection, plaster or steam-
inhalation were excluded.  
CHM intervention plus routine pharmacotherapy (RP) versus RP alone were included. In 
addition, CHM interventions alone compared to a control intervention involving placebo, no 
treatment, or other CHMwere also included. Studies that included co-interventions such as 
CHM formulae plus acupressure, acupuncture or Qigong compared to CHM formulae or 
acupressure or acupuncture or Qigong alone were excluded. 
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4.2.1.4 Types of outcome measures 
In these systematic reviews, studies that reported data for at least one of the outcome 
measures listed below at baseline and at the end of the treatment and/or follow-up period were 
included: Pulmonary function, Health-related quality of life, Frequencies of COPD 
exacerbations and hospitalizations, Symptom relief, BODE index, 6MWD, Body mass index, 
biomarkers and others as well as adverse events recorded.  
1. Pulmonary function 
Pulmonary function testing uses a spirometer that measures the volume and flow velocity of 
air that can be breathed into and out of the lung. A spirometer can be used to generate 
pneumotachographs that can be useful in the diagnosis of respiratory diseases such as asthma, 
COPD and pulmonary fibrosis. Spirometric parameters include the following:  
 FEV1, usually given as FEV1% predicted or Volume of FEV1 (L) (FEV1% predicted is 
the percentage of the ratio of FEV1 / predicted FEV1 that is calculated based on a 
subject’s age, sex, weight and height);  
 FVC, usually given as FVC% predicted or Volume of FVC (L); 
 Peak expiratory flow (PEF);  
 Maximum mid-expiratory flow (MMEF);  
 Maximum voluntary ventilation (MVV);  
 Maximum inspiratory pressure (MIP); and  
 Airway resistance (Raw). 
Respiratory muscle weakness is an important clinical problem among COPD sufferers and 
contributes to their developing mobility disability (299). Measurements of respiratory muscle 
strength are useful for examining the degree of respiratory muscle weakness and for 
evaluating the severity of mobility disability (300). Maximal inspiratory mouth pressure is 
one of the commonly used measurements of inspiratory and respiratory muscle strength (301). 
This measure reflects the pressure developed by the respiratory muscles plus the passive 
elastic recoil pressure of both the lung and chest wall, which is tested using a mouthpiece 
connected to a device as described by the ATS/ERS (American Thorax Society/ European 
Respiratory Society) statement on Respiratory muscle testing (302). 
2. Health-related quality of life 
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For those with COPD, there is a close relationship between FEV1 and their health HRQoL. 
Patients with lower FEV1 values have been shown to have worse HRQoL (303). Therefore, 
health status has been regarded to be a predictor of COPD severity and mortality (304).  
The SGRQ (see Appendix 5) is a standardized, self-administered questionnaire used to assess 
impaired health and perceived HRQoL among those with airways diseases including COPD 
(305, 306). It consists of 76 items that are categorized into the three domains of ‘symptoms’, 
‘activity’ and ‘impact’ and a ‘total score’. The ‘symptoms’ score assesses the patient’s 
perception of his/her most recent (within 4 weeks) respiratory problems. The ‘activity’ score 
assesses the patient’s current disturbances in performing daily physical activities. The ‘impact’ 
score evaluates the whole range of disturbances that the patient currently experiences in daily 
life due to respiratory problems. Finally, the ‘total’ score sums and weighs all of the other 
components. Scores can range from 0 (no impairment) to 100 (very severe impairment) for 
each component; higher scores indicate greater distress and, thus, a worse HRQoL.  
The QolQ is a modified SGRQ that was developed by Cai et al. based on specific conditions 
in China (307). It consists of 35 items that are divided into the following four domains: 
‘activities of daily living’; ‘social activities’; ‘depression’; and ‘anxiety’, as well as a total 
score. Each item is graded from 1 (high Qol) to 4 (low Qol). The calculation of the total score 
for the QolQ is different from that used for the SGRQ. The total score is the sum of each item 
score divided by the number of items.  
3. Reductions in exacerbations of COPD 
Exacerbation of COPD (ECOPD) is recognized as an important cause of COPD morbidity 
and mortality and hospital admissions. It has a strong effect on HRQoL(96). Therefore, 
preventing acute exacerbations is one of the management goals for stable COPD. Assessing 
reductions in ECOPD is determined using two methods: 1) the rate of ECOPD (ratio of the 
number of subjects with ECOPD attacks/number of subjects in the group during the episode); 
and 2) frequency of ECOPD (mean number of ECOPDs that occurred in each group).  
4. Symptom relief 
Assessments of the relief of symptoms were guided by the Guiding Principle of Clinical 
Research on New Drugs of Chinese Medicine (中药新药临床研究指导原则) published in 
2002 (308). Symptom relief was determined either as 1. the average of the total scores of 
symptoms including cough, sputum production, dyspnoea, etc., 2. the averages of the sub-
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scores for each symptom, or 3. the effectiveness rate (ratio of post-test total symptom scores 
minus the pre-test total symptom scores divided by the pre-test total symptom scores).  
Dyspnoea (shortness of breath) is the most common and disabling symptom for patients with 
COPD (309) and is regarded as a clinical indicator of COPD severity and survival (310). 
Dyspnoea was assessed by the Modified Medical Research Council (MMRC) Scale that 
consists of five levels of dyspnoea as in Appendix 6.   
The MRC Scale to assess dyspnoea ranges from 0 to 3: ‘0’ indicates not breathless and is 
equivalent to grades 0-1 on the MMRC; ‘1’ is MMRC grade 2; ‘2’ is MMRC grade 3; and ‘3’ 
is the worst condition and is equivalent to MMRC grade 4 (311).  
5. BODE index 
The BODE index is a grading system that includes four variables: ‘B’ is body mass index; ‘O’ 
is the degree of airflow obstruction, as determined by post-bronchodilator FEV1; ‘D’ is 
dyspnoea assessed by the MMRC dyspnoea scale; and ‘E’ is exercise capacity as assessed by 
the 6-minute walk test. BODE index scores range from 0 to 10, with a higher score indicating 
higher mortality. Thus, the BODE index is a tool for assessing disease severity and can predict 
COPD patients’ survival (312).  
6. 6MWD 
6MWD test measures the distance that a subject can quickly walk on a flat, hard surface in a 
period of 6 minutes, which is a better reflection of the level of functional exercise for daily 
physical activities (313). The 6MWD is also an important tool for assessing the respiratory 
function of patients with COPD (314) and is an even better predictor of COPD mortality and 
survival than is FEV1 (315). 
7. Body-mass index  
Nutritional status, weight loss and cachexia have important prognostic implications for COPD 
patients. The body mass index (BMI) has been used to assess COPD risk, particularly that 
associated with mortality during acute exacerbations of COPD (316).  
8. Arterial blood gas measurements 
Assessing blood gas status is important for both the diagnosis and management of patients 
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with chronic pulmonary diseases, particularly those with severe conditions (317); for example, 
COPD-related respiratory failure. Blood gas analysis includes a number of aspects, such as 
oxygenation and acid-base status within the body. These are discussed in more detail in 
section 4.5.12. The SR focused on analyses of partial pressure of oxygen (PaO2) and partial 
pressure of carbon dioxide (PaCO2). 
9. Biomarkers 
Systemic inflammation has been shown to be involved in the pathogenesis of COPD. 
Increased levels of systemic inflammatory markers are associated with declines in lung 
function, which may have important pathophysiological and therapeutic implications for 
subjects with stable COPD (318). T lymphocyte subgroups including CD3 T cells, CD4 T 
cells, CD8 T cells and CD4/CD8 ratios have been shown to be related to COPD disease 
activity. The numbers of CD4 T cells, CD3 T cells and the CD4/CD8 ratio in peripheral blood 
may decrease, whereas the numbers of CD8 T cells increase in patients with stable COPD 
(319, 320). Variations in the following biomarkers have been used in COPD research: 
inflammatory cytokines, lymphocyte subsets and immunoglobulin levels. In this review, 
inflammatory cytokines, such as IL-8, TNF-α and IL-2 were measured in sputum or serum, 
and lymphocyte subsets and immunoglobulins (Ig) (levels of serum of IgA, IgM and IgG) 
were measured in peripheral blood samples.  
10. Blood rheology index  
In patients with COPD, significant alterations in the peripheral circulation and a relationship 
between the magnitude of peripheral circulation alterations and the severity of COPD were 
found by Boussuges at el (321). A blood rheology index is a key measure of blood circulation 
within the human body. Its parameters include the Hct, haemoglobin concentration and the 
status of red blood cells (322). 
11. Outcome measures for nutrition 
Nutritional deficits are common in COPD patients. COPD patients also have increased energy 
and protein needs, so adequate energy and protein intake is essential for improving pulmonary 
function, maintaining the immune system, preventing weight loss and maintaining muscle 
mass and strength (323). In clinical trials, nutritional outcome measures include measures of 
albumin (ALB), prealbumin (PALB) and leptin.  
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Lung function, symptoms relief, exacerbations and QolQ were reported in SR 1 (chapter 6.1); 
QolQ was reported in SR 2 (chapter 6.2); and all of these outcomes are reported in SR 3 
(chapter 7). 
4.2.2 Search methods for identifying studies 
Search methods included identifying search terms and electronic database searches.  
4.2.2.1 Identifying search terms  
Search terms were identified through PubMed using medical subject headings (MeSH) 
relevant to COPD and from the Cochrane Airways Group Specialized Register of COPD trials. 
The terms were divided into the following three groups:  
1. Terms relevant to COPD, including ‘Pulmonary disease, chronic obstructive’, ‘Bronchitis, 
chronic’, ‘Emphysema’;  
2. Terms relevant to randomized clinical trials, such as ‘Clinical trials’, ‘Randomized 
controlled trials’, ‘Random allocation’, ‘Double-blind method’, ‘Single-blind method’, 
‘Placebo’; and;  
3. Terms relevant to Chinese herbal medicine, including ‘Complementary Therapies’, ‘Plants, 
Medicinal’, ‘Medicine, Chinese traditional’, ‘Medicine, traditional’, ‘Plant extracts’, 
‘Phytotherapy’, ‘Drugs, Chinese herbal’, ‘Drugs, Non-Prescription’, ‘Acupuncture’, and 
‘Massage’. 
4.2.2.2 Electronic database searches 
These searches followed the methods developed by the Cochrane Airways Group for use in 
reviews (324). The electronic databases that were searched included PubMed, CINAHL, 
CENTRAL (Cochrane Central Register of Controlled Trials) and the Chinese e-databases 
CNKI, CQVIP and Wanfang from their respective inceptions to April 2011, without language 
restrictions. The search terms used in PubMed and the search procedures are shown in 
Appendix 7.   
4.2.3 Assessments of risk of bias in included studies 
Assessments of risk of bias used the Cochrane risk of bias that consists of six domains: 
adequate sequence generation; allocation concealment; blinding of study-involved personnel; 
incomplete outcome data addressed; free of selective outcome reporting; and free of other bias 
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(Table 4.7).  
Table 4. 7 Cochrane Collaboration’s tool for assessing risk of bias 
Domain Description Judgment 
Sequence generation 
Describe the method used to generate the 
allocation sequence in sufficient detail. 
Was the allocation sequence adequately 
generated? 
Allocation 
concealment 
Describe all means used to conceal the 
allocation sequence in sufficient detail 
Was allocation adequately concealed? 
Blinding of 
participants, 
personnel and 
outcome assessors 
Describe all means used, if any, to blind 
participating personnel from knowledge of 
which intervention a subject received. 
Was knowledge of the allocated intervention 
adequately prevented during the study? 
Incomplete outcome 
data 
Describe the completeness of outcome data for 
each main outcome, including attrition and 
exclusions from analysis. 
Were incomplete outcome data adequately 
addressed? 
Selective outcome 
reporting 
State how the possibility of selective outcome 
reporting was examined by review authors and 
what was found. 
Are reports of the study free of any suggestion of 
selective outcome reporting? 
Other sources of bias 
State any important concerns regarding bias 
not addressed in the other domains in this tool. 
Was the study apparently free of other problems 
that could put it at a high risk of bias? 
Ref: Cochrane Handbook for Systematic Reviews of Interventions published in 2008 (325) 
A new version of the Cochrane handbook for SRsof interventions (5.1.0) was issued in March 
2011. Some of the domain names in part of C changed and the question mark was removed 
for each domain. The changes in the Cochrane risk of bias tool were the following (326): 
1) ‘Adequate sequence generation?’ was changed to ‘random sequence generation’;  
2) ‘Allocation concealment?’ was changed to ‘allocation concealment’; 
3) ‘Blinding?’ was changed to ‘Blinding of participants and personnel’ and ‘Blinding of 
outcome assessment’; 
4) ‘Incomplete outcome data addressed?’ was changed to ‘Incomplete outcome data’; 
5) ‘Free of selective outcome reporting?’ was changed to ‘Selective reporting’ 
6) ‘Free of other bias?’ was changed to ‘Other bias’ 
Bias categories were as follows: 1) selection bias involving random sequence generation and 
allocation concealment; 2) performance bias (blinding of participants and personnel); 3) 
detection bias (blinding of outcome assessment); 4) attrition bias (incomplete outcome data); 
5) reporting bias (selective reporting); and 6) other bias (focusing on baseline data 
comparability). 
Judgments were denoted simply as either ‘yes’, which meant adequate (i.e., low risk of bias), 
‘no’, which meant inadequate (i.e., high risk of bias) or ‘unclear’, which meant unclear or 
information was not provided (i.e., uncertain risk of bias) based on the Cochrane Handbook 
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for Systematic Reviews of Interventions, 2008 (325).  
Judgment of the risk of bias was guided by this handbook in the earlier two SRs (i.e., Oral 
Ginseng Formulae for Stable COPD and Oral CHM for Improving QoL with Stable COPD). 
Subsequently, for the 101 studies, the judgment for risk of bias of the included studies was 
guided by the updated version of the Cochrane Handbook for Systematic Reviews of 
Interventions published in 2011, which used the terms ‘low risk’ of bias, ‘high risk’ of bias or 
‘unclear risk’ of bias (326). 
4.2.4 Assessments of methodological quality of included studies 
The methodological quality of each study was assessed on a standardized 0-5 point scale that 
was developed and validated by Jadad et al (327). The scale includes the following questions. 
One point was given for a ‘Yes’ and 0 points was given for a ‘No’:  
1) Is the study randomized?  
2) Is the study double blinded?  
3) Is there a description of withdrawals?  
4) Is the method of randomization adequately described and appropriate? 
5) Is the blinding adequately carried out and appropriate?  
6) One point is deducted if the methods of randomization or blinding were inappropriate.  
When there was no description of withdrawals in a study, but the results indicated that the 
number of patients was the same at the beginning and the end of the study, the study was 
considered to have no withdrawals and was given one point. Any disagreement was resolved 
by discussion with one of the other two reviewers.  
4.2.5 Data collection and extraction 
4.2.5.1 Data collection 
Titles, abstracts and citations were reviewed by one reviewer to assess their potential 
relevance for full review. If there was any unclear information in the title or abstract, the full 
article was retrieved for further clarification. Full text articles were assessed by two reviewers 
for study selection. The procedure for determining studies for inclusion was presented as a 
flow diagram based on the template provided by Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) (328).  
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4.2.5.2 Data extraction 
Data were extracted from published, identified studies. Details of each study were extracted, 
including trial design, sample size, methodological quality, participants, severity of COPD, 
syndrome differentiation, intervention, outcome measures and adverse events, as well 
components of each herbal formula as recommended in elaborated CONSORT statement 
(329).  
4.2.5.3 Issues of missing data  
When data extracted from text, tables or figures were missing or not clear, the reviewer 
attempted to contact the authors to request additional information or clarification. 
4.2.5.4 Issues of duplicated trials 
When different outcome measures for the same RCT were reported in different articles and/or 
published in different journals, these were considered duplicated articles for the purpose of 
calculating the number of studies, although the data were combined as one study for the 
purpose of analysis. When different articles reported results at different stages of the same 
trial, for example preliminary results followed by final results, the articles were considered as 
duplicates and only the final results were used in the analysis. When there were articles that 
were considered duplicates by the review authors, for the purpose of referencing the RCT, the 
article that was published earliest was chosen. However, when there was an article in an 
English database plus an article in a Chinese database that reported on the same trial, the 
article in the English database was chosen as the reference.  
4.2.6 Data analysis  
4.2.6.1 Data analysis software and general methods 
Data analysis used RevMan 5.1 (83). Results for dichotomous variables were expressed as 
risk ratios (RR) with their corresponding 95% confidence intervals (CI). Results for 
continuous variables were expressed as mean differences (MD) with 95% CI. Heterogeneity 
was measured using the Z score and a Chi square statistic with significance set at P<0.01. 
Overall results were calculated by a fixed effects model or a random effects model based on 
the I
2
 value. If p>0.05 or I
2
<50%, this was taken as an indication that the same scale was 
being used for the outcome and a meta-analysis was undertaken using a fixed-effects model. 
If p≤0.05 or I2>50%, this was taken as an indication of different scales being used in the 
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outcomes and a random effects model was selected for meta-analysis.  
4.2.6.2 Subgroup analysis, sensitivity analyses and investigating heterogeneity 
Analyses were pooled across studies and subgroup analyses were performed for different 
comparisons, CHM versus placebo and CHM versus RP.  
When heterogeneity was substantially large (I
2
>50%), this indicated that there was a 
substantial level of inconsistency among the studies included in the comparison; thus, it was 
necessary to consider what factors influenced the heterogeneity in the meta-analysis (325). 
Therefore, a sensitivity analysis was performed.  
Specific data sensitivity analysis for the spirometric parameters was based on the length of the 
treatment period. This was stratified into < 3 months and > 3 months.  
4.2.6.3 Assessments of reporting bias 
There are some of types of reporting bias in meta-analyses, including publication bias, time 
lag bias, multiple publication bias, location bias, citation bias, language bias and outcome 
reporting bias (326). Funnel plots can be used to inspect for possible publication bias in a 
meta-analysis (330).  
Results of these SRs are separately reported in two chapters: Chapter 6, SR 1: Oral Ginseng 
Formulae for Stable COPD and SR2: Oral CHM Formulae for Improving QoL with stable 
COPD; and Chapter 7, SR3: Oral CHM Formulae for Specific Outcome Measures. 
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5 Chapter Five: Results of systematic analysis of the classical 
literature on Chinese herbal medicines for disorders analogous 
to COPD 
This part reports the results for each term searched in Zhong Hua Yi Dian using ‘headings 
search’ (Mu lu) and also reports the higher frequency herbs and formulae for each term and 
for combinations of symptoms consistent with the modern conception of COPD. 
5.1 Results for each search term 
5.1.1 Jiu Kesou (Long-term Cough) 
Jiu ke or Jiu sou (久嗽) means Long-term cough in Chinese medicine. For Jiu ke, 21 results 
were found in seven books as listed in Table 5.1. Five items that did not mention a formula, 
one item that was duplicated and one that referred to moxibustion (灸) were excluded. There 
were also three items with 17 formulae for hemoptysis, and twelve items with 68 formulae for 
long-term cough. 
The results for Jiu sou were as follows. A total of 39 items were found in twenty seven books 
(see Table 5.1). Three items that did not mention a formula, 6 items that were duplicated and 
one that was for an intervention with plaster applied to Acupoints were excluded. One 
reference involved hemoptysis for one formula, and two references were for children and 
included ten formulae.  
In total, Jiu ke appeared in seven books the earliest being the diagnostic manual Zhu Bing 
Yuan Hou Lun completed in 610 and the most recent being the Qing dynasty work Qi Xiao 
Jian Bian Liang Fang (1880). Jiu sou was found in books ranging from the Tang dynasty 
work Hua Tuo Shen Fang (c. 682) to Ling Lin Ling Fang (1893). Of the two terms, Jiu ke 
appears to be the earlier whereas Jiu sou became more commonly used from the Song dynasty 
onwards. 
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Table 5. 1 Search terms Jiu ke and Ke sou by the books in which entries were found 
Search term Book name Chinese name Year Freq 
Jiu ke 
Hua Tuo Shen Fang 华佗神方 c. 682 2 
Tai Ping Sheng Hui Fang 太平圣惠方 c. 992 3 
Qi Fang Lei Bian 奇方类编 1719 2 
Yan Fang Xin Bian 验方新编 1846 1 
Qi Xiao Jian Bian Liang Fang 奇效简便良方 1880 2 
Zhu Bing Yuan Hou Lun 诸病源侯论 610 5 
Wai Tai Mi Yao 外台秘要 752 6 
Jiu sou 
Hua Tuo Shen Fang 华佗神方 c. 682 1 
Sheng Ji Zong lu 圣济总录 c. 1117 1 
Ji Feng Pu Ji Fang 鸡峰普济方 1133 1 
Pu Ji Fang 普济方 c. 1406 1 
Cheng Fang Qie Yong 成方切用 1761 1 
Bu Zhi Yi Bi Yao 不知医必要 1880 1 
Yi Fang Ji Jie 医方集解 1682 1 
Yi Fang Lun 医方论 1865 1 
Da Xiao Zhu Zheng Fang Lun 大小诸证方论 1673 3 
Qi Fang Lei Bian 奇方类编 1719 2 
Yan Fang Xin Bian 验方新编 1846 2 
Qi Xiao Jian Bian Liang Fang 奇效简便良方 1880 2 
Hui Zhi Tang Jing Yan Fang 惠直堂经验方 1734 2 
Wai Zhi Shou Shi Fang 外治寿世方 1877 1 
Ling Lin Ling Fang 凌临灵方 1893 2 
Fu Qing Zhu Nan Ke Chong Bian Kao 
Shi 
傅青主男科重编考
释 
1863 3 
Yi Xue Gang Mu 医学纲目 1565 1 
Chi Shui Xuan Zhu 赤水玄珠 1584 1 
Ji Yang Gang Mu 济阳纲目 1626 1 
Tang Huo Dian Xue 痰火点雪 1630 1 
Fu Ke Xin Fa Yao Jue 妇科心法要决 1742 2 
Tong Yuan Yi Shu 彤园医书 1795 1 
You You Xin Shu 幼幼新书 1150 1 
You Ke Zheng Zhi Zhun Sheng 幼科证治准绳 1607 2 
Yi Quan Chu Bian 医权出编 1721 2 
Yi Shuo 医说 1224 1 
Shou Shang Bi Ji 寿山笔记 1814 1 
Freq: frequency 
5.1.2 Ke chuan (Cough and dyspnea) 
For Ke chuan (cough and dyspnea) (咳喘), 13 items were found in eleven books ranging from 
Ji Yan Fang (1170) to Liu Xuan Si Jia Yi An (1900) as listed in Table 5.2. Ke chuan was 
commonly used in the Qing dynasty. Three items were excluded including one without a 
formula and one involving acupuncture treatment, and one being duplicated. Four items were 
for children and included twenty-six formulae.  
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Table 5. 2 Search term Ke chuan by the books in which entries were found 
Search Term Book name Chinese name Year Freq 
Ke chuan 
Yan Shi Ji Sheng Fang 严氏济生方 1253 1 
Qi Fang Lei Bian 奇方类编 1719 1 
Ji Yan Fang 集验方 1170 1 
Lei Jing Tu Yi 类经图翼 1624 1 
Shang Han Guang Yao 伤寒广要 1825 1 
Zhang Shi Yi Tong 张氏医通 1695 1 
Bao You Xin Bian 保幼新编 1644 1 
Sheng Min Qie Yao 生民切要 1664 1 
Jing Xiang Lou Yi An 静香楼医案 1729 2 
Ji Zhi Tang Yi An  
(Liu Xuan Si Jia Yi An) 
继志堂医案 
(柳选四家医案) 
1900 1 
Huai Xi Cao Tang Yi An  
(Liu Xuan Si Jia Yi An) 
怀溪草堂医案 
(柳选四家医案) 
1900 1 
Yi De Ji 一得集 1890 1 
 
5.1.3 Chuan zheng (Dyspnea) 
For Chuan zheng (喘证), 20 items were found in sixteen books as shown in Table 5.3. and 
most were from the Qing Dynasty. Six items did not mention a formula or the term was only 
used in a title, one item was for children with asthma involving fourteen formulae, and one 
was for post partum with one formula. 
Table 5. 3 Search term Chuanzheng by the books in which entries were found 
Search Term Book name Chinese name Year  Freq 
Chuan zheng 
Quan Sheng Zhi Mi Fang 全生指迷方 1119 1 
Shang Han Xuan Jie 伤寒悬解 1748 1 
Gu Jin Yi Tong Da Quan 古今医统大全 1556 1 
Ming Yi Zhi Zhang 明医指掌 1622 1 
Jian Ming Yi Gou 简明医彀 1629 1 
Yi Xue Zhong Zhong Can Xi Lu 医学衷中参西录 1918 1 
Jing Yue Quan Shu 景岳全书 1624 2 
Cang Sheng Si Ming 苍生司命 1515 1 
Yi Fa Yuan Tong 医法圆通 1874 1 
Jing Yue Quan Shu Fa Hui 景岳全书发挥 1844 2 
Ji Shi Quan Shu 济世全书 1616 1 
Fu Ke Xin Fa Yao Jue 妇科心法要诀 1742 1 
Er Ke Cui Jing 儿科萃精 1930 1 
You You Ji Cheng 幼幼集成 1750 1 
You Ke Zhi Nan 幼科指南 1933 1 
You Ke Xin Fa Yao Jue 幼科心法要诀 1742 2 
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5.1.4 Chuan sou (Dyspnea and sputum) 
For Chuan sou (喘嗽), dyspnea with sputum, 46 items were found in thirty-four books, with 
the earliest being the treatment manual Hua Tuo Shen Fang (华佗神方) of the Tang dynasty 
(c. 682) and the latest being written at the end of the Qing dynasty Yi Xue Zhong Zhong Can 
Xi Lu (医学衷中参西录) (published 1918) as listed in Table 5.4. Chuan sou was frequently 
used in the Qing dynasty. In this case, 14 items did not mention a formula, two were for other 
interventions (one for acupuncture and one for an inhalation), two were for lung TB (Fei lao), 
one was for food, one was a duplicated item, five items involved children with 20 formulae, 
four were for acute conditions with four formulae, one was for pregnancy (3 formulae) and 
one was for post partum (2 formulae). 
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Table 5. 4 Search term Chuan sou by the books in which entries were found 
Search Term Book name Chinese name Year  Freq 
 
Chuan sou 
 
 
Sun Zhen Ren Hai Shang Fang 孙真人海上方 c. 907 1 
Hua Tuo Shen Fang 华佗神方 c. 682 3 
Sheng Ji Zong Lu 圣济总录 c. 1117 1 
Ren Zhai Zhi Zhi Fang Lun 仁斋直指方论 1264 3 
Rui Zhu Tang Jing Yan Fang 瑞竹堂经验方 1326 1 
Shi Yi De Xiao Fang 世医得效方 c. 1345 1 
Pu Ji Fang 普济方 c. 1406 4 
Da Xiao Zhu Zheng Fang Lun  大小诸证方论 1673 1 
Ji Xiao Jian Bian Liang Fang 奇效简便良方 1880 1 
Hui Chun Ji 回生集 1789 1 
Zhen Jiu Zi Sheng Jing 针灸资生经 1220 1 
Shang Han Biao Ben Xin Fa Lei Cui 伤寒标本心法类萃 1186 1 
Yi Zhen Yi De 疫疹一得 1794 1 
Mai Zheng Zhi Fang 脉症治方 1564 1 
Fu Qing Zhu Nan Ke Chong Bian Kao Shi 傅青主男科重编考释 1863 1 
Fang Zheng Hui Yao 方症会要 1756 1 
Dan Xi Zhi Fa Xin Yao 丹溪治法心要 1543 1 
Gu Jin Yi Tong Da Quan 古今医统大全 1556 1 
Xuan Qi Jiu Zheng Lun 轩歧救正论 1644 1 
Ru Men Shi Qin 儒门事亲 1228 1 
Yi Xue Zhong Zhong Can Xi Lu 医学衷中参西录 1918 3 
Jing Yue Quan Shu 景岳全书 1624 2 
Fu Ren Gui 妇人归 1624 1 
Guang Si Ji Yao 广嗣纪要 1549 1 
You Ke Fa Hui 幼科发挥 1549 1 
Qian Shi Xiao Er Zhi Jue 钱氏小儿直诀 1119 1 
Zhuan Zhi Ma Sha Chu Bian 专治麻痧初编 1891 1 
Yang Lao Feng Qin Shu 养老奉亲书 1085 1 
Shou Qin Yang Lao Shu 寿亲养老书 1307 1 
Ji Jiu Guang Sheng Ji 急救广生集 1803 1 
Sun Wen Heng Yi An 孙文垣医案 1573 3 
Wang Meng Ying Yi An 王孟英医案 1850 1 
Xu Yi Shuo 续医说 1522 1 
Yi Shou 医说 1224 1 
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5.1.5 Zhi yin (Thoracic fluid retention)  
For Zhi yin (支饮), eight items were found in eight books ranging from the late Tang dynasty 
to the Qing dynasty as shown in Table 5.5. One item had no hits on a formula and was 
excluded.  
Table 5. 5 Search term Zhi yin by the books in which entries were found 
Search 
Term 
Book name Chinese name Year Freq 
Zhi yin 
Tai Ping Sheng Hui Fang 太平圣惠方 c. 992 1 
Sheng Ji Zong Lu 圣济总录 c. 1117 1 
Shi Yi De Xiao Fang 世医得效方 c. 1345 1 
Pu Ji Fang 普济方 c. 1406 1 
Zhu Bing Yuan Hou Lun 诸病源侯论 610 1 
Zheng Yin Mai Zhi 症因脉治 1641 1 
Yi Chun Sheng Yi 医醇剩义 1863 1 
Wai Tai Mi Yao 外台秘要 752 1 
 
5.1.6 Fei zhang (lung distension)  
For Fei zhang (肺胀), lung distension, 13 items were found in twelve books as shown in Table 
5.6. Of these three appeared in the Tang or Song dynasties, and the remaining citations 
appeared in the Qing dynasty. In this case, two items did not mention a formula or were only 
found in a title, and one was for children with 2 formulae. Fourteen actually referred to Fei 
wei (肺痿) which was a type of chronic lung disease caused by heat deficiency, so these were 
consequently excluded. 
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Table 5. 6 Search term Fei zhang by the books in which entries were found 
Search Term Book name Chinese name Year  Freq 
Fei zhang 
Hua Tuo Shen Fang 华佗神方 c. 682 1 
Sheng Ji Zong Lu 圣济总录 c. 1117 1 
Pu Ji Fang 普济方 c. 1406 1 
Zheng Yin Mai Zhi 症因脉治 1641 1 
Zhang Shi Yi Tong 张氏医通 1695 1 
Za Bing Yuan Liu Xi Zhu 杂病源流犀烛 1773 2 
Yi Zong Shuo Yue 医宗说约 1663 1 
Lan Tai Gui Fan 兰台轨范 1764 1 
Chi Shui Xuan Zhu 赤水玄珠 1584 1 
Wai Tai Mi Yao 外台秘要 752 1 
Zheng Zhi Zhun Sheng 证治准绳 1602 1 
Ji Yang Gang Mu 济阳纲目 1626 1 
 
5.1.7 Tanyin kesou (phlegm-fluid with cough) 
For Tanyin kesou (痰饮咳嗽), phlegm-fluid with cough, 25 items were found in fourteen 
books, see Table 5.7. All of the books appeared in the Qing dynasty except for three that were 
from the Song dynasty. Nine items that were duplicated and two items that had no hits on 
formulae were excluded. The final formulae were mainly from three books Tai Ping Hui Min 
He Ji Ju Fang (太平惠民和剂局), Ye Shi Lu Yan Fang (叶氏录验方) and Zheng Zhi Zhai Yao 
(证治摘要).  
Table 5. 7 Search term Tanyin kesou by the books in which entries were found 
Search Term Book name Chinese name Year Freq 
Tanyin  
kesou 
Tai Ping Hui Min He Ji Ju Fang 太平惠民和剂局方 1078 1 
Jin Gui Fang Ge Kuo 金匮方歌括 1811 1 
Ye Shi Lu Yan Fang 叶氏录验方 1186 1 
Gao Zhu Jin Gui Yao Lue 高注金匮要略 1872 1 
Jin Gui Yu Han Yao Lue Ji Yi 金匮玉涵要略辑义 1806 1 
Jin Gui Yu Han Jing Er Zhu 金匮玉涵经二注 1687 1 
Jin Gui Yu Han Yao Lue Shu Yi 金匮玉涵要略述义 1810 1 
Ding Zheng Zhong Jing Quan Shu 订正仲景全书 1743 3 
Jin Gui Yao Lue Xin Dian 金匮要略心典 1729 1 
Jin Gui Yao Lue Qian Zhu 金匮要略浅注 1803 1 
Jin Gui Yao Lue Guang Zhu 金匮要略广注 1682 1 
Jin Gui Xuan Jie 金匮悬解 1756 10 
Jin Gui Yao Lue Fang Lun 金匮要略方论 1065 1 
Zheng Zhi Zhai Yao 证治摘要 1862 1 
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5.1.8 Overall numbers of hits from each search term  
The overall numbers of hits found when searching each term in ZHYD and the details of the 
excluded hits by sub-type are summarized in Table 5.8. 
Table 5. 8 Summary results for each search term with exclusions 
Terms 
Number 
of hits 
Non 
formulae 
Duplicati
on 
Other intervention Other condition 
Jiu ke (久咳) 21 5 1 1 Hemoptysis (n=3)  
Jiu sou 
(久嗽) 
39 3 6 
Acupoint plaster (膏
贴)(n=1) 
Steam (n=2) 
Hemoptysis (n=1) 
Children (n=3) 
Chuan zheng 
(喘证) 
20 6 NS NS 
Children (n=3) 
Asthma (n=1) 
Post partum (n=1) 
Feizhang 
肺胀 
13 2 NS NS 
Children (n=2) 
Fei wei (n=14) 
Chuan sou 
(喘嗽) 
46 14 1 
Acupuncture (n=1) 
Inhalation (n=1) 
Food (n=1) 
Children (n=5) 
Acute (n=1) 
Pregnant (n=1) 
Post partum (n=1) 
Asthma (n=1) 
Insomnia (n=1) 
Ke chuan 
(咳喘) 
13 0 1 acupuncture (n=1) Children (n=4) 
Tanyin kesou 
(痰饮咳嗽) 
25 2 9 NS NS 
Zhi yin (支饮) 8 1 NS NS NS 
 
5.2 Database characteristics 
The full data set contained 1,052 formulae comprised of 6,916 herbs. Two books appeared 
twice in ZHYD. These were Ling Lin Ling Fang (凌临灵方) which appeared in both sections 
4 and 11, the other was You Ke Zheng Zhi Zhun Sheng (幼科证治准) which is the same book 
as Zheng Zhi Zhun Sheng (证治准绳): You ke, which are both in section 9. These resulted in 
53 duplicated herb entries which were subsequently excluded. Also a further 283 herb entries 
were excluded since they were components of formulae that appeared more than once in the 
same book. Therefore, a total of 335 herb entries were excluded leaving 6,581 herb entries 
derived from 1,006 formulae in the data set.  
The most productive search term was Jiu sou which located 221 formulae resulting in 1,325 
herb entries which comprised 20.1% of the data set. This was closely followed by Chuan sou 
which located 19.8% of the HEs in the set of included data (see Table 5.9). 
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Table 5. 9 Frequencies of formulae and herb entries by search term 
Term 
Frequency of 
formulae 
Frequency of HEs Percent HEs 
1. Fei zhang 57 389 5.9 
2. Jiu ke 74 448 6.8 
3. Jiu sou 221 1325 20.1 
4. Ke chuan 115 959 14.6 
5. Chuan sou 196 1300 19.8 
6. Zhi yin 69 315 4.8 
7. Tanyin kesou 132 806 12.2 
8. Chuan zheng 142 1039 15.8 
Total 1006 6581 100.0 
 
The search term Fei zhang did not co-occur with any of the other 7 search terms, nor was 
there any overlap between the other search terms. Therefore each formula entry was intended 
to treat only one of the search terms although it may also have been intended for other 
disorders or symptoms not included in the list of 8 terms. 
The 6,581 herbal entries were derived from 69 different books written between c. 583 and c. 
1934. The most frequently cited books were the multi-volume formulary Pu Ji Fang (c. 1406) 
which provided 21.4% of the herbal entries, followed by Liu Xuan Si Jia Yi An with 10.2% of 
entries. The ten most frequently cited books are listed in Table 5.10. 
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Table 5. 10 Ten most frequently cited books in total data set 
Book code & name Year 
Frequency of 
formulae 
Frequency of 
HEs 
Percent  
of HEs 
267 Pu Ji Fang  
普济方 
c.1406 230 1406 21.4 
859 Liu Xuan Si Jia Yi An  
柳选四家医案 
c.1900 73 673 10.2 
170 Tai Ping Hui Min He Ji Ju Fang  
太平惠民和剂局方 
1078 51 365 5.5 
506 Ji Yang Gang Mu  
济阳纲目 
1626 47 274 4.2 
560 Wai Tai Mi Yao  
外台秘要 
752 51 261 4.0 
166 Tai Ping Sheng Hui Fang 
太平圣惠方 
772 34 245 3.7 
543 Jing Yue Quan Shu 
景岳全书 
1624 40 239 3.6 
171 Sheng ji zong lu 
圣济总录 
1117 39 236 3.6 
473 Zhang Shi Yi Tong  
张氏医通 
1695 24 194 2.9 
507 Zheng Zhi Zhai Yao  
证治摘要 
1862 33 191 2.9 
Total  1006 6581 100.0 
c.: circa; HE: individual herb entry 
Of the 1,006 formulae, 206 were not named. The two most common named formulae were 
Xiao Qing Long Tang which appeared 10 times followed by Xiao Ban Xia Tang which 
appeared 9 times. Ma Huang Gan Cao Jia Xing Ren Sheng Jiang Tang and Yue Bi Jia Ban Xia 
Tang Fang both appeared 7 times. The most frequently cited formulae are listed in Table 5.11. 
There was a considerable diversity of formulae with 464 of the named formulae only being 
cited once and the unnamed formulae also varied in their ingredients. On average, the 
formulae contained 6.5 herbs but some only included one or two herbs, whereas others 
contained ten or more. 
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Table 5. 5 Most frequent formulae in total data set 
Formula code & name Frequency 
Unnamed 205 
61 Xiao Qing Long Tang 10 
59 Xiao Ban Xia Tang 9 
162 Ma Huang Gan Cao Jia Xing Ren Sheng Jiang Tang 7 
3 Yue Bi Jia Ban Xia Tang Fang 7 
5 Xiao Qing Long Jia Shi Gao Tang 6 
57 Xiao Ban Xia Jia Fu Ling Tang 6 
54 Mu Fang Ji Tang 5 
63 Wu Ling San 5 
144 Zao Jiao Jian Wan 5 
319 Wu Hu Tang 5 
Total 1006 
 
5.3 Results for symptoms typical of COPD 
5.3.1 Cough 
Each of the formula entries was scored according to the symptoms of relevance to a diagnosis 
of COPD as follows: cough, dyspnoea, sputum production and chest tightness.  
The most commonly mentioned of the four symptoms was cough (in 70.0% of herbal entries). 
This was not surprising since five of the search terms contained a word for cough. In 398 
formulae, the nature of the cough was not specified but in 303 formulae (27.2% of herbal 
entries) there was the more specific mention of chronic or long-term cough (see Table 5.12).  
Table 5. 6 Frequency of mention of cough in total data set 
Description Frequency of formulae Frequency HEs Percent HEs 
No mention 305 1977 30.0 
Mention of cough 398 2817 42.8 
Chronic/long term cough 303 1787 27.2 
Total 1006 6581 100.0 
HE: individual herb entry 
Cough was mentioned frequently across all eight search terms but did not always occur in 
entries located using search terms that contained a term for ‘cough’ (see Table 5.13). For 
example, 49.1% of the herbal entries located using the term tanyin kesou have no score for 
cough. This is because, not all formulae indexed in the books under this term were 
individually specified for cough. Tan yin is a disease name whereas tanyin kesou is one of the 
syndromes of tanyin. In addition, tanyin is also the pathogenesis of many kinds of diseases. 
Therefore, under this search term some of the symptoms caused by Tan yin, other than cough, 
were included. Cough was most infrequent in citations located by the search term Chuan 
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zheng with 85% of herbal entries having no mention. Chuan zheng is an independent 
syndrome characterised by dyspnea and caused by dysfunction of lung or spleen or kidney. 
Cough and Chuanzheng may present together or separately.  
Table 5. 7 Frequency of mention of cough by search term 
Description 
Fei 
zhang 
Jiu ke Jiu sou 
Ke 
chuan 
Chuan 
sou 
Zhi yin 
Tanyin 
kesou 
Chuan 
zheng 
No mention 
97 
(24.9%) 
0 
20 
(1.5%) 
250 
(26.1%) 
210 
(16.2%) 
121 
(38.4%) 
396 
(49.1%) 
883 
(85.0%) 
Mention of 
cough 
274 
(70.4%) 
26 
(5.8%) 
202 
(15.2%) 
636 
(66.3%) 
971 
(74.7%) 
194 
(61.6%) 
360 
(44.7%) 
154 
(14.8%) 
Chronic/long 
term cough 
18 
(4.6%) 
422 
(94.2%) 
1103 
(83.2%) 
73 
(7.6%) 
119 
(9.2%) 
0 
50 
(6.2%) 
2 (0.2%) 
Total 389 448 1325 959 1300 315 806 1039 
 
These results demonstrate the importance of scoring the entries in terms of the symptoms 
mentioned, rather than only on the basis of the search term that located the entry in ZHYD. 
5.3.2 Dyspnoea 
Dyspnoea was a component of three search terms and was the second most frequently 
mentioned symptom, appearing in 559 formulae and 59.1% of herbal entries. The more 
specific descriptions of ‘dyspnoea that is worse with exercise’ and ‘severe dyspnoea’ were 
infrequent at 2.1% and 3.3% of herbal entries respectively (see Table 5.14). 
Table 5. 8 Frequency of mention of dyspnoea in total data set 
Description Frequency of formulae Frequency HEs Percent HEs 
No mention 447 2694 40.9 
Mention of dyspnoea 502 3531 53.7 
Dyspnoea that is worse with exercise 27 138 2.1 
Severe dyspnoea 30 218 3.3 
Total 1006 6581 100.0 
HE: individual herb entry 
Dyspnoea was a frequent symptom in citations located by all eight search terms but was least 
common under Jiu sou (no mention in 73.8% of herbal entries) and Tanyin kesou (no mention 
in 64.9%). As could be expected, there were few no mentions under Chuan zheng but the 
51.8% of no mentions under Ke chuan was unexpected (see Table 5.15).  
Both cough and dyspnoea are independent diseases so they were not expected to frequently 
co-occur. Under the term Jiusou, dyspnoea can be an associated symptom. In the case of Ke 
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chuan, it belongs in the category of Ke sou, so the focus is on Ke sou and this term is not 
specific for dyspnoea. Tanyin chuanji was also found under the term Tan yin but only in a few 
cases, so it was not included as a search term. The few mentions of dyspnoea under the term 
Tanyin kesou were not surprising. 
Table 5. 9 Frequency of mention of dyspnoea by search term 
Description 
Fei 
zhang 
Jiu ke Jiu sou 
Ke 
chuan 
Chuan 
sou 
Zhi yin 
Tan yin 
ke sou 
Chuan 
zheng 
No mention 
109 
(28.0%) 
225 
(50.2%) 
978 
(73.8%) 
497 
(51.8%) 
202 
(15.5%) 
93 
(29.5%) 
515 
(63.9%) 
75 
(7.2%) 
Mention of 
dyspnoea 
218 
(56.0%) 
198 
(44.2%) 
294 
(22.2%) 
436 
(45.5%) 
1028 
(79.1%) 
201 
(63.8%) 
271 
(33.6%) 
885 
(85.2%) 
Dyspnoea that 
is worse with 
exercise 
0 0 
10 
(0.8%) 
15 
(1.6%) 
54 
(4.2%) 
21 
(6.7%) 
20 
(2.5%) 
18 
(1.7%) 
Severe 
dyspnoea 
62 
(15.9%) 
25 
(5.6%) 
43 
(3.2%) 
11 
(1.1%) 
16 
(1.2%) 
0 0 
61 
(5.9%) 
Total 389 448 1325 959 1300 315 806 1039 
 
5.3.3 Sputum production 
Sputum production was a component of two search terms and was mentioned in 155 formulae 
and 18% of Herbal entries, but in only 8 formulae and 1% of Herbal entries was chronic 
sputum production mentioned (see Table 5.16). 
Table 5. 10 Frequency of mention of sputum production in total data set 
Description Frequency of formulae Frequency HEs Percent HEs 
No mention 854 5400 82.1 
Mention of sputum production 147 1116 17.0 
Chronic sputum production 8 65 1.0 
Total 1006 6581 100.0 
HE: individual herb entry 
 
Although it was expected that sputum production would have been most commonly a feature 
of citations located by the search term Tanyin kesou, only 24.5% of Herbal entries received a 
score (see Table 5.17). This was still the second most productive search term in terms of this 
symptom, but it was less frequent than Fei zhang with 29.8% of Herbal entries receiving a 
score. 
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Table 5. 11 Frequency of mention of sputum production by search term 
Description 
Fei 
zhang 
Jiu ke Jiu sou 
Ke 
chuan 
Chuan 
sou 
Zhi yin 
Tanyin 
kesou 
Chuan 
zheng 
No mention 
273 
(70.2%) 
390 
(87.1%) 
1090 
(82.3%) 
767 
(80.0%) 
1055 
(81.2%) 
310 
(98.4%) 
608 
(75.4%) 
907 
(87.3%) 
Mention of 
sputum 
production 
98 
(25.2%) 
58 
(12.9%) 
193 
(14.6%) 
192 
(20.0%) 
245 
(18.8%) 
5 (1.6%) 
193 
(23.9%) 
132 
(12.7%) 
Chronic 
sputum 
production 
18 
(4.6 %) 
0 
42 
(3.2%) 
0 0 0 5 (0.6%) 0 
Total 389 448 1325 959 1300 315 806 1039 
 
As mentioned above, Tanyin kesou is under the category Tan yin. Tan yin can refer to a 
pathogenesis involving Tan yin which does not necessarily involve sputum as a symptom. 
5.3.4 Chest tightness 
The least frequent of the four symptoms was chest tightness which occurred in only 129 
formulae and 13.3% of Herbal entries (see Table 5.18). 
Table 5. 12 Frequency of mention of chest tightness in total data set 
Description Frequency of formulae Frequency HEs Percent HEs 
No mention 877 5707 86.7 
Mention of chest tightness 129 874 13.3 
Total 1006 6581 100.0 
HE: individual herb entry 
Chest tightness was most frequently mentioned in citations located under Zhi yin (58.4% of 
Herbal entries) and Fei zhang (55.0% of Herbal entries). It was relatively infrequent under the 
other search terms but some citations located by each term did receive scores (see Table 5.19).   
Table 5. 13 Frequency of mention chest tightness by search term 
Description 
Fei 
zhang 
Jiu ke Jiu sou 
Ke 
chuan 
Chuan 
sou 
Zhi yin 
Tanyin 
Kesou 
Chuan 
zheng 
No mention 
175 
(45.0%) 
390 
(87.1%) 
1276 
(96.3%) 
918 
(95.7%) 
1180 
(90.8%) 
131 
(41.6%) 
636 
(78.9%) 
1001 
(96.3%) 
Mention of 
chest 
tightness 
214 
(55.0%) 
58 
(12.9%) 
49 
(3.7%) 
41 
(4.3%) 
120 
(9.2%) 
184 
(58.4%) 
170 
(21.1%) 
38 (3.7%) 
Total 389 448 1325 959 1300 315 806 1039 
 
Overall, each of the eight search terms was productive in terms of locating formula citations 
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which were used to treat each of the primary symptoms of COPD. However, the co-
occurrence of symptoms was somewhat less common than had been expected based on the the 
disease and syndrome names used as search terms. 
5.4 Symptoms, signs and disorders not typical of COPD 
Citations were scored based on three criteria that were atypical of COPD in order to facilitate 
the elimination of formulae unlikely to have been used for COPD.  
5.4.1 Children & specific disorders of women 
For 89 of the formulae located by the 8 search terms, the application was for children, so these 
were not possible cases of COPD. Similarly, 14 formulae were specifically indicated for 
disorders of women in pregnancy or post partum (see Table 5.20). 
Table 5. 20 Frequency of mention of disorders specifically of children or women in total data set 
Description Frequency of formulae Frequency HEs Percent HEs 
No mention 903 5887 89.5 
Children 89 598 9.1 
Women (pregnacy, post-
partum) 
14 96 1.5 
Total 1,006 6,581 100.0 
HE: individual herb entry 
5.4.2 Acute disorders 
Since COPD is a chronic disorder, formulae intended for acute disorders needed to be 
excluded. In 935 (93.1%) citations there was no information specifying that the disorder was 
acute or chronic but 14 citations (1.5% of Herbal entries) were specifically for acute disorders 
and were therefore excluded (see Table 5.21). 
Table 5. 14 Frequency of mention of acute disorders or other disorders unlike COPD in total data set 
Description Frequency of formulae Frequency HEs Percent HEs 
No mention 935 6130 93.1 
No, chronic disorder 57 351 5.3 
Yes, acute disorder 14 100 1.5 
Total 1,006 6,581 100.0 
HE: individual herb entry 
5.4.3 Haemoptysis 
Haemoptysis is a complication of cough that is uncommon in COPD, so formula citations 
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intended for treating haemoptysis were identified and excluded in the latter stages of the 
analysis. There were 40 such citations which accounted for 5.3% of Herbal entries (see Table 
5.22).  
Table 5. 15 Frequency of mention of haemoptysis in total data set 
Description Frequency of formulae Frequency HEs Percent HEs 
No mention 966 6232 94.7 
yes 40 349 5.3 
Total 1,006 6,581 100.0 
 
5.5 Results for formulae and herbs 
5.5.1 Formulae 
After the exclusion of disorders specific to children and women, acute disorders and disorders 
that were unlike COPD, the frequency of unnamed formulae declined from 205 to 187. 
However, the exclusions had little effect on the identity of the higher frequency formulae with 
Xiao Qing Long Tang remaining the most common named formula with its frequency 
unchanged at 10, followed by Xiao Ban Xia Tang (see Table 5.23). 
Table 5. 16 Ten most frequent formulae in total data set following general exclusions* 
Formula code & name Frequency 
Unnamed 187 
61 Xiao Qing Long Tang 10 
59 Xiao Ban Xia Tang 9 
3 Yue Bi Jia Ban Xia Tang Fang 7 
5 Xiao Qing Long Jia Shi Gao Tang 6 
57 Xiao Ban Xia Jia Fu Ling Tang 6 
54 Mu Fang Ji Tang 5 
63 Wu Ling San 5 
144 Zao Jiao Jian Wan 5 
162 Ma Huang Gan Cao Jia Xing Ren 
Sheng Jiang Tang 
5 
Total 898 
*disorders specifically of children or women, acute disorders and other disorders unlike COPD 
 
5.5.2 Herbs 
The most frequent of the 5,858 herbs remaining after the exclusions was Gan cao with a total 
frequency of occurrence of 372 in the 898 formulae. However, Gan cao is present in many 
formulae due to its functional role of harmonizing the combined actions of the herbs, so its 
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presence may have little to do with any specific benefit in COPD (see Table 5.24).  
Table 5. 17 Twenty most frequently occurring herbs in the 898 formulae in the data set following general 
exclusions* 
Rank Herb name Frequency Percent 
1 Gan cao 372 6.4 
2 Ban xia 266 4.5 
3 Xing ren 249 4.3 
4 Ren shen 217 3.7 
5 Fu ling 209 3.6 
6 Wu wei zi 181 3.1 
7 Chen pi 170 2.9 
8 Sang gen bai pi 142 2.4 
9 Sheng jiang 127 2.2 
10 Kuan dong hua 124 2.1 
11 Ma huang 117 2.0 
12 Zi wan 114 1.9 
13 Rou gui 113 1.9 
14 Bei mu 102 1.7 
15 Jie geng 99 1.7 
16 Gan jiang 92 1.6 
17 Mai men dong 87 1.5 
18 Zhi shi 87 1.5 
19 Bai zhu 82 1.4 
20 Da zao 78 1.3 
 Total 5,858 100.0 
*disorders specifically of children or women, acute disorders and other disorders unlike COPD 
The frequency of occurrence of individual herbs was calculated according to the four main 
symptoms (see Table 5.25).  
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Table 5. 18 Most frequently occurring herbs in the 898 formulae in the data set following general 
exclusions* by principal symptom 
 
Total No. Dyspnoea No. Cough No. Sputum No. 
Chest 
tightness 
No. 
Gan cao 372 Gan cao 222 Gan cao 253 Gan cao 72 Ban xia 54 
Ban xia 266 Ban xia 169 Xing ren 203 Ren shen 50 Gan cao 52 
Xing ren 249 Xing ren 150 Ban xia 172 Ban xia 49 Fu ling 33 
Ren shen 217 Ren shen 129 Ren shen 155 Xing ren 43 Ren shen 32 
Fu ling 209 Fu ling 116 Wu wei zi 139 Wu wei zi 41 Rou gui 30 
Wu wei zi 181 Wu wei zi 110 Fu ling 126 Fu ling 35 Chen pi 26 
Chen pi 170 Chen pi 108 
Kuan dong 
hua 
120 Chen pi 32 Xing ren 25 
Sang gen 
bai pi 
142 
Sang gen 
bai pi 
88 
Sang gen 
bai pi 
117 
Sang gen 
bai pi 
32 
Sang gen 
bai pi 
25 
Sheng 
jiang 
127 Ma huang 87 Zi wan 108 Bei mu 27 Shi gao 24 
Kuan 
dong hua 
124 Rou gui 74 Chen pi 102 
Kuan dong 
hua 
25 Ma huang 24 
Ma huang 117 
Kuan dong 
hua 
65 Ma huang 94 
Mai men 
dong 
22 Wu wei zi 23 
Zi wan 114 
Sheng 
jiang 
63 Bei mu 93 Jie geng 21 Sheng jiang 20 
Rou gui 113 Zi wan 59 Sheng jiang 81 Sheng jiang 19 Zhi shi 18 
Bei mu 102 
Mai men 
dong 
53 Rou gui 76 E jiao 17 Gan jiang 17 
Jie geng 99 Jie geng 50 Jie geng 69 Zi wan 17 
Kuan dong 
hua 
17 
Gan jiang 92 Gan jiang 50 Gan jiang 64 Ma huang 16 Fang ji 16 
Mai men 
dong 
87 Xi xin 47 
Mai men 
dong 
61 Zhi mu 14 Bing lang 16 
Zhi shi 87 Zhi shi 46 E jiao 61 Rou gui 13 Zi wan 15 
Bai zhu 82 Bei mu 44 Xi xin 60 Da zao 13 Da zao 14 
Da zao 78 Shi gao 42 Da zao 55 Huang qin 13 Xi xin 13 
Xi xin 75 Da zao 41 Zhi mu 49 Bai zhu 12 Bai zhu 12 
Total 5858 total 3416 total 4206 total 1047 total 861 
*disorders specifically of children or women, acute disorders and other disorders unlike COPD 
Overall, there are only minor variations in the main herbs used according to principal COPD 
symptom. The herbs Gan cao, Ban xia, Xing ren, Ren shen, and Fu ling are always near the 
top of the frequency lists. Some other herbs vary according to their principal uses, for 
example Bei mu is considerably higher on the list of herbs in formulae for sputum compared 
with formulae for chest tightness or dyspnoea. In other cases there was no variation, with 
Sang gen bai pi (also called Sang bai pi) ranking 8
th
 in total for all four main symptoms. 
5.5.3 Hierarchical combination of four principal COPD symptoms  
Firstly, any entries with scores for hemoptysis or any of the general exclusions were removed 
from the analysis. Then, the four principal COPD symptoms were combined into clusters of 
two, three and four respectively using dyspnoea as the leading symptom since it is always 
present in COPD, so that at step 7 all the remaining citations were used for all four symptoms 
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(see Table 5.26).  
Table 5. 19 : Step-wise hierarchical combinations of four principal COPD symptoms: summary data 
 
Step Formulae HE Years 
1 General exclusions* & hemoptysis 859 5524 583-1934 
2.1 dyspnoea + cough  329 2251 583-1900 
2.2 dyspnoea + sputum 71 539 752-1900 
2.3 dyspnoea + chest tightness 96 684 583-1900 
3.1 cough + sputum 108 816 752-1900 
3.2 cough + chest tightness 88 631 583-1900 
4 sputum + chest tightness 24 183 752-1695 
5.1 dyspnoea + cough + sputum  64 79 752-1900 
5.2 dyspnoea + cough + chest tightness 80 579 583-1900 
5.3 dyspnoea + sputum + chest tightness 21 158 752-1695 
6 cough + sputum + chest tightness 24 183 752-1695 
7 dyspnoea + cough + sputum + chest tightness 21 158 752-1695 
*disorders specifically of children or women, acute disorders and other disorders unlike COPD 
Of the combinations of two symptoms, dyspnoea plus cough (step 2.1) was the most common 
combination with 329 citations which referred to 231 different named formulae and 43 
unnamed formulae. The most frequent formulae were Xiao Qing Long Tang (n=7) and Yue Bi 
Jia Ban Xia Tang Fang (n=7) (see Table 5.27).  
Table 5. 20 Most frequent formulae in total data set at step 2.1 (dyspnoea plus cough) 
Formula code & name Frequency 
1 no name 43 
3 Yue Bi Jia Ban Xia Tang Fang 7 
61 Xiao Qing Long Tang 7 
5 Xiao Qing Long Jia Shi gaoTang 5 
4 Ma Huang Tang 4 
8 Zi Wan Tang 4 
144 Zao Jiao Jian Wan 4 
58 Ze Xie Tang 3 
60 Ting Li Da Zao Tang 3 
162 Ma Huang Gan Cao Jia Xing Ren Sheng Jiang Tang 3 
Total 329 
 
At step 2.1 there were 2,251 herb entries for 238 different herbs. Gan cao remained the most 
common, followed by Ban xia, Xing ren and Ren shen (see Table 5.28). Most of the 21 herbs 
are same as in the top 20 in the total data set (Table 5.24) except that Zhi shi, Bai zhu and Da 
zao are not frequent at step 2.1 and Xi xin, Zhi mu, Zao Jia and Ying su ke appear at Step 2. 
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Table 5. 21 Most frequently occurring herbs in the 229 formulae at step 2.1 (dyspnoea plus cough) 
Herb name Frequency Percent 
Gan cao 146 6.5 
Ban xia (zhi) 117 5.2 
Xing ren 103 4.6 
Ren shen 82 3.6 
Wu wei zi 74 3.3 
Fu ling 70 3.1 
Ma huang 67 3.0 
Chen pi 64 2.8 
Sang gen bai pi 59 2.6 
Kuan dong hua 52 2.3 
Zi wan 49 2.2 
Rou gui 46 2.0 
Sheng jiang 40 1.8 
Xi xin 38 1.7 
Bei mu 37 1.6 
Jie geng 33 1.5 
Gan jiang 33 1.5 
Mai men dong 30 1.3 
Zhi mu 29 1.3 
Zao jia 27 1.2 
Ying su ke  27 1.2 
Total 2251 100.00% 
 
When three symptoms were combined, dyspnoea plus cough plus chest tightness was the most 
common (step 5.2, 80 citations) but the combination of dyspnoea plus cough plus sputum 
(step 5.1, 64 citations) more closely matches the current conception of COPD, so lists of 
formulae and herbs were generated at this step. The 64 formula citations comprised 54 
different named and 7 unnamed formulae. The most frequent named formula was Zao Jiao 
Jian Wan (n=3), followed by Ma huang san (n=2) with all the remaining formulae appearing 
once only.  
The most frequent herb was again Gan cao (n=35) followed by Ban xia and Ren shen (see 
Table 5.29). Compared to step 2.1 two new herbs appear on the list, Shan yao and E jiao, 
whereas both Sheng jinag and Gan jiang disappear, as does Zao jiao.  
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Table 5. 22 Most frequently occurring herbs in the 64 formulae at step 5.1 (dyspnoea plus cough plus 
sputum) 
 
Herb name Frequency Percent 
Gan cao 35 7.3 
Ban xia (zhi) 27 5.6 
Ren shen 25 5.2 
Wu wei zi 19 4.0 
Xing ren 19 4.0 
Fu ling 16 3.3 
Chen pi 15 3.1 
Kuan dong hua 14 2.9 
Sang gen bai pi 13 2.7 
Bei mu 12 2.5 
Rou gui 9 1.9 
Zhi mu 9 1.9 
Ma huang 9 1.9 
Mai men dong 8 1.7 
E jiao 8 1.7 
Xi xin 8 1.7 
Ying su ke 8 1.7 
Zi wan 7 1.5 
Shan yao 6 1.3 
Total 479 100.0 
 
 
At step 7 all four symptoms were present leaving 21 citations that satisfied all principal 
criteria. All the 21 formulae at step 7 were different, one was unnamed and the names of the 
others are listed in Table 5.30. All the formulae were derived from 6 books. The most frequent 
source book was Pu Ji Fang (普济方) with 9 formulae followed by Tai Ping Hui Min He Ji Ju 
Fang (太平惠民和剂局方) with 7 formulae.  
In the 21 formulae, 68 different herbs were used but the list of top herbs by total frequency 
varied little from the total set. The main differences are that Ying su ke appears in the top 10 
and Ma huang (n=2) has dropped lower down and off the list (see Table 5.31). This list is very 
similar to step 2.1 with the addition of E jiao and Bai fan and the loss of Gan jiang. 
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Table 5. 30 Frequency of formulae occurring in the data set at step 7 (dyspnea, cough, sputum & chest 
tightness) 
Formula name Frequency Book name Year 
no name 1 Ji Yang Gang Mu 1626 
Ban Xia Yin Fang 1 Pu Ji Fang 1406 
Zi Wan Tang 1 Pu Ji fang 1406 
Zi Wan San Jia Jian 1 Zhang Shi Yi Tong 1695 
Jian Wei Si Wu Tang 1 Ji Yang Gang Mu 1626 
Ban Xia Wan 1 Tai Ping Hui Min He Ji Ju Fang 1078 
Run Fei Wan 1 Tai Ping Hui Min He Ji Ju Fang 1078 
Kuan Dong Hua San 1 Tai Ping Hui Min He Ji Ju Fang 1078 
Xi Xin Wu Wei Zi Tang 1 Tai Ping Hui Min He Ji Ju Fang 1078 
Yang Zhong Tang 1 Tai Ping Hui Min He Ji Ju Fang 1078 
Ren Shen Yang Fei Wan 1 Tai Ping Hui Min He Ji Ju Fang 1078 
Wen Fei Wan 1 Tai Ping Hui Min He Ji Ju Fang 1078 
Zao Jiao Jian Wan 1 Wai Tai Mi Yao 756 
Shen Su Ban Xia Tang 1 Pu Ji Fang 1406 
Shen Ying Dan 1 Pu Ji Fang 1406 
Ren Shen Ding Chuan Tang  1 Pu Ji Fang 1406 
Chen Sha Li Ge Wan 1 Pu Ji Fang 1406 
Dao Tan Wan 1 Pu Ji Fang 1406 
Ting Li San 1 Pu Ji Fang 1406 
Jin Bu Huan San  1 Pu Ji Fang 1406 
Qing Jin Tang 1 Chi Shui Xuan Zhu 1584 
Total 21 6 different books  
 
 
Table 5. 23 Nineteen most frequently occurring herbs (n=3 and above) in the 21 formulae in the data set at 
step 7 
 
Herb name Frequency HE% 
Gan cao 13 8.2 
Ban xia 12 7.6 
Ren shen 8 5.1 
Xing ren 8 5.1 
Wu wei zi 6 3.8 
Fu ling 6 3.8 
Sheng jiang 5 3.2 
Sang gen bai pi 5 3.2 
Ying su ke 5 3.2 
Chen pi 4 2.5 
E jiao 4 2.5 
Kuan dong hua 4 2.5 
Rou gui 3 1.9 
Jie geng 3 1.9 
Zi wan 3 1.9 
Bei mu 3 1.9 
Xi xin 3 1.9 
Zao jiao 3 1.9 
Bai fan 3 1.9 
Total 158 100.0 
 
Overall, the list of herbs remained fairly stable through steps 2.1, 5.1 and 7 with most changes 
being in the less frequent items.  
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5.5.4 Global scores  
The Global scores were based on a subjective assessment that was undertaken through reading 
each full citation. This identified 309 citations that appeared to be a disease other than COPD 
(32.0% of Herbal entries) and 39 citations (3.5% of Herbal entries) that did not provide 
enough information for a judgment to be made (see Table 5.32).  
Table 5. 24 Frequency of global assessments of likelihood of COPD in total data set before general 
exclusions 
 
Description Frequency of formulae Frequency HEs Percent HEs 
Not enough information to decide 39 230 3.5 
Other disease unlike COPD 309 2105 32.0 
Possible COPD 282 1969 29.9 
Possible complication of COPD 294 1681 25.5 
Most likely COPD 82 596 9.1 
Total 1006 6581 100.0 
 
When the two variables for disorders specific of children or women and for acute disorders or 
other disorders unlike COPD were combined and applied as exclusion criteria, 898 formula 
citations and 5,858 Herbal entries remained in the data set. These exclusions reduced the 
number classified as ‘disease unlike COPD’ to 217 but did not affect the numbers classified as 
‘Possible complication of COPD’ or ‘Most likely COPD’, so the exclusion criteria appear to 
have been consistent with the global score criteria (see Table 5.33).  
Table 5. 25 Frequency of global assessments of likelihood of COPD in total data set after exclusion of 
disorders specifically of children or women, acute disorders and other disorders unlike COPD 
 
Description Frequency of formulae Frequency HEs Percent HEs 
Not enough information to decide 27 132 2.3 
Other disease unlike COPD 217 1497 25.6 
Possible COPD 278 1952 33.3 
Possible complication of COPD 294 1681 28.7 
Most likely COPD 82 596 10.2 
Total 898 5,858 100.0 
 
The top 20 formulae based on the total of the three categories are listed in Table 5.34. Of the 
82 formulae in the category ‘most likely COPD’, 16 were unnamed and of the named 
formulae only Ban Xia Yin Fang appeared twice, with the others all only appearing once. 
However, Ban Xia Yin Fang does not appear in Table 5.34, since its overall frequency in the 
three categories was only 2. However, this is one of the formulae included at step 7 (see Table 
5.30). 
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The most frequent of the named formulae was Yue Bi Jia Ban Xia Tang Fang with 7 citations 
but only one of these was for a condition classified as ‘most likely COPD’, with the 
remaining six being for ‘Possible complication of COPD’. Of the top ten named formulae, 
only two received scores in the ‘most likely COPD’ category. Also, only one of the formulae 
in the top 20 in Table 5.34, i.e. Zi Wan San Jia Jian, appeared at step 7. So, in terms of 
formula name, the two lists show little overlap. 
Table 5. 26 Twenty most frequent formulae by global score: full data set (after duplicates removed) 
 
Formula name 
Possible 
COPD 
Possible complication of 
COPD 
Most likely 
COPD 
Total 
1 no name 45 77 16 138 
3 Yue Bi Jia Ban Xia Tang Fang 0 6 1 7 
5 Xiao Qing Long Jia Shi Gao Tang 1 5 0 6 
59 Xiao Ban Xia Tang 4 2 0 6 
54 Mu Fang Ji Tang 0 5 0 5 
61 Xiao Qing Long Tang 3 2 0 5 
144 Zao Jiao Jian Wan 1 3 1 5 
4 Ma Huang Tang 0 4 0 4 
8 Zi Wan Tang 0 4 0 4 
60 Ting Li Da Zao Tang 2 2 0 4 
162 Ma Huang Gan Cao Jia Xing Ren 
Sheng Jiang Tang 
4 0 0 4 
337 Su Zi Jiang Qi Tang 4 0 0 4 
21 Zi Wan San Jia Jian 1 1 1 3 
55 Shi Zao Tang 1 2 0 3 
57 Xiao Ban Xia Jia Fu ling Tang 3 0 0 3 
58 Ze Xie Tang 3 0 0 3 
66 Mu Fang Ji Tang Qu Shi Gao Jia Fu 
Ling Mang Xiao Tang 
0 3 0 3 
127 Jiu Xian San 1 1 1 3 
226 Ren Shen Kuan Dong Hua San 2 0 1 3 
477 Jiu Sou Wan Zi 2 1 0 3 
Total 282 294 82 658 
 
Conversely, when the much shorter list of 21 formulae included at step 7 is considered as the 
basis for comparison (see Table 5.35), 14 were included in the 82 formulae classified as ‘most 
likely COPD’ and the remaining 7 were classified as ‘possible complication of COPD’. 
Therefore the step-wise process identified a sub-set of the formulae that were also identified 
by the broader global scoring procedure. 
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Table 5. 27 Frequency of formulae occurring in the data set at step 7: most consistent with COPD, 
showing Global scores 
 
Formula name Freqency 
Global 
score 4* 
Global 
score 3* 
Book name Year 
1 no name 1 0 1 Ji Yang Gang Mu 1626 
6 Ban xia yin fang 1 1 0 Pu Ji Fang 1406 
8 Zi Wan Tang 1 0 1 Pu Ji Fang 1406 
21 Zi Wan San Jia Jian 1 1 0 Zhang Shi Yi Tong 1695 
33 Jian Wei Si Wu Tang 1 0 1 Ji yang gang mu 1626 
83 Ban Xia Wan 1 0 1 Tai Ping Hui Min He Ji Ju Fang 1078 
92 Run Fei Wan 1 1 0 Tai Ping Hui Min He Ji Ju Fang 1078 
96 Kuan Dong Hua San 1 1 0 Tai Ping Hui Min He Ji Ju Fang 1078 
97 Xi Xin Wu Wei Zi Tang 1 1 0 Tai Ping Hui Min He Ji Ju Fang 1078 
98 Yang Zhong Tang 1 1 0 Tai Ping Hui Min He Ji Ju Fang 1078 
108 Ren Shen Yang Fei Wan 1 0 1 Tai Ping Hui Min He Ji Ju Fang 1078 
112 Wen Fei Wan 1 1 0 Tai Ping Hui Min He Ji Ju Fang 1078 
144 Zao Jiao Jian Wan 1 0 1 Wai Tai Mi Yao 756 
213 Shen Su Ban Xia Tang 1 1 0 Pu Ji Fang 1406 
220 Shen Ying Dan 1 1 0 Pu Ji Fang 1406 
258 Ren Shen Ding Chuan 
Tang  
1 1 0 Pu Ji Fang 1406 
259 Chen Sha Li Ge Wan 1 1 0 Pu Ji Fang 1406 
273 Dao Tan Wan 1 1 0 Pu Ji Fang 1406 
278 Ting Li San 1 0 1 Pu Ji Fang 1406 
454 Jin Bu Huan San  1 1 0 Pu Ji Fang 1406 
484 Qing Jin Tang 1 1 0 Chi Shui Xuan Zhu 1584 
Total 21 14 7 6 different books  
*Global score 4: ‘most likely COPD’; Global score 3 ‘possible complication of COPD’ 
The 20 most frequent herbs are listed in Table 5.36 according to the three main global score 
categories: ‘most likely COPD’, ‘possible complication of COPD’ and ‘possible COPD’. As 
with previous lists of herbs, Gan cao is the most frequent in each category and there is 
considerable similarity between lists. The only notable differences are the inclusion of Ying su 
ke and Zhi mu in the list for ‘most likely COPD’. 
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Table 5. 28 Twenty most frequent HEs by global score: full data set (after duplicates removed) 
Most likely COPD HEs Total HEs 
possible 
complication of 
COPD 
HEs possible COPD HEs 
Gan cao 35 436 Gan cao 91 Gan cao 141 
Ren shen 31 245 Xing ren 82 Ban xia 103 
Ban xia 29 286 Ren shen 70 Xing ren 88 
Wu wei zi 25 193 Ban xia  57 Fu ling 76 
Xing ren 25 292 Zi wan 55 Ren shen 74 
Chen pi 23 185 Ma huang 54 Chen pi 69 
Kuan dong hua 21 137 Wu wei zi 51 Wu wei zi 61 
Fu ling 20 235 Kuan dong hua 48 Sheng jiang 49 
Sang gen bai pi 18 172 Sang gen bai pi 47 Sang gen bai pi 46 
Bei mu 15 124 Rou gui 45 Mai men dong 37 
Ying su ke 14 40 Fu ling 34 Bei mu 36 
Zi wan 12 124 Sheng jiang 33 Jie geng 36 
Mai men dong 11 101 Chen pi 31 Kuan dong hua 33 
Rou gui 10 119 Bei mu 29 Zi wan 32 
Zhi mu 10 66 Xi xin 28 Zhi shi 32 
Sheng jiang 9 143 Shi gao 28 Ma huang 29 
Jie geng 9 113 Gan jiang 26 Da zao 27 
E jiao 8 75 Jie geng 25 Bai zhu 27 
Xi xin 8 77 Da zao 24 Gan jiang 25 
Ma huang 8 139 Fang ji 22 E jiao 25 
Total 596 6581  1681  1969 
 
At step 7, of the 158 Herbal entries, 118 were scored as ‘most likely COPD’ and 40 were 
considered ‘possible complications of COPD’. All herbs of a frequency of 2 or more for ‘most 
likely COPD’ are presented in Table 5.37.  
Within the list of 23 different herbs included under ‘most likely COPD’ are all of the 20 herbs 
listed in Table 5.36 under ‘most likely COPD’ based on the global scores alone. Consequently, 
the same list of high frequency herbs was identified using either procedure. 
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Table 5. 29 Most frequent Herbal entries by global score following exclusions: Step 7 
Most likely COPD Frequency Possible complication of COPD Frequency 
Gan cao* 11 Xing ren 3 
Ban xia* 10 Fu ling 3 
Ren shen* 6 Gan cao 2 
Wu wei zi* 5 Ban xia 2 
Xing ren* 5 Ren shen 2 
Ying su ke* 5 Zao jia 2 
Chen pi* 4 He zi 2 
Sheng jiang* 4  1 
E jiao* 4  0 
Kuan dong hua* 4  0 
Sang gen bai pi* 4  0 
Fu ling* 3  - 
Rou gui* 3  0 
Bei mu* 3  0 
Xi xin* 3  0 
Mai men dong* 2  0 
Zhi mu* 2  0 
Jie geng* 2  1 
Zi wan* 2  1 
Tian nan xing 2  0 
Ma huang* 2  0 
Bai fan 2  1 
Zi su ye 2  0 
total 118  40 
*also included in table 5.36 under ‘most likely COPD 
 
5.5.5 Comparison between the step-wise and the global score approach 
When only the duplicates were excluded, 82 formulae were scored as ‘most likely COPD’, 
294 were ‘possible complications of COPD’ and 282 were classified as ‘possible COPD’ 
using the subjective global scoring approach (see Table 5.32). However, most of the 82 
formulae scored as ‘most likely COPD’ only had a frequency of one so this presented 
difficulties with short-listing them. Similarly, at step 7, the 21 formulae that remained after the 
step-wise exclusions all had frequencies of one. Although the number is considerably smaller 
using the step-wise approach, no hierarchical ranking was possible. However, when both 
approached were combined, 14 formulae were scored as ‘most likely COPD’ and 7 were 
considered ‘possible complications of COPD’. None were considered unlikely instances (see 
Table 5.35). So both approaches appear to have had consistent results and the combination of 
approaches had allowed additional refinement. 
Although step 7, which combined four main symptoms, located a set of herbs and formulae 
that satisfied the main criteria for COPD, and the list of herbs found at this step was consistent 
with those found by the global scoring procedure for ‘most likely COPD’, the total number of 
citations remaining in the data set was relatively small. Therefore, all the 21 formulae only 
109 
 
appeared with a frequency of one and the highest frequency for any of the herbs was only 13 
(for Gan cao). With these low frequencies it is not possible to rank the formulae and it is 
difficult to be confident about the meaningfulness of the relative ranking of the herbs. At step 
5.1 the three main COPD symptoms of dyspnoea plus cough plus sputum are all targeted by 
the 64 included formulae, but the diversity of formula names meant that only two formulae 
had frequencies greater than one. Step 2.1 (dyspnoea plus cough) is less specific but its much 
larger number of citations (329 formulae) allows the ranking of formulae in terms of 
frequency of appearance for these two combined symptoms in the data set. Consequently each 
of these three steps is considered in the following discussion. 
5.6 Discussion of Search terms  
5.6.1 Discussion of search terms 
The main clincally observable symptoms of COPD are related to the progression of COPD. 
Chronic cough tends to occur in the earlier stages with sputum and shortness of breath 
becoming more prominent as the condition deteriorates. Severe dyspnoea and chest tightness 
are characteristic of the later stages and of exacerbations. However, the clinical presentation 
of COPD can vary considerably from person to person and according to stage. Also, the above 
combinations of symptoms can appear in a number of other chronic lung disorders.   
Cough and dyspnoea was found to be the most common combination of any two symptoms in 
the step-wise hierarchical combination of four symptoms of COPD. This is consistent with the 
clinical presentation of COPD in western medicine.  
Of the search terms, chronic cough was most frequently associated with Jiu ke and Jiu sou, 
which was expected since both are terms for ‘cough’. However, descriptions of chronic cough 
appeared for the other terms at less than 10 percent. In particular, for Zhi yin there was no 
mention of chronic cough although 61.6% of citations simply mentioned ‘cough’. For the 
term Chuan zheng mention of ‘cough’ was less than 15% with only 0.2% for ‘chronic cough’. 
Therefore, amongst the eight terms, Zhi yin and Chuan zheng appear the least likely to refer 
to conditions consistent with COPD. 
Mention of dyspnea was predictably high for Chuan zheng and Chuan sou, and lowest for Jiu 
sou (26.2%) and Tanyin kesou (35.1%) compared with almost 72% for Fei zhang. ‘Dyspnoea 
that is worse with exercise’, was not mentioned for Fei zhang or Jiu ke but the the overall 
percentages were low (0.8%-6.7%) for the other terms. ‘Severe dyspnoea’, was not described 
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for Zhi yin or Tanyin kesou, but again there were only low percentages for the other terms 
(1.5%-15.9%). ‘Severe dyspnoea’ appeared highest for Fei zhang. Therefore, based on the 
symptoms, Ke chuan, Zhi yin, Chuan zheng and Jiu sou appear to be the terms least likely to 
correspond with COPD. 
Sputum production is also one of the characteristic symptoms of COPD. However, more than 
70 percent of no mentions were found for all terms. Furthermore, chronic sputum production 
was not described for the terms Jiu ke, Ke chuan, Chuan sou, Zhi yin or Chuan zheng, 
whereas there was mention for the terms Fei zhang, Jiu sou and Tanyin kesou at 4.6%, 3.2% 
and 0.6% respectively. Overall, sputum production was most commonly mentioned for Fei 
zhang but it was not a common mention for any of the terms, so it cannot be used to identify 
any further terms as being less likely to refer to COPD.   
Chest tightness as a symptom of COPD appeared most frequently in Fei zhang and Zhi yin 
followed by Tanyin kesou, Jiu ke and Chuan sou, and was lower for the terms Jiu sou, Ke 
chuan and Chuan zheng. 
In the step-wise combinations of main symptoms, distinction was not made between levels of 
severity of dyspnea or features of cough. When symptoms were combined at steps 2.1, 5.1 
and 7 the numbers of formulae remaining in the data set were dramatically reduced and some 
search terms ceased to be represented. Notably, Zhi yin was elimated at step 5.1 while Jiu ke, 
Ke chuan and Chuan zheng were greatly reduced when compared to the total data set. At step 
7, Ke chuan and Chuan zheng were eliminated leaving Fei zhang, Chuan sou and Tanyin 
kesou as the main terms (see Table 5.38).  
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Table 5. 30 Frequency of formulae by search term at the main stages of the step-wise combinations of 
symptoms (n, %) 
Term 
Frequency of 
formulae total 
Frequency 
of formulae 
2.1 dyspnea 
+ cough 
Frequency of 
formulae 5.1 
dyspnea + 
cough+sputum 
Frequency of 
formulae 7 dyspnea + 
cough+sputum+chest 
tightness 
1. Fei zhang 57 (5.7) 33 (10.0) 6 (9.4) 5 (23.8) 
2. Jiu ke 74 (7.4) 14 (4.3) 2 (3.1) 1 (4.8) 
3. Jiu sou 221 (22.0) 44 (13.4) 11 (17.2) 2 (9.5) 
4. Ke chuan 115 (11.4) 25 (7.6) 3 (4.7) 0 
5. Chuan sou 196 (19.5) 130 (39.5) 23 (35.9) 6 (28.6) 
6. Zhi yin 69 (6.9) 37 (11.2) 0 0 
7. Tanyin kesou 132 (13.1) 30 (9.1) 16 (25.0) 7 (33.3) 
8. Chuan zheng 142 (14.1) 16 (4.9) 3 (4.7) 0 
Total 1006 (100%) 329 (100%) 64 (100%) 21 (100%) 
 
Chuan zheng and Fei zhang are regarded as the classical terms most closely related to COPD 
(331-333). However, chronic cough and sputum production were infrequently described for 
Chuan zheng and this term was infrequent at step 5.1 and eliminated at step 7. Fei zhang 
tended to be consistent in relation to the main symptoms and their combinations. Despite 
having the lowest frequency in the total data set, Fei zhang was one of the three main terms at 
step 7. Cough with dyspnoea was also commonly mentioned for the term Chuan sou which 
also remained a main term at steps 5.1 and 7. However, the term Ke chuan was infrequent at 
step 5.1 and was elimated at step 7. 
Jiu kesou is regard as a disease name in two modern books ((296, 297)) but it was not 
mentioned as an historical term for COPD in the published papers related to the 101 clinical 
trials. The terms Jiu ke and Jiu kesou appear in many classical books and both are included 
under Jiu ke in these data. Chronic cough with dyspnoea was fairly common for Jiu ke 
(approx. 50%) but lower for Jiu sou (approx. 26%) but Jiu sou was the most frequent term in 
the total data set. Both terms remained at steps 5.1 and 7 but as relatively low frequency terms. 
In the case of Tanyin kesou, both cough and dyspnea were relatively common symptoms and 
this term increased its relative frequency at step 5.1 and was one of the three main terms at 
step 7. It is also described in two modern books (248, 334).  
Overall the three terms that were most likely to be associated with conditions that combined 
the four main symptoms of COPD were Fei zhang, Chuan sou and Tanyin kesou, while the 
least likely term was Zhi yin. Chuan zheng and Ke chuan both located a few references that 
combined the three main COPD symptoms. Chuan zheng and Ke chuan tended to be closer to 
112 
 
Xiao zheng (asthma) than COPD in the located references. Zhi yin in the located references 
was more relevant to a ‘possible complication of COPD’ associated with heart disorders such 
as cor pulmonale. It is mentioned as belonging to COPD in one modern book (296). However, 
it was generally excluded by the global scores. Jiu ke is a very common symptom of chronic 
bronchitis which is regarded as one component of COPD. However, if cough is the only 
symptom present or it is combined with sputum production, it is considered to be cough-
variant asthma (CVA) (335).  
5.6.2 Discussion of the most frequent formulae 
In the the next sections, the formulae identified at the various levels of selection are discussed. 
5.6.2.1 Formulae in total data set following exclusions  
The top ten formulae in the total data set following exclusions are presented in Appendix 8. 
These were found in 5 books and were located under the terms Fei zhang, Zhi yin and Tanyin 
kesou.  
In modern CHM, Xiao Qing Long Tang, Xiao Qing Long Jia Shi Gao Tang and Yue Bi Jian 
Ban Xia Tang are still commonly used for wheezing at the acute stage due to attack caused by 
exopathogenic factors. Xiao Qing Long Tang is for treating aversion to wind-cold, cold 
phlegm accumulated in the lung and obstructing lung qi, while for conditions complicated 
with interior heat, Xiao Qing Long plus Shi Gao Tang is used. Yue Bi Jian Ban Xia Tang is 
used for wheezing caused by aversion to wind-heat and phlegm heat accumulated in the lung. 
Xiao Qing Long Tang is also used in treating both thoracic fluid retention and subcutaneous 
fluid retention.  
Mu Fang Ji Tang and Wu Ling San are applied for different syndromes of thoracic fluid 
retention; Mu Fang Ji Tang’s action is similar to Xiao Qing Long Tang for cold fluid retention 
in lung while Wu ling San is for deficiency of spleen and kidney yang. Zao Jiao Jian Wan was 
for dyspnea in the original books which gave its actions as tonify qi and resolve phlegm to 
calm dyspnea but it is no longer in common use.  
Ma Huang Gan Cao plus Xing Ren Sheng Jiang Tang is used for cough with a lot of sputum 
caused by wind-cold and its actions are to warm lung to dispel cold, and resolve phlegm to 
suppress cough. Xiao Ban Xia Tang and Xiao Ban Xia Jia Fu Ling Tang are mostly used for 
nausea caused by phlegm-fluid retention in the spleen and stomach.  
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These formulae are mostly used for acute disorders or for removing fluid. Such formulae can 
be used for a wide range of lung disorders. However, these kinds of conditions are not good 
examples of COPD, although some may be related to exacerbations of COPD. Therefore, 
formula selection based on the symptoms alone did not provide formulae directly relevant to 
the treatment of stable COPD, only to COPD exacerbations.  
5.6.2.2 Formulae selected by Global score as possible, likely or possible complication of 
COPD 
The 20 most frequent formulae in the data set defined by the global scores as ‘possible’, 
‘likely’ or ‘possible complication’ of COPD are presented in Appendix 9. These were found in 
10 books under the terms of Fei zhang, Zhi yin, Tan yin ke sou, Chuan zheng, Chuan sou and 
Jiu ke sou.  
Eight of the nine named high frequency formulae found in the total data set following general 
exclusions (see Appendix 8) also appeared in Appendix 9. So there is a broad consistency 
between the formulae remaining after the general exclusions and those considered to be 
associated with conditions that were at least possible instances of COPD. The exception is Wu 
Ling San which is mainly used for fluid retention rather than for cough or dyspnea and did not 
get selected under any of the three global scores.  
Some of newly appearing formulae in Appendix 9 are for removing fluid – in fact all the 
following are for thoracic fluid retention with cold fluid retention in lung: Shi Zao Tang, Ting 
Li Da Zao Tang, Ze Xie Tang and Mu Fang Ji Tang Jia Jian. Other formulae are for acute 
conditions that may be exacerbations, including Ma Huang Tang, Zi Wan Tang, Jiu Sou Wan 
Zi and Su Zi Jiang Qi Tang, which are for cough, dyspnea and wheezing with excess patterns 
but Su Zi Jiang Qi Tang is also used when there is fullness above and deficiency below. Those 
that appear most relevant to stable COPD are Zi Wan San Jian Jian, Jiu Xian San and Ren 
Shen Kuan Dong Hua San which are all for long-term cough with dyspnea. However, none of 
these formulae appear in the top ten based on these selection criteria. Therefore, these general 
criteria tended to include many formulae that may be relevant to the treatment of COPD 
exacerbations but only a few relevant to stable COPD (336). 
5.6.2.3 Formulae located in the step-wise combinations of four principal COPD 
symptoms 
Of the nine most frequently named formulae at step 2.1 (dyspnea + cough), five were also in 
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the top 10 formulae found in the total data set (after general exclusions) and the remaining 
four were included in the top 20 formulae identified by the global scoring procedure.  
All of these formulae are used for acute condidtions which may include exacerbations of 
COPD characterised by wheezing or dyspnea with excess patterns or for thoracic fluid 
retention with cold fluid retention in lung. Therefore, combining the symptoms of dyspnea 
plus cough still mainly located formulae for exacerbations. Acute condition was one of the 
general exclusions, but entries were excluded as ‘acute condition’ when the entry explicitly 
stated this, whereas this aspect frequently was not mentioned.  
At step 5.1 (dyspnoea plus cough plus sputum) there were 54 different formulae identified but 
only two of the named formulae had frequencies greater than one. One of these, Zao Jiao Jian 
Wan, was included at step 2.1 as well as in the top 10 formulae overall and in the top 10 
formulae identified by the global scoring system (see Table 5.23 & 5.34). The other is Ma 
Huang San (麻黄散) (Gan cao, Rou gui, Xing ren, Ma huang, Ke zi, Kuan dong hua) which 
did not appear amongst the higher frequency items in the earlier lists but is actually a variant 
on the more common and frequently occurring formula Ma Huang Tang. Ma Huang San was 
used for treating chronic cough caused by phlegm accumulated in the lung. Both of these 
higher frequency formulae were for the actute stages of a lung disorder. Two of the three 
formulae identified by the global scores (Appendix 8) as relevant to stable COPD, Zi Wan San 
Jia Jian and Ren Shen Kuan Dong Hua San, remained in the list of 54 formulae at step 5.1 but 
due to the excessive number of formulae remaining at this stage, the individual actions of all 
the various formulae are not discussed.  
At step 7, there remained 21 formulae that all appeared once but when the global scores were 
also applied, 14 were scored as ‘most likely COPD’ while the other 7 were all considered 
‘possible complications of COPD’. The main reason for this division is those considered 
‘possible complication’ tended to have more acute symptoms.  
For ‘most likely COPD’, the 14 formulae are presented in Appendix 10. They were found in 5 
different books under the search terms of Fei zhang, Tanyin kesou, Chuan sou and Jiu kesou. 
All of the 14 formulae in the data set at step 7 and also ranked as ‘most likely COPD’ (see 
Appendix 10) are not commonly used in modern CHM but most of their constituent herbs 
remain in use. Six of the 14 formulae are ginseng formulae. Ginseng is considered one of the 
most suitable herbs for stable COPD in modern TCM. However, with the exception of Ren 
shen, Wu wei zi and Fu ling which are used for tonifying qi, most of the herbs in these 
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formulae are for diffusing the lung to resolve phlegm, suppressing cough or for calming 
dyspnea. Overall, about half of these formulae were focused on the symptoms and the 
remainder included herbs for tonifying qi and/or yin. For example, Qing Jin Tang also 
included herbs for strengthening spleen and resolving damp along with herbs for cough and 
phlegm. The remaining formulae were mainly focused on cough with dyspnea which may be 
an exacerbation of a chronic condition, for example Shen Ying Dan, Ban Xia Yin Fang, Kuan 
Dong Hua San, Xi Xin Wu Wei Zi Tang, and Jin Bu Huan San (336). 
For ‘possible complications of COPD’, seven formulae were located under Fei zhang, Tanyin 
kesou or Chuan sou in four books issued from the Song to Qing dynasties (see Appendix 11). 
None were associated with the search terms Jiu ke, Jiu sou, Ke chuan, Chuan zheng or Zhi yin. 
Four of the seven formulae were focused on the symptoms while the others also included 
herbs for tonifying qi such as Ren shen, Ge jie, Huang qi, Fu ling, Shan yao.  
Zao Jiao Jian shown in Appendix 8 and Zi Wan Tang in Appendix 9 were discussed earlier 
(sections 5.3.8.1 and 5.3.8.2). Ban Xia Wan is Xiao Ban Xia Tang plus Bai fan and the action 
is similar to Xiao Ban Xia Tang. These three formulae are used for phlegm-fluid retention 
with an excess pattern in modern TCM. This is more characteristic of the aggravation stage of 
a chronic condition.  
The formula Jia Wei Si Wu Tang uses the therapeutic principle of regulating qi and resolving 
phlegm and blood stasis without using herbs for tonifying qi. This is similar to one of the 
concepts for treating COPD in modern TCM but it focuses on contribution of the phlegm and 
blood stasis rather than on qi deficiency. 
Ting Li San is a modification of Shen Ge Tang which is used for cough with dyspnea with a 
pattern of upper excess and lower deficiency, which may be applied in the acute or remission 
stages of cough with dyspnea. Ren Shen Yang Fei Wan is the only formula which includes 
Ren shen and Huang qi for tonifying the lung and fortifying the spleen to resolve phlegm. 
This is consistent with principles for treating stable COPD in modern TCM.  
Overall, from the viewpoint of modern TCM, most of the formulae remaining at step 7 would 
be considered applicable for exacerbations of COPD involving cough, phlegm-fluid retention 
and/or dyspnea rather than for stable COPD. This was irrespective of the two categories of 
global score applied at this stage. The probable reason is the difficulty in making a global 
decision that distinguishes an ‘exacerbation’ from ‘likely COPD’. Since the scoring procedure 
focused on symptoms and had eliminated recently occurring symptoms due to external 
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pathogenic factors, the remaining formulae all address these symptoms. At step 7 most of the 
formulae that focused on fluid retention, which is more likely to be associated with heart 
failure than COPD alone, had been removed. Of the included formulae, about half addressed 
both the presenting symptoms and the underlying syndromes (qi and/or yin deficiency, blood 
stais etc) and a few formulae such as Jia Wei Si Wu Tang, Ren Shen Yang Fei Wan and Qing 
Jin Tang showed similarities to formulae used in the modern CHM management of COPD.  
Also, this step which combines four symptoms, may have been overly restrictive since a 
number of candidate formulae identified using the global scores were eliminated, such as Zi 
Wan San Jian Jian, Jiu Xian San and Ren Shen Kuan Dong Hua San. It is not necessarily the 
case that all four symptoms would be present in COPD or these symptoms would be 
sufficiently remarkable to be recorded in a particular case, even when there was an 
exacerbation. 
5.6.3 Discussion of the most frequent herbs 
5.6.3.1 Herbs in total data set following general exclusions  
The top of twenty-one frequent herbs after general exclusions (see Table 5.24) are Gan cao, 
Ban xia, Xing ren, Ren shen, Fu ling, Wu wei zi, Chen pi, Sang bai pi, Sheng jiang, Kuan 
dong hua, Ma huang, Zi wan, Rou gui, Bei mu, Jie geng, Gan jiang, Mai men dong, Zhi shi, 
Bai zhu, Da zao and Xi xin.  
For each of the terms dyspnoea, cough, sputum and chest tightness, there are few differences 
among the top twenty-one frequent herbs. E jiao and Zhi mu are more frequent for cough and 
replaced Bai zhu and Zhi shi; Rou gui replaced Wu wei zi in chest tightness. E jiao, Zhi mu 
and Huang qin are more frequent for phlegm and replaced Gan jiang, Zhi shi and Xi xin; Shi 
gao is more frequent and replaced Bai zhu; Shi gao, Fang ji and Bing lang are more frequent 
for chest tightness and replaced Bei Mu, Jie geng and Mai men dong. These differences 
reflect the uses of these herbs for these specific symptoms. 
The top herbs at this step were not necessarily the same as the herbs included in the top ten 
formulae at this step, for example, some of the herbs included in these formulae, such as Ze 
xie, Shi gao, Zhu ling, Shao yao and Gui zhi did not appear in 20 most frequent herbs in the 
total data set following exclusions (see Table 5.25).  
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5.6.3.2 Herbs selected by Global score as used for possible, likely or possible 
complication of COPD 
According to the global score analysis (see Table 5.39), for ‘most likely COPD’, there was no 
change in the top ten herbs except that Bei mu replaced Sheng jiang which dropped to number 
16. This was likely due to the exclusion of formulae for conditions related to exterior wind-
cold pathogens. Other notable changes were that Ying su ke appeared in 11
th
 place along with 
the following other new herbs in the top 20: Zhi mu and E jiao while Ma huang dropped to 
number 20 and Bai zhu, Gan jiang, Zhi shi, and Da zao were not in the top 20. These changes 
appear due to a greater focus on treating cough.  
For ‘possible complications of COPD’, Fu ling, Sheng jiang and Chen pi were replaced by Zi 
wan, Ma huang and Rou gui in the top ten. The new herbs Fang ji and Shi gao entered the top 
20 while Bai zhu, Zhi shi and Mai men dong dropped off the list. This reflects the greater 
focus on the symptoms of cough, dyspnea and chest tightness. Rou gui was included for its 
actions, along with herbs such as Fang ji as well as the more frequent Fu ling and Ban xia, in 
removing the fluid build up associated with dyspnea and chest tightness. 
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Table 5. 31 Comparison of high frequency herbs: Total data set after general exclusions versus subsets 
defined by step-wise exclusion and global scores 
 
Rank 
Total data 
set 
Step 2.1 Step 5.1 Step 7 
Global score 
3 
Global score 4 
1 Gan cao Gan cao Gan cao Gan cao Gan cao Gan cao 
2 Ban xia Ban xia (zhi) Ban xia (zhi) Ban xia Ren shen Xing ren 
3 Xing ren Xing ren Ren shen Ren shen Ban xia Ren shen 
4 Ren shen Ren shen Wu wei zi Xing ren Wu wei zi Ban xia 
5 Fu ling Wu wei zi Xing ren Wu wei zi Xing ren #Zi wan 
6 Wu wei zi Fu ling Fu ling Fu ling Chen pi #Ma huang 
7 
Chen pi #Ma huang Chen pi Sheng jiang 
Kuan dong 
hua 
Wu wei zi 
8 Sang gen bai 
pi 
Chen pi Kuan dong hua Sang gen bai pi 
Fu ling Kuan dong hua 
9 
Sheng jiang 
Sang gen bai 
pi 
Sang gen bai pi Ying su ke 
Sang gen bai 
pi 
Sang gen bai pi 
10 Kuan dong 
hua 
Kuan dong 
hua 
#Bei mu Chen pi 
#Bei mu Rou gui 
11 Ma huang Zi wan Rou gui E jiao Ying su ke *Fu ling 
12 Zi wan Rou gui Zhi mu Kuan dong hua Zi wan Sheng jiang 
13 
Rou gui *Sheng jiang Ma huang Rou gui 
Mai men 
dong 
*Chen pi 
14 Bei mu #Xi xin Mai men dong Jie geng Rou gui Bei mu 
15 Jie geng Bei mu E jiao Zi wan Zhi mu Xi xin 
16 Gan jiang Jie geng Xi xin Bei mu Sheng jiang Shi gao 
17 Mai men 
dong 
Gan jiang Ying su ke Xi xin 
Jie geng Gan jiang 
18 
Zhi shi 
Mai men 
dong 
*Zi wan Zao jiao 
E jiao Jie geng 
19 Bai zhu Zhi mu Shan yao Bai fan Xi xin Da zao 
20 Da zao Zao jia   *Ma huang Fang ji 
21 Xi xin Ying su ke     
Not 
on list 
 
Bai zhu 
Zhishi 
Da zao 
Sheng jiang, Bai 
zhu, Gan jiang, 
Zhi shi, Da zao 
Baizhu, Gan 
jiang, Zhi shi, 
Da zao, Ma 
huang 
Bai zhu, Gan 
jiang, Zhishi, 
Da zao 
Bai zhu, Zhi 
shi, Mai men 
dong 
Herbs appearing at each step but not in column 1 (total data set) are in bold. Herbs that have markedly increased 
in relative frequency compared to column 1 are marked with a hash #, whereas those that have decreased are 
marked with an asterisk*. The total data set: Total classical data set (after general exclusions); Step 2.1: dyspnea 
+ cough; Step 5.1: dyspnea + cough+sputum; Step 7: dyspnea + cough+sputum+chest tightness; Global score 4: 
‘likely COPD’; Global score 3: ‘complication of COPD’ 
 
Some of the herbs in the top formulae based on global score, such as Shi gao, Shan yao, Zao 
jiao, Bing lang, Ting li zi, Shao yao and Gui zhi did not appear in the 20 most frequent herbs 
in the total data set following exclusions listed in Table 5.25. Overall, the number of different 
herbs was high, so only herbs that appeared in many different formulae also appeared high up 
the frequency list for individual herbs. 
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5.6.3.3 Herbs located in the step-wise hierarchical combinations of four principal COPD 
symptoms 
Based on the analysis of the hierarchical combinations of the four principal COPD symptoms, 
the most common combination of any two symptom terms was for dyspnoea plus cough with 
346 formulae (step 2.1). At this step the top ten herbs remained similar to the full list 
following general exclusions, except that Ma huang had moved up the list replacing Sheng 
jiang which dropped to number 13, while Xi xin moved up to 14
th
 place (see Table 5.39). 
Three new herbs appeared on the list: Zhi mu, Zao jia and Ying su ke replacing Bai zhu, Zhi 
shi and Da zao. These changes appear to reflect a greater focus on dyspnea (Ma huang, Xi 
xin), chronic cough (Zhi mu & Ying su ke).  
When the three symptoms of dyspnoea plus cough and sputum were combined (step 5.1), out 
of 479 herb citations (see Table 5. 22) the top ten herbs remained similar, with Bei mu entering 
the list replacing Sheng jiang which dropped off the list together with Bai zhu, Gan jiang, Zhi 
shi and Da zao. The herbs that entered the list were Zhi mu, E jiao and Ying su ke for cough 
and sputum plus the tonic herb Shan yao.  
In the 21 formulae that remained after the combination of four symptoms (step 7), the only 
differences in the top ten herbs were that Ying su ke appeared in 9th place while Kuan dong 
hua dropped to number 12. Other new herbs on the list were E jiao, Zao jia and Bai fan while 
Bai zhu, Gan jiang, Zhi shi, Da zao, and Ma huang had all dropped out of the top 20. These 
changes mostly reflect a greater focus on chronic cough and phlegm.  
A number of the herbs that composed the formulae at step 7, such as Qian hu, Su zi, Bing lang, 
Dang gui, Zhu ye, Di huang, Da huang, Dan pi, Sang ye, Yi yi ren, Ting li zi, Gua lou, Bo he 
and others did not appear in the list of most frequent herbs or the list of high frequency herbs 
at step 7. This is because the overall number of different herbs used was high, so the 
frequency of many of the herbs was relatively low.  
5.6.3.4 General characteristics of the most frequent herbs 
All of the 20 herbs included in the full list after general exclusions (see Table 5.25) were 
recorded in earliest and most famous book belonging to the Ben Cao genre, which is Shen 
Nong Ben Cao Jing (神农本草经) and was issued in or soon after the Han dynasty. In this 
book, herbs were divided into a hierarchy of three groups. Herbs in the top grade were 
regarded as Chief or King Medicines without toxicity that could be taken for long time and 
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benefit long life. Herbs in the medium grade were recognized as Deputy or Minister 
Medicines without or with little toxicity that can treat disease and strengthen a weak person. 
Herbs in the inferior grade were referred as Assistant or Adjutant medicines with greater 
toxicity, which are for dispelling heat and cold evil, breaking up abdominal masses and 
treating diseases but which should not be taken long term.  
Among the top herbs at step 7 (see Table 5.31), Gan cao, Ren shen, Mai men dong, E jiao, Xi 
xin, Fu ling, Wu wei zi, Rou gui (Mu gui or Jun gui) and Chen pi (Juyou or Jupi) belong to 
the top grade in Shen Nong Ben Cao Jing. Bei mu, Zhi mu, Ma huang, Zi wan, Kuan dong 
hua, Sang gen bai pi are in the medium grade, and Bai fan, Ban xia, Jie geng, Xing ren, and 
Zao jia occupy the inferior grade. In addition, Sheng jiang belongs to medium grade in the 
Ben Cao Tu Jing (本草图经) issued in the Song dynasty.  
Ying su ke (called Yu mi ke) was found in Ben Cao Fa Hui (本草发挥) but this did not 
indicate to which grade it belonged. Ying su ke has the actions of astringing the lung and 
nourishing the kidney, so it is mostly used with Wu wei zi for treating Jiu kesou and the 
deficiency syndrome of Chuan zheng.  
Zhi mu which appeared at steps 2.1 and 5.1 and for the global score ‘most likely COPD’ is a 
medium grade herb that belongs to the category of purging fire drugs with a bitter flavor and 
cold property and has the effect of nourishing yin. It is commonly used with Bei mu for 
treating cough.  
Since COPD is a long-term disorder, herbs that can be used over a long time are necessary, 
and these kinds of herbs appear frequently in the formulae. COPD also can present in the 
exacerbation stage, so herbs that address the main symptoms also appear, such as Ma huang 
for dyspnea, Zi wan for cough and Bei mu for phlegm. Conditions that were considered ‘most 
likely COPD’ appeared to include those presenting with coexisting syndromes of deficiency 
and excess, which are more complex than single syndromes or symptoms. So a varity of herbs 
with different functions would be expected to appear on the lists of herbs. 
The actions of the main herbs and the associated research in relation to COPD are discussed 
in detail in chapter 8. 
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6 Chapter Six: Results of systematic reviews of oral ginseng 
formulae for stable COPD and oral CHM for improvement of 
QoL with stable COPD 
This section reports the systematic reviews (SRs) on studies in which oral CHM formulae 
containing ginseng were used for treating suffers with stable COPD (84) and in which oral 
formulae affect on quality of life of patients with stable COPD.  
6.1 A systematic reviews for Oral Ginseng formulae for stable COPD 
6.1.1 Introduction  
In herbal medicine practice, stable COPD is considered as a pattern of Qi deficiency involving 
lung and/or spleen. Qi is refined nutritive substance involved with functional activities (337). 
Ginseng, the root of a perennial plant, is a potent tonic herb used to restore and replenish the 
Qi of the Lung and Spleen to improve their functions. It has been used for treating a wide 
range of chronic respiratory conditions, can be used as a single herb, and is included in many 
formulae for respiratory disorders (338).  
There is an increasing number of CHM clinical trials for the management of stable COPD 
including the use of Ginseng and Ginseng formulae (i.e. a combination of ginseng with 
several herbal ingredients) (339). This review aimed to evaluate of effects of oral ginseng 
formulae for stable COPD through four outcome measures including spirometric parameters, 
symptom improvement, HRQoL and ECOPD.  
Study selection focused on studies using Ginseng formulae. The included studies needed to 
report at least one of the following four outcome measures: spirometric parameters, symptom 
improvement, HRQoL or ECOPD. 
6.1.2 Search results 
The initial searches identified 938 entries from English databases and Chinese databases, as 
described in the search method above, from their respective inceptions to June 2009, without 
language restriction. Further screening of abstracts and full texts identified 477 citations 
requiring detailed evaluation. Of these 465 were excluded for various reasons, including 165 
studies that were not solely orally administered CHM and 251 studies that were not for stable 
COPD and/or included non-COPD patients. Finally, twelve studies met all the selection 
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criteria and were included in this SR (Figure 6.1). 
 
 
Figure 6. 1 Flowchart of the study selection process for the review of Ginseng formulae for stable COPD 
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6.1.3 Description of included studies 
Of the 12 studies that met the selection criteria, 11 were conducted in China and one in Israel. 
The characteristics of the included studies are summarized in Table 4.3. There were no 
disagreements in data extraction between the two reviewers. The 12 studies involved a total of 
1,560 stable COPD patients, ranging from 36 to 600 with four studies having more than 100 
subjects (340-343). Eight subjects dropped out and they were excluded in one study (79), and 
1,552 subjects (1,050 males and 502 females, mean age 63.73) were included in the data 
analysis.  
As shown in Table 6.1, the severity of COPD of participants in five studies (69, 341, 342, 344, 
345) were classified as mild, moderate or severe. Three studies (340, 346, 347) employed the 
classification system developed by the Chinese Medical Association of Respiratory Diseases 
(91), which stratified the severity of participants’ COPD as stages I to III. One study (79) 
adapted the American Thoracic Society’s Standardization of Spirometry (348) and moderate 
severity of COPD was defined as FEV1 50-65% of predicted. Three studies (80, 343, 349) did 
not specify the stage of COPD of the participants, and none of the papers referenced quality 
standards of spirometry performance (350).  
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Table 6. 1 Characteristics of included studies for the review of Ginseng formulae for stable COPD 
First author, 
year  
[ref. no.] 
Location of 
Hospital 
Source of 
patients 
Number of 
Participants 
(R/A) 
Number of  
Male 
/Female 
Age 
Mean ± SD 
(years) 
Severity of COPD Syndrome 
Differentiation of 
CM 
COPD 
History 
Mean ± SD 
(years) 
Chen,2007[340] 
Chendu, 
China 
Outpatients 
T: 59/59 
C: 58/58 
T: 45/14 
C:42/16 
T:59.03±6.70 
C: 58.59±6.29 
T: I: 13, IIA: 20, IIB: 18, III: 8 
C: I: 16, IIA: 19, IIB: 17, III: 6 
Lung & Kidney 
deficiency 
NS 
Chen, 
2004[344] 
Nanping, 
China 
Inpatients 
T: 30/30 
C: 30/30 
35/25 65.00±NA Mild 15, Moderate 26, Severe 19 NS 60.21±NS 
Gross, 
2002[79] 
Tel Aviv, 
Israel 
NS 
T&C: 100/91 
T: 51; C: 41 
T: 30/21 
C: 25/16 
T: 59.0±12.6 
C: 62.0±10.5 
FEV1: 50-65% of predicted NS NS 
Guo,2008[345] 
Tangshan, 
China 
Outpatients 
T: 50/50 
C: 50/50 
T: 36/14 
C:34/16 
T: 56.00±NA 
C: 55.00±NA 
T: mild 8, moderate 33, severe 9 
C: mild 7, moderate 35, severe 8 
NS 
T: 16.00±NS 
C: 14.00±NS 
Hong, 
2005[346] 
Zhangzhou, 
China 
Inpatients & 
outpatients 
T: 18/18 
C: 18/18 
T: 16/2 
C: 15/3 
T: 67.56±5.19 
C: 66.00±6.40 
T: II: 3, III: 5; C: II: 3, III: 15 
Lung & Spleen & 
Kidney deficiency 
T: 15.22±5.12 
C: 14.17±6.15 
Huang, 
2005[347] 
Guangzhou, 
China 
Outpatients 
T: 32/32 
C: 31/31 
T: 21/11 
C: 23/8 
T: 69.50±11.80 
C: 68.80±10.60 
T: II: 17, III: 15; C: II: 18, III: 13 NS 
T: 8.50±3.20 
C: 8.30±3.50 
Huang, 
2002[341] 
Xuzhou , 
China 
Inpatients & 
outpatients 
T: 300/300 
C: 300/300 
T: 185/115 
C: 202/98 
T: 52.50±4.40 
C: 57.20±10.40 
Mild to moderate 
Lung & Kidney 
deficiency 
T: 7.20±4.40 
C: 8.50±3.60 
Li, 2006[69] 
Zhengzhou, 
China 
NS 
T: 31/31 
C: 31/31 
T: 22/9 
C: 23/8 
T: 72.00±5.00 
C: 71.00±7.00 
T: mild 5,moderate 21,severe 6 
C: mild 4,moderate 21, severe 5 
Lung & Kidney 
deficiency 
T: 18.40±1.10 
C:19.50±6.60 
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First 
author,  
date  
Location of 
Hospital 
Source of 
patients 
Number of 
Participants 
(R/A) 
Number of  
Male 
/Female 
Age 
Mean ± SD 
(years) 
Severity of COPD 
Syndrome 
Differentiation of 
CM 
COPD History 
Mean ± SD 
(years) 
         
Lin, 
2003[349] 
Guangzhou, 
China 
inpatients & 
outpatients 
T: 30/30 
C: 30/30 
T: 20/10 
C: 22/8 
T: 62.00±NS 
C: 60.50±NS 
NS Spleen deficiency 
T: 16.00±NS 
C: 15.40±NS 
Wu, 
2006[342] 
Xinxiang, 
China 
Inpatients & 
outpatients 
T: 100/100 
C: 100/100 
T: 68 /32 
C: 72/28 
T: 71.87±4.37 
C: 69.33±5.71 
T: mild 21, moderate 48, severe 
31 C: mild 23, moderate 51, 
severe 26 
Lung & Kidney   
deficiency 
T: 18.70±3.72 
C: 17.81±4.57 
Xiong, 
2008[80] 
Shenzhen, 
China 
Inpatients & 
outpatients 
T: 30/30; 
C: 30/30 
T: 20/10 
C: 21/9 
T&C: 72.00±NS Average of  FEV1: 52.3% 
Lung & Kidney 
deficiency 
NS 
Xu, 1996[343] 
Luzhou, 
China 
Inpatients & 
outpatients 
T: 72/72 
C: 30/30 
T: 52/20 
C: 21/9 
T: 63.50±NS; 
C: 60.80±NS 
NS Qi deficiency 
T: 9.50±NS 
C: 9.00±NS 
T: treatment; C: control; NS: not specified; COPD: chronic obstructive pulmonary disease; SD: standard deviation; CM: Chinese medicine; 
[]
reference’s number.
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Guided by Chinese medicine syndrome differentiation guidelines such as the Chinese 
Medicine Clinical Research Guidelines for New Drugs (351), eight studies reported stable 
COPD patients as Lung deficiency with Kidney and/or Spleen deficiency (69, 80, 340-342, 
346, 349) or Qi deficiency (343). Six of the 12 studies compared oral Ginseng formulae with 
placebo or no treatment (69, 79, 341, 342, 346, 349). Two studies compared Ginseng 
formulae with other oral CHM formulae without Ginseng (340, 343). Four studies compared 
the Ginseng formulae plus RP or Ginseng formulae alone with RP (inhaled β2 agonist and 
anti-cholinergic or oral theophylline alone) (80, 344, 345, 347) (Table 6.2). Duration of 
treatment ranged from one month in three studies (341, 343, 345), two months in three studies 
(69, 342, 349), three months in three studies (340, 344, 347), to six months in three studies 
(79, 80, 346). Three studies mentioned a 6-month follow-up period (340, 346, 347). None of 
the included studies mentioned a run-in period (Table 6.2). 
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Table 6. 2 Characteristics of interventions and outcome measures of included studies for the review of Ginseng formulae for stable COPD 
First author, 
year  
[ref. no.] 
Intervention  
(ingredients of Ginseng formulae) 
Controlled Interventions 
Jadad’s 
scale 
Duration/ 
Follow 
up 
Adverse 
event 
Outcome measures 
Spirometric 
parameter 
PESI QoL FCOPDE 
Chen,2007[340] 
Feikongning capsule (Panax Ginseng, 
Cordyceps, Radix Salviae Miltiorrhizae, Semen 
Armeniacae Amarum), 3 capsules, 3 times daily 
Jinshuibao capsules 
(Fermented Cordyceps 
powder), 3 capsules, 3 times 
daily 
2 
3 mths / 
6 mths 
No Yes Yes NS Yes  
Chen, 
2004[344] 
Yifei pill (Panax Ginseng, Gecko, Fructus 
Psoraleae) 2 pills, 3 times daily 
Pharmacotherapy (NS) 1 
3 mths / 
NS 
NS Yes NS NS NS 
Gross, 
2002[79] 
Panax Ginseng extract 100mg, twice daily Placebo control 5 
6 mths / 
NS 
No Yes NS NS NS 
Guo,2008[345] 
Jianfei capsule (Panax Ginseng, Gecko,  
Rhizoma Fagopyri Dibotryis, Bulbus Fritillariae 
Cirrhosae, Lumbricus, Semen Armeniacae 
Amarum) 2-3 pills, 3 times daily 
Pharmacotherapy (Long 
acting β2 agonists & 
Theophyline) 
1 
1 month / 
NS 
NS NS Yes NS NS 
Hong, 
2005[346] 
Yufeining pill (Panax Ginseng, Radix Astragali, 
Rhizoma Atractylodis Macrocephalae, Radix 
Saposhnikoviae, Placenta Hominis, Semen 
Armeniacae Amarum, Semen Cuscutae, Fructus 
Corni, Fructus Schisandrae, Semen Juglandis, 
Fructus Trichosanthis, Semen Persicae) 
No treatment 2 
6 mths / 
6 mths 
No Yes NS NS NS 
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First author, 
year  
[ref. no.] 
Intervention  
(ingredients of Ginseng formulae) 
Controlled Interventions 
Jadad’s 
scale 
Duration/ 
Follow 
up 
Adverse 
event 
Outcome measures 
Spirometric 
parameter 
PESI QoL FCOPDE 
6g, twice daily 
Huang, 
2005[347] 
Jianpiyifei granule (Panax Ginseng, Rhizoma 
Atractylodis Macrocephalae, Poria, Radix 
Ophiopogonis, Cortex Mori, Radix Astragali) 
10g, 3 times daily 
Pharmacotherapy (NS) 1 
3 mths /  
6 mths 
Mild Yes NS Yes Yes 
Huang, 
2002[341] 
Bufeiguben granule (Panax Ginseng, Gecko, 
Herba Epimedii, Semen Juglandis, Fructus 
Psoraleae, Fructus Schisandrae), 10g, 3 times 
daily 
Placebo (Hawthorn) 1 
1 month / 
NS 
NS Yes NS NS NS 
Li, 2006[69] 
Bufeiyishen granule (Panax Ginseng, Radix 
Astragali, Radix Saposhnikoviae, Fructus 
Psoraleae, Fructus Schisandrae, Rhizoma 
Ligusticum, Semen Armeniacae Amarum, etc.) 
10g, 3 times daily 
Placebo control (Hawthorn 
fruit and Malt) 
2 
2 mths / 
NS 
NS Yes NS NS NS 
Lin, 2003[349] 
Jianpiyifei granule (Radix Ginseng, Rhizoma 
Atractylodis Macrocephalae, Poria, Radix 
Ophiopogonis, Cortex Mori, Radix Astragali), 
10g, 3 times daily 
Placebo control (Stroma 
granule) 
1 
2 mths / 
NS 
NS Yes Yes NS NS 
Wu, 2006[342] 
Jiaweishenge granule (Panax Ginseng, Gecko, 
Semen Armeniacae Amarum, Bulbus Fritillariae 
Placebo control (Hawthorn, 
Fructus Hordei Germinatus, 
1 
2 mths / 
NS 
No Yes NS NS NS 
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First author, 
year  
[ref. no.] 
Intervention  
(ingredients of Ginseng formulae) 
Controlled Interventions 
Jadad’s 
scale 
Duration/ 
Follow 
up 
Adverse 
event 
Outcome measures 
Spirometric 
parameter 
PESI QoL FCOPDE 
Cirrhosae, Poria, Cortex Mori, Radix Astragali, 
Rhizoma Atractylodis Macrocephalae, 
Cordyceps, Rhizoma Ligusticum , Lumbricus) 
60.5g/packet, 1 packet, 3 times daily 
medicated leaven) 
Xiong, 
2008[80] 
Shenge granule (Panax Ginseng, Gecko), 5g, 
twice daily 
Pharmacotherapy (Inhaled 
Salmeterol & fluticasone, 
50/250 ug, one puff, twice 
daily) 
1 
6 mths / 
NS 
NS Yes Yes NS NS 
Xu, 1996[343] 
Yiqimianyi granule (Panax Ginseng, Rhizoma 
Atractylodis Macrocephalae, Poria) 20g, 3 
times daily 
Zhenqi Fuzheng granule 
(Fructus Ligustri Lucidi, 
Radix Astragali) 15g, twice 
daily 
1 
30 days / 
NS 
NS NS Yes NS NS 
NS: Not specified; PESI: Percentage of effectiveness of symptoms improvement; QoL: Quality of life; FCOPDE: Frequency of COPD exacerbation;
 []
reference’s number. 
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6.1.4 Risk of bias assessment 
This SR was conducted in 2010, so risk of bias assessment was based on Cochrane handbook 
for SRsof interventions (version 5.0.1) 2008 (352), consisting of six domains of potential bias 
which were answered by denoting ‘yes’ (low risk of bias), or ‘no’ (high risk of bias) or 
‘unclear’ (uncertain risk). 
Information on sequence generation was adequate for three studies at low risk of bias (yes) 
(79, 340, 346) and inadequate for nine studies with unclear risk of bias (unclear) (69, 80, 341-
345, 347, 349). The methods of allocation concealment were judged as ‘unclear’ in all studies. 
Blinding was reported in two studies with one being described as double blind (79) and 
another as single blind (347). However blinding of participants, personnel and outcome 
assessors in all studies was ‘unclear’. Low risk of bias from incomplete outcome data was 
noted in 11 studies (69, 79, 80, 340, 342-347, 349), and one was ‘unclear’ (341). Intention-to-
treat analysis was not conducted in any of these studies. Selective outcome reporting was 
judged as low risk of bias in six studies (69, 340, 341, 343, 347, 349) and as high risk of bias 
in six studies (79, 80, 342, 344-346). Assessments of other sources of bias involved baseline 
data imbalance. All 12 studies indicated no significant difference of baseline data between the 
two groups; none of the studies reported the sample size calculation method, therefore 
information on early stopping was insufficient. Overall, other sources of bias were ‘unclear’. 
Detailed information is provided in Figure 6.2. 
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Figure 6. 2 Summary of assessment of risk of bias for the review of Ginseng formulae for stable COPD 
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6.1.5 Methodological quality assessment by Jadad’s scale 
One study was rated with a score of 5 (highest quality) (79); three studies with a score of 2 
(69, 340, 346) and eight studies with a score of 1 (80, 341-345, 347, 349) (see Table 6.2). 
6.1.6 Outcomes 
Spirometric parameters was performed in ten studies, symptom improvement was assessed 
five by studies, HRQoLusing SGRQ or Cai’s QoLQ was reported in two studies and COPD 
exacerbations was mentioned in two studies. 
6.1.7 Results of all outcomes for ginseng formulae 
6.1.7.1 Spirometric parameters 
Pre and post-treatment mean FEV1 (69, 80, 340-342, 346, 347) (Fig 6.3) and FEV1 % 
predicted (69, 340, 344, 346) (80, 342, 349) (Fig 6.4) were reported in seven studies 
respectively. Another study did not report post-treatment FEV1 (79) and it was not included in 
this analysis.  
Marginal but significant differences in absolute FEV1 (MD 0.30, 95%CI 0.02 to 0.58) (69, 
341, 342) and FEV1 % predicted (MD 9.43, 95%CI 3.64 to 15.21) (69, 342, 349) were found 
between Ginseng formulae and placebo. Similar changes were shown in studies comparing 
Ginseng formulae with non-Ginseng formulae, absolute FEV1 (MD 0.25, 95%CI 0.06 to 0.44), 
and FEV1% predicted (MD 4.76, 95%CI 0.36 to 9.16) (340). Such changes were not observed 
using Ginseng formulae alone versus no treatment (FEV1 [MD 0.10, 95%CI -0.11 to 0.31] 
and FEV1 % predicted [MD 2.32, 95%CI -6.84 to 11.48]) (346) or versus RP alone (FEV1 
[MD 0.25, 95%CI -1.84 to 2.34] and FEV1 % predicted [MD 2.03, 95%CI -2.63 to 6.69]) (80) 
(Figures 6.3 & 6.4). 
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Figure 6. 3 Ginseng formulae versus placebo, no treatment, non-Ginseng formulae, or pharmacotherapy 
as well as Ginseng formulae plus pharmacotherapy versus pharmacotherapy for pre-post changes of FEV1 
(L) of patients with stable COPD 
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Figure 6. 4 Ginseng formulae versus placebo, no treatment, non-Ginseng formulae, or pharmacotherapy 
as well as Ginseng formulae plus pharmacotherapy versus pharmacotherapy for pre-post changes of FEV1 
(%) of patients with stable COPD 
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6.1.7.2 Symptom improvement 
The Ginseng formulae group showed a higher percentage of symptom improvement when 
compared with placebo (RR 1.53, 95%CI 1.09 to 2.16) (349), or non-Ginseng formula group 
(RR 1.11, 95%CI 1.00 to 1.24) (340, 343), or Ginseng formulae plus pharmacotherapy versus 
pharmacotherapy (RR 1.14, 95%CI 1.00 to 1.31) (345). However such a change was not 
observed using Ginseng formulae alone versus pharmacotherapy alone (RR 1.17, 95%CI 0.93 
to 1.48) (80) (Figure 6.5). 
 
 
Figure 6. 5 Ginseng formulae versus placebo, no treatment, non-Ginseng formulae, or pharmacotherapy 
as well as Ginseng formulae plus pharmacotherapy versus pharmacotherapy for pre-post changes of 
symptoms improvement of patients with stable COPD 
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6.1.7.3 Quality of life 
In the study in which QoL was measured by using a validated instrument (SGRQ), there was 
an improvement in the SGRQ when comparing Ginseng formulae plus pharmacotherapy to 
pharmacotherapy alone (MD -10.32, 95%CI -14.99 to -5.65) (347). Furthermore, a positive 
QoL improvement was also reported by another study (346) using a self-modified 
questionnaire developed by Cai et al.  
6.1.7.4 Exacerbation of COPD  
Two studies (340, 347) reported on ECOPD during the follow-up period. Significant 
reduction in the number of patients developing ECOPD was reported in the study using a 
Ginseng formula compared to a non-Ginseng formula (RR 0.40, 95%CI 0.18 to 0.90) (340), 
but no additional benefit of a Ginseng formula to pharmacotherapy was shown (RR 0.68, 
95%CI 0.42 to 1.09) (347). In addition, one study compared Ginseng formula with no 
treatment and reported that the number of COPD exacerbations per annum was significantly 
less in the treatment group (MD -1.52 95%CI-2.32 to -0.72) (346). 
6.1.7.5 Adverse events 
One study involving 63 subjects stated that dry mouth, mild stomach bloating and reduced 
appetite were observed in three subjects (two from the treatment group and one in the control 
group). These symptoms disappeared within one week without medical interventions (347). 
Four studies reported that there were no adverse events in the trials (79, 340, 342, 346). The 
remaining seven studies did not report adverse events (69, 341, 344, 345) (80, 343, 349). 
6.1.8 Discussion of results for ginseng formulae 
This review shows that the Ginseng formulae were more effective in improving FEV1 when 
compared with placebo (69, 341, 342, 349) or non-Ginseng formulae (340) for subjects with 
stable COPD at various stages. Ginseng formulae were also associated with higher 
percentages of symptom improvement versus placebo or pharmacotherapy. A Ginseng 
formula was beneficial for QoL based on SGRQ (347) and two Ginseng formulae reduced the 
frequency of exacerbations (340, 347). Overall, Ginseng formulae were well tolerated by 
subjects. 
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The majority of the 12 included studies suffered from methodological weaknesses based on 
assessment of the Cochrane risk of bias and the Jadad’s scale. The inadequacy of blinding and 
placebo control (353), allocation concealment and sequence generation (354) were the major 
sources of potential bias as well as treatment durations ranging from one month (341, 343, 
345) to six months (79, 80, 346) and using Ginseng formulae as an add-on treatment to RP for 
COPD (80, 344, 345, 347). Therefore, the findings from this review need to be interpreted 
with caution. 
Despite the methodological weakness and potential risk of bias, the findings of the present 
review are promising. Particularly for the improvement of the lung functions based on pre and 
post FEV1 and FEV1 % predicted between Ginseng formulae and placebo or no treatment or 
non-Ginseng formulae groups. These findings are consistent with recent RCTs on the effect of 
a phosphodiesterase-4 (PDE4) inhibitor (roflumilast) (206) on lung function in patients with 
moderate to severe COPD who were on salmeterol and tiotropium treatment. The two trials, 
involving 1,676 COPD subjects, concluded that, compared with placebo, 24 weeks of 
roflumilast treatment significantly and consistently improved mean pre and post-
bronchodilator FEV1 (p < 0.0001).  
A large study involving almost 6,000 subjects conducted in 37 countries demonstrated that 
prolonged intervention (4 years) of a long acting bronchodilator, tiotropium, on moderate 
COPD patients (GOLD Stage II) was effective in reducing the rate of decline of post-
bronchodilator FEV1. However, such changes were not shown in pre-bronchodilator FEV1 
between the treatment groups (188). Tiotropium also improved the general health status, QoL 
based on SGRQ as well as reducing the frequencies of exacerbations and subsequent 
hospitalizations (355). It was therefore concluded earlier and long-term intervention is critical 
to the treatment of COPD.  
When Ginseng formulae were compared with placebo or non-Ginseng formulae, the observed 
benefits were clearly demonstrated (69, 80, 340-342, 344, 349). Such findings showed the 
potentially important role that Ginseng might have played in these studies, particularly in the 
study in which a standardized Ginseng extract was used alone (79).  
Ginseng as the key herb possesses a broad range of pharmacological activities which may 
offer plausible explanations to the observed clinical benefits found in this review. For 
example, Ginseng raw extract or purified ginsenosides have been shown to enhance markedly 
the action of the diterpene forskolin in elevating intracellular cAMP levels in rat cultured 
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glioma cell (356). Two ginsenosides, panaxadiol (PD) and panaxatriol (PT) have been shown 
to have potent inhibitory effects on the expression of matrix metalloproteinase-9 (MMP-9) 
(357). Compound K of ginseng showed similar effects in an experiment with human 
astroglioma cells (358). Ginseng taken daily for 4 weeks has been found to linearly increase 
plasma concentrations of certain antioxidants in smokers. 
These findings are significant since oxidative damage caused by free radicals associated with 
smoking is thought to contribute to the development of COPD (359). Protopanaxadiol 
ginsenosides (PPDGs) such as Rb1 and Rb2 have been demonstrated to have significant 
potency as inhibitors of lipopolysaccharide-induced production of tumor necrosis factor-alpha 
(TNF-α) in murine (RAW264.7) cells and human (U937) macrophages (360). This effect was 
significantly enhanced by various TNF-α antagonists (360).  
It is also important to note that due to the heterogeneity of the studies included in this review, 
the observed benefits could be a combined outcome of inclusion of unspecified proportions of 
patients at various stages of COPD, the use of a range of herbal formulations, the uncertain 
quality of spirometric measurements; and the potential of real benefit of Ginseng in treating 
COPD. 
Generally speaking adverse event reporting in the included studies was inadequate. However, 
the safety profile of Ginseng has been demonstrated in a systematic review, which concluded 
that Panax ginseng mono-preparations are rarely associated with adverse events or drug 
interactions (361). 
6.1.9 Conclusions for ginseng formulae  
Despite the quality concerns of the included studies, the observed benefits of Ginseng 
formulae are encouraging. Further trials are warranted to determine the true benefits of 
Ginseng. These trials must address the methodological problems identified in this review. 
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6.2 Effectiveness of CHM for improving health-related quality of life  
6.2.1 Introduction 
COPD causes impairment in HRQoL of these patients. Even with optimal medical treatment, 
the HRQol status inevitably worsens (362). Therefore new interventions that slow the decline 
in HRQoL are needed. A second SR on CHM for improving HRQoL was conducted in June 
2010, and the search data was updated in April 2011. The updated version was accepted by 
Journal of Alternative Complementary Medicine in September 2011.  
In this SR the search strategy including the search terms and databases searched was the same 
as in the above section on methods for SRs (Section 4.2). 
Study selection inclusion criteria were: 1. RCTs of CHM for stable COPD; and 2. using a QoL 
questionnaire (QoLQ) as a primary outcome measure; 3. the comparison was with placebo, no 
treatment or RP and 4. the CHM was orally administered 
6.2.2 Search results 
A total of 1,713 potential articles were initially identified. Further screening of abstracts and 
full texts identified 348 requiring detailed evaluation. Of these 321 were excluded for various 
reasons, including six studies that administered the CHM via IV drip and 3 studies that used 
QoLQ as an outcome. Finally, twenty-seven studies met all the selection criteria and were 
included in this SR (Figure 6.6). 
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Fig 6.6. Flow diagram for study selection process 
1713 Records identified 
through database searches:  
Pubmed, EMBASE, Scopus, 
CINAHL, Cochrane & CNKI, 
CQVIP, WANFANG  
 
1597 Records after duplicates 
removed  
 
1597 Records screened  
 
1249 Records excluded  
 
348 Full-text articles assessed 
for eligibility  
 
321 Full-text articles 
excluded, with reason:  
1. CHM was administrated by IV 
drop (n=6) 
2. Not RCTs (n=30) 
3. Patients with asthma & cor 
pulmonale (n=26) 
4. Oral CHM for not stable COPD 
(n=157)  
5. Duplicated trials (n=20) 
6. QolQ not used as outcome 
measure (n=74) 
7. CHM as control groups (QolQ 
used) (n=3) 
8. Other (n=5) 
 
27 Studies included in 
qualitative synthesis  
 
24 Studies included in 
quantitative synthesis  
(Meta-analysis) 
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Figure 6. 6 Flow diagram for study selection process for review of Chinese herbal medicine for Quality of 
Life improvement in stable COPD 
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6.2.3 Characteristics of included studies 
The main characteristics of the individual studies: study location, study design, sample size, 
gender, average age of patients, and the severity of COPD, Chinese medicine syndrome 
differentiation, and average years of COPD are summarized in Table 6.3.  
6.2.3.1 Participants  
The twenty-seven included studies were all conducted in China. They involved 1,966 
participants. The average ages ranged from 59.4 to 72.0 across the studies. All participants 
were in the stable stage and diagnosis was based on the GOLD guideline modified by the 
CSRD (91). There were drop-outs during the treatment period in five studies totaling 52 
participants but intention-to-treat (ITT) analysis was not applied (363-367). In twenty studies 
the severity of COPD in individual patients was described as four stages: I - mild, II - 
moderate, III - severe, IV - very severe (235, 312, 346, 347, 363-365, 368-378), which was in 
accord with the guidelines by CSRD (91). Severity of COPD was not described in seven 
studies (367, 379-384). CM differentiation of syndromes was described in ten studies (235, 
346, 368, 369, 371, 376, 379, 381, 383, 384). Sixteen studies reported the average number of 
years patients had suffered from COPD (235, 346, 347, 366, 369, 372-374, 376, 377, 379, 
381-384). 
6.2.3.2 Duration of treatment and follow up  
Duration of treatment was up to two months in six studies (366, 373, 375, 381, 383, 384), two 
to four months in six studies (312, 347, 365, 368, 369, 376), and six months in fifteen studies 
(235, 346, 363, 364, 367, 370-372, 374, 377-380, 382, 385). A follow up period was 
mentioned in four studies (346, 364, 366, 380) (see Table 6.3). 
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Table 6. 3 Characteristics of included studies for the review of Ginseng formulae for stable COPD 
First 
author, 
year 
[ref. no.] 
Location, Design 
[duration / 
follow up] 
Out /in 
patients 
No. subjects 
(R/A) 
M/F 
Age 
Mean SD 
(years) 
Severity of COPD: No. 
subjects 
CM Syndrome 
Differentiation 
COPD history 
(years) 
Chen, 
2009
[312]
 
Fujian, China 
RCT [3 mths/NS] 
Out patients 
T: 30/30 
C: 30/30 
29/31 70.1 III & IV: NS NS NS 
Fang, 
2008
[363]
 
Guangdong, China 
RCT [6 mths /NS] 
NS 
T: 35/30 
C: 35/26 
T: 26/4 
C: 23/3 
T: 68.0 ± 5.70 
C: 68.0±4.96 
T: I 8, II 22 
C: I 6, II 20 
NS NS 
Feng, 
2005
[368]
 
Beijing, China 
RCT [3 mths/NS] 
Out patients 
T: 35/35 
C: 37/37 
T: 16/19 
C: 18/19 
T: 60.59±8.99 
C: 56.57±8.81 
T: 0 8, I 9, II 9, III 9 
C: 0 8, I 12, IIA 9, III 8 
Qi deficiency & 
blood stasis 
NS 
Feng, 
2007
[368]
 
Beijing, China 
RCT [3 mths/NS] 
Out patients 
T: 46/46 
C: 30/30 
T: 25/21 
C: 14/16 
T: 63.37±8.99 
C: 62.26±8.72 
T: II 24, III 22 
C: II 16, III 14 
Qi deficiency & 
blood stasis 
T: 6.15±1.71 
C: 6.23± 1.59 
Feng, 
2008
[379]
 
Hebei, China 
RCT [6 mths/NS] 
NS 
T: 60/60 
C: 60/60 
NS 63.0 ± 5.0 NS 
Lung & Spleen & 
Kidney deficiency 
14.0±5.0 
Hong, 
2005
[346]
 
Fujian, China  
RCT [6 mths/6 mths] 
NS 
T: 20/20 
C:18/18 
T: 17/3 
C: 16/2 
T: 67.7±5.68 
C: 66.89±5.57 
T: II 5, III 15 
C: II 4, III 14 
Lung & Spleen & 
Kidney deficiency 
T: 15.05±5.54 
C: 14.33±7.28 
Huang, 
2005
[347]
 
Guangdong, China 
RCT [3 mths/NS] 
Out patients 
T: 32/32 
C: 31/31 
T: 21/11 
C: 23/8 
T: 69.5±11.8 
C: 68.8±10.6 
T: II 17, III 15 
C: II 18, III 13 
NS 
T: 8.5±3.2 
C: 8.3±3.5 
Jia, 
2007
[370]
 
Jiangsu, China 
RCT [6 mths/NS] 
NS 
T: 30/30 
C: 25/25 
T: 23/7 
C: 17/8 
T: 61.6±6.1 
C: 63.2±5.3 
T: I 5, II 18, III 7 
C: I 3, II 17 III 5 
NS NS 
Jian, 
2008
[371]
 
Guangdong, China 
RCT [6 mths/NS] 
Out/ 
In patients 
T: 23/23 
C: 22/22 
T: 18/5 
C: 16/6 
T: 71±9.6 
C: 69±8.9 
T: I 7, II 16 
C: I 7, II 15 
Lung & Kidney 
deficiency 
NS 
Lang, 
2010
[380]
 
Shanghai, China 
RCT [6 mths/6 mths] 
NS 
T: 30/30 
C: 30/30 
NS NS NS NS NS 
Liang, 
2009
[372]
 
Guangxi, China Out patients T: 32/32 T: 20/12 T: 69.73±NS T: IIA13, III 12, IV 7 NS T: 17.32±NS 
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First 
author, 
year 
[ref. no.] 
Location, Design 
[duration / 
follow up] 
Out /in 
patients 
No. subjects 
(R/A) 
M/F 
Age 
Mean SD 
(years) 
Severity of COPD: No. 
subjects 
CM Syndrome 
Differentiation 
COPD history 
(years) 
RCT [6 mths/NS] C: 33/33 C: 22/11 C:70.69±NS C: IIA 15, III 12, IV 6 C: 17.02±NS 
Liu, 
2005
[364]
 
Guangdong, China 
RCT [6 mths/6 mths] 
NS 
T: 30/26 
C: 30/25 
T: 22/4 
C: 23/2 
T: 68.0 ± 5.70 
C: 68.0±4.96 
T: I 4, II 22 
C: I 5, II 20 
NS NS 
Liu, 
2006
[385]
 
Guangdong, China 
RCT [6 mths/NS] 
Out/ 
In patients 
T: 30/30 
C: 30/30 
T: 25/5 
C: 23/7 
T: 67.37±6.03 
C: 67.27±5.75 
T: I 4, II 26 
C: I 5, II 25 
NS 
T: 3.62±2.07 
C: 3.62±2.07 
Liu, 
2010
[386]
 
Shanghai, China 
RCT [6 mths/NS] 
Out patients 
T: 30/30 
C: 30/30 
T: 18/12 
C: 16/14 
T: 65.12±5.36 
C: 64.12±7.36 
T: 0 5, I 9, II 16 
C: 0 6, I 10, II 14 
Qi deficiency and 
phlegm stasis  
T: 17.32±2.36 
C: 16.12±2.06 
Mai, 
2009
[373]
 
Guangdong, China 
RCT [2 mths/NS] 
Out patients 
T: 40/40 
C: 40/40 
T: 22/18 
C: 24/16 
T: 67.70±6.80 
C: 66.89±5.87 
T: II 12, III 28 
C: II 10 III 30 
NS 
T: 13.05±6.84 
C: 14.53±6.05 
Ni, 
2008
[381]
 
Shanghai, China 
RCT [2 mths/NS ] 
Out patients 
T: 34/34 
C: 34/34 
T: 19/15 
C: 20/14 
T: 64.35±6.77 
C: 64.62±7.05 
NS Kidney deficiency 
T: 11.24±5.02 
C: 10.50±4.56 
Shan, 
2007
[374]
 
Guangdong, China 
RCT [6 mths/NS] 
Out/ 
In patients 
T: 28/28 
C: 27/27 
T: 24/4 
C: 24/3 
T: 66.75±5.95 
C: 66.89±6.18 
T: I 5, II 23 
C: I 6, II 21 
NS 
T: 17.32±7.23 
C: 16.15±6.18 
Shi, 
2009
[382]
 
Tianjin, China 
RCT [6 mths/6 mths] 
NS 
T: 90/90 
C: 90/90 
103/87 63.0±5.0 NS NS 14.0±5.0 
Sun, 
2009
[374]
 
Tianjin, China 
RCT [1 mth/NS] 
Out patients 
T: 30/30 
C: 30/30 
T: 21/9 
C: 22/8 
T: 60.97±8.97 
C: 59.54±10.87 
II & III: NS NS NS 
Tang, 
2009
[383]
 
Guangdong, China 
RCT [2 mths/NS] 
Out/ 
In patients 
T: 30/30 
C: 30/30 
T: 27/3 
C: 26/4 
T: 63.2± NS 
C: 65.5± NS 
NS 
Lung Qi & Kidney Qi 
deficiency 
T: 7.2±NS 
C: 7.5±NS 
Tang, 
2010
[375]
 
Shanghai, China 
RCT [3 mths/NS] 
Out patients 
T: 34/34 
C: 35/35 
T: 23/11 
C: 26/9 
T: 72.18± 10.78 
C: 71.00± 10.53 
T: I-II 8, III-IV 26 
C: I-II 8,  III-IV 27 
Lung & Spleen & 
Kidney deficiency 
T: 14.53±9.15 
C: 15.46±10.89 
Wang, 
2009
[384]
 
Zhejiang, China 
RCT [2 mths/NS] 
In patients 
T: 30/30 
C: 32/32 
T: 24/6 
C: 25/7 
T: 70.5± NS 
C: 69.8± NS 
NS 
Lung Qi & Spleen Qi 
deficiency 
T: 7.3±NS 
C: 6.8±NS 
Wu, 
2007
[365]
 
Guangdong, China NS T: 71/63 T: 49/14 T: 61.5±NS T: I 15, II 29, III 19 NS NS 
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First 
author, 
year 
[ref. no.] 
Location, Design 
[duration / 
follow up] 
Out /in 
patients 
No. subjects 
(R/A) 
M/F 
Age 
Mean SD 
(years) 
Severity of COPD: No. 
subjects 
CM Syndrome 
Differentiation 
COPD history 
(years) 
RCT [4 mths/NS] C: 62/59 C: 43/16 C: 61.9±NS C: I 14, II 27, III 18 
You, 
2008
[366]
 
Hunan, China 
RCT [2 mths/1 year] 
Out patients 
T: 32/30 
C: 32/30 
T: NS 
C: NS 
T: 59.43±11.56 
C: 56.23±10.69 
I & II:NS NS 
T: 6.15±1.71 
C: 6.23± 1.59 
Zhang, 
2006
[377]
 
Guangdong, China 
RCT [6 mths/NS] 
NS 
T: 24/24 
C: 22/22 
T: 18/6 
C: 17/5 
T: 66.70±6.60 
C: 67.89±4.57 
T: II 5, III 14 
C: II 4, III 18 
NS 
T: 14.05±6.54 
C: 15.33±5.0 
Zhang, 
2009
[368]
 
Guangdong, China 
RCT [6 mths/NS] 
Out patients 
T: 60/56 
C: 60/48 
NS 68.4±NS NS NS NS 
Zhu, 
2007
[378]
 
Guangdong, China 
RCT [6 mths/NS] 
Out/ 
In patients 
T: 35/35 
C: 32/32 
T: 16/19 
C: 15/17 
T: 72.0±10.3 
C: 71.7±9.5 
T: I 22, II 13 
C: I 20, II 12 
NS NS 
 
NS: not specified; R: number subjects randomized; A: number subjects analysed; RCT: randomized controlled trial; CM: Chinese medicine; 
[]
reference’s number.  
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6.2.3.3 Intervention and control groups 
CHM was compared with placebo alone in one study (375), with no treatment control in 
seven studies (346, 347, 363-365, 367, 373), and with RP in one study (378). In one study 
CHM plus RP was compared with placebo plus RP (381). The remaining studies compared 
CHM plus RP with RP alone.  
6.2.3.4 Routine pharmacotheropy used in the studies 
The RP used was variable. It mainly involved bronchodilators such as the beta 2 agonists 
salbutamol and salmeterol, anticholinergics (e.g. ipratropium bromide) or theophylline. These 
were used alone or in combination (366, 368, 372-374, 381, 384, 385). Five studies used 
inhalation of a β2 agonist or an anticholinergic alone or a combination of β2 agonist and 
anticholinergic (235, 312, 370, 371, 378). Inhalation of a β2 agonist with oral theophylline 
was used in three studies (372, 381, 384). One study used inhalation of a β2 agonist plus a 
glucocorticosteriod (Becotide) (366). Oral theophylline was used alone in two studies (374, 
385). CHM alone versus inhalation of ipratropium bromide aerosol was used in one study 
(378). One study mentioned that the RP included antibiotics, expectorants and bronchodilators 
but provided no further detail (381). Seven studies did not provide information on the RP 
used(347, 369, 373, 376, 379, 380, 382) (see Table 6.4).  
CHM formulae were in the form of pills, capsules, granules, syrup or decoctions (see table 2). 
The individual formulae comprised from 1 to 17 different herbs. Two studies used syndrome 
differentiation according to CHM principles to select the most appropriate of four CHM 
treatment interventions. Both these studies used very similar designs and formula selection 
(379, 382). Another two studies investigated almost identical formulae (368, 369). Two 
studies investigated modified versions of formulae of the same name (Zhou Fei Tang) (363, 
364).  
6.2.3.5 Herbs used in the studies 
Eighty three different herbs were used in the studies (see Table 6.4). The five most commonly 
used herbs were: 
1) Huang qi Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao (root) in 
fourteen studies (235, 312, 346, 347, 363-365, 367-370, 372, 373) (376, 377, 379, 382);  
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2) Bai zhu Atractylodes macrocephala Koidz (rhizome) in thirteen studies (235, 312, 346, 
347, 365, 366, 372, 374, 376, 377, 379, 382, 384);  
3) Dang shen Codonopsis pilosula (Franch.) Nannf. (root) in twelve studies (312, 363-365) 
(235, 373-377, 379, 382);  
4) Fu ling Poria cocos (Schw.) Wolf (sclerotium) in twelve studies (312, 347, 365-367, 374, 
377, 379, 382, 384-386) ; and  
5) Wu wei zi Schisandra chinensis (Turcz.) Baill (fruit) in ten studies (312, 346, 363, 364, 
373, 374, 378, 379, 381, 382) (Table 6. 4).  
Quality control data on the herbal ingredients was not provided in any of the studies.  
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Table 6. 4 Interventions, controls and adverse events for review of Chinese herbal medicine for Quality of Life improvement in stable COPD 
First 
author, year 
[ref. no.] 
Intervention  
Control 
Adverse 
events 
Formula name (form): Dose, ingredients Plus RP 
Chen, 
2009
[312]
 
Qiweiduqitang (decoction): 250 ml Bid 
Shanzhuyu, Shanyao, Shudihuang, Mudanpi, Zexie, Fuling, Wuweizi, 
Huangqi, Dangshen, Baizhu 
Salmeterol 50μg & 
fluticasone 500μg inhaled 
Bid 
Salmeterol 50μg & 
fluticasone 500μg inhaled 
Bid 
No 
Fang, 
2008
[363]
 
Zoufei Granule:10g Tid  
Dangshen, Guizhi, Ziyuan, Kuandonghua, Wuweizi, Xingren, Taoren, 
Chenxiang, Zishiying.  
No No treatment NS 
Feng, 
2005
[368]
 
Yiqihuoxuehuatan Formula (decoction): 1 packet per day 
Huangqi, Shuizhi, Beimu, Guangdilong etc.  
OR Feikang Granule: 10g daily 
Huangqi, Shuizhi, Huangjing, Danggui, Chenpi etc. 
+ Bailing Capsule: 0.8g Tid, extract of Dongchongxiacao 
Stage 0: No treatment 
Stage 1: Bronchodilators 
(short-acting as needed) 
Stage 2: Bronchodilators OR 
glucocorticoids (inhaler) 
 
Stage 0: No treatment 
Stage 1: 
Bronchodilators(short-acting 
as needed) 
Stage 2: Bronchodilators OR 
glucocorticoids (inhaler) 
NS 
Feng, 
2007
[369]
 
Yiqihuoxuehuatan Formula (decoction): 1 packet per day 
Huangqi, Shuizhi, Banxia, Guangdilong etc.  
OR Feikang Granule: 3g daily.  
Huangqi, Shuizhi, Huangjing, Danggui, Chenpi etc. 
+ Bailing Capsule: 4 caps Tid, extract of Dongchongxiacao 
Routine medication Routine medication NS 
Feng, 
2008
[379]
* 
Bufeitang (decoction): 1 packet per day, in 2 doses (morning & night) 
Dangshen, Huangqi, Baizhu, Shanyao, Wuweizi, Maidong, Yuzhu, Zhimu, 
Jiegeng, Chenpi, Baibu, Zhigancao  
OR Qiweiduqiwan + Shengmaisan (decoction): as above 
Shudi, Shanzhuyu, Shengshanyao, Fuling, Danpi, Gouji, Wuweizi, 
Taizishen, Maidong, Nvzhenzi, Hanliancao  
OR Jinguishenqiwan (decoction): as above 
Shudi, Shanzhuyu, Chaoshanyao, Fuling, Shufuzi, Rougui, Lujiaojiao, 
Tusizi, Dangshen, Baizhu, Danshen, Huainiuxi, Yiyiren  
OR Suzijiangqitang (decoction): as above 
Zisuzi, Banxia, Qianhu, Houpo, Danggui, Chenpi, Rougui, Gancao 
Routine medication Routine medication NS 
Hong, 
2005
[346]
 
Yufeining Pill: 6g Bid  
Renshen, Huangqi, Baizhu, Fangfeng, Ziheche, Hetaorou, Tusizi, 
Shanzhuyu, Wuweizi, Xingren, Gualou, Danshen, Taoren. 
No No treatment No 
Huang, Yupingfeng Granule: 5g Tid  Routine medication Routine medication Yes 
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First 
author, year 
[ref. no.] 
Intervention  
Control 
Adverse 
events 
Formula name (form): Dose, ingredients Plus RP 
2005
[347]
 Huangqi, Fangfeng, Baizhu 
+ Jianpiyifei Granule: 10g Tid 
Renshen, Baizhu, Fuling, Maidong, Sangbaipi, Huangqi. 
+ Bailing Capsule: 1g Tid, extract of Dongchongxiacao 
Jia,  
2007
[370]
 
Yiqihuoxue Formula (decoction): 1 packet per day 
Huangqi, Dilong, Xuanshen, Danshen, Taizishen, Danggui, etc 
Anticholinergics 
(ipratropium bromide 
inhaler) 
Anticholinergics 
(ipratropium bromide 
inhaler)  
NS 
Jian,  
2008
[371]
 
Pingchuan Capsule: 4 capsules Tid 
Renshen, Gejie, Tianqi etc.  
Ipratropium inhaler, 2 puffs, 
Bid 
Ipratropium inhaler, 2 puffs, 
Bid 
NS 
Lang, 
2010
[379]
 
Baibuyangfei Syrup: NS 
Baibu etc. 
Routine medication Routine medication No 
Liang, 
2009
[372]
 
Dongpingtang (powder in decoction): 1 packet per day 
Dongchongxiacao, Huangqi, Baizhu, Fangfeng. 
Stage 1: Salmeterol inhaler, 
200μg up to Tid 
Stage 2: Theophylline 
tablets: 0.1-0.2g Tid OR 
terbutaline sulfate tablets 
2.5mg Bid OR salmeterol 
inhaler, 200μg up to Qid (if 
dyspnoea severe) 
Stage 3: Theophylline 
tablets: 0.1-0.2g Tid OR 
terbutaline sulfate tablets 
2.5mg Tid OR salmeterol 
inhaler, 200μg up to 6 
times/day (if dyspnoea 
severe) 
Stage 1: Salmeterol inhaler, 
200μg up to Tid 
Stage 2: Theophylline 
tablets: 0.1-0.2g Tid OR 
terbutaline sulfate Tablets 
2.5mg Bid Or salmeterol 
inhaler, 200μg up to Qid (if 
dyspnoea severe) 
Stage 3: Theophylline 
tablets: 0.1-0.2g Tid OR 
terbutaline sulfate tablets 
2.5mg Tid OR salmeterol 
inhaler, 200μg up to 6 
times/day (if dyspnoea 
severe) 
Liang, 
2009 
Liu,  
2005
[364]
 
Zoufeitang (decoction): 200ml Bid 
Dangshen, Gejie, Taoren, Wuweizi, , Guizhi, Ziyuan, Kuandonghua, 
Hutaoren, Wuweizi, Kuxingren, Chenxiang, Yangfei. 
No No treatment NS 
Liu,  
2006
[385]
 
Huatanhuoxue Formula (decoction): 1 packet per day 
Chenpi, Fabanxia, Laifuzi, Zisuzi, Zhebeimu, Xingren, Taoren, Fuling, 
Maodongqing, Baijiezi, Gancao.  
Theophylline 0.2g Bid Theophylline 0.2g Bid NS 
Liu, 
2010
[386]
 
Yiqihuoxuehuatantongluo Formula (decoction): 1 packet per day 100ml 
Bid 
Huangqi, Dangshen, Fuling, Baizhu, Chuanbeimu, Dilong, Danshen, 
Xixin, Baijiezi, Zishiying, Hongjingtian 
Salbutamol inhaler 1 or 2 
puffs daily OR salbutamol 
tablet 10g daily 
Salbutamol inhaler 1 or 2 
puffs daily OR salbutamol 
tablet 10g daily 
 
NS 
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First 
author, year 
[ref. no.] 
Intervention  
Control 
Adverse 
events 
Formula name (form): Dose, ingredients Plus RP 
+ Bailing Capsule: 1-2g daily, extract of Dongchongxiacao or Jinshuibao 
Capsule: 1.65g daily 
extract of Dongchongxiacao 
Mai, 
2009
[373]
 
Bufeitang + Renshengejietang (decoction): 200ml per day 
Dangshen, Huangqi, Shudihuang, Wuweizi, Ziyuan, Sangbaipi, Gejie etc. 
Routine medication 
(antibiotics, expectorants, 
bronchodilators) 
Routine medication 
(antibiotics, expectorants, 
bronchodilators) 
NS 
Ni,  
2008
[381]
 
Bushennaqi Granule: 10g Tid 
Buguzhi, Yinyanghuo, Fupenzi, Wuweizi 
Salbutamol inhaler, 
theophylline, prednisone 
Placebo (sShanzha granule) 
+ Salbutamol inhaler, 
theophylline, prednisone 
NS 
Shan, 
2007
[373]
 
Peitushengjintang (decoction): 1 packet per day 
Dangshen, Wuzhualong, Fuling, Baizhu, Shanyao, Wuweizi, 
Kuandonghua, Xingren, Taoren, Suzi, Jineijin. 
Theophylline tablets 0.2g 
Bid 
Theophylline tablets 0.2g 
Bid 
NS 
Shi, 
2009
[382]
* 
Bufeitang (decoction): 1 packet per day, in 2 doses (morning & night) 
Huangqi, Dangshen, Baizhu, Jiegeng, Chenpi, Zhigancao, Chaoshanyao, 
Zhimu, Wuweizi, Maidong, Yuzhu, Zhibaibu 
OR Qiweiduqiwan + Shengmaisan (decoction): as above 
Shudi, Shanyurou, Shengshanyao, Gouji, Maidong, Nvzhenzi, Hanliancao, 
Fuling, Danpi, Wuweizi, Taizishen   
OR Jinguishenqiwan (decoction): as above 
Shudi, Danshen, Yiyiren, Shanyurou, Chaoshanyao, Fuling, Dangshen, 
Baizhu, Huainiuxi, Shufuzi, Tusizi, Rougui, Lujiaojiao   
OR Suzijiangqitang (decoction): as above 
Zisuzi, Banxia, Qianhu, Houpo, Chenpi, Danggui, Rougui, Gancao.  
Routine medication Routine medication NS 
Sun,  
2009
[375]
 
Bufei Granule: 16g Bid 
Dangshen, Shudihuang, Danggui, Shanzhuyu, Mahuang, Sangbaipi, 
Chenpi, Ziyuan. 
No Placebo No 
Tang, 
2009
[383]
 
Bailing Capsule: 3 capsules Tid 
extract of Dongchongxiacao. 
No routine medication but 
medical support provided as 
required 
No routine medication but 
medical support provided as 
required 
NS 
Tang, 
2010
[376]
 
Jianpiyishen Formula (decoction): 1 packet per day 
Huangqi, Dangshen, Baizhu, Shashen (Nan), Shashen (Bei), Buguzhi, 
Bajitian, Danggui etc. 
Smoking cessation + 
Routine medication 
Smoking cessation + 
Routine medication 
NO 
Wang, 
2009
[384]
 
Sanshenjianfeitang (decoction): 1 packet per day 
Taizishen, Danshen, Shashen, Fuling, Baizhu, Honghua, Danggui, Taoren, 
Jiegeng, Chishao, Tianhuafen, Zhibanxia, Shenggancao, Sharen, Xiangfu, 
Juhong etc. 
Salbutamol inhaler: 200 μg  
OR theophylline tablets 
OR if dyspnoea more severe: 
theophylline 0.25g + 0.9% 
Salbutamol inhaler: 200 μg 
OR theophylline tablets 
OR if dyspnoea more 
severe: theophylline 0.25g + 
NS 
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First 
author, year 
[ref. no.] 
Intervention  
Control 
Adverse 
events 
Formula name (form): Dose, ingredients Plus RP 
Saline OR 5% GS (250-
500ml) IV drip 15 drip/min  
0.9% NS OR 5% GS (250-
500ml) IV drip 15 drip/min  
Wu,  
2007
[365]
 
Liujunzitang (decoction):100ml Bid  
Dangshen, Baizhu, Fuling, Chenpi, Zhibanxia, Gancao. 
Erythromycin 100g Bid 
(to relieve airway 
inflammation) 
No treatment NS 
You,  
2008
[366]
 
Yifei Mixture (decoction): 100ml Bid 
Yinyanghuo, Xianmao, Renshen, Fuling, Baizhu, Danshen, Fabanxia, 
Zhuru, Gualoupi, Houpo, Zhiqiao. 
Salbutamol or Becotide 
inhaler & theophylline 
tablets 
Salbutamol or Becotide 
inhaler & theophylline 
tablets 
NS 
Zhang, 
2006
[377]
 
Jiapiyifeibushen Formula (decoction): 1 packet per day 
Huangqi, Dangshen, Baizhu, Fuling, Maidong, Shashen, Buguzhi, Tusizi, 
Nvzhenzi, Gejie, Xingren, Gualou, Beimu, Danshen, Chuanxiong 
No No treatment NS 
Zhang, 
2009
[368]
 
Yifeiyangyintang (decoction): 300ml Bid  
Baihe, Shengdihuang, Shudihuang, Chuanbei, Jiegeng, Zhiqiao, Maidong, 
Baishao, Danggui, Shashen, Huaishanyao, Fuling, Huangqi, Shenggancao. 
No routine medication but 
medical support as required 
+ Smoking cessation 
No routine medication but 
medical support as required 
+ Smoking cessation 
NS 
Zhu,  
2007
[378]
 
Tianlongkechuanling Capsule: 4 capsules, Tid  
Qingtiankui, Kuandonghua, Fabanxia, Shufuzi, Wuweizi etc.  No 
Salbutamol + Becotide 
inhaler 
2 puffs, Qid 
NS 
 
* Use of syndrome differentiation in selection of Chinese medicine formula; RP: routine pharmacotherapy; NS: not stated; GS: Glucose solution; 
[]
reference’s number.
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6.2.4 Assessment of risk of bias 
Assessment of the Cochrane risk of bias revealed that there was adequate sequence generation 
in nine studies (346, 368, 369, 371, 376, 378, 383-385) and only one study provided 
information on allocation concealment (383). Seven studies were not blinded since they 
compared CHM with no treatment (346, 363-365, 367, 377, 383). Blinding was not described 
adequately in the two single blind studies (347, 381) and blinding was not mentioned in the 
remaining nineteen studies. Incomplete outcome data was addressed in seventeen studies (235, 
346, 347, 369, 371-379, 382, 383, 385); and seventeen studies were judged as free of selective 
reporting (235, 312, 346, 347, 363, 365, 367, 368, 370, 373-377, 379, 381, 383, 385). All but 
one of the studies was free of bias of baseline data incomparability (Figure 6.7) (235, 346, 347, 
363-385). 
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Figure 6. 7 Methodological quality summary: review authors' judgments about each methodological 
quality item for each study in review of Chinese herbal medicine for Quality of Life improvement in stable 
COPD 
 
+ Yes (low risk of bias) ？ Unclear (uncertain risk) 

No (high risk of bias) 
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6.2.5 Outcome measure-quality of life questionnaire  
SGRQ was used in ten studies (312, 347, 365-367, 370, 375, 376, 378, 380) and a modified 
SGRQ was used in three studies (235, 368, 369). The remaining fourteen studies used Cai’s 
QolQ (346, 363, 364, 371-374, 377, 379, 381-385). The twenty seven included studies were 
grouped into six types according to the study design. Three studies did not report data suitable 
for meta-analysis (235, 368, 369). 
6.2.6 Results of QoLQs 
6.2.6.1 CHM compared to placebo (n=2) 
One study compared CHM with placebo and used SGRQ as an outcome (n = 60) (375). CHM 
was significantly better than placebo in improving QoL: [MD]: -8.60, 95% CI [-14.54, -2.66] 
(see Figure 6.8). Further analysis was conducted of the individual domains of SGRQ: 
symptoms [MD]: -3.20, 95% CI [-6.13, -0.27]); activity [MD]: -1.23, 95% CI [-2.78, -0.32]); 
and impact [MD]: -4.47, 95% CI [-7.02, -1.92]), all of which showed significant improvement. 
Cai’ QoLQ was used in other one with sixty eight participants (381). It was found to have a 
significant improvement QoL when CHM plus RP was compared to placebo plus RP, but the 
data were not suitable entry RevMan.  
6.2.6.2 CHM compared to no treatment (n=7) 
Pooling of data for the two studies using SGRQ (n = 226) found a significant improvement in 
total scores in the CHM group compared with no treatment (MD -6.07, 95% CI [-9.21, -2.93]) 
with low heterogeneity (Chi
2
 = 1.32, df = 1 (P =0.25); I
2
 = 24 %) (365, 367) (Figure 6.8). Five 
studies using Cai’s QoLQ (n = 251) were pooled and a significant improvement in total scores 
again was found (MD: -0.20 95% CI [-0.32, -0.07]) with severe heterogeneity (Chi
2
 = 37.43, 
df = 4 (P =0.00001); I
2
 = 89 %) (346, 363, 364, 377, 383) (Figure 6.9). The two studies using 
SGRQ did not report information on the scores for individual domains. Further analysis of 
individual domains of Cai’s QoLQ showed significant improvement of: activities of daily 
living (MD: -0.16 95% CI [-0.30, -0.01]); depression (MD -0.28 95% CI [-0.51, -0.06]); and 
anxiety (MD -0.28 95% CI [-0.47, -0.09]) but not in social activities (MD: -0.11 95% CI [-
0.36, 0.13]) (363, 364, 383). 
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6.2.6.3 CHM compared to RP (n=1) 
One study with 67 participants compared CHM alone versus RP using SGRQ. Analysis 
revealed a significant improvement in total score (MD: -7.05 95% CI [-13.55, -0.55] (378) 
(Figure 6.8) and in the individual domains of symptoms (MD: -12.76 95% CI [-18.02, -7.50]) 
and activity (MD -7.18 95% CI [-12.70, -1.66]) but not for impact (MD: 0.77 95% CI [-4.29, 
5.83]) 
6.2.6.4 CHM plus RP compared to RP (n=17) 
Sixteen of the eighteen studies that compared CHM plus RP with RP alone reported data 
suitable for analysis. Seven studies used SGRQ (n = 427). Significant improvements were 
found for total score in seven studies with 471 participants (MD -5.15 95% CI [-7.26, -3.05) 
(235, 312, 347, 366, 370, 376, 380) (Figure 6.8). Four studies also reported data on the 
individual domains of: symptoms (MD -5.15 95% CI [-7.26, -3.05]) with moderate 
heterogeneity (Chi
2
 = 22.70, df = 6 (P =0.0009); I
2
 = 74 %); and four studies reported in terms 
of activity (MD -5.21 95% CI [-5.86, -4.57]) and impact (MD -5.73 95% CI [-6.35, -5.12]) 
individually (366, 370, 376, 380). Eight studies used Cai’s QolQ (n = 664). For Cai’s QoLQ, 
only six studies reported total scores (n = 364) (371-374, 384, 385). A significant change in 
the total score was found (MD-0.25 95% CI [-0.37, -0.13]) with severe heterogeneity (Chi
2
 = 
66.83, df = 5 (P =0.00001); I
2
 = 93 %) (Figure 6.9). In the eight studies (n = 664) that reported 
data for individual domains there were significant changes in: activities of daily living (MD -
0.30 95% CI [-0.42, -0.19]); social activities (MD -0.36 95% CI [-0.57, -0.15]); depression 
(MD -0.38 95% CI [-0.55, -0.21]); and anxiety (MD -0.39 95% CI [-0.56, -0.23]) (371-374, 
384, 385).  
Two studies used a modified SGRQ (368, 369) and reported significant differences for CHM 
plus RP versus RP alone for total scores as well as the individual scores for symptoms, 
activity and impact. The actual scores were not available for these studies, even after 
contacting the authors. Therefore, data for these studies were not included in the meta-
analyses. 
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Figure 6. 8 Comparison of CHM versus placebo, no treatment or routine pharmacotherapy in patients 
with stable COPD: Total SGRQ score at the end of treatment in review of Chinese herbal medicine for 
Quality of Life improvement in stable COPD 
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Figure 6. 9 Comparison of CHM versus no treatment or routine pharmacotherapy in patients with stable 
COPD: Total Cai’s QolQ score at the end of treatment in review of Chinese herbal medicine for Quality of 
Life improvement in stable COPD 
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6.2.7 Results for adverse events  
Adverse events were reported in five studies. In four of these, no adverse events were 
observed (312, 346, 375, 380). In one study (63 participants), two subjects in the CHM 
treatment group reported dry mouth, mild stomach bloating and one subject in the control 
group reported reduced appetite (347). There was no mention of adverse events in the 
remaining studies (363-367) (235, 368-374, 376-379, 381-385). 
6.2.8 Discussion  
This systematic review includes all RCTs of CHM for stable COPD available at the time of 
searching that included outcome measures of the quality of life of participants. All of the 
included studies were conducted and published in China from 2000 to 2010. Two of these 
were also indexed in MEDLINE (346, 368).  
Meta-analysis indicated most studies showed oral CHM improved the health status of patients 
with stable COPD when compared with no treatment, placebo. CHM combined with RP was 
also found to be better than RP. Considerable heterogeneity was evident in comparisons (see 
6.8.4 in Figure 6.8 and 6.9.1, 6.9.2 in Figure 6.9). The variation in COPD severity in patients 
is a likely source of the wide range in HRQoL scores. Overall, methodological quality was 
problematic. Only two studies used a placebo in the control and no study satisfied all of the 
methodological criteria included in the Cochrane risk of bias, so the findings of the meta-
analyses should be considered with caution. The absence of severe adverse events suggests 
the CHMs were well tolerated.   
Meta-analyses (Figs 6.8 & 6.9) suggest that the combination of CHM and RP is better at 
promoting HRQoL in patients with stable COPD compared to RP alone. However, the effects 
of the RPs used in the included studies may not have been optimal. According to the GOLD 
guidelines, theophylline in the management of stable COPD is controversial (9). Also, a 
recent review suggested that newer long-acting β2 agonists and long-acting anticholinergic 
medications are better than the combination of salbutamol and ipratropium bromide for 
moderate and severe COPD (190). In future studies the RP should be standardized to 
international best practice. 
COPD is a chronic disease with progressive development that requires long-term therapy so 
the 15 studies that lasted six months are the most relevant. Of these, the largest were Shi 2009 
158 
 
(n=180), Feng 2008 (n=120) and Zhang 2009 (n=120). Feng 2008 and Shi 2009 included the 
five most commonly used herbs whereas Zhang 2009 included two of them (huangqi & 
fuling). For each of the five most commonly used herbs there is additional evidence for 
bioactivity related to the respiratory system. Experimental studies on extracts of Huangqi in 
mice found that airway hyperresponsiveness was inhibited by astragaloside IV (387) and an 
aqueous extract decreased inflammatory infiltration and mucus secretion in lung tissues (388). 
There is human experimental evidence to suggest Dangshen can improve respiratory 
symptoms in acute altitude sickness (389). Extracts of Baizhu were found to have anti-
inflammatory effects in acute and chronic animal models (390) and on rat lung cells (391). 
Fuling has been shown to have anti-inflammatory effects (392-394). Wuweizi is considered an 
‘adaptogen’ with stress protective effects (395) and its constituent schisandrin demonstrated 
anti-inflammatory activity in mice (396). These herbs appear to warrant further investigation. 
6.2.9 Conclusions  
CHM appears to be a well-tolerated addition to pharmacotherapy for stable COPD and may 
confer an additional benefit in terms of improving HRQoL of these patients. Such potential 
benefits need to be further evaluated through trials that address the identified methodological 
deficiencies and provide quality control data for the CHM interventions. Trials should employ 
randomized double-blind method using standard outcome instruments. Comparisons should 
be with placebo or a RP which reflects current best practice.  
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7 Chapter Seven: Results of systematic review and data analyses 
of oral CHM for stable COPD with physiological and 
symptomatic outcome measures 
This chapter includes the search results and descriptions of each study, the risk of bias and 
methodological quality assessments, the meta-analyses of outcome data and the analyses of 
herbal useage for all included studies.  
The methods used in this SR are in accordance with the method for SRsthat has been 
described in section 4.2.2. Therefore, the search results are reported directly without repeating 
the method. 
7.1 Search results 
Search data were updated in April 2011 which was the same time as for SR2 of oral CHM for 
improvement in HRQoL in patients with stable COPD. A total of 1,715 records were 
identified through the initial searches of the databases.  
After removing duplicates, 1,599 records were screened by reading the abstracts. Finally 349 
full-text articles were assessed for eligibility. Eventually, 101 articles matched the selection 
criteria and were included. The study selection process is shown in Figure 7.1. 
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1715 Records identified 
through database searches:  
Pubmed, EMBASE, Scopus, 
CINAHL, Cochrane & CNKI, 
CQVIP, WANFANG and hand search 
 
1599 Records after duplicates 
removed  
 
1599 Records screened  
 
1250 Records excluded  
 
349 Full-text articles assessed 
for eligibility  
 
248 Full-text articles excluded, with 
reason:  
1. CHM was administrated by IV drop 
(n=6) 
2. Not RCTs (n=30) 
3. Patients included asthma, chronic 
bronchitis & cor pulmonale (n=27) 
4. Oral CHM for not stable COPD (n=157)  
5. Duplicated trials (n=21) 
6. Other (n=4) 
7. Study included children (n=1) 
8. Study used antibiotics (n=1) 
9. Same ingredient of capsules in two 
groups: (n=1) 
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Figure 7. 1 Flow diagram for selection study process in review of Chinese herbal medicine for stable 
COPD physiological and symptomatic outcome measures 
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7.2 Description of the included studies 
The characteristics of the individual studies including study design, study location, patients’ 
source, age and gender of participants, diagnosis and severity of COPD, syndromes of 
Chinese medicine, COPD history, smoking history as well as duration of treatment and 
follow-up are provided in Appendix 12. These details are summarised below.  
7.2.1 Characteristics of included studies  
Of the 101 included studies, 98 studies were conducted in China, three studies were 
conducted in Japan and one in Israel. Most articles were retrieved from Chinese language 
databases or from English databases and published in Chinese language journals. A few 
articles located from English language databases were published in English language journals. 
7.2.2 Characteristics of excluded studies 
Based on screening from reading the abstracts, 1,250 articles were eliminated and a further 
248 were excluded after reading the full text and applying the exclusion criteria. One study 
included patients aged less than 18 years and 27 studies included patients with pulmonary 
diseases such as asthma, chronic bronchitis, cor pulmonale or chronic respiratory failure. In 
157 studies the condition was acute COPD, or both acute and stable COPD, or the COPD 
status could not be verified, so these were excluded. In 21 articles there were duplicated 
publications of the same study which were combined when different papers reported on 
different outcome measures. In one study the comparison was between two varieties of 
Cordyceps, which was considered an inappropriate comparison, therefore this study was 
excluded (397).  
7.2.3 Participants 
There were 8,014 participants in total in the included studies. Of these 4,165 participants were 
randomized into the CHM treatment groups and 3,798 participants were randomized into the 
control groups. All participants were inpatients or outpatients of hospitals in different regions 
and were diagnosed as COPD at the stable stage. The age of participants ranged from 24 to 88 
years old, but two studies did not mention the age of participants (380, 398). Most studies 
reported mean ages ranging from 50 to 70 years old, but mean age was not reported in six 
studies (399-404). The numbers of males were 5,022 and females were 2,648.  
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Withdrawals were described in 11 studies with 98 participants dropping out during the 
treatment period. Eight participants who were randomized did not enter into treatment (79). 
There were 28 withdrawals from the CHM treatment groups in seven studies (363, 366, 367, 
405-408), while there were 37 withdrawals from the control groups in seven studies (363, 366, 
367, 384, 405, 406, 408). For 25 withdrawals in four studies it was not indicated which group 
these drop-outs were from (364, 365, 404, 409). The numbers of male and female withdrawals 
were not mentioned in any studies.  
7.2.4 Diagnosis and severity of COPD 
‘Guideline for diagnosis and management of chronic obstructive pulmonary disease’ is based 
on the GOLD guideline. It was modified by the CSRD and issued in 1997, with a revision in 
2002 (91). The latest version issued by CSRD in 2007 is in accordance with the GOLD 
guideline (92).  
Participants in eleven studies were diagnosed as stable COPD according to the diagnostic 
criteria specified by CSRD in 1997, fifty one studies used the CSRD criteria published in 
2002, and sixteen studies used the 2007 CSRD criteria. Diagnosis of COPD was based on the 
GOLD guideline in one study (410). Participants in seven studies were diagnosed according 
to the guideline issued by the National Heart Lung and Blood Institute (NHLBI) and World 
Health Organization (WHO) in 2001 (69, 368, 369, 383, 398, 411, 412).  
Inclusion criteria for participants in one study were defined by FEV1% predicted that was 
based on ‘Standardization of Spirometry’ issued by the ATS (79). In a few studies, 
participants’ diagnosis of COPD was based on medical books such as ‘The standardization of 
diagnosis and management of diseases’ (疾病诊疗标准) written by Wang Zhenhai in 1983 in 
one study (413), or the textbook of Chinese Internal Medicine (中医内科学）by Tian Delu 
(414) in one study (415), or The Practice of Internal Medicine (实用内科学) written by Lin et 
al. (416) in one study (343). Eleven studies did not mention how to diagnose patients (65, 341, 
342, 366, 382, 399, 417-421).  
According to the GOLD guideline, the severity of COPD was classified into five stages based 
on spirometric classification, that is, post bronchodilator the ratio of FEV1 / FVC <0.70 or the 
value of FEV1 % predicted. The severity of COPD was described as: stage 0 ‘at risk’; stage I: 
‘mild’ (FEV1≥80% predicted); stage II: ‘moderate’ (50 %≤FEV1<80% predicted); stage III: 
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‘severe’ (30%≤FEV1<50% predicted); and stage IV: ‘very severe’ (FEV1<30% predicted or 
FEV1<50% predicted plus chronic respiratory failure).  
There is no difference in classification between GOLD and the new version of CSRD 
published in 2007. However, the version of CSRD published in 2002 was modified from 
GOLD, and the severity of COPD was classified as: IIA ‘moderate’; IIB ‘severe’; and III 
‘very severe’. When available, COPD severity is reported in Appendix 12. 
In the 101 studies, patients were diagnosed as COPD and further classified by severity in 57 
studies. There was no study that only included patients diagnosed as COPD at the mild stage; 
only patients with moderate COPD were included in two studies (73, 422), and only 
participants defined as FEV1 50-65% of predicted at moderate stage were included in one 
study (79). Patients with mild to moderate COPD were included in seven studies (69, 341, 
378, 423-426); patients with moderate to severe COPD were included in six studies (369, 375, 
398, 404, 427, 428); patients at the stages mild, moderate or severe COPD were included in 
twenty two studies (69, 342-345, 363, 364, 366, 368, 371, 374, 385, 386, 406, 412, 419, 429-
434); patients with moderate to very severe were included in eight studies (346, 347, 372, 373, 
377, 405, 435, 436); patients at all stages of COPD were included in ten studies (340, 365, 
370, 376, 408, 420, 437-440); patients with severe and very severe COPD were included in 
one study (312). Forty three studies did not mention the severity of COPD of the participants.  
7.2.5 Chinese medicine syndrome differentiation 
According to CM theories on COPD at the stable stage, the CM syndrome differentiation can 
be classified as: Lung qi deficiency, Lung and spleen Qi deficiency, or Lung, spleen and 
kidney Qi deficiency, with or without phlegm stasis or blood stasis. However, of the 101 
studies, forty three studies (see Appendix 12) mentioned syndrome differentiation involving 
seventeen different syndromes as follows. Lung and Kidney Qi deficiency was reported in 11 
studies (69, 80, 340-342, 371, 383, 415, 422, 429, 441); Lung and Spleen Qi deficiency in 6 
studies (73, 417, 426, 436, 442, 443); Lung, Spleen and Kidney Qi deficiency in 4 studies 
(346, 347, 433, 434), Lung Qi deficiency in three studies (423, 432, 444), Qi deficiency with 
blood stasis was mentioned in three studies (368, 369, 411); Spleen and Kidney Qi deficiency 
with phlegm in one study (445), and Lung and Spleen deficiency with phlegm in one study 
(425).  
Other syndromes were mentioned in one study each: Qi deficiency (343); Spleen deficiency 
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(349); Kidney deficiency (381); Kidney deficiency with phlegm (446); Yin deficiency of 
Lung and Kidney (447); Yin deficiency of Kidney (407); Qi deficiency and phlegm stasis 
(386); Sanyin Xuhan, Xinfei luobi (Emptiness and Cold of the hand three Yin, heart and lung 
channel blocked) (439); Liver Qi stasis (448); or Spleen and stomach deficiency (440). 
Multiple syndromes were included in 4 studies (379, 382, 401, 404). The remaining 58 studies 
did not differentiate syndromes.  
7.2.6 The COPD history and smoking history  
The COPD history of subjects ranged from 3 to 30 years. The mean or average was between 5 
and 22 years in sixty eight studies. However the COPD history was not described in thirty 
three studies. In addition, the smoking history of subjects was mentioned in three studies (420, 
438, 449).  
7.2.7 Duration of treatment and follow up and run in 
The lengths of duration of treatment were variable in the included studies, and ranged from 10 
days to one year.  
The lengths of duration of treatment were less than three months in forty five studies, 
involving only 10 days in one study (418), three weeks in two studies (450, 451), one month 
(four weeks) in fourteen studies (341, 343, 345, 375, 400, 419, 425, 428, 440, 444, 449, 452-
454), 6 weeks in two studies (405, 421), and two months (eight weeks) in twenty six studies 
(69, 344, 349, 366, 373, 381, 383, 384, 401, 404, 406, 407, 410, 417, 423, 424, 432, 433, 435, 
436, 440, 442, 447, 455, 456). 
The lengths of duration of treatment were more than three months in fifty six studies 
including three months or 90 days in twenty five studies (73, 312, 340, 347, 368, 369, 376, 
399, 408, 409, 411-413, 429-431, 434, 437, 438, 446, 448, 457-460), four months in one 
study (365); six months or twenty four weeks in twenty seven studies (65, 79, 80, 346, 363, 
364, 367, 370-372, 374, 377-380, 382, 385, 386, 398, 402, 415, 422, 426, 427, 439, 441, 445); 
and one year of treatment duration in three studies (403, 420, 460).  
The lengths of the follow up period were mentioned in thirteen studies. Two months of follow 
up period was performed in one study (421), four months in one study(381), six months in 
four studies (340, 346, 380, 382), nine months in two studies (399, 412), ten months in one 
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study (442), and one year in four studies (366, 415, 439, 446).  
None of the included studies mentioned a run-in period in their study design. 
7.2.8 Sample size  
There were seventeen studies with more than one hundred participants (79, 340-343, 345, 365, 
367, 379, 382, 400, 406, 407, 415, 419, 429, 455). Huang 2002 was the largest study with 300 
participants in the CHM treatment group and 300 participants in the control group (341). 
Sample size calculation was not mentioned in any studies.  
7.3 Assessment of risk of bias in included studies 
The risk of bias of included studies was assessed using Cochrane Risk of Bias with six 
domains as below. The results from the judgments of the review authors for each item of risk 
of bias for each included study and the overview of the findings are summarized in Fig 7.2 
below. 
7.3.1 Random sequence generation 
Of the 101 studies, 28 specified the method of randomization including a random number 
table, computer generated numbers, stratified blocked randomization, or randomized block 
design (69, 73, 79, 340, 346, 364, 366, 368, 369, 371, 374, 378, 383, 385, 403, 407, 410, 412, 
423, 425, 426, 432, 435, 436, 444, 452, 460, 461), all of which were judged as low risk of 
bias. The remaining studies did not provide details of the randomization process and were 
judged as unclear risk of bias.   
7.3.2 Allocation concealment 
Allocation concealment using opaque envelopes was described in one study which was 
judged as low risk of bias (383). The remaining studies did not mention information on 
allocation concealment and were judged as unclear risk of bias.  
7.3.3 Blinding 
Double blinding was performed in three studies (79, 404, 461). Although limited information 
about the blinding procedure was provided, they were judged as low risk of bias. Single 
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blinding, which is not a suitable method of blinding, was performed in three studies with no 
further details available. They were judged as high risk of bias (347, 376, 411). The remaining 
studies did not provide information on blinding and were considered as unclear risk of bias.  
7.3.4 Incomplete outcome data 
Twelve studies had incomplete outcome data due to dropouts during the treatment period with 
or without the reasons being provided. Since the data analysis excluded the withdrawals in 
eleven studies, these studies were judged as high risk of bias (79, 363, 364, 366, 404, 406, 
409). In contrast, intention to treat (ITT) was applied in one study which was considered low 
risk of bias (408).  
In seven studies the number of participants at completion of treatment was not specicifed in 
the data table, these were judged as unclear risk of bias. Complete data were provided in the 
remaining studies which were judged as low risk of bias.  
7.3.5 Selective reporting 
Bias due to selective reporting was considered low risk of bias in seventy nine studies because 
the complete results of each outcome were reported in the studies. Some results were 
incomplete for the stated outcome measures in twenty two studies and these were judged as 
high risk of bias (65, 73, 340, 343, 345, 399, 400, 403, 417, 419, 421, 428, 432, 439, 442, 445, 
448, 450, 451, 454, 458, 462).  
7.3.6 Other bias 
In this review, other bias focussed on baseline data comparability involving demographic and 
outcome data. Baseline data comparability was adequately addressed in 99 studies which were 
considered as low risk of bias. However, there was no mention of information on baseline 
data comparability in two studies. They were judged as unclear risk of bias (65, 402) (Figure 
7.2).  
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Figure 7.2 Summary of review authors’ judgements about risk of bias for studies included in review of Chinese herbal medicine 
for stable COPD with physical and symptomatic outcome measures 
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7.4 Methodological quality assessment of all included trials by Jadad’s 
scale 
The results of the methodological quality of each study as assessed by Jadad’s scale are shown 
in Appendix 13. 
7.4.1 Description of randomization 
All the included studies were described as ‘randomized’. Randomization using a random digit 
table was reported in 22 studies (69, 79, 340, 346, 366, 368, 369, 371, 378, 385, 403, 407, 410, 
423, 426, 432, 435, 436, 444, 452, 460, 461); stratified blocked randomization was applied in 
one study (376); randomized block design was applied in one study (412); and randomization 
was described as simple randomization in four studies (73, 364, 374, 425). Randomization 
generated by clinic order was described in one study but this was not considered a suitable 
method of randomization (434).   
7.4.2 Withdrawals 
The reasons for withdrawals included patients dropping out due to onset of exacerbation of 
their condition or death were reported in six studies and these received one point (366, 384, 
404, 405, 407, 408). However, there was no description of the reason for withdrawals in six 
studies so these did not receive one point (79, 363-365, 406, 409). In addition, neither the 
number of withdrawals nor the number of participants completing the study was reported in 
fifteen studies, so these did not receive a point (65, 69, 73, 312, 341, 343, 398, 419, 422, 427, 
433, 438, 440, 451, 454). The remaining studies reported complete outcome data so each 
received one point. In all of the included studies, no participant dropped out due to an adverse 
event of CHM. 
7.4.3 Description of double blinding 
Double blinding was described in three studies which received one point. However, there was 
no further information on how the blinding was performed and who were blinded.  
7.4.4 Jadad’s scale for each study 
Of the 101 studies, a final score of ‘4’ was achieved in one study (461), ‘3’ was achieved in 25 
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studies (79, 340, 346, 366, 368, 369, 371, 374, 376, 378, 385, 403, 404, 407, 410, 412, 423, 
425, 426, 432, 435, 436, 444, 452, 460), ‘2’ in 56 studies (69, 73, 80, 342, 344, 345, 347, 349, 
364, 367, 370, 372, 373, 375, 377, 379-384, 386, 399-402, 405, 408, 411, 413, 415, 417, 418, 
421, 424, 428-431, 436, 437, 439, 441, 442, 445-448, 450, 453, 455-459, 462) and ‘1’ in 19 
studies (65, 312, 341, 343, 363, 365, 398, 406, 409, 419, 422, 427, 433, 434, 438, 440, 449, 
451, 454), see Appendix 13. 
7.5 Intervention and control groups 
In this review, a number of different types of control groups were used. The types of 
comparisons between treatment and control groups are summarised below: 
7.5.1 Comparison of CHM with placebo control  
Oral administration of CHM formulae or extracts of single herbs was compared with placebo 
in twelve studies (73, 79, 341, 342, 349, 375, 381, 411, 426, 435, 449, 454).  
Three studies involved CHM plus RP compared to placebo plus RP (79, 381, 426). The RP 
used in the two studies that provided details was Theophylline Sustained-release Tablets (Shu 
Fu Mei Pian) in one study and theophylline plus Salbutamol inhaler (Chuan Le Ning Qi Wu Ji) 
in the other study.  
The use of bronchodilators in both groups was mentioned in one study but no details were 
provided (79) (Appendix 14). 
7.5.2 Comparison of CHM alone with RP 
CHM alone was compared to RP in fifteen studies (80, 378, 402, 403, 407, 421, 423, 428, 432, 
439, 440, 444, 445, 455, 459).  
The RP involved using theophylline tablets or Theophylline Controlled Release Capsules 
(Cha Jian Kong Shi Jiao Nang) alone in three studies (423, 444, 459); compound 
aminophylline tablets with salmeterol xinafoate/ fluticasone propionate (Shu Li Die) or 
theophylline with Ipratropium Bromide Aerosol (Yi Bing Tuo Xiu An Qi Wu Ji) Pulmicort 
Aerosol (Budesonode) (Pu Mi Ke Qi Wu Ji) or theophylline with Salbutamol and Ipratropium 
Bromide in three studies (402, 439, 445); Theophylline Sustained-release Tablets (Cha Jian 
Huan Shi Pian) with ambroxol hydrochloride (Yan Suan An Xiu Suo) in one study (428); and 
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Theophylline Controlled Release Tablets (Cha Jian Kong Shi Pian) plus Ultrasonic atomizing 
inhalation in one study (455) (see details in Appendix 15).  
In addition, three studies used salbutamol or Compound Ipratropium Bromide Aerosor (Ke Bi 
Te Qi Wu Ji) (consists of Ipratropium Bromide and Salbutamol sulfate) or salmeterol 
xinafoate/fluticasone propionate (Shu Li Die) alone was used in two studies (80, 378).  
Non RPs such as the immune enhancing medication nucleotide and Casein Oral Solution and 
Mannatide tablets were used in two studies (407, 432); Diastase Pancreatin and Pepsin Tablet 
as an aid to digestion medications were used in two studies (421, 440). One study mentioned 
bronchodilators being used in the control group but no specific details were provided (403) 
(Appendix 15). 
7.5.3 Comparison of CHM plus RP with RP  
CHM plus RP was compared with RP alone in forty six studies. Oral methylxanthines 
including Theophylline, Doxofylline, Theophylline Sustained-release were used in both 
groups in seven studies (374, 385, 401, 430, 431, 448, 453); theophylline plus Ipratropine was 
used in one study (417); theophylline plus terbutaline sulfate was used in one study (458) 
and theophylline plus Bromhexine Hydrochloride was used in one study (460); Theophylline 
plus Salbutamol or Becotide inhaler was used in one study (366); theophylline controlled 
release plus Carbocisteine was used in one study (457).  
Theophylline was combined with two kinds of drug, such as β2-agonists and/or 
anticholinergics and/or inhalation of glucocorticosteriods and/or expectorants in five studies 
(345, 372, 419, 438, 447).  
Salbutamol inhaler was used in both groups in one study (378); Salbutamol (or Albuterol) 
inhaler or Theophylline were used in both groups in three studies (366, 384, 456); and 
Salbutamol inhaler plus Ambroxol Hydrochloride in one study (436).  
Adavir (Salmeterol plus Fluticasone propionate) was used in three studies (312, 404, 427); 
and Adavir plus Singulair (Montelukast Sodium) was used in one study (386). Ipratropium 
bromide was used in both groups in four studies (370, 371, 412, 415); and an expectorant 
alone was used in one study (446).  
Bronchodilators were used in both groups in two studies (398, 463) but no details on the RPs 
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were provided. Bronchodilators and inhalation of glucocorticoids were used in both groups, 
without further information being available, in two studies (368, 376).  
The use of RP was mentioned in eleven studies (344, 347, 369, 373, 379, 380, 382, 405, 410, 
450, 451) but details of the medications used were not supplied (Appendix 16). 
7.5.4 Comparison of CHM with no treatment  
CHM was compared to a no treatment control group in sixteen studies (346, 363-365, 367, 
377, 383, 400, 406, 408, 409, 411, 413, 420, 424, 462). No treatment means no use of RP or 
other medications (Appendix 17).  
7.5.5 Comparison of test CHM with other CHM 
A test CHM was compared with another CHM in twelve studies (340, 343, 399, 422, 429, 433, 
434, 437, 441, 442, 452, 461). In these studies the control CHMs were all medicines with a 
history of use for COPD and/or other respiratory disorders.   
Gubenkechuan tablets were used in the control groups in four studies (433, 434, 441, 461). 
Jinshuibao capsule which contains an extract of Dongcongxiacao (Cordyceps sinensis) was 
used in the control group in four studies (340, 422, 429, 437). 
Zhen Qi Fu Zheng capsule which consists of Nv zhen zi (Ligustrum lucidum) and Huang qi 
(Astragalus membranaceus), was adminstered to the control group in two studies (343, 399). 
Other formulae with unspecified ingredients were used in the control groups in two studies 
(442, 452) (Appendix 18). 
7.6 Outcome measures 
7.6.1 Pulmonary function 
Pulmonary function measurements were performed in 70 studies with 5,574 participants. 
FEV1 % predicted was reported in 52 studies with 3,332 participants; volume of FEV1 (L) was 
reported in 37 studies with 3,475 participants. FVC % predicted was reported in 12 studies 
with 730 participants and volume of FVC (L) was measured in 30 studies with 2,283 
participants.  
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FEV1/RVC% was reported in 37 studies with 2,635 participants, PEF% or PEF (L/s) was 
reported in 4 studies with 257 participants, MMEF in 8 studies with 575 participants, MVV in 
11 studies with 455 participants, MIP in one study with 60 participants, and Raw was reported 
in one study of 54 participants. 
7.6.2 Reduction of COPD exacerbations 
Exacerbations of COPD including exacerbation rate and frequency of exacerbation were 
reported in 21 studies with 1,619 participants. In addition, days of hospitalization was 
reported in 3 studies with 245 participants. 
7.6.3 Symptom relief  
Relief of symptoms was assessed in 55 studies with 3,885 participants. Two approaches were 
used:  
1. The percentage of effectiveness based on the number of patients who reported symptom 
improvement in each group;  
2. Reduction in total scores of symptoms and the subscores for chronic cough, sputum 
production and dysponea.  
In addition, the MMRC dysponea scale was reported in 3 studies with 180 participants. 
7.6.4 BODE index, the six-minute-walk distance test and body-mass index 
The BODE index was reported by two studies with 133 participants. The six-minute-walk 
distance (6MWD) test was performed in ten studies with 366 participants. Body-mass index 
(BMI) was measured in four studies with 232 participants.  
7.6.5 Arterial blood gas measurement 
Arterial blood gas measurement involving PaO2 and PaCO2 was reported in ten studies with 
713 participants. 
7.6.6 Biomarkers 
Biomarkers involving inflammatory cytokines, lymphocyte subsets and immunoglobulins 
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were measured in 23 studies in SR3 with 1,431 participants. Inflammatory cytokines such as 
IL-8, TNF-α and IL-2 were measured in ten studies with 531 participants and lymphocyte 
subsets were measured in 8 studies with 605 participants. Immunoglobulins (Ig) consisting of 
the level of serum Ig A, Ig M and Ig G were measured in nine studies with 600 participants.  
Blood rheology index was tested in three studies with 239 participants.  
Outcome measures of nutrition involving ALB, prealbumin and leptin were performed in four 
studies with 234 participants.  
The levels of superoxidase and LPO were tested in one study with 60 partcipants.  
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7.7 Results of physiological and symptomatic outcome measures 
7.7.1 Results of spirometric parameters 
In this review, a spirometry test was performed in 70 studies that included 5,574 participants 
suffering from COPD at a stable stage. In these studies 89 participants dropped out from 11 
studies during the treatment period, eight participants were randomized but did not enter into 
treatment (79).  
The CHM was compared with placebo control in 10 studies; with no treatment control in 14 
studies; with other CHM in 8 studies and with RP in 7 studies. CHM plus RP was compared 
with RP in 31 studies.  
Duration of treatment ranged from 10 days to one year. For the purpose of conducting 
sensitivity analyses, the studies were divided into two groups based on duration: Group 1 
‘short term’ of less than three months, or Group 2 ‘long term’ of three months and longer.  
The twenty eight studies forming group 1 had durations of treatment less than three months. It 
was only 10 days in 1 study (418), one month (four weeks or 28 days or 30 days) in 9 studies 
(341, 375, 401, 425, 440, 449, 451-453), six weeks in 1 study (405), and two months (eight 
weeks or 60 days) in 17 studies (69, 342, 349, 366, 373, 381, 404, 406, 410, 423, 424, 433, 
435, 436, 447, 455, 456).  
There were 38 studies in group 2 with durations of treatment for 3 months or longer including 
three months (12 weeks) in 20 studies (312, 340, 344, 347, 364, 385, 386, 409, 413, 429-431, 
434, 437, 438, 446, 448, 457, 459, 461), four months in 1 study (365), and six months (24 
weeks) in 17 studies (79, 80, 346, 367, 370, 372, 377, 379, 383, 402, 408, 412, 415, 422, 426, 
427, 441).  
Duration of the follow up period was six months in one study (408), nine months in one study 
(412), and one year in 4 studies (366, 413, 415, 446). The remaining 64 studies did not report 
follow up. 
The spirometric parameters performed included: FEV1, FVC, PEF and MMEF, MVV and 
MIP, as well as Raw. These methods have been described as above (section 4.2.1.5).  
According to the GOLD guideline for COPD, the diagnosis and severity of COPD depend on 
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the level of FEV1 and FEV1/FVC, therefore, this section focuses on analyzing FEV1 and 
FEV1/FVC between the intervention and control groups. In addition, some measurements 
have two forms of expression, such as FEV1 expressed as FEV1 % predicted or volume (L), 
FVC expressed as FVC % predicted or volume (L) and PEF expressed as percentage or 
velocity of flow (L/s). The results for each measurement are reported separately below. 
7.7.1.1 FEV1% predicted 
FEV1% predicted was measured and reported in 52 studies with 1,698 participants in the 
treatment groups and 1,634 participants in the control groups (Figure 7.3).  
Late response of FEV1% was reported in 32 studies with 2,075 participants in the long term 
treatment group (3 months and longer), while the early response of FEV1% was reported in 20 
studies with 1,324 participants in the short term treatment group (less than 3 months).  
Sensitivity analysis was performed for the long term and short term therapy groups (Figures 
7.4 & 7.5).  
CHM Vs Placebo 
FEV1% predicted was measured and reported in nine studies on 716 participants. Among 
these studies, CHMs were compared with placebo alone in six studies with 458 participants 
(69, 342, 349, 375, 435, 449), while CHM plus RP versus placebo plus RP was the 
comparison in three studies with 258 participants (79, 381, 426).  
Meta-analysis manifested significant improvement of FEV1% predicted between CHM and 
placebo groups (MD 7.46 95% CI [3.72, 11.20]) with moderate heterogeneity (Chi
2
 = 13.15, 
df = 5 (P = 0.02); I
2
 = 62%).  
However, the meta-analysis of the He (2010) and Ni (2008) studies (CHM plus RP versus 
placebo plus RP) showed no significant change in FEV1% predicted (MD 5.78, 95%CI [-
27.60, 39.16]) due to the fact that one study demonstrated significant change in FEV1% 
predicted while the other study found no significant change (381, 426).  
One study did not provide a value for FEV1% post treatment, so it could not be included in 
the meta-analysis. However, the authors reported that no significant change of FEV1% 
predicted after treatment was found in this study (79).  
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CHM Vs RP 
FEV1% predicted was measured in seven studies with 451 participants (80, 402, 403, 423, 440, 
455, 459), which showed a significant change between CHM and RP at completion of 
treatment (MD 8.52, 95%CI [2.51, 14.54]) with high heterogeneity (Chi
2
 = 101.26, df = 6 (P 
< 0.00001); I
2
 = 94%).  
CHM plus RP Vs RP 
Comparison of CHM plus RP with RP was performed for 21 studies with 1,263 participants 
(312, 344, 366, 370, 372, 373, 385, 386, 401, 404, 410, 412, 425, 427, 436, 438, 447, 451, 
453, 457, 460).  
Meta-analysis indicates that there was a significant improvement of FEV1% predicted 
between the two groups post treatment (MD 5.74, 95%CI [4.49, 6.98]) with moderate 
heterogeneity (Chi
2
 = 60.64, df = 20 (P = 0.00001); I
2
 = 67%).  
CHM Vs Other CHM 
Lung function was tested in nine studies that compared CHM with other CHM. The FEV1% 
predicted was measured in eight studies with 550 participants (340, 422, 429, 433, 434, 437, 
441, 461).  
There was significant improvement of FEV1% predicted after treatment (MD 3.22, 95%CI 
[1.09, 5.35]) with low heterogeneity (Chi
2
 = 7.76, df = 7 (P =0.35); I
2
 = 10 %). However, the 
FEV1% result was not reported in one study (452). 
CHM Vs No Treatment Control 
The FEV1% predicted was conducted in eight studies with 444 participants that compared 
CHM with no treatment (346, 363, 364, 377, 383, 408, 413, 424).  
There was significant improvement of the FEV1% predicted after treatment between the two 
groups (MD 4.19, 95%CI [2.13, 6.26]) with no heterogeneity (Chi
2
 = 4.23, df = 7 (P =0.75); I
2
 
= 0 %).  
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Figure 7. 3 Meta-analysis of CHM versus control with FEV1 % at end of treatment as outcome  
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Sensitivity Analysis of FEV1% predicted  
1) Long term therapy (study duration of three months or more) 
For the long term therapy group, meta-analysis found a significant improvement in FEV1% of 
participants treated with CHM compared to RP in 4 studies on 228 participants (MD 7.94, 
95%CI [4.18, 11.69]) with high heterogeneity (Chi
2
 = 24.41, df = 3 (P < 0.0001); I
2
 = 88%) 
(80, 402, 403, 459). Heterogeneity was reduced but remained high. 
For CHM plus RP compared to RP, there was a significant improvement in 12 studies on 731 
participants (MD 5.89, 95%CI [3.40, 8.37]) with moderate heterogeneity (Chi
2
 = 35.84, df = 
11 (P = 0.002); I
2
 = 69%) (312, 344, 370, 372, 385, 386, 412, 427, 438, 447, 457, 460). 
For CHM compared to other CHM, there was a significant improvement in 7 studies on 512 
participants (MD 2.86, 95%CI [0.42, 5.29]) with low heterogeneity (Chi
2
 = 7.05, df = 6 (P = 
0.32); I
2
 = 15%) (340, 422, 429, 434, 437, 441, 461).  
For CHM compared to no treatment, there was a significant improvement in eight studies on 
444 participants (MD 4.19, 95%CI [2.13, 6.26]) without heterogeneity (Chi
2
 = 4.23, df = 7 (P 
= 0.75); I
2
 = 0%) (346, 363, 364, 377, 383, 408, 413, 424).  
In addition, the duration of treatment was more than three months in two studies of 160 
participants which compared CHM to placebo with RP in both studies (69, 426).  
A significant improvement in FEV1% of participants treated with CHM compared to placebo 
was found in 1 study on 62 participants (MD 10.88, 95%CI [4.16, 17.61]) (69), and for CHM 
plus RP compared to placebo plus RP in 1 study on 98 participants (MD 22.35, 95%CI [20.66, 
24.04]) (426) (see Figure 7.4). 
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Figure 7. 4 Meta-analysis of CHM group versus control with FEV1 % at the end of treatment as the 
outcome (treatment period ≥ 3 months) 
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2) Short-term therapy - less than three months 
For the short term therapy group, meta-analyses found a significant improvement in FEV1% 
of participants treated with CHM compared to placebo in 5 studies on 396 participants (MD 
7.75, 95%CI [5.47, 10.03]) with moderate heterogeneity (Chi
2
 = 12.40, df = 4 (P = 0.01); I
2
 = 
68%) (342, 349, 375, 435, 449).  
For CHM compared to RP a significant improvement was found for 3 studies on 223 
participants (MD 16.19, 95%CI [14.61, 17.76]) with high heterogeneity (Chi
2
 = 26.20, df = 2 
(P < 0.00001); I
2
 = 92%) (423, 440, 455).  
For CHM plus RP compared to RP there was significant improvement based on 10 studies 
with 599 participants (MD 7.35, 95%CI [7.12, 7.58]) with moderate heterogeneity (Chi
2
 = 
21.34, df = 9 (P = 0.01); I
2
 = 58%) (366, 373, 401, 404, 410, 425, 436, 447, 451, 453).  
In addition, a significant improvement in FEV1% of participants treated with CHM compared 
to other CHM was found in 1 study on 38 participants (MD 5.06, 95%CI [0.29, 9.83]) (p<0.04) 
(433), whereas no difference in FEV1% between CHM plus RP and placebo plus RP was 
found for one study on 68 participants (MD -11.72, 95%CI [-22.87, -0.57]) (381) (see Figure 
7.5). 
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Figure 7. 5 Meta-analysis of CHM group versus control with FEV1 % at the end of treatment as the 
outcome (treatment period < 3 months) 
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7.7.1.2 Volume of FEV1 (L) 
FEV1 (L) was measured and reported in 37 studies with 1,819 participants in the treatment 
groups and 1,656 participants in the control groups (Figure 7.6).  
CHM Vs Placebo 
The volume of FEV1 (L) was reported in three studies with 862 participants. There was a 
marginally significant change after treatment (MD 0.30, 95%CI [0.02, 0.58]) but 
heterogeneity was high (Chi
2
 = 26.12, df = 2 (P < 0.00001); I
2
 = 92%) (69, 341, 342). 
CHM Vs RP 
In contrast, there is no significant change of the volume of FEV1 (L) in three studies 
comparing CHM to RP with 188 participants (MD 0.16, 95%CI [-0.01, 0.33]) (80, 423, 459).  
CHM plus RP Vs RP 
The volume of FEV1 (L) was measured in eighteen studies with 1,378 participants (347, 373, 
379, 385, 386, 404, 405, 415, 418, 427, 430, 431, 446, 447, 453, 456, 457, 460). A meta-
analysis showed a significant improvement of the volume of FEV1 (L) after treatment (MD 
0.22, 95%CI [0.12, 0.33]). Heterogeneity was high (Chi
2
 = 153.70, df = 17 (P < 0.00001); I
2
 = 
89%). 
CHM Vs Other CHM 
The volume of FEV1 (L) was measured in four studies with 337 participants (340, 429, 437, 
461). There was no significant change in the volume of FEV1 (L) after treatment between the 
experimental CHM and the other CHM (MD 0.20, 95%CI [-0.01, 0.42]).  
CHM Vs No treatment control 
The volume of FEV1 (L) was reported in 9 studies that included 710 participants (346, 363-
365, 367, 406, 409, 420, 424). A meta-analysis indicated a significant improvement in the 
volume of FEV1 (L) at completion of treatment (MD 0.20, 95%CI [0.06, 0.35]). Heterogeneity 
was high (Chi
2
 = 59.48, df = 8 (P < 0.00001); I
2
 = 87%).   
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Figure 7. 6 Meta-analysis of CHM group versus control with FEV1 (L) at the end of treatment as the 
outcome 
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Sensitivity analysis of volume of FEV1 (L) 
1) Long-term therapy - three or more months  
Long-term therapy was conducted in 24 studies with 1,759 participants. Meta-analysis 
indicated a significant improvement of FEV1 (L) when CHM plus RP was compared to RP in 
11 studies with 823 participants (MD 0.27, 95%CI [0.11, 0.42]), but heterogeneity was high 
(Chi
2
 = 84.45, df = 10 (P < 0.00001); I
2
 = 88%) (P=0.0006) (347, 379, 385, 386, 415, 427, 
430, 431, 446, 457, 460).  
For CHM compared to no treatment there was a significant improvement in 7 studies with 
481 participants (MD 0.18, 95%CI [0.01, 0.34]), but heterogeneity was high (Chi
2
 = 49.29, df 
= 6 (P < 0.00001); I
2
 = 88%) (p=0.04) (346, 363-365, 367, 409, 420).  
There was no significant change of FEV1 (L) when CHM was compared to RP in two studies 
with 118 participants (MD 0.06, 95%CI [-0.16, 0.29]), but heterogeneity was high (Chi
2
 = 
0.03 df = 1 (P=0.86); I
2
 = 0%) (80, 459).  
There was no significant change of FEV1 (L) when the experimental CHM was compared to 
other CHM in four studies with 337 participants (MD 0.20, 95%CI [-0.01, 0.42]), but 
heterogeneity was again high (Chi
2
 = 7.92, df = 3 (P =0.05); I
2
 = 62%) (340, 429, 437, 461) 
(Figure 7.7). 
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Figure 7. 7 Meta-analysis of CHM group versus control with FEV1 (L) at the end of treatment as the 
outcome (treatment period ≥ 3 months) 
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2) Short-term therapy - Less than three months 
A meta-analysis for short term therapy was conducted for thirteen studies with 1,716 
participants. This found a significant improvement of FEV1 (L) for CHM compared to 
placebo in three studies with 862 participants (MD 0.22, 95%CI [0.15, 0.28]), but 
heterogeneity was high (Chi
2
 = 26.12, df = 2 (P < 0.00001); I
2
 = 92%) (P<0.00001) Li, 2006 
#82}(341, 342).  
For CHM plus RP versus RP there was a significant improvement in 7 studies with 555 
participants (MD 0.13, 95%CI [0.08, 0.17]), and heterogeneity was moderate (Chi
2
 = 13.70, 
df = 6 (P =0.03); I
2
 = 56%) (P<0.00001) (404, 405, 418, 432, 447, 453, 456). 
For CHM compared to no treatment in two studies with 229 participants, there was a 
significant improvement (MD 0.28, 95%CI [0.13, 0.42]) but heterogeneity was high (Chi2 = 
5.86, df = 1 (P =0.02); I
2
 = 83%) (P=0.0002) (406, 424).  
In addition, for the comparison of CHM with RP in one study on 70 participants there was 
significant improvement of FEV1 (L) (MD 0.29, 95%CI [0.03, 0.55]) (423) (Figure 7.8). 
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Figure 7. 8 Meta-analysis of CHM group versus control with FEV1 (L) at the end of treatment as the 
outcome (treatment period < 3 months) 
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7.7.1.3 FEV1/FVC% 
FEV1/FVC% was measured and reported in 37 studies with 1,376 participants in the treatment 
groups and 1,259 participants in the control groups.  
A meta-analysis (Figure 7.9) showed that there was a significant improvement of 
FEV1/FVC% for: 
 CHM compared with placebo based on two studies with 96 participants (MD 3.88, 95%CI 
[0.78, 6.97]), with no heterogeneity (Chi
2
 = 0.06, df = 1 (P =0.81); I
2
 = 0%) (P=0.01) (375, 
435); 
 CHM compared with RP in four studies with 215 participants (MD 4.77, 95%CI [1.36, 
8.18]) with high heterogeneity (Chi2 = 9.56, df = 3 (P = 0.02); I
2
 = 69%) (P=0.007) (80, 
402, 403, 440);  
 CHM plus RP compared with RP in 20 studies with 1,389 participants (MD 4.05, 95%CI 
[2.10, 5.99]) with high heterogeneity (Chi
2
 = 149.59, df = 19 (P < 0.00001); I
2
 = 87%) 
(P<0.0001) (347, 366, 370, 372, 373, 379, 401, 404, 405, 410, 412, 415, 418, 425, 427, 
430, 431, 436, 438, 451); and  
 CHM compared with other CHM in five studies with 390 participants (MD 5.08, 95%CI 
[2.55, 7.62]) with no heterogeneity (Chi
2
 = 2.22, df = 4 (P=0.70); I
2
 = 0%) (P<0.0001) 
(340, 422, 429, 434, 452) and  
 CHM compared with no treatment in five studies with 477 participants (MD 5.05, 95%CI 
[3.37, 6.73]) with low heterogeneity (Chi
2 
= 8.00, df = 4 (P=0.09); I
2
 =50%) (P<0.00001) 
(365, 367, 377, 406, 409).  
In contrast, there was no significant improvement for FEV1/FVC% when CHM plus RP was 
compared with placebo plus RP in one study with 68 participants (MD -7.47, 95%CI [-14.54, 
-0.43]) (381).  
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Figure 7. 9 Meta-analysis of CHM group versus control with FEV1 / FVC (%) at the end of treatment as 
the outcome 
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7.7.1.4 FVC% predicted 
FVC% predicted was reported in 12 studies with 378 participants in the treatment groups and 
352 in the control groups. 
A meta-analysis (Figure 7.10) showed a significant improvement of FVC% predicted for:  
 CHM compared with RP in two studies with 162 participants (MD 7.95, 95%CI [1.70, 
14.20]) with moderate heterogeneity (I
2
 = 63%) (p=0.01) (455, 459); and  
 CHM compared with other CHM in three studies with 178 participants (MD 5.97, 95%CI 
[1.95, 9.99]) with no heterogeneity (I
2
 = 0%) (p=0.004) (434, 441, 452) and  
 CHM compared with no treatment in two studies with 122 participants (MD 7.02, 95%CI 
[1.10, 12.94]) with no heterogeneity (I
2
 = 0%) (p=0.02) (346, 424).  
There was a non-significant change in FVC % predicted in favour of the experimental groups 
when CHM plus RP was compared to RP in four studies on 232 participants (MD 2.50, 
95%CI [-0.05, 5.06]), with no heterogeneity (I
2
 = 0%) (p=0.05) (312, 410, 412, 457).  
In addition, there was no change of FVC % predicted in one study of 60 participants that 
compared CHM with a placebo group (MD 3.77, 95%CI [-6.22, 13.76]) (375). 
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Figure 7. 10 Meta-analysis of CHM group versus control with FVC (%) at the end of treatment as the 
outcome 
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7.7.1.5 The volume of FVC (L) 
FVC (L) was measured and reported in 30 studies with 1,215 participants in the treatment 
groups and 1,068 participants in the control groups. A meta-analysis indicated a significant 
improvement in the volume of FVC (L) treated for: 
 CHM compared to RP in three studies on 184 participants (MD 0.25, 95%CI [0.07, 0.43]) 
with no heterogeneity (I
2
 = 0%) (p=0.007) (80, 423, 459); 
 CHM plus RP compared to RP in 14 studies on 1,119 participants (MD 0.21, 95%CI [0.13, 
0.29]) with high heterogeneity (I
2
 = 70%), (p<0.0001) (344, 347, 370, 379, 386, 415, 418, 
430, 431, 447, 453, 456, 457, 460); and 
 CHM compared with no treatment in 7 studies on 545 participants (MD 0.28, 95%CI 
[0.15, 0.42]), with moderate heterogeneity (I
2
 = 66%) (p<0.0001) (346, 365, 383, 406, 409, 
413, 424).    
In addition, a significant improvement of the volume of FVC (L) was found for CHM versus 
placebo in one study with 60 participants (MD 0.42, 95%CI [0.16, 0.67]) (349).  
However, there was no significant change in the volume of FVC (L) after treatment for CHM 
versus other CHM in 5 studies with 375 participants (MD 0.17, 95%CI [-0.03, 0.38]) with 
high heterogeneity (I
2
 = 85%), (p<0.0001) (340, 429, 433, 437, 461) (Figure 7.11). 
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Figure 7. 11 Meta-analysis of CHM group versus control with FVC (L) at the end of treatment as the 
outcome 
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7.7.1.6 The maximum mid-expiratory flow  
The MMEF was reported in 8 studies with 575 participants in the treatment groups and 555 
participants in the control groups.  
A significant improvement of MMEF was found for the comparson of CHM versus other 
CHM in one study with 38 participants (MD 0.74, 95%CI [0.08, 1.40]) (433). There was an 
apparent change of MMEF which did not achieve significance for CHM versus placebo group 
in two studies with 800 participant (MD 0.43, 95%CI [-0.01, 0.86]) (341, 342). A similar 
result was found for CHM plus RP compared with RP in three studies with 176 participants 
(MD 1.30, 95%CI [-0.59, 3.19]) (344, 453, 457).  
There was no significant difference for CHM compared to RP in one study with 54 
participants (MD 0.16, 95%CI [-0.38, 0.70]) (459), or for CHM compared to no treatment in 
one study with 62 participants (MD 0.06, 95%CI [-0.43, 0.56]) (424) (Figure 7.12).   
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Figure 7. 12 Meta-analysis of CHM group versus control with MMEF (L/s) at the end of treatment as the 
outcome  
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7.7.1.7 The maximum voluntary ventilation 
MVV was measured and reported in 11 studies with 455 participants in the treatment groups 
and 378 participants in the control groups.  
Meta-analysis showed a significant improvement in MVV when CHM plus pharmacotherapy 
was compared with pharmacotherapy in seven studies with 549 participants (MD 8.04, 95%CI 
[3.83, 12.24]) with high heterogeneity (I
2
 = 72%) (p=0.0002) (370, 372, 412, 418, 453, 456, 
457).  
In addition, a significant improvement in MVV was found for CHM versus placebo in one 
study with 60 participants (MD 7.59, 95%CI [2.79, 12.39]) (349).  
There was no change in MVV for CHM versus no treatment in one study with 62 participants 
(MD 4.94, 95%CI [-5.01, 14.89]) (424), or for CHM versus pharmacotherapy in two studies 
with 162 participants (MD 9.92, 95%CI [-3.78, 23.63]) (455, 459) (Figure 7.13).  
       
Figure 7. 13 Meta-analysis of CHM group versus control with MVV (L/min) at the end of treatment as the 
outcome         
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7.7.1.8 The peak expiratory flow (%) 
The PEF% was reported in two studies each having 60 participants. A significant change of 
PEF % was found for CHM versus other CHM in one study with 60 participants (MD 12.60, 
95%CI [3.04, 22.16]) (434).  
No change in PEF % was found for CHM plus RP versus RP in one study with 60 participants 
(MD 4.55, 95%CI [-2.32, 11.42]) (410) (Figure 7.14).   
 
Figure 7. 14 Comparison of CHM plus RP versus RP, or CHM versus other CHM in patients with stable 
COPD: PEF (%) at the end of treatment 
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7.7.1.9 The peak expiratory flow (L/s) 
The value of PEF (L/s) was reported in two studies with 76 participants in the treatment 
groups and 61 participants in the control groups. No change in FEF (L/s) was found for CHM 
compared with placebo in one study with 62 participants (MD 0.56, 95%CI [-0.05, 1.18]) (69); 
or for CHM plus pharmacotherapy (RP) compared with pharmacotherapy in one study with 
75 participants (MD -2.60, 95%CI [-4.42, -0.78]) (446) (Figure 7.15).   
 
Figure 7. 15 Comparison of CHM versus placebo or CHM plus RP versus RP in patients with stable 
COPD: PEF (L/s) at the end of treatment             
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7.7.1.10 The maximum inspiratory pressure 
MIP was reported by one study with 60 participants and found no significant change between 
CHM and placebo (MD 0.55, 95%CI [-0.04, 1.14]) (349) (Figure 7.16).  
 
Figure 7. 16 Comparison of CHM versus placebo in patients with stable COPD: MIP at the end of 
treatment 
 
7.7.1.11 Airway resistance  
Raw was measured by one study on 54 participants and found no significant change when 
comparing CHM with pharmacotherapy (MD -0.12, 95%CI [-0.76, 0.52]) (459) (Figure 7.17).   
 
Figure 7. 17 Comparison of CHM versus routine pharmacotherapy in patients with stable COPD: Raw at 
the end of treatment 
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7.7.2 Effectiveness of CHM on prevention of exacerbation of COPD 
ECOPD involving acute exacerbation or relapse or hospitalizations were reported in 21 
studies on 1,619 participants with 4 withdrawals in one study during the treatment period. Ten 
studies with 699 participants specifically indicated that ECOPD was observed over at least 
one year including the treatment period and follow up period. Two studies with 185 
participants observed ECOPD for 2 month treatment and two seasons (half year) follow-up 
period (340, 381). One study with 69 participants observed ECOPD for three months 
treatment and half year follow up periods (376). The remaining studies did not state there was 
a follow up period in their studies. 
ECOPD rate was reported in nine studies on 377 participants in the treatment groups and 319 
participants in the control groups (Figure 7.18), while frequency of ECOPD was reported in 
eleven studies with 427 participants in the treatment groups and 421 participants in the control 
groups (Figure 7.19).  
In addition, ECOPD leading to days of hospitalization was reported in three studies with 123 
participants in the treatment groups and 122 in the control groups. Frequency of ECOPD and / 
or days of hospitalization due to ECOPD were reported in two studies with 124 participants 
(370, 376). However, the means and / or standard deviations of their measurements were not 
provided by authors, so these could not be analyzed by RevMan 5.1.  
7.7.2.1 Reduction of ECOPD rate 
A significant reduction in the number of ECOPDs was found for two studies with 154 
participants when CHM was compared to pharmacotherapy (RR 0.68, 95%CI [0.52, 0.90]); 
when CHM was compared to no treatment in one study with 99 participant (RR 0.25, 95%CI 
[0.07, 0.85]) and when CHM plus RP was compared to RP in three studies with 179 
participants (RR 0.53, 95%CI [0.38, 0.76]). However, no significant reduction in the 
percentage of ECOPD was found when CHM was compared to other CHM in three studies 
with 264 participants (RR 0.50, 95%CI [0.23, 1.13]) (Figure 7.18). 
201 
 
 
Figure 7. 18 Meta-analysis of CHM group versus control with Number of ECOPD at the end of treatment 
as the outcome  
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7.7.2.2 Frequency of ECOPD 
Significant reductions of the frequency of ECOPD per participant were found when:  
 CHM was compared with placebo in two studies with 166 participants (MD -0.93, 
95%CI [-1.17, -0.70]); 
 CHM plus RP was compared with RP in six studies with 489 participants (MD -126, 
95%CI [-1.41, -1.12]);  
 CHM was compared with other CHM in three studies with 239 participants (MD -0.84, 
95%CI [-1.08, -0.60]); and  
 CHM was compared with no treatment in one study with 60 participants (MD -1.20, 
95%CI [-1.14, -0.99]) (Figure 7.19).  
The two studies which compared CHM plus pharmacotherapy to pharmacotherapy did not 
provide the Mean and Standard Deviation, so they were not included in the Meta-analysis. 
However, a significant reduction in the frequency of ECOPD was reported by each study. 
 
Figure 7. 19 Meta-analysis of CHM group versus control with frequency of ECOPD at the end of 
treatment as the outcome  
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7.7.2.3 Days of hospitalization and ECOPD occurrence  
Significant reductions in days of hospitalization due to ECOPD occurrence were found for 
CHM compared to placebo in one study with 68 participants (MD -1.65, 95%CI [-3.12, -0.18]) 
(381); CHM plus RP compared to RP in one study with 60 participants (MD -3.70, 95%CI [-
7.21, -0.19]) (366); and for CHM versus other CHM in one study with 109 participants (MD -
5.44, 95%CI [-6.78, -4.11]) (Figure 7.20).  
 
Figure 7. 20 Comparison of CHM versus placebo, CHM plus RP versus RP, or CHM versus other CHM in 
patients with stable COPD: days of hospitalization at the end of follow up 
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7.7.3 Effectiveness of CHM for relieving symptoms  
Measures of the relief of symptoms included percentage of effectiveness for the relief of 
symptoms; and reduction in the total scores for an individual’s symptoms and/or sub-scores 
for specific symptoms including: chronic cough, sputum production and dyspnea.  
In addition, dyspnoea was assessed by the MMRC Dyspnea Scale.  
Relief of symptoms was reported in 55 studies on 3,885 participants, with 24 withdrawals 
during the treatment period in four studies. Four studies reported assessments of the 
effectiveness for each symptom but did not provide total scores or percentage effectiveness 
for symptoms, so these aspects could not be entered into RevMan 5.1 and analyzed (363, 364, 
452, 455).  
7.7.3.1 Effectiveness rate for symptoms 
Effectiveness rate for symptoms is calculated by the ratio of the total scores for symptoms 
before treatment minus the total scores for symptoms after treatment, divided by the total 
scores of symptoms before treatment. The percentage of effectiveness for symptoms can 
range from 0 to 100. Less than 30% means ‘no improvement’, greater than or equal to 70% 
means ‘symptoms remarkably relieved’ and greater than or equal to 90% means ‘symptoms 
completely relieved’. Percentage of effectiveness was reported in forty three studies with 
1,673 participants in the treatment groups and 1,441 participants in the control groups. Six 
participants dropped out during the treatment period but their data were not analyzed by intent 
to treat. Meta-analysis indicated a significant improvement in effectiveness rate for symptoms 
was found for:  
 CHM compared to placebo in two studies with 120 participants (RR 1.91 95% CI [1.01, 
3.60]) with moderate heterogeneity (Chi
2
 = 2.41, df = 1 (P =0.12); I
2
 = 58 %) (p=0.05) 
(349, 375); 
 CHM compared to RP in nine studies with 636 participants (RR 1.33 95% CI [1.15, 1.53]) 
with moderate heterogeneity (Chi
2
 = 18.96, df = 8 (P =0.02); I
2
 = 58 %) (p<0.0001) (80, 
402, 403, 407, 421, 423, 428, 439, 445);   
 CHM plus RP compared to RP in twenty two studies with 1,603 participants (RR 1.25 
95% CI [1.16, 1.35]) with moderate heterogeneity (Chi
2
 = 54.45, df = 21 (P < 0.0001); I
2
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= 61 %) (p<0.00001) (345, 372-374, 376, 380, 384, 386, 401, 410, 412, 417, 419, 425, 
430, 431, 438, 446-448, 456, 458); 
 CHM compared to other CHM in seven studies with 586 participants (RR 1.19 95% CI 
[1.07, 1.33]) with moderate heterogeneity (Chi
2
 = 12.72, df = 6 (P =0.05); I
2
 = 53 %) 
(p=0.001) (340, 343, 399, 429, 434, 441, 461) and  
 CHM compared to no treatment in three studies with 169 participants (RR 2.03 95% CI 
[1.13, 3.66]) with moderate heterogeneity (Chi
2
 = 7.76, df = 2 (P =0.02); I
2
 = 74 %) 
(p=0.02) (408, 413, 432) (Figure 7.21).  
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Figure 7. 21 Meta-analysis of CHM group versus control with effectiveness rate of symptoms at the end of 
treatment as the outcome  
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7.7.3.2  Reduction of the total scores of symptoms 
The total scores were calculated as the average of the sum of the scores for each symptom 
including cough, dyspnea and sputum production. The score for each symptom ranged from 0 
(no symptoms) to 3 (severe symptoms); higher scores denote greater distress and thus, worse 
symptoms, which was according to the Guiding principle of Clinical Research on New Drugs 
of Chinese medicine (308).  
The reduction of the total scores of symptoms was reported in ten studies with 394 
participants in the treatment groups and 326 participants in the control groups (Fig 7.22), and 
reduction in the score of each component such as chronic cough, production of sputum and 
dyspnea was reported in fourteen studies with 540 participants in the treatment groups and 
466 participants in the control groups (Figs 7.23-5).  
A significant reduction of the total scores for symptoms was found in the following studies 
which compared: CHM with placebo including 60 participants (MD -3.40, 95%CI [-5.19, -
1.61]) (375); CHM with other CHM including 100 participants (MD -1.29, 95%CI [-1.77, -
0.81]) (429); and CHM with no treatment including 74 participants (MD -3.90, 95%CI [-4.11, 
-3.69]) (420).  
A meta-analysis comparing CHM plus RP with RP in six studies with 362 participants showed 
significant reduction in the total scores for symptoms (MD -1.36, 95%CI [-1.99, -0.74]) with 
moderate heterogeneity (Chi
2
 = 45.07, df = 5 (P =0.00001); I
2
 = 89%) (p<0.0001) (376, 380, 
404, 410, 425, 427). However, reduction in the total scores for symptoms did not achieve 
significance when CHM was compared to RP in one study with 124 participants (MD -0.56, 
95%CI [-1.13, 0.01]) (Figure 7.22) (439).  
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Figure 7. 22 Meta-analysis of CHM group versus control with reduction of the total scores of symptoms at 
the end of treatment as the outcome  
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7.7.3.3 Reduction of the scores for chronic cough, production of sputum and dyspnea 
The reduction of scores for individual symptoms was reported by fourteen studies with 1,044 
participants. Six participants dropped out in one study (407). The fourteen studies are as 
follows: CHM was compared to placebo in two studies with 128 participants, to RP in two 
studies with 182 participants; CHM plus RP compared to RP in five studies with 349 
participants; CHM compared to other CHM in three studies with 220 participants; and CHM 
compared to no treatment in two studies with 127 participants.  
Scores for chronic cough 
A significant reduction in the score for chronic cough was found for: 
 CHM compared to placebo in two studies (MD -1.49, 95%CI [-1.98, -1.00]) with high 
heterogeneity (Chi
2
 = 8.60, df = 1 (P =0.003); I
2
 = 88%) (p<0.00001) (375, 381); and  
 CHM compared to RP in two studies with 182 participants (MD -0.39, 95%CI [-0.62, -
0.17]) with low heterogeneity (Chi
2
 = 1.44, df = 1 (P =0.23); I
2
 = 30%) (p=0.0007) (407, 
428); 
 CHM plus RP compared to RP in five studies on 349 participants (MD -0.23, 95%CI [-
0.36, -0.11]) with moderate heterogeneity (Chi
2
 = 8.08, df = 4 (P =0.09); I
2
 = 50%) 
(p=0.0002) (345, 366, 376, 380, 410);  
 CHM compared to other CHM in three studies (MD -0.33, 95%CI [-0.47, -0.20]) with 
moderate heterogeneity (Chi
2
 = 1.43, df = 2 (P =0.49); I
2
 = 0%) (p<0.00001) (429, 434, 
442) and  
 CHM compared to no treatment in two studies with 127 participants (MD -0.42, 95%CI [-
0.61, -0.22]) with moderate heterogeneity (Chi
2
 = 2.02, df = 1 (P =0.16); I
2
 = 50%) 
(p<0.0001) (424, 432) (Figure 7.23).  
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Figure 7. 23 Meta-analysis of CHM group versus control with reduction of the scores of chronic cough at 
the end of treatment as the outcome  
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Scores for production of sputum 
A significant reduction in the score for production of sputum was found for:  
 CHM plus RP compared to RP (MD -0.37, 95%CI [-0.51, -0.23]) with low heterogeneity 
(Chi
2
 = 5.70, df = 4 (P =0.22); I
2
 = 30%) (p<0.00001) (345, 366, 376, 380, 410);  
 CHM compared to other CHM (MD -0.25, 95%CI [-0.40, -0.11]) with low heterogeneity 
(Chi
2
 = 1.47, df = 2 (P =0.48); I
2
 = 0%) (p=0.0004) (429, 434, 442); and 
 CHM compared to no treatment (MD -0.40, 95%CI [-0.58, -0.22]) with low heterogeneity 
(Chi
2
 = 0.05, df = 1 (P =0.82); I
2
 = 0%) (p<0.0001) (424, 432).  
However, no reduction in sputum scores was found when CHM was compared to placebo in 
two studies with 128 participants (MD -0.33, 95%CI [-0.84, 0.18]); or when CHM was 
compared to RP in two studies with 182 participants (MD -0.19, 95%CI [-0.40, 0.01]) (407, 
428) (Figure 7.24). 
 
Figure 7. 24 Meta-analysis of CHM group versus control with reduction of the scores of sputum 
production at the end of treatment as the outcome  
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Scores for dyspnoea 
A significant reduction in the score for dyspnea was found for:  
 CHM compared to placebo (MD -1.25, 95%CI [-1.70, -0.80]) with no heterogeneity (Chi2 
= 0.00, df = 1 (P =0.95); I
2
 = 0%) (p<0.00001)  (375, 381);  
 CHM compared to RP (MD -0.32, 95%CI [-0.51, -0.14]) with low heterogeneity (Chi2 = 
0.92, df = 1 (P =0.34); I
2
 = 0%) (p=0.0005) (407, 428);  
 CHM plus RP compared to RP (MD -0.23, 95%CI [-0.39, -0.07]) with low heterogeneity 
(Chi
2
 = 4.72, df = 4 (P =0.32); I
2
 = 15%) (p=0.005) (345, 366, 376, 380, 410); 
 CHM compared to other CHM (MD -0.27, 95%CI [-0.40, -0.15]) with low heterogeneity 
(Chi
2
 = 0.97, df = 2 (P =0.61); I
2
 = 0%) (p<0.0001) (429, 434, 442); and 
 CHM compared to no treatment (MD -0.50, 95%CI [-0.74, -0.25]) with low heterogeneity 
(Chi
2
 = 0.05, df = 1 (P =0.82); I
2
 = 0%) (p<0.0001) (424, 432)  (Figure 7.25). 
 
Figure 7. 25 Meta-analysis of CHM group versus control with reduction of the scores of dyspnoea at the 
end of treatment as the outcome  
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7.7.3.4 Reduction in the Modified Medical Research Council Dyspnea scale 
This scale was administrated in three studies with 90 participants in each of the treatment and 
control groups (312, 375, 408). 
A significant reduction in the Modified Medical Research Council Dyspnea scale was found 
in each study comparing CHM with placebo (MD -0.33, 95%CI [-0.66, 0.00]); CHM plus RP 
with RP (MD -0.45, 95%CI [-0.84, -0.06]); and CHM with no treatment (MD -0.49, 95%CI [-
0.92, -0.06]) (Figure 7.26). 
 
Figure 7. 26 Meta-analysis of CHM group versus control with reduction of scores of MMRC dyspnoea at 
the end of treatment as the outcome  
 
7.7.4 CHM impact on 6MWD and BODE index and BMI  
6MWD test was reported in 10 studies with 366 participants in the treatment groups and 357 
participants in the control groups. Duration of treatment included 1 month (28 days) in two 
studies (345, 452), three months in 5 studies (312, 347, 386, 408, 434), six months in 2 studies 
(415, 422) and one year in 1 study (420).  
BODE index was measured in two studies with 68 participants in the treatment groups and 65 
participants in the control groups, and the duration of treatment was 3 months in both (312, 
408).  
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BMI was reported in four studies with 125 participants in the treatment groups and 107 
participants in the control groups. Duration of treatment included one month in 2 studies (440, 
454), two months in 1 study (417) and three months in 1 study (408). Results from these 
measurements are showed individually as follows.  
7.7.4.1 6MWD 
Meta-analysis found that a significant improvement in the exercise capacity and tolerance of 
participants assessed by 6MWD performance for: 
 CHM plus RP compared to RP in five studies with 403 participants (MD 41.39, 95%CI 
[28.69, 54.10]) (Chi
2
 = 5.41, df = 4 (P =0.25); I
2
=26%) (p<0.00001) (312, 345, 347, 386, 
415); 
 CHM compared to other CHM in three studies with 173 participants (MD 33.31, 95%CI 
[15.55, 51.07]) (Chi
2
 = 0.97, df = 2 (P =0.88); I
2
 = 0%) (p<0.0002) (422, 434, 452) and 
 CHM compared to no treatment in two studies with 147 participants (MD 67.54, 95%CI 
[58.65, 76.43]) (Chi
2
 = 1.36, df = 1 (P =0.24); I
2
 = 26%) (p<0.00001) (408, 420).  
The heterogeneity was consistent at I
2
<50% for each comparison, so a fixed effect model was 
used (Figure 7.27).   
 
Figure 7. 27 Meta-analysis of CHM group versus control with improvement of 6MWD at the end of 
treatment as the outcome  
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7.7.4.2 BODE index 
A significant decline in the mean of BODE index was found when comparing CHM plus RP 
with RP in one study with 60 participants (MD -1.21, 95%CI [-2.34, -0.08]) (312) and CHM 
versus no treatment in one study with 73 participants (MD -1.50, 95%CI [-2.68, -0.32]) (408) 
(Figure 7.28). 
 
Figure 7. 28 Comparison of CHM plus RP versus RP or CHM versus no treatment in patients with stable 
COPD: BODE index at the end of treatment as the outcome  
 
7.7.4.3 BMI index 
Body-mass index (BMI) is a calculation using weight and height. It measures the level of 
nutrition represented as four classes of leanness or obesity, being < 20 kg/m
2 ‘underweight’; 
20 to 24 kg/m
2
 ‘normal’; 24 to 29 kg/m2 ‘overweight’; >29 kg/m2 ‘obese’. BMI was reported 
in four studies with 232 participants.  
A significant increase of the mean BMI index was found for: CHM compared with placebo in 
one study with 60 participants (MD 1.59, 95%CI [0.79, 2.39]) (454); and for CHM plus RP 
compared with RP in one study with 54 participants (MD 2.13, 95%CI [1.84, 2.42]) (417). 
There was no difference in the mean BMI index when CHM was compared to RP in one study 
with 45 participants (MD -0.90, 95%CI [-2.25, 0.75]) (440) and CHM was compared to no 
treatment in one study with 73 participants (MD 0.94, 95%CI [-0.52, 2.40]) (408) (Figure 
7.29). 
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Figure 7. 29 Comparison of CHM group versus control groups in patients with stable COPD: BMI index 
at the end of treatment as the outcome  
 
7.7.5 Effect of CHM on arterial blood gas measurements 
The arterial blood gas measurement includes multiple items such as arterial oxygen tension 
(PaO2), PaCO2, oxygen saturation (SaO2) and blood pH. This section focuses on analysis of 
PaO2 and PaCO2. Normally, the value of PaO2 ranges from 10.6 to 13.3KPa (80-100mmHg). 
PaO2 <80mmHg (10.6 KPa) suggests hypoxia; <60mmHg (8KPa): respiratory failure; 
<40mmHg severe hypoxemia; and <20mmHg non survival.  
The value of PaCO2 ranges from 35 to 45 mmHg (4.67 to 6.0KPa). A PaCO2 >50 mmHg
（6.67 KPa) suggests respiratory acidosis, and PaCO2 <35 mmHg (4.67 KPa) respiratory 
alkalosis. When considering the combination of PaO2 and PaCO2, a PaO2 <60mmHg (8KPa) 
combined with PaCO2 <50 mmHg (6.67 KPa) is diagnosed as stage I respiratory failure. If 
PaO2 <60mmHg (8KPa) is combined with PaCO2 >50 mmHg (6.67 KPa), it should be 
diagnosed as stage II respiratory failure.  
Arterial blood gas measurement was measured and reported in ten studies with 706 
participants. These studies involved the following intervention and duration: CHM compared 
with placebo in one study for 2-months, CHM compared with RP in one study for 3-months, 
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CHM compared with no treatment in one studiy for 6-months, CHM compared with other 
CHM in three studies for 3-months, and CHM plus RP compared to RP in four studies, with 
Wang 2006 lasting for 28-days and the others for 3-months. A 9-month follow-up was 
recorded in Zhao (2009) but data were not reported at completion of follow up (446). 
7.7.5.1 PaO2 
A significant difference of PaO2 was reported at completion of treatment for CHM versus 
placebo in one study with 60 participants (MD 0.68, 95%CI [0.23, 1.12]) (349), and for CHM 
versus no treatment in one study with 104 participants (MD 0.53, 95%CI [0.14, 0.93]) (367). 
However, no statistically significant increase in the level of PaO2 for CHM versus RP was 
found in one study with 54 participants (MD 0.09, 95%CI [-0.65, 0.83]) (459).  
A meta-analysis of four studies with 251 participants showed a significant change for: CHM 
plus RP compared to RP (MD 0.42, 95%CI [0.15, 0.69]) with no heterogeneity (I
2
 = 0%) 
(p=0.002) (312, 446, 453, 457). However, significant increase in the level of PaO2 with high 
heterogeneity was found in three studies with 237 participants that compared experimental 
CHM with other CHM (MD 0.77, 95%CI [0.02, 1.51]) I
2
 = 86%) (p=0.04) (340, 437, 461) 
(I
2
>50%, so random effects applied) (Figure 7.30).  
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Figure 7. 30 Comparison of CHM CHM group versus control groups in patients with stable COPD: PaO2 
(KPa) at the end of treatment as the outcome  
 
7.7.5.2 PaCO2 
A meta-analysis indicated a significant decrease in the level of PaCO2 in three studies with 
237 participants that compared CHM with other CHM (MD -0.34, 95%CI [-0.64, -0.04]) with 
consistent heterogeneity (I
2
 = 0%) (p=0.02) (340, 437, 461). In addition, a significant decrease 
in the level of PaCO2 was found at completion of treatment when CHM was compared with 
no treatment in one study with 104 participants (MD -1.59, 95%CI [-1.95, -1.23]) (367).   
In contrast, meta-analysis showed no significant decrease in the level of PaCO2 in four studies 
with 251 participants that compared CHM plus RP to RP (MD -0.26, 95%CI [-0.59, 0.06]) 
(312, 446, 453, 457).  
In addition, no change in the level of PaCO2 was found in one study on 60 participants which 
compared CHM to placebo in one study on 60 participants (MD -0.03, 95%CI [-0.63, 0.03]) 
(349), and CHM to RP in one study on 54 participants (MD -0.05, 95%CI [-0.41, 0.31]) (459) 
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(Figure 7.31).  
 
Figure 7. 31 Comparison of CHM group versus control groups in patients with stable COPD: PaCO2 
(KPa) at the end of treatment as the outcome  
 
7.7.6 Effect of CHM on biomarkers  
COPD is a complex disease with multiple pathogeneses. Airway inflammation plays an 
imperative role in pathogenesis of COPD and the level of inflammatory cells are associated 
with the phenotype of COPD, which needs descriptive measures through levels of 
biochemical biomarkers to provide a more comprehensive and clinically accurate assessment 
of COPD (464).  
In this section, the results of biomarker measurements are analyzed for inflammatory 
chemokines and cytokines in sputum or in serum, T lymphocyte subsets and the level of 
immuneglobulins in serum as well as other measurements. 
Inflammatory chemokines and cytokines and T lymphocyte subsets and immune globulin 
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were tested and reported in twenty three studies on 1,431 participants with four withdrawals 
during the treatment period. Although four studies with 254 participants reported the use of 
tests of IL-8, IL-1, IL-6, TNF-α, TGF-β (transforming growth factor) and/or C-reactive 
protein (CRP), the original data were not provided by the authors so it could not be analyzed 
by RevMan 5.1 (369, 398, 411, 463). 
7.7.6.1 Measurements of IL-8 and TNF-α and IL-2 
Inflammatory chemokines and cytokines including IL-8, IL-2 or TNF-α were tested in ten 
studies with 531 participants. The IL-8 and TNF-α levels were tested by sputum or serum 
examination. The level of IL-8 in sputum was reported in four studies with 158 participants. 
The level of IL-8 in serum was tested by two studies with 98 participants. The level of TNF-α 
was measured in three studies by sputum on 167 participants and in another three studies by 
serum on 146 participants. The level of IL-2 only was tested by serum in two studies with 175 
participants.  
Level of IL-8 in sputum 
The level of the chemokine IL-8 in sputum was measured in four studies with 158 participants. 
A significant decrease of the level of IL-8 in sputum was found when comparing CHM with 
placebo in one study with 36 participants (MD -0.94, 95%CI [-1.70, -0.18]) (435), and CHM 
plus RP compared with RP in two studies with 86 participants (MD -2.43, 95%CI [-3.52, -
1.34]) with low heterogeneity (Chi
2
 = 0.03, df = 1 (P =0.85); I
2
 = 0%) (405, 436). However, 
no significant change in the level of IL-8 in sputum was found in one study with 36 
participants that compared CHM to no treatment (MD -1.18, 95%CI [-2.99, 0.62]) (346) 
(Figure 7.32).   
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Figure 7. 32 Comparison of CHM group versus control groups in patients with stable COPD: IL-8 in 
sputum at the end of treatment as the outcome  
 
Level of IL-8 in serum 
There was a significant decrease in the mean level of serum IL-8 in the following two studies. 
When CHM was compared with RP in one study that included 60 participants (MD -10.35, 
95%CI [-12.76, -7.94]) (80) and when an experimental CHM was compared to other CHM in 
one study that included 38 participants (MD -0.23, 95%CI [-0.32, -0.15]) (433) (Figure 7.33).  
Enzyme-linked immunosorbent assay (ELISA) was applied in Xiong (2008) using ng/L as the 
unit of measurement. However, pg/ml was used as the unit of measurement in Sun (2007-a) 
with no description of the assay that was used to measure IL-8. Therefore the units of 
measurement were not the same in these two studies. 
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Figure 7. 33 Comparison of CHM group versus control groups in patients with stable COPD: IL-8 in 
serum at the end of treatment as the outcome  
 
Level of TNF-α in sputum 
There were three studies with 146 participants that found significant decreases in the level of 
TNF-α in sputum when comparing CHM plus RP with RP (MD -0.58, 95%CI [-0.68, -0.49]) 
with low heterogeneity (Chi
2
 = 1.08, df = 2 (P =0.58); I
2
 = 0%) (p<0.00001) (405, 425, 436) 
(Figure 7.34). 
 
Figure 7. 34 Comparison of CHM plus RP versus RP in patients with stable COPD: the level of TNF-α in 
sputum at the end of treatment as the outcome  
 
Level of serum TNF-α 
There was a significant decrease in the level of serum TNF-α when CHM was compared to 
placebo in one study with 40 participants (MD -10.22, 95%CI [-18.60, -1.84]) (449); CHM 
compared to RP in one study with 60 participants (MD -7.96, 95%CI [-10.36, -5.56]) (80) and 
CHM plus RP compared to RP in one study with 67 participants (MD -4.56, 95%CI [-6.27, -
2.85]) (447) (Figure 7.35). 
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Figure 7. 35 Comparison of CHM group versus control groups in patients with stable COPD: TNF-α in 
serum at the end of treatment as the outcome  
 
Level of serum IL-2 
A significant increase in the mean level of serum IL-2 was found when CHM plus RP was 
compared with RP in one study with 67 participants (MD 21.40, 95%CI [15.60, 27.20]) (447), 
whereas no significant change was observed between CHM and RP in one study with 108 
participants (MD 0.03, 95%CI [-0.01, 0.07]) (455)(Figure 7.36).  
 
Figure 7. 36 Comparison of CHM group versus control groups in patients with stable COPD: IL-2 in 
serum at the end of treatment as the outcome  
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7.7.6.2 Measurements of T lymphocyte subsets 
Serum T lymphocyte subgroups were measured in eight studies with 323 participants in the 
treatment groups and 282 participants in the control groups. 
Level of serum CD4 
A meta-analysis found a significant increase in the level of CD4 when CHM plus RP was 
compared with RP in three studies with 239 participants (MD 6.23, 95%CI [3.44, 9.01]) with 
severe heterogeneity (Chi
2
 = 11.04, df = 2 (P =0.004); I
2
 = 82%) (p<0.0001) (372, 450, 455) 
and CHM compared to no treatment in two studies with 122 participants (MD 5.49, 95%CI 
[3.80, 7.18]) with low heterogeneity (Chi
2
 = 0.19, df = 1 (P =0.66); I
2
 = 0%) (p<0.0001) (383, 
424). 
In addition, a significant increase in the level of CD4 was found when CHM was compared to 
placebo in one study with 62 participants (MD 6.00, 95%CI [5.01, 6.99]) (69) and CHM 
compared to RP in one study with 80 participants (MD 8.67, 95%CI [6.37, 10.97]) (444).  
However, no difference in the level of CD4 between experimental CHM and other CHM was 
observed in one study with 102 participants (MD 0.90, 95%CI [-1.13, 2.93]) (343) (Figure 
7.37). 
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Figure 7. 37 Comparison of CHM group versus control groups in patients with stable COPD: CD4 in 
serum at the end of treatment as the outcome  
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Level of serum CD8 
There was significant decrease in the level of CD8 when CHM was compared to placebo in 
one study with 62 participants (MD -1.99, 95%CI [-2.66, -1.32]) (69).  
However, no significant change in the level of CD8 was found when CHM was compared to 
RP in one study with 80 participants (MD -0.98, 95%CI [-2.27, 0.31]) (444); or CHM plus RP 
was compared to RP in three studies with 239 participants (MD -6.06, 95%CI [-20.33, 8.22]) 
(372, 450, 455); or CHM was compared to other CHM in one study with 102 participants 
(MD 2.51, 95%CI [0.40, 4.62]) (343); or CHM was compared to no treatment in two studies 
with 122 participants (MD -0.60, 95%CI [-2.20, 1.00]) (383, 424) (Figure 7.38).  
 
Figure 7. 38 Comparison of CHM group versus control groups in patients with stable COPD: CD8 in 
serum at the end of treatment as the outcome  
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Level of serum CD3 
A meta-analysis indicated a significant increase in the level of CD3 when CHM plus RP was 
compared to RP in three studies with 239 participants (MD 5.88, 95%CI [2.99, 8.78]) with 
severe heterogeneity (Chi
2
 = 10.28, df = 2 (P =0.005); I
2
 = 81%) (p<0.0001) (372, 450, 455).   
In addition, a significant increase of the level of CD3 was found when CHM was compared 
with placebo in one study with 62 participants (MD 6.87, 95%CI [5.63, 8.11]) (69) and CHM 
compared with RP in one study with 80 participants (MD 5.17, 95%CI [3.07, 7.27]) (444). 
However, no difference was found between experimental CHM and other CHM in one study 
with 102 participants (MD -0.34, 95%CI [-3.13, 2.45]) (343) and between CHM and no 
treatment control group in two studies with 122 participants (MD 1.75, 95%CI [-4.22, 7.91]) 
(383, 424) (Figure 7.39). 
 
Figure 7. 39 Comparison of CHM group versus control groups in patients with stable COPD: CD3 in 
serum at the end of treatment as the outcome  
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Level of the ratio of serum CD4/CD8 
A meta-analysis indicated a significant increase in the ratio of CD4/CD8 when CHM plus RP 
was compared to RP in two studies with 131 participants (MD 0.55, 95%CI [0.19, 0.91]) with 
severe heterogeneity (Chi
2
 = 5.08, df = 1 (P =0.02); I
2
 = 80%) (p=0.003) (372, 450); and 
CHM was compared to a no treatment control group in two studies with 122 participants (MD 
0.20, 95%CI [0.08, 0.32]) with severe heterogeneity (Chi
2
 = 3.49, df = 1 (P = 0.06); I
2
 = 71%) 
(p = 0.0007) (383, 424). 
In addition, a significant increase in the ratio of CD4/CD8 was also found when comparing 
CHM with placebo in one study with 62 participants (MD 0.36, 95%CI [0.11, 0.61]) (69); and 
when CHM was compared to RP in one study with 80 participants (MD 0.33, 95%CI [0.15, 
0.51]) (444).  
However, no significant change in the ratio of CD4/CD8 between experimental CHM and 
other CHM was observed in one study with 102 participants (MD -0.38, 95%CI [-0.56, -0.20]) 
(343) (Figure 7.40). 
 
Figure 7. 40 Comparison of CHM group versus control groups in patients with stable COPD: CD4/CD8 in 
serum at the end of treatment as the outcome  
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7.7.6.3 Measurements of immune globulins 
Immune globulins include immune globulin A (IgA), immune globulin G (IgG) and immune 
globulin M (IgM), which were measured and reported in nine studies with 600 participants.  
Level of serum IgA 
A meta-analysis showed a significant increase of the level of IgA when CHM was compared 
to RP in two studies with 145 participants (MD 0.44, 95%CI [0.21, 0.66]) with low 
heterogeneity (Chi
2
 = 1.17, df = 1 (P =0.28); I
2
 = 15%) (p=0.0001) (432, 444); and CHM plus 
RP was compared with RP in three studies with 191 participants (MD 0.44, 95%CI [0.27, 
0.62]) with low heterogeneity (Chi
2
 = 3.20, df = 2 (P =0.20); I
2
 = 38%) (p<0.00001) (372, 410, 
450).  
In addition, there was a significant increase in the level of IgA found when comparing CHM 
with placebo in one study with 62 participants (MD 0.54, 95%CI [0.27, 0.81] (69).  
However, no difference was observed between experimental CHM and other CHM in two 
studies with 140 participants (MD -0.11, 95%CI [-0.62, 0.39]) (343, 433); or for CHM 
compared with no treatment group in one study with 62 participants (MD -0.60, 95%CI [-1.21, 
0.01]) (424) (Figure 7.41). 
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Figure 7. 41 Comparison of CHM group versus control groups in patients with stable COPD: IgA in 
serum at the end of treatment as the outcome  
 
Level of serum IgM 
There was no significant difference in the level of IgM when CHM was compared to placebo 
in one study with 62 participants (MD 0.09, 95%CI [-0.24, 0.42]) (69); or when CHM was 
compared to RP in two studies with 145 participants (MD 0.10, 95%CI [-0.68, 0.87]) (432, 
444); or when CHM plus RP as compared with RP in three studies with 191 participants (MD 
0.27, 95%CI [-0.20, 0.74]) (372, 410, 450); or when experimental CHM was compared to 
other CHM in two studies on 140 participants (MD 0.06, 95%CI [-0.02, 0.14]) (343, 433); or 
when CHM was compared to no treatment control group in one study on 62 participants (MD 
0.01, 95%CI [-0.47, 0.49]) (424) (Figure 7.42). 
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Figure 7. 42 Comparison of CHM group versus control groups in patients with stable COPD: IgM in 
serum at the end of treatment as the outcome  
 
Level of serum IgG 
A meta-analysis found a significant increase of the level of IgG when CHM was compared to 
RP in two studies with 145 participants (MD 1.80, 95%CI [0.87, 2.73]) with low 
heterogeneity (Chi
2
 = 0.03, df = 1 (P =0.86); I
2
 = 0%) (p=0.0002) (432, 444); and CHM plus 
RP was compared to RP in three studies with 191 participants (MD 2.42, 95%CI [1.65, 3.18]) 
with low heterogeneity (Chi
2
 = 3.15, df = 2 (P =0.21); I
2
 = 38%) (p <0.00001) (372, 410, 450).  
In addition, there was a significant increase in the level of IgG found when CHM was 
compared to placebo in one study with 62 participants (MD 2.32, 95%CI [1.13, 3.51]) (69).  
However, there was no different change in the level of IgG between experimental CHM and 
other CHM in two studies with 140 participants (MD 0.03, 95%CI [-0.73, 0.79]) (343, 433).  
On the other hand, a contrary result was found for CHM compared to no treatment control 
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group in one study with 62 participants (MD -3.19, 95%CI [-4.68, -1.70]) (424) (Figure 7.43).  
 
Figure 7. 43 Comparison of CHM group versus control groups in patients with stable COPD: IgG in 
serum at the end of treatment as the outcome  
 
7.7.6.4 Measures of level of nutriton 
The nutrition parameters consist of the level of serum ALB measured in four studies and Pre 
ALB (PALB) in five studies and Leptin in two studies. One study did not provide orginal data 
for PALB, so it could not be analyzed by meta-analysis (463). 
Level of serum albumin  
Serum ALB was tested in four studies with 219 participants. A significant increase in the level 
of serum ALB was found by one study with 60 participants when CHM was compared to 
placebo (MD 2.04, 95%CI [0.92, 3.16]) (454). However, no difference was found when CHM 
was comparied to RP in one study with 45 participants (MD 1.00, 95%CI [-2.52, 4.52]) (440), 
and CHM plus RP was compared to RP groups in two studies on 134 participants (MD 0.65, 
95%CI [-0.40, 1.71]) (410, 417) (Figure 7.44).  
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Figure 7. 44 Comparison of CHM group versus control groups in patients with stable COPD: serum ALB 
at the end of treatment as the outcome  
 
Level of serum Prealbumin  
Serum PALB was tested in four studies with 230 participants. A significant increase in the 
level of serum PALB was found  when CHM was compared to placebo in one study that 
included 60 participants (MD 14.90, 95%CI [8.97, 20.83]) (454), and CHM plus RP was 
compared to RP in 2 studies with 125 participants (MD 52.78, 95%CI [49.20, 56.36]) (398, 
417), whereas no difference was found when CHM was compared to RP in one study with 
114 participants (MD 20.00, 95%CI [-27.61, 67.61]) (440) (Figure 7.45). 
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Figure 7. 45 Comparison of CHM group versus control groups in patients with stable COPD: serum 
PALB at the end of treatment as the outcome  
 
Level of serum leptin 
A significant increase in the level of serum Leptin was found by one study with 60 
participants when CHM was compared to placebo (MD 1.12, 95%CI [0.83, 1.41]) (454). 
However, no difference was found when CHM plus RP was compared to RP in one study with 
54 participants (MD -0.19, 95%CI [-0.93, 0.55]) (417) (Figure 7.46). 
 
 
Figure 7. 46 Comparison of CHM group versus control groups in patients with stable COPD: serum 
Leptin at the end of treatment as the outcome  
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7.7.6.5 Measurement of superoxidase dismutase and lipid peroxide 
The level of serum superoxidase dismutase (SOD) and Lipid peroxide, which are the major 
relevant factors for maintaining the balance of oxidants and antioxidants, were reported by 
one study with 60 participants.  
Level of superoxidase dismutase  
A significant increase in the level of serum SOD was found by one study when CHM was 
compared to placebo with 60 participants (MD 20.31 95%CI [7.09, 33.53) (73) (Figure 7.47).  
 
Figure 7. 47 Comparison of CHM versus placebo in patients with stable COPD: plasma SOD at the end of 
treatment as the outcome  
 
Level of lipid peroxide 
A significant reduction in the level of serum LPO was found in one study when CHM was 
compared to placebo with 60 participants (MD -0.68 95%CI [-1.12, -0.24) (73) (Figure 7.48). 
 
Figure 7. 48 Comparison of CHM versus placebo in patients with stable COPD: plasma LPO at the end of 
treatment as the outcome  
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7.7.6.7 Measurement of blood rheology parameters 
Measurements of blood rheology, specifically plasma viscosity and hematocrit, were reported 
by three studies with 239 participants.  
Level of plasma viscosity shear rate 
A significant reduction of the level of plasma viscosity, measured as shear rate, was found 
when CHM plus RP was compared to RP with 59 participants (MD -0.60 95%CI [-0.81, -0.39) 
(384); and CHM was compared to no treatment in one study with 120 participants (MD -0.65 
95%CI [-0.72, -0.58) (400). Whereas no difference was found when experimental CHM was 
compared to other CHM in one study with 60 participants (MD -0.06 95%CI [-0.14, 0.02) 
(441) (Figure 7.49).   
 
Figure 7. 49 Comparison of CHM group versus control groups in patients with stable COPD: plasma 
viscosity at the end of treatment as the outcome  
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Level of plasma hematocrit 
A significant reduction in the level of plasma hematocrit was demonstrated when CHM plus 
RP was compared to RP in one study with 59 participants (MD -15.00 95%CI [-20.88, -9.12) 
(384), and when CHM was compared to no treatment in one study with 120 participants (MD 
-5.87 95%CI [-7.41, -4.33) (400). Whereas, no difference was found in one study with 60 
participants when experimental CHM was compared to other CHM (MD -1.13 95%CI [-5.00, 
2.74) (441) (Figure 7.50).   
 
 
Figure 7. 50 Comparison of CHM group versus control groups in patients with stable COPD: plasma 
hematocrit at the end of treatment as the outcome  
 
7.7.7 Adverse event recording  
Among the 101 included studies (see Table from 4.7 to 4.12), 17 studies reported that no 
adverse events were observed during the treatment period (73, 79, 312, 340, 346, 375, 376, 
380, 412, 424, 426, 428, 432, 435, 440, 452, 461); 4 studies reported minor adverse events 
were observed during the treatment period (347, 365, 405, 420); and adverse events were not 
mentioned in 80 studies. 
In some of the studies, liver and kidney function as a measure of the safety of the CHM were 
tested using blood taken before and after treatment. There was no change between pre and 
post treatment which meant the CHM treatment had no adverse effect on liver and kidney 
function of patients in these six studies (375, 376, 380, 432, 440, 461). However, protocols 
that included observation of adverse events and blood tests involving liver and kidney 
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function were set up in two studies but no results were reported (403, 404).  
Minor adverse events were reported by 4 studies. In one study, five subjects had abdominal 
bloating during the treatment period but it was not mentioned which group they belonged to 
(405). Two participants who were in the treatment group had mild stomach symptoms, and 
then changed intake of the CHM to after meals and the symptoms disappeared (420). Five 
patients had mild stomach symptoms such as nausea, vomiting and diarrhea. One of them 
took ‘Live Bacillus Licheniformis preparation’ for two days and the symptoms disappeared. 
The others did not take any medications and recovered (365). Minor adverse events were 
recorded in Huang 2005 (347) and the details have been described in the Ginseng formulae 
section (SR1).  
No severe adverse event was reported among the 101 studies. The participants who dropped 
out from the studies did not attribute their dropping out to adverse events of CHM. 
7.8 Results of herbs and formulae from all clinical trials for stable COPD 
7.8.1 Types of herbs 
A total of 139 different herbs were used in this review. All of the herbs in the included studies 
were included under fourteen types according to the categories of Materia Medica as listed in 
Appendix 19. 
Among these types of herbs, the most commonly used herbs belong to tonifying herbs. 
7.8.2 Frequency of use of herbs in all 101 included studies 
141 different herbs were used in these studies. The orders of frequency of use of herbs were 
ranked as following from high to low: 
The 4 most commonly used herbs were each used in excess of 40 times as follows: Huang qi 
in 55 studies, Bai zhu in 54 studies and Fu ling in 45 studies and Dang shen in 40 studies 
(including repeats due to multiple formulae being used in the studies by Fang, 2008 and Shi, 
2009).   
4 herbs were used more than 30 times: Gan cao in 34 studies, Wu wei zi in 34 studies 
(including repeats due to multiple formulae being used in the studies by Fang, 2008 and Shi, 
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2009) and Chen pi in 32 studies as well as Di huang in 30 studies (including Gan di huang, 
Sheng di huang and Shu di huang). 
There are 6 herbs that were used in the range of 20 to 30 times: Ban xia in 25 studies 
(including Fa ban xia and Zhi ban xie); Dan shen and Mai dong in 24 studies each; Ge jie in 
23 studies, Dang gui in 21 studies, and Ren shen (ginseng) in 20 studies (including Hong shen 
3, Sheng shai shen 1, Gao li shen 1 and  Xi yang shen 3).  
There are five herbs for resolving phlegm and suppressing cough and two herbs for activating 
blood; the remaining herbs are for tonifying lung and kidney, and fortifying spleen.  
The 18 herbs that were used from 10 to 20 times in individual studies were: Shan yao (19), 
Shan zhu yu (Shan yu rou) (19), Xing ren (17), Su zi (15) Kuan dong hua (14), Bei mu (14) 
(including Zhe bei mu and Chuan bei mu), Bu gu zhi, (13), Di long (13), Sang bai pi (13), Tao 
ren (13), Fang feng (12), Jie geng (12), Dong chong xia cao (11), Sha shen (11), Zi wan (11), 
Yin yang huo (Xian ling pi) (10), Tu si zi (10) and Zi he che (10) (see Table 7.1). 
Table 7. 1 The top twenty herbs most frequently used in the 101 RCTs 
  Herbs Frequencies  
1 Huang qi (Zhi) 55 
2 Bai zhu 54 
3 Fu ling 45 
4 Dang shen 40 
5 Wu wei zi 34 
6 Gan cao (Zhi) 34 
7 Chen pi 32 
8 Di huang (Shu) 30 
9 Ban xia 25 
10 Mai men dong 24 
11 Dan shen 24 
12 Ge jie 23 
13 Dang gui 21 
14 Ren shen 20 
15 Shan yao (Sheng) 19 
16 Shan zhu yu 19 
17 Xing ren (Bei) 17 
18 Su zi (Zi) 15 
19 Beimu 14 
20 Kuandonghua 14 
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Five herbs were used in 7 to 9 studies: Rou gui was used in 9 studies, Fu zi was used in eight 
studies (including Zhi fu zi and Shu fu zi); Bai jie zi, Chen xiang and Shui zhi were each used 
in seven studies. 
5 herbs were used in six studies: Chai hu, Chuan xiong, Dan pi, Dong chong xia cao jun si, 
and Ma huang. 
There are 8 herbs that were used in five studies: Bai bu, Gua lou, Gui zhi, Lu jiao jiao, Niu xi, 
Nu zhen zi and Sheng ma, and Tai zi shen.  
In the 101 studies 79 herbs were used fewer than 5 times: Gou ji, Hong hua, Hou po, Huang 
qin, Hu tao ren, Lai fu zi, San qi, Yu zhu, Ze xie, Zhi qiao and Zi shi ying (4 times; Bai shao, 
Bai guo (Yin xing ye), Chi shao, E zhu, Gan jiang, Gui zhi, He tao rou, Huang jing, Ju hong, 
Kan qi, Qian hu, Xuan shen, Yi yi ren and Zhi mu (3 times); Bai ji tian, Chan tui, Da zao, Du 
zhong, Gua lou pi, Han lian cao, Jiao gu lan, Jin yin hua, Ling zhi, Mao dong qing, Pi ba ye, 
Quan xie (Quanchong), Rou cong rong (Yucongrong), Shi chang pu, Tian hua fen, Ting li zi, 
Wu zha long, Xuan fu hua (Jin fei cao), Yang fei, Yu xing cao, and Zhu ru (2 times); 
There were 33 herbs that were applied only once in different formulae: Bai he, Ban lang en, 
Cang zhu, Che qian zi, Chuan shan long, Ci wu jia, E jiao, Fu pen zi, Gui ban jiao, Hai ge 
qiao, Hong jing tian, Ji nei jin, Jin qiao mai gen, Jin ying zi, Lian qiao, Ling ci shi, Bo he, 
Qing tian kui, Qi ye yi zhi hua, Sang shen, Shan yin hua, She gan, Sheng jiang, Shi gao, Tu 
bie chong, Wei jin, Wu gong,  Xiang fu, Xian mao, Xi xin, Yi mu cao, Yi zhi ren and Yu jin. 
In the sensitivity analysis conducted for the 59 studies with durations of three months or more, 
the five most commonly used herbs were Huang qi (33), Bai zhu (30), Dang shen (27), Fu 
ling (27), and Wu wei zi (26). This is the same set of herbs as for the 101 studies in total. 
Therefore, these herbs were not only frequently used in the studies as a whole, but also in the 
subset of studies most relevant to the treatment of stable COPD over a longer term.  
A comparison of the most frequenty used herbs in classical data setand the herbs most 
commonly used in the RCTs can be found in Chapter 8. 
7.8.3 Frequency of use of particular formulae 
CHM formulae were used in the form of pills, capsules, granules, syrups or decoctions in the 
included studies. The individual formulae comprised from 1 to 27 different herbs. Extracts of 
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the single herbs Ren shen, Bai guo, Bai bu and Dong chong xia cao were applied in one study 
each (79, 380, 383, 415, 435). The most complex formulae was in Ji (2010) with 27 different 
herbs in the test formula (431). 
7.8.3.1 Liu Jun Zi Tang 
The most commonly used formulae was Liu Jun Zi Tang, with or without modification, which 
was used in 7 studies (73, 365, 408, 417, 419, 421, 440). The ingredients of each formula are 
shown in Appendices 14 to 17. In these 7 studies: 
 CHM was compared to placebo in one study (Zhuan, 2006) with 60 participants with 
biomarkers as the outcome measure (73). 
 CHM was compared to RP in two studies with 107 participants (421, 440); relief of 
symptoms was reported in Wu (2006); lung function and BMI as well as ALB were 
measured in Wu (2009). 
 CHM plus RP was compared to RP in two study with 176 participants; relief of 
symptoms, BMI as well as ALB were measured in Chen (2) (2009); relief of symptoms 
was measured in Peng (2010). 
 CHM was compared to no treatment in two studies with 204 participants; lung function, 6 
MWD test and BODE index were measured in Zhang (2008), lung function and QoLQ 
were measured in Wu (2007).  
Therefore, two pairs of Liu Jun Zi Tang studies were comparable but the lung function 
measures were different in Zhang 2008 and Wu 2007. For relief of symptoms both the Liu Jun 
Zi Tang studies show a small benefit for Liu Jun Zi Tang plus RP compared to RP alone 
(Figure 7.51).  
 
Figure 7. 51 Comparison of CHM (Liu Jun Zi Tang) plus RP versus RP in patients with stable COPD: 
effective rate at the end of treatment as the outcome  
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7.8.3.2 Bu Fei Tang 
Modified Bu Fei Tang was used in 3 studies (375, 437, 447). The ingredients of each formula 
are shown in Appendices 14, 16 and 18. 
 CHM was compared to placebo in one study with 60 participants (Sun, 2009); lung 
function, QoLQ, and relief of symptoms were measured. 
 CHM plus RP was compared to RP in one study (Hu, 2009) with 67 participants; lung 
function, biomakers and relief of symptoms were measured. 
 Experimental CHM was compared to other CHM in one study with 60 participants 
(Huang 2009); lung function and blood gas measurement were tested. 
Lung function (FEV1%) was an outcome in three studies (see Figure 7.3) but since the 
comparators were different no pooling was possible. 
7.8.3.3 Shen Ge Tang 
Original or modified Shen Ge Tang was used in five studies (80, 342, 344, 422, 427); and 
both Bu Fei Tang and Shen Ge Tang were applied together in one study (373). The ingredients 
of each formula are shown in Appendices 14-16 and 18. 
 CHM was compared to placebo in one study with 200 participants (Wu, 2006); lung 
function was an outcome measure. 
 CHM was compared to RP in one study with 60 participants (Xiong, 2008); lung function, 
biomakers and relief of symptoms were measured. 
 CHM plus RP was compared to RP in three studies with 140 participants; lung function 
was tested in Chen (2004); lung function and relief of symptoms were measured in Pu 
(2010); lung function, QoLQ and relief of symptoms were measured in Mai (2009). 
 Experimental CHM was compared to other CHM in Sun (2007a) with 45 participants; 
lung function, QoLQ, 6 MWD test and relief of symptoms were measured. 
Significant improvement in FEV1% predicted was reported in these five studies (see Figure 
7.3); relief of symptoms including percentage of effectiveness and reduction of the total 
scores and the scores of each symptom (cough, dyspnea and sputum production) was found to 
be significantly improved in each study. 
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The most comparable studies were Chen (2004), Mai (2009) and Pu (2010) which found 
significant improvement in lung function in favour of CHM plus RP compared to RP (Figure 
7.52). However, relief of symptoms with percentage of effectiveness and reduction of the total 
scores were incomparable in these studies.   
 
Figure 7. 52 Comparison of CHM (Shen Ge Tang) plus RP versus RP in patients with stable COPD: 
FEV1% at the end of treatment as the outcome  
 
7.8.3.4 Bu Zhong Yi Qi Tang 
Bu Zhong Yi Qi Tang was used in 3 studies (65, 398, 402). The ingredients of each formula 
are shown in Appedices 14 and 16. 
 CHM was compared to RP in one study (Hu 2005) with 62 participants; lung function and 
exacerbation COPD were measured.  
 CHM plus RP was compared to RP in two studies with 106 participants; biomarkers 
including CRP, TNF-α and IL-6 as well as PALB were tested in both studies (398, 463). 
QoLQ was measured in Tatsumi (2009). 
Significant decreases for CRP, TNF-α and IL-6 were reported in the Bu Zhong Yi Qi Tang 
groups but these were unchanged in the control groups in both studies; PALB level increased 
in the Bu Zhong Yi Qi Tang groups but was unchanged in the control groups. However, data 
suitable for pooling was not provided. 
7.8.3.5 Multi syndrome differentiation 
Two studies used syndrome differentiation according to CHM principles to select the most 
appropriate of four CHM treatment interventions (379, 382). Both of these two studies used 
very similar designs and formula selection (see Appendix 16). Feng (2008) was conducted in 
Jizhou Hospital in Hebei; and Shi (2009) was conducted in Tianjing Chest Hospital. Cai’s 
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QoLQ was used in both studies which compared CHM to RP. Lung function, including FEV1 
(L), FEV1/FVC% and FVC (L), was only reported in the Feng study (Figure 7. 6, Figure 7. 9 
and Figure 7. 11). Since both studies reported data for the subscores but not for the total, they 
were not included in the pooled data in section 2 of chapter (see Figure 6. 9). These QoL are 
pooled in Figure 7.53. In both studies the CHMs produced a greater improvement in all 
HRQoL sub-scores compared with RP. 
 
Figure 7. 53 Comparison of CHMs (based on syndrome differentiation) versus RP in patients with stable 
COPD: Subscores of Cai’s QolQ at the end of treatment as the outcome 
 
7.8.3.6 Formulae used in multiple clinical trials 
Five formulae were used in multiple clinical trials at the same sites but at different times.  
Li Jin granule 
Lijin granule was used in two studies which compared CHM to RP (423, 444) in Ruikang 
Hospital Affiliated to Guangxi University of Chinese medicine (CM) (see Appendix 15). Lung 
function and relief of symptoms with significant improvements were reported in Chen (2006), 
whereas biomarkers with significant effectiveness were reported in the later study (444). 
Therefore there was no opportunity for pooling data. 
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Fei Kang Granule  
Fei Kang Granule was used in two studies which compared CHM plus RP to RP (368, 369) 
and in one study which compared CHM to no treatment (411) in Dongzhimen Hospital 
Affiliated to Beijing University of CM (see Appendices 16-17). QoLQ was reported in Feng 
(2005); biomarkers were reported in Su (2005); QoLQ and biomarkers were reported in 
Feng’s later study (2007). The author’s reported significant improvement in QoLQ in both 
studies (Feng 2005 &2007) and significant effectiveness in biomakers in Su (2005) and Feng 
(2007). However, the data were not suitable for meta-analysis. 
Man Zhi Ke Chuan Ning liquid 
Man Zhi Ke Chuan Ning liquid was applied in the study by Lin 2008 which compared CHM 
to no treatment and Xiao 2000 which compared CHM to RP in Zhanjiang Second Hospital of 
TCM in Guangdong (424, 455). Lung function, relief of symptoms and biomarkers were 
reported in both of studies. The authors reported significant improvement in lung function and 
relief of symptoms as well as improvement in immune function in both studies when CHM 
groups were compared to control groups. Due to the difference in study design these data 
could not be pooled. 
Jian Pi Yi Fei Granule 
Jian Pi Yi Fei Granule was investigated by Lin 2003, Xu 2008 and Xu 2009 (349, 450, 454) in 
Guangdong Provincial Hospital of CM. Comparison of CHM with placebo was used in Lin 
(2003) and Xu (2008); comparison of CHM plus RP with RP was used in Xu (2009). Lung 
function, relief of symptoms and blood gas analysis were reported in Lin; BMI and nutrition 
outcome were reported in Xu (2008); and biomarkers were reported in Xu (2009). The authors 
reported significant effects for each outcome when CHM was compared to control groups in 
these studies. Due to the differences in outcome measures, data could not be pooled. 
Zhou Fei Tang  
Modified versions of Zhou Fei Tang were investigated in two studies (363, 364) which 
compared CHM to no treatment in Guangdong University of CM (see Appendix 17) lung 
function, QoLQ and relief of symptoms were reported in both studies. The comparable studies 
were Fang (2008) and Liu (2005) which found significant improvement in QoLQ (Figure 7.54) 
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in favour of CHM compared to no treatment, whereas no difference in FEV1% was found 
(Figure 7.55). The authors also reported significant relief of symptoms of cough, dyspnea and 
sputum production etc. However, these data could not be pooled. 
 
 
Figure 7. 54 Comparison of CHM (Zhou Fei Tang) versus no treatment in patients with stable COPD: the 
total scores of Cai’s QolQ at the end of treatment as the outcome  
 
 
 
Figure 7. 55 Comparison of CHM (Zhou Fei Tang) versus no treatment in patients with stable COPD: 
FEV1% at the end of treatment as the outcome  
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7.9 Results of funnel plots  
An obvious asymmetry was found in the funnel plot of the data based on the outcome of 
effectiveness rate of symptoms when CHM was compared to placebo, RP and CHM plus RP 
was compared to RP, and CHM was compared to no treatment, and experimental CHM was 
compared to other CHM, which indicated potential publication bias or bias due to other 
sources (Figure 7.56).   
 
Figure 7. 56 Funnel plot comparison of CHM with control groups based on outcome: effectiveness rate of 
symptoms 
 
Also, an asymmetry was found in the funnel plot of the data based on the outcome of 
reduction of ECOPD rate when CHM was compared to placebo, RP and CHM plus RP was 
compared to RP, and CHM was compared to no treatment, and experimental CHM was 
compared to other CHM, which indicated potential publication bias or bias due to other 
sources (Figure 7.57). 
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Figure 7. 57 Funnel plot comparison of CHM with control groups based on outcome: reduction of 
exacerbation rate  
 
7.10 Discussion  
7.10.1 Summary of the main results 
This systematic review and analyses of RCTs set out to investigate the effects of oral CHM 
formulae and single herb extracts on clinical endpoints in patients with stable COPD using 
direct comparisons from all available randomized controlled trials. One hundred and one 
parallel trials, involving 8,014 participants were identified. All of the included studies were 
conducted and published in China from 2000 to 2010 except one study that was conducted in 
Israel and two studies in Japan. About 20 of articles were also indexed in MEDLINE.  
Meta-analysis demonstrated that oral CHM formulae or single herb extracts were more 
effective than control in: 
 Increasing FEV1 and FEV1 /FVC from baseline compared to placebo, no treatment, RP etc 
(see Figures 7.3, 7.6 & 7.9); 
 Reducing exacerbations of COPD compared to placebo, RP, no treatment and other CHM 
(Figures 7.18 & 7.19) and reducing related hospitalizations compared to placebo, RP and 
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other CHM (Figure 7.20); 
 Relief of symptoms compared to placebo, no treatment, RP etc (Figures 7.21-7.25). 
 Each of these outcomes is discussed in detail below (section 7.10.2). The results for 
quality-of-life were discussed in SR2 (chapter 6). 
7.10.2 Discussion of the effects of CHM formulae on main outcomes 
The main results are discussed below beginning with lung function, followed by effect on 
exacebations and symptoms. 
7.10.2.1 Discussion of the effects of CHM formulae on pulmonary function 
Various pulmonary function tests were performed and reported in 70 studies with 5,574 
participants, with 89 participants withdrawing from 11 studies.  
Discussion of FEV1 % predicted 
This review found changes in spirometric parameters that appeared clinically significant, 
particularly in FEV1. Overall this review found a significant increase in FEV1% based on 
pooling 3,332 participants and FEV1(L) with pooled data from 3,475 participants when CHM 
was compared to placebo, RP, or other CHM as well as when CHM plus RP was compared to 
RP.  
Improvements in FEV1% predicted were most evident when CHM plus RP was compared to 
RP in the meta-analysis of 20 studies (Figure 7.3). Eight studies showed clearest benefit (344, 
370, 386, 401, 404, 425, 427, 460). The same RP of Salmeterol xinafoate/Fluticasone 
propionate was used by Chen (2009-1), Liu (2010), Pu (2010) and Zhu (2010); Theophylline 
was used by Feng (2006), Liang (2005), Liu (2006-1), Luo (2002), Wang (2006); 
Theophylline plus Salbutamol Sulfate was used by Hu (2009), Liu (2007) and You (2008); 
Ipratropium bromide was used in the study by Jia (2007) and Wu (2009-2); Salbutamol Sulfate 
was used Wang (2005) and Zhou (2007) (see Figure 7.58). However, Chen (2004), Qiu (2009) 
and Yang (2010) did not specify which RP was used. So it is difficult to evaluate whether the 
benefit found by Chen was due to the efficacy of the CHM used or the inefficacy of the RP; in 
Liang (2009) the RP used was based on the participant’s COPD stage. Overall, the pooled 
data suggest that the most consistent evidence for a benefit of the addition of CHM is for the 
combination with RP except Theophylline plus Salbutamol Sulfate in Hu (2005) and Liu 
250 
 
(2007). The participants employed in those studies were at severe COPD stage, so 
participants’ FEV1% was worse than those in other studies. Therefore, CHM plus 
Theophylline and Salbutamol for treatment of patients with severe COPD needs further 
evaluation. 
Among these 20 studies, Huang qi (12 studies), Ren shen (4 studies) and/or Dang shen (9 
studies), Bai zhu (9 studies), Di long (7 studies), Wu wei zi (6 studies), Fu ling (6 studies) and 
Ge jie (5 studies) were used most frequently in the formulae. Although the ingredients of each 
formula are different, herbs that tonify qi play a key role in these formulae.  
 
 
Figure 7. 58 Comparison of CHM plus RP versus RP in patients with stable COPD: FEV1% at the end of 
treatment as the outcome  
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Disscussion of FVE1 (L) 
Improvements in FVE1 (L) were most evident in the meta-analysis of 18 studies in which 
CHM plus RP was compared to RP (Figure 7. 6). Nine studies showed the greatest benefit 
(386, 404, 405, 418, 427, 430, 431, 447, 460). Among 18 studies, Che (2005), Feng 2008, 
Huang 2005 and Mai (2009) did not specify which RP was used so it is difficult to evaluate 
whether the benefit found was due to the CHM used or other factors. The same RP of 
Salmeterol xinafoate/Fluticasone propionate was used by Liu, Pu and Zhu; and Theophylline 
was used by Hao (2008), Ji (2010), Liang (2005), Liu (2006-1), Luo (2002) and Wang (2006); 
with the addition of Salbutamol sulfate aerosol in the studies by Hu and Liu (2008); 
Ipratropium bromide was used by Zhang (2010) (see Figure 7.59 below). Expectorant was 
used by Zhao (2009). The results of the pooled data are comparable except for Zhang (2010).  
Among the 18 studies (see Figure 7.6), Renshen or Dangshen plus Huang qi were used by 
Feng (2008), Hu (2009), Huang (2005) and Ji (2010) and in both the studies by Liu (2008 & 
2010). Ren shen or Dang shen as a key herb were used by Liang and Pu. Huang qi or Ren 
shen was used in Zhu based on the Chinese medicine syndrome. Huang qi was used in Che 
(2005) and Zhao (2009). On the other hand, herbs that diffuse the lung to resolve phlegm 
were used in Liu (2006-1) and Wang (2006). Therefore, tonify lung qi therapy was the main 
strategy applied in these studies, except for Hao (2009), which used tonify and warm kidney. 
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Figure 7. 59 Comparison of CHM plus RP versus RP in patients with stable COPD: FEV1 (L) at the end of 
treatment as the outcome  
 
When a sensitivity analysis was applied for FVE1% predicted and FEV1 (L) based on duration 
of therapy (short term Vs longer term), the overall result remained the same. This suggested 
that CHM therapy may have a longer term potential for improving the level of FEV1 or 
prevention of decline in FEV1. 
Discussion of FEV1/FVC 
Also, the meta-analyses showed significant increases in the ratio of FEV1/FVC in 2,635 
participants when CHM was compared to placebo, compared to RP, compared to no treatment, 
when experimental CHM was compared to other CHM, as well as when CHM plus RP was 
compared to RP (see Figure 7.9). Improvements in FEV1/FVC were most evident in the meta-
analysis of 20 studies in which CHM plus RP was compared to RP (Figure 7. 9). The clearest 
benefit for improvement in FEV1/FVC was demonstrated in seven studies (372, 373, 401, 404, 
418, 427, 451). The same RP of Salmeterol xinafoate /Fluticasone propionate was used by Pu 
(2010) and Zhu (2010). Also, similar RP were evident in a number of studies with 
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Theophylline (Doxofylline) in Feng 2006, Hao (2008) and Ji (2010); and Theophylline plus 
Salbutamol being used in Liu (2007 & 2008) and You (2008).  
Salbutamol was used in Wang (2005) and Zhou (2007). Ipratropium bromide was used in Jia 
(2007), Wu (2009-2) and Zhang (2010). However, Che (2005), Huang (2005), Feng (2008), 
Mai (2009), Qiu (2009) and Yang (2010) did not specify which RP was used. In Liang (2009) 
the RP used was based on the participant’s COPD stage, so the results of these studies are 
more difficult to evaluate.  
Consequently, the two pairs of studies that were most comparable in terms of the RPs used 
were pooled (see Figure 7.60). The pooled data for Pu and Zhu are comparable with 
significant improvements in FEV1 / FVC. Similar results were found for Theophylline and 
Theophylline plus Salbutamol. However due to high heterogeneity, the four studies are 
incomparable. 
Among the twenty studies, the therapeutic approach of tonify lung qi was applied in most 
studies, with Ren shen, Dang shen and Huang qi being the key herbs in these formulae. 
Huang qi (12), Dang shen (5) or Ren shen (5), Bai zhu (8), Fu ling (7), Wu wei zi (6), Ge jie 
(5) and Di long (5) were used most frequently in the formulae. The therapeutic approach of 
diffuse the lung to suppress cough and calm panting was applied in one study which used Ma 
huang, Shi gao, Xing ren and Shan yin hua etc (Yang 2010).  
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Figure 7. 60 Comparison of CHM plus RP versus RP in patients with stable COPD: FEV1 / FVC at the end 
of treatment as the outcome  
 
Disscussion of other parameters of pulmonary function 
Improvements in MVV were most evident when CHM plus RP was compared to RP in the 
meta-analysis of seven studies (344, 370, 412, 418, 453, 456, 457) (see Figure 7. 13).  
The studies by Jia (2007), Li (2) 2006, Liu (2008) and Wu (2) 2009 showed the clearest 
benefit but only Jia and Wu used the same RP (Ipratropium Bromide). However, there were 
distinct similarities in the four CHMs. All aimed to strengthen ‘Lung qi’ with Huang qi being 
used in three (Liu, Li, Jia) with the addition of ginseng in Liu 2008, and with Wu (2) 2009 
using Dangshen as the main herb. However the evidence for CHM plus RP compared to RP 
was mixed when MMEF was the outcome (Figure 7.12).  
Of the three studies (Chen 2004, Lou 2002 and Wang 2006), only one (Chen 2004), which 
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used a ginseng-containing formula that aimed to tonify lung qi, showed a clear benefit for the 
addition of the CHM. In the other two studies the RP was theophylline but Chen (2004) did 
not specify which RP was used, so it is difficult to determine whether the benefit found by 
Chen was due to the efficacy of the CHM used or the inefficacy of the RP. 
The outcomes, MIP and Raw were only reported in single studies so no comparisons were 
possible.  
Disscussion of FEV1 and QoL 
FEV1 is the traditional metric used to define the progression of COPD as well as the strongest 
spirometric predictor of mortality in COPD patients (465). FEV1 as a primary spirometric test 
outcome is more usually used to assess respiratory function in clinical trials than other 
parameters (466). However, besides pulmonary functional abnormalities, COPD is also 
associated with significant systemic effects, so spirometry is not a unique outcome for the 
assessment of the severity and mortality of COPD. Therefore, the effects found in these 
studies may not be specific to COPD. 
Moreover, Ries (2006) has pointed that reductions in objective pulmonary function 
measurements, such as FEV1, are not well-correlated with the patient's perception of 
symptoms and with HRQOL (467). Currently, health related QoLQ and BODE index are 
considered the main predictors for prognostic assessment in COPD (468). Therefore, any 
improvements in lung function found in these studies may not reflect discernible benefits on 
the part of the COPD sufferers. Nevertheless, as discussed in SR2, certain CHMs, appeared to 
also improve HRQoL.  
In SR2, QoLQ and lung function were measured in 18 studies. Improvement of QoL was 
most evident when CHM plus RP was compared to RP in six studies that used SGRQ (312, 
347, 366, 370, 376, 386) (Figure 6. 8). Huang (2005) and Tang (2010) did not specify the RP 
used, Jia (2007) used Ipratropium bromide, both Chen (2009-1) and Liu (2010) used 
Salmeterol xinafoate plus Fluticasone propionate, and You (2008) used Theophylline plus a 
β2 adrenergic receptor agonist.  
The most comparable studies (Chen 2009-1 and Liu 2010) found the CHM plus RP to be 
superor to the RP alone in Liu (2010), but Chen (2009-1) found no benefit for the addition of 
the CHM. Positive results for both lung function (FEV1) and QoLQ were found in Huang 
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(2005), Jia (2007) and Liu (2010). However, the further pooling data was not appropriate due 
to the different RP used, as discussed above (see section 7.5.2). Nevertheless, the CHMs used 
by Jia (2007) and Liu (2010) both aimed to tonify qi and move blood stagnation and were 
comparable in terms of their ingredients since both contained Huangqi, Dilong and Danshen.  
7.10.2.2 Discussion of CHM formulae for reducing exacerbations of COPD 
Frequent AECOPDs are associated with poor quality of life and more rapid decline in lung 
function, so for all clinical trials AECOPDs should be a key outcome measure for the 
evaluation of the clinical approach. The findings of this review indicated that CHM formulae 
were more effective in reducing exacerbation rate and frequency of exacerbations when CHM 
was compared to placebo, to RP, or to no treatment, and when CHM plus RP was compared 
with RP based on 21 studies on 1,619 participants. Due to the differences in duration and 
follow-up periods in the included trials, there was moderate heterogeneity, so a sensitivity 
analysis was performed and found no difference based on study duration.  
Reduction of hospitalization days and cost were only reported in three studies with 
incomparable data due to different study designs. Also, the overall cumulative incidence of 
exacerbation-related hospitalizations and all-cause mortality were not measured in any of the 
included studies. 
Of the various study designs, CHM plus RP compared with RP best reflects clinical practice 
and this design provided the best data for meta-analysis. Based on three studies (Ao 2007, 
Huang 2005, Luo 2002), the addition of the CHM reduced exacerbations from 50 to 30 
incidents. The same RP (Theophylline) was used in both Ao (2007) and Luo (2002) so the 
pooled data are comparable, but the herbal therapeutics were different with different strategies, 
formulae and herbs. The formula Shao Yao San for smoothing liver and regulating qi 
(comprising Chai hu, Huang qin, Bai shao etc.) was applied in Ao while Tonify lung and 
spleen qi (using Dang shen, Huang qi, Mai dong etc.) was applied in Luo. Therefore the herbs 
used in these studies are incomparable. On the other hand, Huang (2005) used the strategy 
Tonify lung and spleen qi and used similar herbs to Luo (e.g Huang qi, mai dong) but did not 
specify which RP was used, so it is difficult to evaluate the effectiveness of the CHM in this 
study.  
There was also a significant reduction on the mean number of exacerbations when data from 
six studies were pooled with the greatest decreases in the studies by Liang 2009 and Zhang 
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2010. In Liang (2009) the RP used was based on the participant’s COPD stage, whereas 
Zhang (2010) used Ipratropium bromide for all participants. However, similar herbs were 
used in the two studies, Dong chong xia cao plus Huang qi, Bai zhu and Fang feng were used 
in Liang 2009 and an extract of Dong chong xia cao was used in Zhang 2010, but due to the 
different kinds of bronchodilators used, the data were unsuitable for further pooling.  
The number of days of hospitalization was found to have decreased in the study by You (2008) 
when CHM was combined with Salbutamol inhaler as the RP. You (2008) employed similar 
herbs to those used in other studies including Renshen, Fu ling and Bai zhu etc. However, 
only three studies in this review reported hospitalization days of patients due to acute onset of 
COPD, and You (2008) was the only study that included a comparison with RP. Therefore the 
question of whether CHM treatment may have an effect on reduction of hospitalization days 
that needs further investigation via more clinical studies. 
The benefits observed with oral CHM formulae for exacerbations and related hospitalizations 
were not large but these aspects are clinically important. Acute exacerbations in COPD are 
increasing and these result in significant morbidity and mortality and drive significant health 
care costs due to increased physician visits and additional medications. Also, exacerbations 
are a leading cause of hospital admissions worldwide, with 35% of COPD patients having at 
least one admission a year and up to 40% of admitted patients having two or more 
readmissions a year (469-471). These acute hospital admissions contribute tremendously to 
the disease burden and account for the majority (52–84%) of the overall direct costs related to 
COPD (472). COPD exacerbation also leads to adverse impacts on quality of life and lung 
function and causes morbidity and mortality. So therapies that reduce their frequency or 
severity are a key aspect of any paradigm of COPD therapy.  
7.10.2.3 Discussion of CHM formulae for relieving symptoms 
Relieving symptoms was reported in 55 studies on 3,885 participants, with 24 withdrawals 
during the treatment period from four studies. It was assessed through symptom scores 
involving composites of symptoms or individual symptom scores for cough, dyspnoea and 
sputum. In addition, the degree of dyspnea was assessed by the Modified Medical Research 
Council Dyspnea Scale.  
In this review, meta-analyses of the effective rate of symptom improvement, or reduction in 
the total symptom score, or the individual symptom score found that CHM formulae were 
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more effective in alleviating symptoms in patients with stable COPD when compared to any 
type of control group, regardless of whether short term or long term therapy was used.  
Disscussion of Effective rate results for symptom improvement 
Positive results for the effective rate for symptom improvement were found when CHM was 
compared to placebo, no treatment and to RP, when CHM plus RP was compared to RP, and 
when experimental CHM was compared to other CHM in 3,114 participants.  
In the meta-analysis of 22 studies that compared CHM plus RP to RP, which was the largest 
sub-group, a better effective rate for symptom improvement was found in 12 out of 22 studies 
(see Figure 7. 21). The RP used was not specified in Lang (2010), Mai (2007), Qiu (2009) and 
Tang (2010), and the use of RP was based on the patient’s COPD stage in Liang (2009). So 
these studies were unsuitable for further data pooling.  
Theophylline was used in Ao (2007), Feng (2006), Hao (2008), Ji (2010) and Shan (2007), 
Theophylline plus β2adrenergic receptor agonist were used in Guo (2008), Hu (2009), Liu 
(2007), Tian (2005) and Wang (2009). Ipratropium bromide was used in Chen (2009-2) and 
Wu (2009-2), so the pooled data for these groups of studies were comparable.  
The pooled data for the five studies that employed theophylline, found that the addition of the 
CHM improved the effective rate, especially in Shan (2007), Ao (2007) and Feng (2006). A 
similar result was found for the five studies that combined CHM with Theophylline plus β2-
adrenergic receptor agonist, especially the study by Wang (2009). 
Theophylline plus Salmeterol xinafoate /Fluticasone were used in Peng (2010); Salmeterol 
xinafoate/Fluticasone propionate was used in Liu (2010) and Salmeterol was used in Zhou 
(2007) (Figure 7.61), so the pooled data for these studies are less comparable. An expectorant 
was used in Zhao (2009).  
Among the twenty two studies, the therapeutic approach of tonify lung qi was applied in most 
studies with Ren shen, Dang shen and Huang qi being the key herbs in these formulae. Huang 
qi (12), Dang shen (11) or Ren shen (1) or Tai zi shen (1), Bai zhu (10), Fu ling (8), Wu wei zi 
(7), Ge jie (5) and Di long (5) were used most frequently in the formulae. The therapeutic 
approach of tonify qi was used in Shan (2007), Feng (2006) and Wang (2009) while Smooth 
the liver and regulate qi was applied in Ao (2007) with Chai hu, Bai shao, Huang qin and Bai 
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zhu etc. being used in combination with remove phlegm and suppress cough herbs.  
 
 
Figure 7. 61 Comparison of CHM plus RP versus RP in patients with stable COPD: Effective rate of 
symptom improvement at the end of treatment as the outcome  
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Discussion of CHM formulae for relieving Dyspnea 
Dyspnea is a common symptom of COPD which manifests as sensations of respiratory 
discomfort. Relief from dyspnea is an important goal of pharmacotherapy. The degree of 
dyspnea has been demonstrated to influence and predict health related quality of life, as well 
as survival (310, 473). In COPD, dyspnea can be due to dynamic hyperinflation, 
neuromechanical dissociation, gas exchange abnormalities, and inspiratory muscle weakness, 
as well as cognitive and psychological factors. Therefore, the effective assessment of the 
degree of dyspnea is important for the monitoring of patients, guiding treatment and 
improving prognosis. 
A variety of instruments are available to measure the degree of dyspnea during exercise, 
including: the visual analogue scale (VAS) (474); the Borg scale (475); Oxygen Cost Diagram 
(OCD) (476); Baseline Dyspnea Index (BDI) and Transition Dyspnea index (TDI) (477); as 
well as the Shortness Of Breath Questionnaire (SOBQ) (478). Each of these instruments has 
its strong points and weak points (467), but none of these instruments addresses all aspects of 
this symptom (479).  
MMRC is one of the components of the BODE multidimensional index for assessment of 
level of functional dyspnea. It is a simple, easy-to-use grading system for the assessment of 
patients’ level of dyspnea, which is valid and reliable and commonly used. The MMRC 
dyspnea scale provides an independent dimension that is not measured by pulmonary function 
tests or by measuring dyspnea in an exercise laboratory. So it is widely used in patients with 
COPD (310) and as an outcome measure in clinical trials.  
However, the MMRC dyspnea scale was only used in three of the studies located and none of 
the other established scales mentioned above were reported. In each case, the CHM formulae 
were found to be more effective in reducing dyspnea as measured by the MMRC Dyspnea 
Scale when compared with placebo in one study on 60 participants (375), no treatment in one 
study on 60 participants (408), or CHM plus RP compared to RP in one study on 60 
participants (312). However, meta-analysis could not be performed due to the differences in 
study design. The greatest reduction of dyspnea in the three studies was in Chen (2009-1). 
The herbs included tonify lung and kidney herbs such as Dang shen, Huang qi, Bai zhu and 
Shan zhu yu etc. in combination with Salmeterol xinafoate/Fluticasone propionate which was 
the RP used.  
261 
 
Disscusion of Symptom scores for individual COPD symptoms 
Individual symptoms were reported by fourteen studies with 1,044 participants. Of these five 
studies with 349 participants compared CHM plus RP to RP and reported scores for dyspnea, 
chronic cough and sputum production. The RP used were not specified in Lang (2010), Qiu 
(2009) and Tang (2010). Theophylline plus β2 adrenergic receptor agonists were used in both 
You (2008) and Guo (2008). 
For chronic cough, better reduction of the scores of chronic cough was found in three studies 
out of five when CHM plus RP was compared to RP (366, 376, 410) (see Figure 7. 23). 
Theophylline plus β2 adrenergic receptor agonist was found to be superior to the RP alone in 
You (2008), but, Guo (2008) found no benefit for the addition of the CHM.  
For sputum production, a greater reduction in symptom scores was found in four studies when 
CHM plus RP was compared RP (345, 366, 380, 383) (Figure 7. 24), whereas Qiu 2009 
showed no additional benefit. Both the studies that used Theophylline plus a β2adrenergic 
receptor agonist (i.e. Guo 2008 and You 2008) found a benefit for the addition of the CHM.  
For dyspnea, the best relief was reported in Lang (2010) but the RP was not specified. An 
extract of Bai bu was used in this study whereas the other studies used multi-herbs 
formulations. The most comparable studies (You 2008 and Guo 2008) found no additional 
benefit for the CHM for dyspnea (see Figure 7.25). 
Although, pooling data was difficult due to the different RP used, two studies were directly 
comparable in terms of RP and similar therapeutics of Tonify Qi and strengthen spleen were 
used in four of the studies. The exception was Lang (2010) which aimed to stop cough and 
resolve sputum only.  
Ren shen or Dang shen as key herbs were used in Qiu (2009), Tang (2010). You (2008) and 
Guo (2008), Fu ling and Bai zhu were also used in Qiu (2009) and You (2008), while Huang 
qi was only used in Tang (2010). The two most comparable studies in terms of RP, only had 
one herb in common (Ren shen) but they both showed benefit for sputum production, You 
(2008) also showed benefit for cough but neither showed benefit for dyspnea. 
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7.10.2.4 Discussion of the impact of CHM on BODE index, 6MWD and BMI index  
Disscussion of BODE index 
The BODE index is a new tool incorporating measurements that reflect the multi component 
nature of COPD through assessment of nutrition, airflow limitation, dyspnea and exercise 
capacity, which has been established as multidimensional staging tool (480). In addition, it is 
useful in predicting and monitoring mortality and hospitalizations and in reflecting disease 
progression, and has been found to be very good surrogate outcome of mortality of COPD 
(481, 482). However, BODE index was only used in two studies in this review. The BODE 
index would be suggested to be primary outcome in further CHM clinical trials.  
This review found that the CHM formulae were more effective in reducing the BODE index 
when CHM plus RP was compared with RP in one study with 60 participants (Chen 1 2009) 
or when CHM was compared to no treatment in one study with 73 participants (Zhang 2008). 
In both studies the duration of treatment was three months. Four patients withdrew in Zhang 
2008 and intent to treat was applied in the data analysis.  
The formula used in Zhang 2008 was Liu Jun Zi Wan, while it was Qi Wei Dou Qi Tang in 
Chen (2009-1). Liu Jun Zi Tang is the most commonly used formula overall but Qi Wei Dou 
Qi Tang is infrequent. Also, the principle of treatment for Liu Jun Zi Wan (strengthen spleen 
qi) is different than in Qi Wei Dou Qi Tang (strengthen kidney), but, three ingredients of 
these formulae, i.e. Dang shen, Bai zhu, Fu ling are the same in both studies. So the formulae 
are more similar than their names suggest. These three herbs are frequently used together to 
replenish spleen. This suggests that the strategy of replenish spleen plays an important role in 
the treatment for patients with stable COPD. 
Disscusion of the 6MWD Test 
6MWD test is used to assess the functional exercise capacity of patients with moderate-to-
severe heart or lung disease. 
Meta-analysis in this review found that the CHM formulae were effective in improving 
exercise capacity as measured by the 6MWD test when compared to RP, other CHM or no 
treatment in ten studies on 723 participants with no statistical heterogeneity. Short term 
therapy was reported in 2 studies (345, 452), and long term therapy in eight studies (312, 347, 
386, 408, 415, 420, 422, 434).  
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Most of the formulae employed the treatment principle of replenishing lung and tonifying 
spleen and kidney using modified Ren Shen Ge Jie San (345, 422), Qi Wei Du Qi Wan (312), 
Jian Pi Yi Fei granule (347), Gu Ben Ke Chuan Granule (434) as well as Bai Ling Capsules 
(415). The treatment principle of tonifying qi and activating blood was applied in two studies 
(386, 420). 
Benefit was most evident in the five studies that compared CHM plus RP with RP (312, 345, 
347, 386, 415). Of these Chen (2009-1) & Liu (2010) used the same RP (Salmeterol & 
Fluticasone), employed similar formulae, both of which contained Huang qi, Dang shen, Fu 
ling, and Bai zhu, and both trials found a benefit for the addition of the HMs (see Figure 7. 27).  
Also, Chen (2009-1), Liu (2010) and Huang (2005) used similar CHMs which all included 
Huang qi, Bai zhu and Fu ling. Ginseng was used in both Guo (2008) and Huang (2005), and 
Dang shen appeared in Liu 2010 and Chen 2009. Two studies used Dong chong xia cao 
capsules (Zhang 2010 and Huang 2005). Of these studies, the longest were Zhang (2010) and 
Liu (2010) (6 months) followed by Huang (2005) (3 months) so these studies would appear 
the most relevant to clinical practice.  
Disscusion of BMI index 
Nutritional depletion and weight loss are features of COPD. The incidence of malnutrition is 
24 to 23% in patients with moderate to severe COPD when using the criteria of weight <90% 
of ideal body weight or weight loss of 5 to 10% of initial body weight. BMI has been found to 
be an independent negative determinant of survival in patients with COPD (483). BMI index 
is also one of components of the BODE multidimensional index for assessment of nutrition 
status.  
BMI index was reported in four studies (408, 417, 440, 454) with 232 participants, that found 
CHM to be effective when compared to placebo in Xu (2008) and CHM plus RP was more 
effective when compared to RP in Chen (2009-2). Although some herbs were different in the 
two studies, the major therapeutic strategy was fortifying spleen in both of them, and Dang 
shen or Ren shen plus Bai zhu and Fu ling were the key herbs.  
In Chinese medicine, fortifying spleen is an important therapeutic strategy for strengthening 
muscle function and enhancing exercise tolerance. However, malnutrition and muscle 
weakness in patients with COPD are chronic conditions. Therefore, longer term treatment 
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with CHM therapy than the one or two months used in these trials is needed to clearly assess 
the effects on BMI.  
7.10.2.5 Discussion of effects of CHM formulae on arterial blood gas measurements 
Arterial blood gas (ABG) analysis provides information about oxygenation, ventilation and 
acid-base status of the body and is used in the clinical assessment of patients with acute 
exacerbations of chronic obstructive pulmonary disease (AECOPD) (317). Oxygen level and 
dynamic hyperinflation have also been demonstrated to be related to airway oxidative stress in 
stable patients with COPD by Garcia-RioF 2011 (484). Patients with severe COPD may 
present with resting hypoxaemia that is defined by arterial blood gas analysis. Hypoxaemia is 
associated with QoL and survival of patients with severe COPD, particularly in those with 
stable conditions. Therefore, therapies that can improve arterial blood gas parameters are 
clinically important.  
Arterial blood gas was measured and reported in ten studies on 706 participants. Results from 
this review showed that oral CHM were more effective in increasing of the level of PaO2 
when compared with placebo in one study, or no treatment in one study, when CHM plus RP 
was compared with RP in four studies, and when experimental CHM was compared with 
other CHM in three studies. Conversely, when CHM was compared with RP, the effect was 
the same. With regard to the level of PaCO2, a similar pattern of results was found with the 
greatest reduction being in the single study that compared CHM with no treatment, and a 
marginally significant reduction for the pooled data of the four studies that compared CHM 
plus RP to RP.  
Increase in PaO2 was most evident in the pooled results of four studies that compared CHM 
plus RP with RP (312, 446, 453, 457) (see Figure 7.30). Chen (2009-1) and Zhao (2009) 
showed the greatest increase in the level of PaO2. The same RP (Theophylline) was used in 
Luo (2002) and Wang (2006) and neither study showed a clear benefit for the addition of the 
CHM. Salmeterol plus Fluticasone was used in Chen (2009-1) whilst the RP was not specified 
in Zhao (2009).  
Tonify qi was the strategy applied in both Chen (2009-1) and Zhao (2009) over the same 
duration of treatment (12 weeks), and the herbs Huang qi and Bai zhu were used in both 
studies. The formula in Chen (2009-1) tended to strengthen spleen and tonify kidney with 
Huang qi and Bai zhu plus Dang shen, Fu ling, Wu wei zi and Shan zhu yu etc. whereas the 
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formula in Zhao (2009) focused on ‘diffuse lung and calming dyspnea’ using Huang qi and 
Bai zhu plus Bai guo, Ma huang, Su zi and Kuan dong hua etc. Also, Luo (2002) used a 
similar strategy to Chen (2009-1) with Dang shen, Huang qi and Yin yang huo etc for three 
months of treatment.  
The herbs in Wang (2006) included Bai jie zi, Su zi, Bai qian and Jin fei cao which all belong 
to the category of herbs that remove phlegm. This formula did not contain tonifying herbs and 
had quite different ingredients to the other studies. Although, this formula has been 
demonstrated to reduce swelling of bronchial mucous membranes, reduce resistance in small 
airways and have anti-inflammatory effects (66), it appears to have been less clinically 
effective than the tonifying formulae used in the other three studies.  
With regard to the clinical significance of these results, patients whose PaO2 at sea level > 70 
mmHg do not need oxygen supplementation as suggested by GOLD (174). In most of these 
studies, the levels of PaO2 of participants were more than 60 mmHg whereas PaCO2 levels 
were normal or slightly higher than normal, so these patients had hypoxemia without 
hypercapnia and were suitable for treatment by CHM in addition to RP without the use of 
oxygen therapy. The results from these studies showed that the addition of the CHM appeared 
to increase the level PaO2 through improvement of ventilation function. 
Improvement of hypoxemia is an important aspect of COPD therapy particularly in patients 
whose level of PaO2 are less than 50 mmHg and who depend on long term oxygen therapy. 
Extended periods of oxygen therapy at a low flow rate are very important for the deceleration 
of disease progression. The included studies did not include patients receiving oxegen therapy, 
but the results for PaO2 suggest that the addition of CHM to such patients’ therapy could 
produce a benefit. Therefore, future clinical trials that aim to evaluate the effects of CHMs on 
ABG should involve patients undergoing long term oxegen therapy and include 
measurements of the amount of oxygen therapy that patients receive in order to further 
investigate the effects of CHMs on ABG and produce clinically meaningful results. 
7.10.2.6 Discussion of the effect of CHM formulae on biomarkers  
A range of biomarkers identified in the serum of patients with COPD have be found to 
correlate with clinical variables known to predict disease outcome including degree of airflow 
limitation, lung transfer factor, functional capacity, BODE index and exacerbation frequency 
(485).  
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A number of biomarkers were measured in 23 studies. The biomarkers included chemokines, 
inflammatory cytokines, lymphocyte subsets, immune globulins, ALB and PALB and Leptin, 
SOD and LPO and blood rheology parameters. 
Discussion of Inflammatory markers 
COPD is a multi-component disease and systemic inflammation is one of the possible 
mechanisms underlying its systemic manifestations, including skeletal muscle weakness and 
cachexia, so changes in these aspects might be related to changes in biomarkers of systemic 
inflammation (486, 487).  
Measures of inflammatory markers included: the serum levels of IL-2 in 2 studies (447, 455), 
IL-8 in 4 studies (80, 369, 411, 433), IL-6 in 2 studies (398, 463), TNF-α in 6 studies (65, 80, 
369, 398, 447, 449), C-reactive protein (CRP) in 2 studies (398, 463); and measures of the 
sputum levels of IL-8 in four studies (346, 405, 435, 436) and TNF-α in three studies (405, 
425, 436).  
Pinto-plata (2007) found that serum levels of both TNF-α and IL-8 correlated with FEV1, 
BODE index and exacerbation rate (485). Increased systemic CRP, which is regulated by IL-6 
(487), is also associated with poorer health status, comorbidities, hospitalisations and death 
(488, 489). Since increased levels of IL-8, TNF-α and CRP are correlated with worse disease 
severity, exacerbation rates, and lung function decline, they are not only proxy measures of 
inflammation but are also of clinical relevence. 
The results found an increase in the serum level of IL-2 when CHM plus RP was compared to 
RP (1 study). A reduction in the serum level of TNF-α was found when CHM was compared 
to placebo (449) (1 study), or RP (80) (1 study), or when CHM plus RP was compared to RP 
(447) (1 study). However, there was no change in the level of TNF-α in sputum in the meta-
analysis of three studies that compared CHM plus RP to RP (405, 425, 436).  
A reduction in the serum level of IL-8 was found in one study that compared CHM to RP (80) 
and compared experimental CHM to other CHM (433). In addition, CHM was found to be 
more effective in reducing the level of IL-8 in sputum when compared to placebo (435) or 
when CHM plus RP was compared to RP (405) (one study each). Due to differences between 
studies, the pooled data were not comparable. 
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Ren shen and Ge jie were used in Xiong (2008) which was the longest study (half year). 
Huang qi plus Lian qiao, Huang qin, Zi wan and Kuan dong hua etc were used in Che (2005), 
Huang qi, Dang shen, Bai zhu, Fu ling and Kuan dong hua were used in Wang (2005), Huang 
qi, Jin yin hua, Su ye and Jie geng etc were used in Zhou (2007). The principle of Tonify Qi 
and Kidney was applied in Xiong (2008) and, the principles of tonify qi and diffuse the lung 
to resolve phlegm were applied in the other three studies. Huang qi was the key herb in the 
formulae used in the three shorter term studies (from 4 to eight weeks). These four studies 
showed reduced levels of IL-8 and TNF-α in serum or sputum in patients with stable COPD 
which suggests the formulae enhanced the immune function of the patients.  
CRP was measured in one study (Tatsumi 2009) and IL-6 was measured in both Tatsumi 
(2009) and Shinozuka (2007) which implied that CHM may decrease the level of CRP and IL-
6 in serum, but detailed data were not provided (398, 463). The authors reported that the 
CHM reduced the chances of common cold and consequent exacerbations and that the CHM 
may have antibacterial and/or antiviral effects.  
Raised serum levels of TNF-α, IL-6 and CRP have been found in COPD patients compared to 
normal subjects. This supports their use as biomarkers of systemic inflammatory response in 
stable COPD patients (490). TNF-α and IL-6 were found to be higher in severe COPD and in 
those patients in an exacerbation stage (485, 491) but no relationship between CRP level and 
COPD severity was found (491). However, no change was detected in TNF-α or IL-6 
following the remission of exacerbations (485, 490). Raised TNF-α level has also been found 
to be associated with weight loss in COPD patients by Karadag F et al. 2008 (490). CRP level 
has been found to predict death in COPD patients and is associated with exercise tolerance, 
health status and muscle strength (487).  
Higher sputum levels of IL-8 and IL-6 have been found during exacerbations compared to 
periods of stable COPD, and raised IL-6 was associated with common cold symptoms (492), 
but the clinical significance of sputum levels of cytokines remains unclear since the use of 
liquefaction agents in sampling may affect results (493).  
It has recently been shown by Sin (2008) that the use of inhaled corticosteroids (ICSs), with 
or without the long-acting β2-adrenergic agonist Salmeterol, does not affect serum IL-6 and 
CRP levels (494). However, theophylline was found to decrease the level of TNF-α and IL-8 
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in sputum in seventeen COPD patients with long-term treatment (495). Therefore, it appears 
plausible that the CHMs may also have this effect. 
CRP is a surrogate marker that reflects the status of systemic inflammation (318). A higher 
level of CRP was found in COPD patients with lower BMI associated with malnutrition (491) 
and is also a marker of prognosis in patients with mild and moderate COPD and a predictor of 
higher risk of mortality (482, 496). Therefore, CRP is an important indicator of the 
progression and morbidity of COPD. In this SR, CRP was only tested in one study and needs 
to be examined in further clinical trials. 
TNF-α and IL-8 in serum, plus measures of lung function and the effectiveness rate of 
improvement of symptoms were reported in Xiong (2009), which found that the CHM may 
decrease the level of TNF-α and IL-8 in serum, as well as improve lung function and relieve 
symptoms for moderate COPD patients. Also, lung function and TNF-α in sputum were 
reported in Che (2005), Wang (2005) and Zhou (2007) which found reductions in the level 
TNF-α in sputum was associated with improvements in lung function.  
These results suggest that the levels of inflammatory markers are relevant to other outcomes 
of COPD, such as lung function and symptoms. However, due to different meathods used to 
measure the inflammatory markers, the small number of studies, and the small population 
samples used, the effect of these CHMs on these inflammatory markers cannot be confirmed. 
The findings of the studies in this analysis indicated that some CHM formulae appear to 
reduce systemic inflammatory response in patients with stable COPD. 
Discussion of lymphocyte subsets  
It is known that COPD is characterised by an abnormal inflammatory immune response in the 
lung in response to cigarette smoke or other particles (497). Both CD4 and CD8 T 
lymphocytes play key roles in the in the pathogenesis of COPD, but the complex procedure of 
systemic inflammation in the pathogenesis of COPD is not yet clear (498).  
In subjects with COPD, the level of lymphocyte subsets CD3, CD4, and the ratio of CD4/CD8 
in periferal blood have been found to be lower, and the level of CD8 is higher compared to 
normal subjects (499). The level of CD4/CD8 is positively related to FEV1% predicted (500), 
CD8 is more closely correlated with GOLD stage in stable COPD than is CD4 (498), also, 
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CD4 level is correlated with FEV1 in smokers with COPD (501). So changes in the levels of 
these lymphocytes appear to be related to clinical measures of COPD severity.  
ICSs used for long-term therapy, such as fluticasone, in combination with salmeterol have 
been found to have anti-inflammatory actions through reduction of the level of neutrophils, 
macrophages and CD8 and CD4 lymphocytes in sputum and can attenuate decline in lung 
functon in patients with moderate to severe COPD, but adding LABAs does not enhance these 
effects (502, 503). However, due to the risk of pneumonia, the use of ICSs for long term 
therapy in patients with COPD should consider this risk factor (197).  
In a clinical trial that investigated the immunomodulatory actions of the synthetic dipeptide 
pidotimod in patients with exacerbation of COPD, found that pidotimod increased the level of 
CD4 in perifieral blood and increased the ratio of CD4/CD8 after 15 days treatment and 
decreased the level of CD8 after 30 days treatment (504).  
In this SR, levels of CD3, CD4, CD8 and CD4/CD8 in blood were tested in 8 studies (Figs: 
37-40). The CHM formulae were found to be potentially effective in increasing CD3 and CD4 
as well the ratio of CD4/CD8 when compared to either placebo or RP, or when CHM plus RP 
was compared to RP, whereas no difference was found when the test CHM was compared 
with other CHM or no treatment. The most evidence was when CHM plus RP was compared 
to RP (3 studies). However, due to the different RP used, the pooled data was not comparable.  
Dong chong xia cao, Huang qi, Bai zhu and Fang feng were used in Liang (2009) with 6 
months treatment; Ren shen, Huang qi, Bai zhu and Fu ling etc were used in both Xiao (2000) 
with 2 months treatment and Xu (2009) with 3 weeks treatment. Therefore, tonify qi plus 
replenish spleen or tonify kidney herbs may have anti-inflammatory effects in patients with 
stable COPD. 
However, these CHM formulae seemed to have no clear effect on CD8. In these studies, there 
was no healthy subject control group, so it was not possible to determine how much higher 
the level of CD8 was in the trial subjects compared to healthy subjects. Also, in Kim (2002), 
the level of CD8 was observed to be only slightly higher when compared to healthy smokers 
or to healthy non-smokers (319), and in Chen (06) changes in CD8 were only detected after 
30 days of treatment (504). So a change in the level of CD8 between intervention and control 
groups after treatment may be difficult to detect.  
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Discussion of Immune globulins 
The serum levels of Immune globulins IgA, IgM and IgG were found to be lower in stable 
COPD patients than in healthy subjects (505). IgG levels were found to be higher in epithelial 
fluid in COPD patients with recurrent stable versus normal control subjects with a history of 
tobacco consumption of 30 pack-years (506). Also, IgM was found to be slightly higher in 
stable COPD patients than in healthy subjects, but for IgA and IgG no differences were found 
between stable COPD patients and healthy subjects. This study suggested that IgA, IgM and 
IgG may not be sensitive outcome measures for stable COPD (507).  
Immune globulins IgA, IgM and IgG were measured in 9 studies in this SR. The normal 
values for adults are in the following ranges: IgG 7.6-16.6g/L; IgA 0.71-3.35g/L; IgM 0.48-
2.12g/L.  
In all these studies the reported values were within the normal ranges and after treatment 
some were close to, but still lower than, maximum.  
The results suggest that the CHM formulae were potentially effective in increasing IgA and 
IgG when CHM was compared to placebo (69), was compared to RP (433, 508), and when 
CHM plus RP was compared to RP (372, 410, 450), whereas no difference was found when a 
test CHM was compared with other CHM or no treatment. CHM formulae seemed to have no 
clear effect on IgM in the two studies with short-term treatment (2 months of treatment in Qiu 
2009 and 3 weeks of treatment in Xu 2009), whereas a better effect on Ig M was found in 
Liang after 6 months of treatment (2009). So any effect may be related to duration of 
treatment.  
Both Huang qi and Bai zhu were used in these six studies. Ren shen or Dang shen were used 
in four studies (Li 2006-1, Qiu 2009, Sun 2007-2 and Xu 2009), Dong chong xia cao, Mai 
dong and Fu ling were each used in three studies. Therefore, tonify qi plus replenish spleen or 
tonify kidney herbs may have an immunomodulation effect in patients with stable COPD.  
Although immune deficiency has been postulated as a factor in COPD aetiology, this theory is 
not well-established and increases in IgA may refect response to pathogens (509). Also, the 
roles of immunoglobulins in immune response are complex and there is contradictory 
evidence for the meaning of Ig levels (510). It appears that IgA levels may rise in 
exacerbations related to respiratory tract infections (511) but in stable COPD measures of 
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serum immune globulins are difficult to interpret and may not have clear clinical significance.  
IgM that are specific for community-aquired pneumonia caused by various pathogens, 
including atypical types such as Mycoplasma and Legionella, show increased serum IgM 
levels in plasma and are predictive of the pathogens involved in the pneumonia (512). 
Therefore, changes in the level of IgM may e indicative of the type of bacterial infection in 
COPD patients at the exacerbation stage, but such measures do not appear useful for 
determining the progression in stable COPD. 
The level of IgD in serum is a quite old measure but relevance to various diseases and 
conditions remains unclear (513). Also, it was found to be significantly higher in elderly 
patients with stable COPD than in normal controls (507). It appears to have 
immunomodulatory effects and the level seems to be higher or lower in disorders 
characterized by immunodeficiency with increases being associated with infection. 
Consequently, IgD level may be a useful measure of exacerbations of COPD but its 
significance in stable COPD remains unclear (514).  
Discussion of albumin, Prealbumin and Leptin 
Nutritional depletion is common in COPD patients. It is due to imbalance between low-
energy intake and high-energy requirements, and affects morbidity and mortality (515). 
Therefore, nutritional support is generally implemented in pulmonary rehabilitation 
programmes (516). Nutritional status is assessed in various ways. However, nutritional 
depletion is represented as a loss of body weight, so body mass index (BMI) is the most 
commonly used measure in clinical practice either as a single measure or as part of a 
composite score such as BODE (517).  
Serum ALB has been used as a proxy measure of nutritional status (518) and has been found 
to correlate with lung function (519). However, it is not typically used in contemporary 
clinical studies.   
The level of serum Leptin was positively correlated with BODE index and a negatively 
correlated with Fat-free mass index (FFMI) in stable COPD patients (520), but it was found 
not to be related to anorexia and weight loss in COPD patients and no difference was found 
between COPD patients during stable and acute exacerbation stages (521). ALB, PALB and 
Leptin as markers for the assessment of nutritional status were measured in six studies (65, 
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398, 410, 417, 440, 454). The effect was most evident when CHM was compared to placebo 
(454), which found ALB, PALB and leptin all increased after one month treatment using Ren 
shen, Bai zhu, Fu ling, Mai dong, Sang bai pi, and Huang qi. PALB was increased in two 
studies which compared CHM plus RP with RP and used similar formulae (Liu Jun Zi Tang 
and Bu Zhong Yi Qi Tang) (398, 417). The results seem to be not correlated with the duration 
of treatment which was two months in Chen (2009-2) and six months in Tatsumi (2009). 
Although these markers have been used as proxy measures of nutritional status, the clinical 
significance of changes appear less clear than direct measures such as BODE index. Therefore 
the results found in this review for these measures are difficult to interpret.   
Discussion of Superoxidase dismutase and Lipid peroxide  
Oxidative stress has an important role in the pathogenesis and progression of COPD (522). 
Impairment in oxidant-antioxidant balance was found in patients with stable or exacerbation 
of COPD and even in healthy smokers by Hanta L et al (523). SOD as a parameter of 
antioxidative defence was found to be decreased in patients with COPD when compared to 
healthy subjects, also, lipid peroxidation products acting as signalling molecules can induce 
release of inflammatory mediators from lung cells (524). Therefore, finding new therapeutic 
interventions to repair oxidant antioxidant imbalance in COPD may prevent the further 
progression of COPD (523). 
Serum SOD and LPO were examined in one study that used Liu Jun Zi Tang (Dang shen, Bai 
zhu, Fu ling, Chen pi, Ban xia, Gan cao) taken for three months (73). The results from Zhuan 
(2005) showed that this CHM formula may rectify the imbalance of oxidation/anti-oxidation 
through increasing the level of SOD and decreasing the level of LPO. 
Discussion of blood rheology parameters  
Damage of pulmonary vessels is related to the progression of COPD and vascular change is 
present in endothelial and microvascular dysfunction (525). Also, the magnitude of changes in 
periferial circulation is related to the severity of COPD (321). Changes in hemorheology in 
COPD were found to be associated with hypoxemia (526). Hypoxia may lead to 
prothrombotic state or hypercoagulable state in COPD and also increase the risk of venous 
thromboebolism (527), which can be measured by Plasma D-dimer (528). The level of plasma 
D-dimer was observed to be slightly higher in stable COPD than in healthy subjects, but was 
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significantly higher in exacerbation of COPD (529). Therefore, plasma D-dimer is commonly 
used in exacerbation COPD and very important for treatment (529). Plasma D-dimer was not 
measured in any of the RCTs in this review; however a number of blood rheology parameters 
were used to assess blood viscosity. 
Blood rheology parameters provide a measurement and assessment of the condition of the 
periferial circulation in various diseases (530). A study showed that changes in blood rheology 
parameters in patients with COPD were greater than in healthy subjects. Due to oxygen 
deficiency, repeated infection or respiratory acidosis, COPD may lead to changes in the 
quality and quantity of erythrocytes and increase blood viscosity (531), and polycythaemia 
may develop. Blood stasis syndrome is associated with the severity of COPD so blood 
rheology parameters are frequently used in China as an objective measurement of blood stasis 
syndrome (532).  
Blood rheology parameters were tested in 3 studies. In two studies (Wang 2009, Cui 2008) 
measures of viscosity, shear rate and hematocrit level indicated that the CHM formulae were 
more effective in reducing plasma viscosity and erythrocyte aggregation when CHM plus RP 
was compared to RP (384), and when CHM was compared to no treatment (400).  
The herbs Tai zi shen, Dan shen, Dang gui, Tao ren, Hong hua and Chi shao etc were used in 
Wang (2009); and Huang qi, E zhu and Tao ren etc were used in Cui (2008). Both formulae 
used the methods tonify qi and activate blood. Both included the blood activating and stasis-
resolving herb Tao ren plus other herbs with similar effects such as Dan shen, Hong hua and E 
zhu.  
In the study by Guo et al (2010), the comparison was between two CHMs. The test CHM 
formula comprised Sheng sha shen, Shu di huang, Dang gui, Zhi ban xia, Chen pi, Fu ling, Lu 
jiao pian, Zhi ma huang, Xing ren, Bai jie zi, Chuan xiong, E zhu, Wu wei zi, and Zhi gan cao 
whereas the control group used Gu Ben Ke Chuan Tablet (Dang shen, Bai zhu, Fu ling, Mai 
dong, Zhi gan cao, Wu wei zi, Bu gu zhi). There was a non-significant improvement in blood 
rheology in the test medication but it only included two blood stasis removing herbs i.e. 
Chuan xiong and E zhu. Therefore a large effect would not have been expected.  
Dan shen (Salvia miltiorrhiza) belongs to the category of blood-activating and stasis-
dispelling herbs. Pharmacological studies have demonstrated that Dan shen has effects on 
hemorheology (533). Also, a clinical trial showed that Dan shen injection may relieve airway 
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inflammation, improve pulmonary ventilation and immune function (534). 
In Chinese Medicine, a recent study showed blood stasis syndrome to be more frequent as the 
severity of COPD increased, and increased COPD severity was associated with increased 
erythrocyte aggregation and higher hematocrit (532). Therefore, blood stasis plays an 
important role in the pathogenesis of COPD. Also, the incidence of pulmonary hypertension is 
very high in patients with COPD, and it was found that a high proportion of patients with 
pulmonary hypertension showed the CM syndrome of blood stasis (535). Although few 
studies measured blood rheology, the CHMs in numerous studies included herbs that have 
blood activating and stasis removing actions, for example Dan shen was used in 24 studies 
and Tao ren was used in 13 studies, as was Di long. Therefore removing blood stasis is an 
important strategy in managing COPD and in the prevention of co-morbidity. These studies 
demonstrated that certain CHMs may reduce blood viscosity and regulate blood flow and 
thereby prevent blood stasis forming in COPD. These actions may prevent or slow the disease 
progression. 
7.10.3 Discussion on syndrome differentiation, formula use and main herbs 
In CM, the selection of the most appropriate CHM treatment intervention is usually based on 
CHM principles that depend on syndrome differentiation. Of the 101 included studies, 
participants were diagnosed by Chinese medicine syndrome differentiation in 43 studies. In 
the majority of these studies the main syndromes identified involved ‘deficiency of lung’ (28 
studies), with multiple deficiencies being identified in other studies such as: ‘deficiency of 
lung and kidney’, ‘deficiency of lung and spleen’ or ‘deficiency of lung and spleen and 
kidney’, with or without existing ‘phlegm’ (4 studies) or ‘blood stasis’ (4 studies). Therefore 
the principles of treatment are predominantly ‘reinforce qi’, especially ‘reinforce the spleen to 
benefit lung’, ‘supplement spleen to nourish lung’, or ‘tonify the kidney to improve 
inspiration’. 
Also, even when a study did not explicitly state which syndrome was the focus of the 
intervention, the formula used may indicate what the treatment principle was, and from this 
the main syndrome can be inferred. For example, in Chen 2009, the selection criteria were set 
up but the Chinese medicine syndrome was not specified. Based on the formula used in 
treatment (Qi Wei Dou Qi Tang plus Dang shen, Huang qi and Bai zhu), it can be inferred that 
the patients included in this study were classified as deficiency of lung and kidney qi. 
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As introduced in Chapter three, the pathogenesis of COPD according to CM is associated 
with ‘deficiency’, ‘phlegm’ and ‘blood stasis’. Among the studies that reported on syndrome 
differentiation, the majority reported deficiency of qi, in particular deficiency of the qi of lung, 
lung and kidney, lung and spleen, or lung and spleen and kidney, which may be combined 
with phlegm or blood stasis.  
Syndromes involving single organ deficiency versus multi organ deficiency may be 
representative of the progressive development of COPD and may also reflect the relationship 
between the degree of deficiency and the severity of COPD. It is very meaningful to further 
explore the pathogenesis of COPD in CM terms to determine the progression of syndromes 
and hence the appropriate treatment principles at different stages in this disease. 
Based on the Chinese medicine syndromes identified and the formulae used in these studies, 
replenish qi and/ or fortify spleen and/or tonify kidney were the predominant treatment 
strategies in most studies with the addition of resolve phlegm or activate blood in certain 
studies. The most commonly used formulae and herbs are as follows:  
Formulae: Bu Fei Tang (Tonjfy the lung), Liu Jun Zi Tang (Fortify the spleen and replenish 
qi), Shen Ge Tang (Tonify the lung and supplement the kidney) and Fei Kang Granule (Tonify 
qi and activate blood). 
Among top twenty herbs, the majority of herbs are tonifying herbs, such as Huang qi (Tonify 
qi and upraise the middle qi, strengthen the defense and secure the exterior), Dang shen 
(Tonify and replenish the middle qi, engender fluid and nourish blood) or Ren shen (Greatly 
tonify the original qi, fortify the spleen and replenish the lung), Bai zhu (Tonify qi and fortify 
the spleen, induce diuresis to dry dampness), Fu ling (Fortify the spleen and replenish the 
middle qi), Wu wei zi (constrain the lung and enrich kidney, engender fluid and secure the 
exterior to check sweating), Ge jie (Tonify the lung and supplement the kidney), Shan yao 
(fortify spleen), Shan zhu yu (tonify kidney) and Mai men dong. 
The next most frequent group were herbs used of resolving phlegm and suppressing cough: 
Ban xia, Bei mu, Kuan dong huan and Su zi and Xing ren. Followed by herbs for activating 
blood and dissipating stasis: Dan shen and Dang gui.  
Gan cao was one of highest frequency herbs used in both the classical literature and the 
modern clinical trials. Its effects are resolving phlegm and suppressing cough and it also 
276 
 
regulates spleen and stomach.  
Study design, study quality and the meaningfulness of results 
The primary goals of the treatment for stable COPD are to prevent decline of lung function, 
improve HRQoL and reduce exacerbations. Five studies used QoL, lung function and 
exacerbations as outcomes (Huang 2005, Jia 2007, Ni, 2008, Tang 2009, Zhang 2006) (347, 
370, 377, 381, 383). However, due to differences in the study designs, the pooled data were 
not comparable.  
The best study design involving CHM plus RP was applied in Ni (2008) with 68 participants 
for two months treatment, since the control group used RP plus placebo. However, multiple 
types of RP were used in the Ni study which makes the results difficult to interpret.  
CHM plus RP versus RP was applied in Huang (2005) with 63 participants for three months 
treatment and Jia (2007) with 55 participants for six months treatment, but information on the 
RP was not provided in Huang (2005). Therefore, the degree of effectiveness of the CHM 
could not interpreted in Ni or Huang. Ipratropium bromide was used in Jia (2007) which 
found a significant improvement of QoL and FEV1% and reduction of exacerbations of 
COPD in favour of the CHM. 
QoLQ and lung function were measured in 20 studies. The best evidence was when CHM 
plus RP were compared to RP in 8 studies. RP including Salmeterol, Ipratropium bromide, 
Salmeterol Xinafoate/Fluticasone Propionate, theophylline Sustained-release were used in 
five studies (Chen 2009-1, Jia 2007, Liu 2006-1, Liu 2010 and You 2008) (312, 366, 370, 385, 
386). RP was not provided by two studies (347, 379) and multi medicines were used in one 
study (372). 
The best results from FEV1% and QoL assessed by SGRQ were found in Jia (2007) with 55 
participants for six-month treatment and Liu (2010) with 60 participants with three months. 
Although the score of methodological quality assessed by Jadad’s scale was 2 in these two 
studies, most domains were judged as unclear risk of bias by the Cochrane method. Also, the 
diagnostic criteria, classification of severity of COPD, CM syndromes and set up of the 
outcome measures as well as the data analysis methods were described in both studies. The 
deficiencies of these two studies are small sample size, and lack of description of generation 
of randomisation and double blinding as well adverse events.  
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Qi-tonifying and blood-activating therapeutics were applied in two studies with similar 
formulae including the herbs Huang qi, Dang shen or Tai zi shen, Dan shen and Di long. In 
one study (Chen 2009) (312) with 60 participants for three months treatment, Salmeterol 
Xinafoate/Fluticasone Propionate was used in both the treatment group and control group. 
This study appears frequently in the results since it reported on many outcomes including 
pulmonary function, quality of life questionnaire, dyspnea scale by MMRC, BODE index and 
arterial gas measurement as well as adverse events. However, this study showed the same as 
the above-mentioned problems of methodological quality reporting. Nevertheless, the 
outcomes measured in Chen (2009-1) are recommended to be used in clinical trials for stable 
COPD, in particular BODE index. However, MMRC and BODE index were used in only a 
few of the 101 RCTs. 
Surrogate biomarkers specific for COPD have not been found. However, some of the main 
biomarkers of inflammation such as IL-8 and TNF-α were tested in sputum or serum in 
several studies. These studies provided evidence that the level of IL-8 and TNF-α in sputum 
or serum were correlated with stable COPD patients and that the CHMs may have potential 
effects on anti-inflammation and reduction of inflammatory response in stable COPD patients.  
Therefore, the oral CHMs used in these studies appear to have potential benefits for stable 
COPD sufferers but the evidence should be interpreted with caution due to the potential risks 
of bias due to the identified methodological issues. 
7.10.4 Agreements and disagreements with other studies or reviews  
A recent systematic review on RCTs of herbal medicines for COPD (536) included 14 RCTs, 
two of which were also included in these reviews (79, 343). The reasons for exclusion from 
this review are as follows: two studies were not on a CHM(537, 538); two involved 
intravenous injection (539, 540); one study included patients with COPD in children (541); 
one study included some patients who had COPD accompanied with pulmonary heart disease 
(542); and six studies included patients with acute chronic bronchitis or chronic bronchitis 
(543-548). Consequently, these studies have not been included in these three SRs on oral 
CHMs for stable COPD. 
The electronic data search for the SR by Guo et al (2006) was limited to English language 
databases and this was a major factor in the relatively small number of included studies.  
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The outcome measures in the studies included in the SR by Guo et al (2006) involved 
pulmonary function, symptom scores, and health related quality of life (SGRQ) but the small 
number of included studies and the diversity in these studies meant that there were few 
opportunities for data pooling and meta-analyses were not undertaken. The conclusions of this 
review indicated that the effectiveness of herbal medicines for treating COPD was not 
established beyond reasonable doubt due to methodological weaknesses, based on scores on 
the Jadad scale, and possible publication bias in favour of positive studies.  
In these three SRs, the methodological reporting of the study methods was inadequate in the 
majority of cases with the result that bias was judged as ‘unclear’ or ‘high’ in many studies. 
This is broadly consistent with the earlier review. 
All of the 101 included studies reported at least some positive results for the experimental 
arms. This suggests the presence of publication bias, however, the meta-analyses of the 
reported data found a mix of positive and negative results.  
7.10.5 Limitations to the evidence reported in this review 
The observations reported above should be interpreted with caution considering that the 
results might be influenced by: 1) incompleteness in the data search and collection processes; 
2) differences in the participants, size and duration of trials; 3) differences in study design and 
interventions; 4) weaknesses in the study methodology; 5) variability in the procedures for 
diagnosis and collecting outcome measure data; 6) reporting bias, since not all trials reported 
results suitable for inclusion in the meta-analysis for each outcome; and 7) variation in the 
form, composition and dosage of the CHMs used. 
7.10.5.1 Overall completeness of the evidence 
Although large and comprehensive searches were conducted in this review, only 101 studies 
were identified and included. Due to there being two phases of COPD, all of the studies on 
patients with exacerbations of COPD were excluded. Also, all of the studies of HM 
interventions that involved injections or administration routes other than oral were excluded. 
So, not all forms of CHM interventions are represented in the data. 
Among the 101 trials, 98 were conducted and published in Chinese. Two were conducted in 
Japan and one in Israel and were published in English journals. To avoid language bias and 
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location bias, no potential studies were excluded based on publication language, but potential 
dissemination bias could not be excluded. Extensive searches for unpublished material were 
undertaken, but few of the trials identified qualified for inclusion. However, the possibility 
that trials with negative findings may remain unpublished can not be disregarded. 
7.10.5.2 Diversity in participants, sample size and duration of studies 
Participants in the full range of the COPD trials were diverse in terms of age, whether they 
were in-patients or out-patients, their stage of COPD and in other aspects of their background 
and medical history. This diversity was limited in the SRs since only patients with stable 
COPD and without acute exacerbations were included. Since most of the participants were 
recruited from Chinese populations this contributed to the comparability between studies. On 
the other hand, this aspect could impact on the applicability of the interventions when used in 
other populations. Also, since stable COPD is one of phenotypes of COPD, the results of 
these SRs may not be applicable to exacerbations of COPD. 
Many of the trials had relatively small sample sizes. For example, six of the 101 trials 
included 40 or fewer participants. There are, however, 26 trials with sample sizes of 80 or 
more and there are a number of large studies, for example Huang et al (2002) had 600 
participants. Small sample size reduces the reliability of the results, so this issue needs to be 
considered when interpreting results.  
COPD is a chronic disease with progressive development, so long term therapy is better for 
treatment and the inclusion of short-term studies may affect the outcomes. Among the 101 
included studies, the duration of treatment period was more than three months in 59 studies. 
Therefore a substantial proportion of the data was derived from longer studies. Also, no 
difference was found in the sensitivity analysis for lung function and for the most frequently 
used herbs. This suggests that the duration of study did not affect the overall outcome but 
sensitivity analyses were not conducted for other outcome measures due to the relatively 
fewer trials that used comparable measures. 
7.10.5.3 Diversity in study design and interventions 
There is variation in the design of studies and in the control interventions used. Placebo 
controls were used in 12 trials; CHM alone was compared to no treatment in 18 studies; CHM 
plus RP was compared with RP in 47 studies; and CHM alone was compared to RP in 13 
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studies.  
Even when the same or similar herbal medicine is used as the test intervention, it is difficult to 
interpret the results when the study design is different. For example, when the CHM was 
compared with placebo in one study, but the same CHM plus RP was used in another. In the 
meta-analyses, this issue was addressed by conducting sub-group analyses based on study 
design, amd the the studies that combined CHM plus RP, further sub-group analyses were 
conducted based on the type of RP. However, while the general designs of these studies are 
comparable, other factors may differ. This limitation needs to be considered when interpreting 
the results of meta-analyses. 
In addition to the conventional study designs mentioned above, a test CHM was compared to 
another CHM in 11 studies. Manufactured herbal medicines such as Guben Kechuan tablets 
have been used in China for 30 years for respiratory disorders and Bailing capsules have been 
used for over 10 years, so these CHMs could be considered a form of RP. Therefore, when 
these herbal medicines were used in the control groups they could be regarded as active 
controls, similar to the use of the RPs of Western medicine. Nevertheless, this sub-group of 
studies is considered separately in the meta-analyses.  
In China, patients suffering with COPD are usually relunctant to participate in RCTs that 
employ a placebo, so placebo controls are not widely applied in clinical trials. Instead, active 
controls in the form of the Western or Chinese medicines that are frequently used for COPD 
are used in clinical trials, especially in those aiming at developing new medicines. In addition, 
numerous trials used combinations of medicines, such as Chinese plus Western medicine in 
the test arm. This approach allows all patients to receive an active treatment whilst evaluating 
the additive effect of the combination therapy. Such an approach is clinically relevant since it 
reflects actual practice but introduces complexity into the trial design which can make the 
results more difficult to interpret. 
Even when the CHM formula interventions were same or similar, they may be administered 
using different treatment regimens with regard to the dosage, frequency and duration of 
treatment. This factor also limits the interpretability of pooled data. The sensitivity analysis 
that was performed on treatment duration did not find any significant differences based on 
this aspect but it was impractical to conduct sensitivity analyses on all variables.  
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7.10.5.4 Risk of bias and methodological quality of the evidence 
1) Cochrane risk of bias 
All the 101 RCTs in this SR had methodological weakness and potential risks of bias as 
assessed by Cochrane risk of bias. In most cases the risk of bias was unclear due to limited 
descriptions of the study design, methods of randomization, allocation concealment and 
blinding. Information about the method of generation of randomization was provided in only 
23 studies and an unsuitable randomization method was used in one study. In a few studies 
there were large differences in the number of participants in each group, but the baseline data 
were considered by the researchers to be comparable. This design creates difficulties in the 
generation of randomization and is less likely to produce baseline comparability.  
The use of double blinding was described in only three studies. However no further details 
were available on who were blinded, or which outcomes were blinded.  
Many of the included trials were in heterogeneous populations that could include adults or 
elderly patients with mild to severe of COPD. Morever, 44 studies did not report the stage of 
COPD, only that it was stable. This is likely to have been a major factor in the heterogenity 
found in a number of the meta-analyses.  
The selection criteria for participants were specified in 42 studies and the outcome measures 
were described and reported on in 72 studies, so these were considered free from selective 
reporting of results and were judged as low risk of bias, whereas any study that did not report 
all outcomes was judged as high risk.  
Withdrawals were reported in only 11 studies and this represents a 1.22 percent withdrawal 
rate. As would be expected, the withdrawal rate was higher in the seven longer-term studies 
which ranged from three months to six months (withdrawal rate 1.48%). However, only one 
of these studies used intention-to-treat data analysis to control for the effect of withdrawals. 
Overall, the withdrawal rate was low, so the lack of ITT analysis is unlikely to have affected 
the overall outcomes. 
2) Methodological quality assessed by Jadad’s scale 
Jadad’s scale emphasizes the description of three aspects, randomization, double blinding and 
withdrawals. If the score is greater or equal to three, the methodological reporting can be 
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considered to be of good quality. Scores of 3 or more were found for 26 studies. The major 
reasons for the lower scores were: no double blinding performed, the authors did not describe 
whether there were withdrawals or not, as well no explanation of the reasons for withdrawals 
in the studies.  
Published SRs of CHM clinical studies for the treatment of various diseases, have often found 
that the methodological quality as assessed by Jadad’s scale was low (549-551). The need to 
improve the design and methodological reporting of CHM clinical trials has been a concern 
for a number of years and the quality of studies appears to be improving (552).  
Because of the high risk of bias of blinding and allocation concealment in the most included 
studies, the results for outcome measures that involve subjective assessment are less reliable 
and must be interpreted with caution. These include symptom scores, effective rate, 
exacerbation rates and adverse events which are subject to interpretation by physicians and 
Qol questionnaires which may be affected when patients know their group allocation. On the 
other hand, measures such as lung function and the results of laboratory tests should be less 
affected by blinding issues. 
Although, methodological shortcomings such as inadequate generation of the randomization 
code, insufficient concealment of random allocation and lack of blinding are likely to have 
contributed to discrepancies among the results of these trials, the following other factors also 
may impact on the reliability of the results of these analyses.  
The relatively small sample sizes and short lengths of duration of treatment may impact on the 
reliability of the outcomes and on the generalisability of the results to a clinical setting in 
which long-term therapy is a necessity. Amongst the 101 studies only 4 were for one year 
(363, 403, 420, 460). 
Therefore, besides proper trial design and methodological reporting, large sample size, long-
term duration of treatment and patients at a consistent COPD stage, preferably stage one or 
two, are strongly recommended in future clinical trials.  
These SRs have also provided evidence to suggest a difference in exacerbation rates or 
frequencies between COPD patients treated by CHM alone or CHM plus RP and those treated 
by RP alone. However, since patients with exacerbations were excluded from these studies at 
randomization, this outcome does not indicate that the CHMs were effective for treating 
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exacerbations, only that they may have reduced the incidence of exacerbation in patients with 
stable COPD.  
7.10.5.5 Variability in the procedures for diagnosis and collecting outcome measure 
data 
Diagnostic criteria 
Among the one hundred and one included trials, most of the participants were diagnosed as 
COPD by either the guideline for the diagnosis and management of COPD produced by the 
CSRD in 1997, 2002, 2007 or by GOLD. In addition, a few of trials set up selection and 
diagnostic criteria based on books on internal medicine. However, ten studies did not indicate 
how the participants were diagnosed.  
In the latest version (2007), the national standard for the diagnosis and management of COPD 
issued by CSRD is in accordance with the the GOLD international standard, and earlier 
versions were similar to the GOLD guidelines. Therefore, guidelines similar or equivalent to 
GOLD are not only widely used in clinical practice and trials, but are also recommended as 
the criterion for the definition of COPD in China. Consequently, variations in diagnosis and 
inclusion criteria appear to be less variable that might be expected given the use of different 
standards. 
Classification of the severity of COPD was described in 57 studies. However, most of these 
studies did not report a description of the performance of pulmonary function tests except in 
one study in which the performance of a spirometric test was based on the standard procedure 
in the GOLD guideline. Therefore, there may be variation in the way in which the severity of 
COPD was assessed. This may have impacted on results and may limit comparability between 
trials.  
The majority of included studies were from China and all used Chinese herbal medicines, but 
only 43 studies characterized participants according to the syndrome differentiation procedure 
used in Chinese medicine. Since the specific syndromes are the basis for the selection of 
formulae and herbs used in treatment, the lack of syndrome differentiation is a major 
shortcoming in a clinical trial and the inappropriate use of a formula may affect results. One 
reason for not using or not reporting the use of syndrome differentiation is the lack of a 
national standard. Therefore, it is very important that a standard for for the CM diagnostic 
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criteria and syndrome differentiation for COPD be set up and for this to be linked to the 
stages of COPD progression.  
Procedures for collecting and reporting outcome measure data  
As mentioned above, the procedures for performing pulmonary function tests were seldom 
described in the articles. Also, few trials reported that procedures were based on the 
guidelines developed by GOLD.  
Especially when multiple spirometric indices are measured, it is important that the 
performance procedures be clear, since variation in procedures within a trial can affect results 
and when different procedures are used between trials this can affect the comparability of the 
results. This aspect is less of an issue when a standardized test such as QoL using SGRQ or 
Cai’s questionnaire are used.   
7.10.5.6  Reporting bias 
Duplicated publication of articles on the same RCTs may result in bias since such articles tend 
to each report on specifc outcome measures only. This issue was identified at the beginning of 
the SRs and any multiple publications were counted as a single RCT and any selective 
outcome measure reporting issues were identified and assessed under Risk of Bias. 
Another aspect of reporting bias is exclusion of unpublished material. Efforts were made to 
idenfify such material in the extensive searches, but few of the trials identified qualified for 
inclusion. However, it remains possible that trials with negative findings may remain 
unpublished. This may be due to the lack of awareness of the need to register clinical trials in 
China and/or journal editors rejecting the negative trials. The evidence suggests there is 
publication bias in favour of positive studies in China and other countries [202, 203]. In the 
future, it is important that both positive and negative studies be reported.  
There are also deficiencies in the reporting of safety aspects, ethics approval, the use of 
consent forms signed by subjects with these being reported in only a few of the published 
articles. Also, most articles did not provide a protocol so it was difficult to determine whether 
there was selective reporting.  
When only symptom scores are reported as outcome measure, there is the potential for 
subjectivity in measurement especially when blinding is inadequate. All of these aspects need 
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to be considered and improved in future trials. 
7.10.5.7 Variation in the form, composition and dosage of the CHMs used and adverse 
event reporting  
There are wide variations among the tested Chinese herbal medicines. These may involve 
formulae or single herb extracts that may be used the form of pills, capsules, granules, syrups 
or decoctions.  
Furthermore, in most of the studies information on the quality standards for the production of 
the CHM preparations or the manufacture of the CHM products is lacking. This limits the 
comparability of trials and the meaningfulness of dosage specifications. Future trials should 
provide information about product standardization including composition, quality control, 
concentration of key phytochemicals, and detailed dose regimen. 
There was inadequate reporting on adverse events in the included trials. Eighty trials did not 
mention any results about adverse effects. 4 trials reported inconsistent minor adverse effects 
which were not related to the herbal medicine and 17 trials reported that no adverse event was 
observed in their studies. These results suggest that the herbal medicines were well tolerated, 
but they may also reflect inadequate data collection on this aspect and/or inconsistent methods 
for interpreting what consists an adverse event, a serious adverse event or which adverse 
event is a result of the intervention.  
In some studies, the safety of the herbal medicine was demonstrated through pre and post 
blood tests including liver function and kidney function that indicated no adverse effect of the 
CHM on the blood test results for these functions in six studies. In future studies, adequate 
reporting on adverse events is needed and the safety of the herbal medicines needs to be 
monitored and reported in the published results of the clinical trial. 
7.10.6 Interpreting the meaning of outcome measures and meta-analysis results 
7.10.6.1 Lung function 
The best method of evaluating the effectiveness of a therapeutic approach is measuring 
changes in spirometric parameters. Due to the stability of measurement, repeatability and high 
resolution, FEV1 and FVC as well as the ratio of FEV1/FVC are commonly used in clinical 
trials for COPD. FEV1 is an important spirometric parameter which is most relevant to the 
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diagnosis and classification of the severity of COPD. It may be increased by 12% (200 ml) 
soon after inhalation of a Beta-2 agonist such as Salbutamol (10, 174).  
In two studies of CHM versus placebo over 2 months, there was an average increase of 
FEV1% predicted of 13% in Wu (2006) (342) with 200 participants and 10.88% in Li (2006-1) 
with 62 participants (69). In a longer study in which CHM was compared to no treatment, a 
relative benefit of 11.49% was found in Zhang (2006) with 46 participants for six months, 
with participants in the no treatment group showing little change and those in the CHM group 
improving (377). In Hong (2005) in which 38 participants were given CHM or no treatment 
for six months, the FEV1 increased slightly from a baseline of 0.982 (L) to 0.998 (L) at six 
months follow up (i.e. one year later) in the treatment group, whereas there was a decline 
from 0.987 (L) to 0.911 (L) in the control group. These four studies suggest the CHM alone 
was effective improving and/or reducing decline in lung function in the short to medium term 
when compared to control groups. However, patients with FEV1 % predicted of 40% to 50%, 
may not benefit from oral CHM. 
When CHM was used in conjunction with theophylline was compared to theophylline, Feng 
(2006) reported an improvement of FEV1% predicted of 7.42% in 69 participants over 30 
days (401) and an improvement of 8.22% was found in Liang (2005) with 63 participants for 
one year (460) (Fig 7.3). Also, an increase in FEV1% of 22.35% was reported by He (2010) 
for CHM plus theophylline sustained-release vs placebo plus theophylline sustained-release 
with 98 participants over six months (426).  
Improvements in FEV1% predicted ranging from 7.95% to 10.43% were reported in three 
studies of CHM plus Salmeterol Xinafoate/Fluticasone Propionate versus Salmeterol 
Xinafoate/Fluticasone Propionate, with 60 participants for six months in Liu (2010) (386) and 
Pu (2010) (427), and with 58 participants for two months in Zhu (2010) (404). Similarly, an 
improvement of 12.46% was found in Jia (2007) for CHM plus Ipratropium bromide vs 
Ipratropium bromide with 55 participants over 6 months.  
Although these studies demonstrated improvements in FEV1, a considerable number of 
studies found no significant benefit (Fig 7.3). These differences in effect may have been 
related to the severity of the COPD of the participants, the particular CHMs and dosages used, 
or other factors. These issues require further clinical evaluation. 
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7.10.6.2 Symptoms  
The results suggest that oral CHMs can markedly relieve symptoms including chronic cough, 
sputum production and dyspnea. However, most studies used subjective scales so the 
magnitude of the effect is difficult to assess. In the 3 studies that used the MMRC dyspnea 
scale there was a significant improvement (p<0.05) in dyspnea scores, but in each of the 3 
studies that the relative benefit was less than 0.5. While this is a modest effect, considering 
the distress that dyspnea produces, relief of this symptom is clinically important. . 
7.10.6.3 Quality of Life 
Scores on the SGRQ range from 0 to 100 with a higher score indicating a decline in quality of 
life. A change of 4 units or more is considered to be clinically meaningful (553). The change 
in SGRQ score was more than 4 units when CHM was compared to placebo in one study with 
60 participants for over one month (375); and when CHM was compared to no treatment in 
Zhang (2009-1) (367) with 104 participants for over six months and in Wu (2007) with 122 
participants for over 4 months (365); and when CHM was compared to Ipratropium Bromide 
with 67 participants for over six months (Zhu 2007).  
Also, when CHM plus Salmeterol Xinafoate/Fluticasone Propionate was compared to 
Salmeterol Xinafoate/ Fluticasone Propionate in Liu (2010) with 60 participants for six 
months, an average improvement of 6 points was found (386).  
In other studies, the effectiveness of the CHM was difficult to interpret. For example, the RP 
was not provided in Huang (2005) (347); multiple medicines were used in You (2008) (366). 
However, based on the overall results, oral CHM may improve QoL, particulary when used as 
long-term therapy.  
7.10.6.4 Exacerbation incidence 
The meta-analysis found that oral CHM plus ipratropium bromide or theophylline may reduce 
COPD exacerbation frequency in the range MD -0.34 to -1.80 (95% CI) (p<0.01) in one year 
based on three studies (412, 415, 460) and when CHM alone was compared to no treatment in 
one study the reduction was MD -1.20 (95% CI) (p<0.00001) (383).  
According to GOLD, patients with Moderate COPD have 0.7-0.9 exacerbations per year, 
Severe COPD patients have 1.1-1.3 exacerbations per year and Very Severe COPD patients 
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have 1.2-2.0 exacerbations. In the included studies, the level of COPD severity was not 
clearly defined and patients may have different levels, so it is unclear whether the reduction of 
around one exacerbation found in the studies was related to a sub-group of the COPD patients. 
Nevertheless, since exacerbations are associated with morbidity and mortality, any reduction 
is clinically significant and the potential benefit of CHM treatment on this aspect of COPD 
warrents further research.  
7.10.6.5 6MWD 
The best results were an average increase of 40 meters or more when CHM plus RP was 
compared to RP (312, 345, 347, 386, 415), and when CHM was compared to no treatment 
(408, 420). For example, CHM plus Salmeterol Xinafoate/Fluticasone Propionate versus 
Salmeterol Xinafoate/Fluticasone Propionate was used in Chen (2009-1) and in Liu (2010), 
both with 60 participants over three months with relative increases of 47 and 66 meters 
respectively.  
CHM plus Ipratropium Bromide versus Ipratropium Bromide was used in Zhang (2010) with 
120 participants over six months with a difference of 35 meters. However, the RP was not 
provided in Huang (2005) or Guo (2008) so the results are difficult to interpret.  
In Shao (2006), the value for 6WMD was slightly lower after one year compared to baseline 
in the no treatment control group which suggests that the CHM prevented decline over the 
year. 
Overall, oral CHM plus Salmeterol Xinafoate/Fluticasone Propionate or Ipratropium Bromide, 
as well as CHM alone appeared to produce a clinically significant improvement in the 
exercise tolerance of patients with stable COPD.  
7.10.6.6 Surrogate outcomes 
BODE index was used as a surrogate outcome in two studies which reported reductions of 
about 1.3-1.5 (p=0.04 or p=0.01). When the BODE index is decreased by one, the survival 
rate will be increased by 1.6 times (480), so the decline found was clinically significant. Since 
the BODE index is an internationally recognized measure that is associated with clinical 
outcomes it is recommended to be included in future clinical trials.  
Inflammation is an important feature of COPD, so a number of surrogate outcomes for 
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systemic inflammation were measured including inflammatory cytokines, lymphocyte subsets, 
and CRP. Due to the small number of studies, the effectiveness of the oral CHMs could not be 
assesed by meta-analysis and the significance of the changes reported is difficult to interpret. 
None of the biomarkers measured are specific for COPD but recent studies tend to favour 
measures of CRP, IL-8 and TNF-α since these are correlated with lung function and may even 
be predictors of the severity of COPD (482, 496). Therefore, these are useful outcome 
measures for future clinical trials. 
The levels of immuneglobulins were included in some trials on the basis that they reflect the 
immune status of patients with COPD. However, these are not sensitive outcomes for patients 
with stable COPD.  
In this SR, D-dimer antigen test was not measured in any studies. It is useful outcome 
measure for patients with moderate or severe COPD, particularly in the acute exacerbation 
stage. Whether it is correlated with syndrome of blood stasis or not could be evaluated in 
future studies. 
7.10.6.7 Other outcome measures  
Blood gas analysis 
In the studies that used P02 as an outcome, the best result was an average increase of 0.68 
KPa (5.1 mmHg) in Lin et al 2003 for CHM vs placebo over 2 months (Fig 7.30). Although 
this change was not large, it is clinically significant. A similar change (0.64 KPa / 4.8 mmHg) 
was found in Chen et al (1) 2009, for the combination of CHM plus Salmeterol & Fluticasone 
over 3 months. However, in some studies the change was too small to be clinically useful. 
Also, it appears unlikely that this level of improvement would be evident in the longer term. 
Blood rheology parameters 
The effectiveness of the oral CHMs on blood rheology could not interpreted by meta-analysis 
due to the small number studies that measured the level of plasma viscosity, shear rate and 
hematocrit. Increase in blood viscosity reflects the progression of COPD. Also, in Chinese 
medicine, increased blood viscosity it is regarded as relevant to the syndrome of blood stasis 
and can be used to guide the selection of herbs and formulae. Hematocrit levels of over 55% 
can indicate polycythemia in response to low oxegen availability, so hematocrit reductions in 
these patients are clinically important. However, in the few trials that measured hematocrit, it 
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was not clear how many patients achieved hematocrit reductions.  
Further research is required on the effects of blood activating herbs on blood rheology and 
also which herbs can reduce elevated hematocrit levels in COPD patients. 
Nutrition status 
Nutritional status is of particular concern in patients with COPD so relevant outcome 
measures should be included in clinical trials. BMI index was measured in four studies. It is a 
component of the BODE Index and is important measure of nutritional status in COPD 
studies. Other proxy measures of nutritional status included the level of serum ALB in four 
studies, PALB in five studies and Leptin in two studies. However, as discussed above, each of 
these proxy measures presents data interpretation difficulties in COPD. Therefore the 
evidence of CHM action on nutrition provided by this SR remains unclear. Further studies 
that focus on nutritional status and include outcome measure such as BODE Index and fat free 
mass are needed. 
7.10.7 Authors’ conclusions 
This evidence should be interpreted with caution due to the potential risks of bias in many of 
the included trials. Larger, longer-term trials are necessary to assess the validity of these 
results, which would be of major clinical relevance if replicated in well designed, adequately 
powered RCTs. The use of CHMs that employ the principal strategies identified in this SR 
appear to benefit a majority of stable COPD patients. However, their usefulness in 
exacerbations remains unclear, and it is difficult to determine whether these benefits would be 
evident with long term treatment.  
Few instances of adverse effects were reported and none were severe AEs, so it appears that 
the safety profile of the CHMs used in the 21 studies that rported AEs was good. However, 80 
studies did not report these important data, so the safety profile of the CHMs used in these 
studies remains unclear. 
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8 Chapter Eight: General Discussion 
This chapter summarises, compares and contrasts the main results from the two parts of this 
thesis and discusses how the commonly used formulae and herbs may function in the 
treatment of COPD from both the experimental and traditional perspectives. Finally, the 
strengths and weaknesses of this study are discussed and directions for further research are 
identified. 
8.1 Summary of results from the analyses of classical literature and 
modern clinical trials  
This project included two main parts: an analysis of the Chinese classical literature and an 
analysis of the results of modern clinical trials of herbal medicines. These two parts employed 
different methodologies and criteria to investigate the use of Chinese herbs and herbal 
formulae for treating stable COPD. Prior to searching the Chinese classical literature, COPD 
was defined. Several disease and symptom names used in the classical medical literature that 
were considered relevant to COPD were selected as search terms for the classical literature. 
Herbs and formulae recorded in classical books to treat these COPD-related diseases were 
searched using these terms in the Zhong Hua Yi Dian (ZHYD CD). In the second part, an 
analysis of the modern clinical trial literature was conducted according to the guidelines of the 
Cochrane Review Airway Group. This analysis evaluated the effectiveness and safety of oral 
Chinese herbal medicines (CHMs) for treating patients with stable COPD using SRsand meta-
analyses.  
8.1.1. Main findings from the analyses of the classical literature  
When the findings of the two main parts of this study were compared, distinct differences 
were evident in the concepts of COPD-related disorders that were found in the classical 
literature and COPD in the clinical trials, even though both employed the conceptual 
framework of TCM. Related to these differences, differences were found in the herbal 
formulae used and in the primary herbs used between the citations in classical books and the 
RCTs. Each of these three aspects is discussed below. 
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8.1.1.1 Traditional terminology relevant to COPD 
COPD as a medical condition has a short history of only several decades; thus, there was no 
mention in the classical literature of a term that corresponded directly to COPD. The aetiology 
and pathogenesis of this disease are very complex. As discussed in Chapter 2, COPD can 
develop from chronic bronchitis, asthma, emphysema or other respiratory diseases. In modern 
TCM, COPD is commonly known as Fei zhang (251, 332). 
In the classical Chinese medical literature, because no particular disease name could be 
assumed to correspond to COPD, respiratory disorders that shared similar symptoms and 
signs with COPD needed to be identified. Based on the descriptions of the symptoms and 
signs of these respiratory conditions used in the classical texts, it was very difficult to make a 
diagnosis or to assess the stage, length, severity or acuity of disease development. 
Nevertheless, in order to identify citations on conditions that may have been COPD, a 
quantitative and qualitative system was established to assess each respiratory disease 
mentioned in the sample of 1,000 classical books in order to best exclude those medical 
conditions that were unlikely to have been COPD and to identify diseases that were possibly 
or likely to have been conditions that would now be considered COPD. 
Seven search terms were identified as being relevant to COPD-related diseases in the classical 
literature. These were: Jiu ke sou (long-term cough); Ke chuan (cough and dyspnoea); Chuan 
sou (dyspnoea and sputum); Chuan zheng (dyspnoea); Fei zhang (lung distension); Tanyin 
kesou (phlegm-fluid with cough); and Zhi yin (thoracic fluid retention). They were all used to 
search the ZHYD, with each citation extracted to a database and analysed for its specific 
relevance to the modern concepts of stable COPD and COPD exacerbations. The period 
ranging from the 11
th
 century (Song dynasty) to the early 20
th
 century (late Qing dynasty) 
produced the highest number of citations. 
Based on its presentation, COPD may be classified as either being in the stable stage or in the 
acute stage. Different stages exhibit different symptoms and require different treatment plans. 
At the stable stage, COPD patients mostly display the clinically observable symptoms of 
sputum production and shortness of breath upon exercise or chronic cough and sputum 
production. It is at the exacerbation stage when the symptoms of dyspnoea and chest tightness 
become more evident. 
When only a few symptoms are present, the clinical differentiation of chronic bronchitis, 
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emphysema, asthma, heart failure and a variety of other disorders is difficult; this is 
particularly so when the descriptions of the symptoms are brief. Consequently, to find the 
closest correspondences to COPD in the classical literature, combinations of ‘non-acute’, ‘no 
haemoptysis’, ‘cough’, ‘sputum production’, ‘dyspnoea’ and ‘chest tightness’ were the main 
criteria used to limit the data set. However, the result of this was to find conditions that were 
possible COPD at the severe stage and/or COPD exacerbations. At the same time it was not 
possible to screen out all other severe lung disorders, because decisions could only be made 
based on the information included in the citations, which may have been incomplete.  
Therefore, even when all selection criteria were applied, citations were likely to include some 
respiratory conditions that were not COPD. Also, citations that referred to possible examples 
of stable COPD and were likely to be in the data set were not identified when all selection 
criteria were applied, because these were much more difficult or impossible to distinguish 
from other related conditions due to their lack of distinctive clinical manifestations.  
Among the search terms used, some were more or less closely aligned with the main 
symptoms of COPD. Zhi yin was found to be an unlikely term, whereas Fei zhang was found 
to be associated with all of the main symptoms. This did not mean that Fei zhang was the 
classical term for COPD; rather, this term was only used for conditions that were consistent 
with severe COPD and/or COPD exacerbations. It could have been used for other conditions 
as well, but this issue was not explored. Similarly, Tanyin kesou and Chuan sou were used to 
refer to conditions that were consistent with severe COPD, but may also have been used for 
disorders like chronic bronchitis and other respiratory diseases. 
Therefore, among the search terms, Fei zhang (lung distension), Tanyin kesou (phlegm-fluid 
with cough) and Chuan sou (dyspnoea and sputum) were found to be the most similar to 
COPD, although not all of the citations found under these search terms were analogous to 
COPD.  
Modern TCM books consider that Fei zhang was analogous to COPD and also mention that 
COPD was classified under Tanyin. During the search, Tanyin was too broad a term to be 
considered, although a number of citations identified under Tanyin kesou were consistently 
likely to be COPD (248). In contrast, Chuan sou is not mentioned in modern TCM books as a 
classical term for COPD and is generally not included as a disease category, although it is 
listed in Zhong Yi Da Ci Dian (中医大辞典) (554). 
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8.1.1.2 Aetiology and pathogenesis of COPD 
Although COPD was not mentioned in the classical literature, there were discussions on the 
aetiology and pathogenesis of various types of cough, dyspnoea and lung distension (Fei 
zhang).  
In the book Mu Jing Da Cheng (目经大成) (c 1741), the term Ke sou, which now refers to 
‘cough’, was divided into the terms Ke (咳), which had ‘sound’ but was unproductive, and 
Sou, which was productive but without ‘sound’ (嗽) (555). From the modern perspective, Sou 
is a symptom that is typical of stable COPD. However, these two terms were generally 
combined as Ke sou (cough with sputum) so the separate searching of Sou was not feasible. 
Ke sou could be due to external factors, such as wind and heat, or to phlegm or food and were 
mainly treated with formulae and herbs that eliminated these pathogenic factors. In modern 
TCM, these kinds of cough are mainly associated with acute respiratory infections. However, 
these kinds of cough can also appear as complications and exacerbations of chronic conditions, 
including COPD. 
In addition to the external pathogenic types of cough mentioned above, the Mu Jing Da 
Cheng (目经大成) said that cough could also be caused by qi deficiency and explained that 
this cough was due to lung weakness that failed to produce water and resulted in the 
production of heat. Therefore, it was treated by formulae like Bu Fei Tang, which included 
Ren shen and Huang qi for tonifying the lung, Zi wan and Sang bai pi for clearing the lung, 
and Di huang and Wu wei zi for replenishing the lung (555). This type of cough is closer to 
the symptoms of stable COPD and the aetiological explanation is consistent with modern 
TCM concepts of some types of COPD (333, 556). 
The Zheng Yin Mai Zhi (症因脉治) (c 1641) explained that qi deficiency cough could be due 
to damage to the lung qi or to excess food and drink that damaged the spleen qi, which would 
lead to lung damage with shortness of breath and Sou (sputum production). These types 
belong to the syndrome category of Qi deficiency cough (qi xu ke sou). The treatment should 
aim to strengthen the spleen and lung using formulae like Si Jun Zi Tang, Shen Zhu Gao, Bu 
Zhong Yi Qi Tang, Qiong Yu Gao or Sheng Mai San (557). In modern TCM, a similar 
approach is also used and formulae based on Si Jun Zi Tang and Bu Zhong Yi Qi Tang were 
evident in the RCTs.  
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In modern TCM, the pathogenesis of COPD involves turbid phlegm accumulation in the lung, 
which impairs lung function, together with qi deficiency associated with prolonged illness. 
This combination of qi deficiency that fails to promote the movement of blood, and phlegm 
that blocks the circulation of blood can lead to blood stasis. Blood stasis is considered an 
important factor in the modern TCM concept of COPD, but it was seldom referred to in the 
classical citations. Consequently, herbs that aim to remove blood stasis (e.g. Dan shen, Tao 
ren) appear frequently in the RCT formulae, but are infrequent in the classical formula lists. 
Blood stasis as an aspect of aetiology is prominent in modern TCM, but it is not absent in the 
classical literature. Zhu Danxi (ca. 1281-1358) in the Dan Xi Xin Fa (丹溪心法) mentioned 
blood stasis as an aspect of the pathogenesis of lung distension (Fei zhang). He said that 
‘people with Fei zhang have sputum and cannot sleep, not on their right or left side, this 
disease is due to phlegm (tan) combined with blood stasis (yu xue 瘀血) obstructing the qi. 
The treatment should nourish the blood (yang xue 养血) and promote the flow (liu dong 流动) 
of qi, subdue fire and course liver (jiang huo shu gan 降火疏肝) to clear the phlegm.’ He 
suggested using Si Wu Tang plus Tao ren, He zi, Qing pi, Zhi li, ginger juice and others (558). 
The condition described here was more like an acute exacerbation than a stable condition, 
although the combination of phlegm and blood stasis was similar to the modern TCM concept 
of COPD aetiology. 
This was not a typical example of the treatment for Fei zhang in the classical literature, so the 
frequency of the herbs mentioned was not high. Nevertheless, it provides an early illustration 
of the principle of removing blood stasis that has become a more standard approach in modern 
CHM. As can be seen in the lists of higher frequency herbs in the RCTs, herbs like Dang gui, 
Di huang and Tao ren are all included, whereas none of these herbs are high in the classical 
lists (see table 8.1). 
Modern Chinese medicine considers that the aetiology and pathogenesis of COPD has a 
deficiency at its root (ben) and an excess in its branch (biao). Its nature is phlegm, deficiency 
and stasis and its development is due to turbid phlegm accumulation in the lung that impairs 
lung function. Because it is a prolonged illness, this causes qi deficiency and a further failure 
to promote and circulate the movement of blood, which leads to blood stasis (559). This view 
is more detailed than the descriptions found in the classical literature, although it is based on 
the classical understanding of chronic respiratory diseases.  
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8.1.1.3 Investigations into the nature and pathogenesis of COPD in modern Chinese 
medicine 
Since the 1980s, research into the concept that COPD has a deficiency at its root (ben) and an 
excess in its branch (biao) has gradually progressed. Phlegm was regarded as characteristic of 
an excess in the branch, which manifested as various syndromes involving phlegm, such as 
heat-phlegm, cold-phlegm, phlegm-dampness and phlegm-dryness. These phlegm syndromes 
were shown to be correlated to the level of damage to neutrophils and ciliated columnar 
epithelium as well as to changes in the concentration of cAMP and the cAMP/cGMP ratio, 
particularly in the heat-phlegm syndrome.  
With regard to research on the concept that the root of COPD was deficiency, research has 
focused on exploring correlations between deficiency and immune functions, endocrine 
functions, energy metabolism and autonomic nervous system functions (560).  
Investigations using chest X-rays and measures of pulmonary function have shown 
differences between the lung deficiency, spleen deficiency and kidney deficiency types of 
COPD, which indicates that these syndromes represent a change from a mild to a severe 
condition.  
For lung deficiency syndromes, chest X-rays displayed lung markings with the diaphragm 
position and activity in their normal ranges, although there was a decline in the PEF that 
indicated pulmonary dysfunction in the small, medium and large airways. In lung and spleen 
deficiency, chest X-rays displayed increased lung markings of the blur, net and/or spot 
shadow types, the diaphragm position was slightly lowered and there were declines in FVC, 
VC and IC, which implied that lung elasticity had diminished and Raw had increased.  
When kidney deficiency was also present, the lung markings appeared slender and sparse, the 
diaphragm was lower and its mobility had decreased. The X-ray appeared bright as in 
emphysema or there were pulmonary bullae, and the functional residual capacity was 
increased (561). 
Other correlations between deficiency syndromes and disease deterioration were reported in a 
study by Zhu et al. (2008), in which they found that phlegm turbidity, deficiency and blood 
stasis reflected the progressive development of COPD (e.g. from mild to severe). Significant 
interrelationships were found between the changes in pulmonary function of COPD patients 
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who had turbid phlegm accumulation, deficiency and/or blood stasis. This study showed that 
patients with turbid phlegm accumulation only had better pulmonary function, whereas worse 
pulmonary function was correlated with increased levels of deficiency and blood stasis (562). 
8.1.1.4 Progression of disease between organs 
The initial site of disease in COPD is in the lung. Prolonged illness then affects the spleen and, 
later, the kidney. This disease progression has been verified by research. A study by Tang at al. 
(2005) showed that there was a very close relationship between the five organs in Chinese 
medicine and the progression of COPD at different developmental phases. This study 
collected clinical case reports and established a database. 
At the earlier stages, chronic bronchitis was related to the lung and liver, and the combination 
of chronic bronchitis and emphysema was associated with the lung, spleen and kidney. With 
further development of emphysema involving heart disease, the organs affected then included 
the lung, spleen, heart and kidney or the lung, spleen, heart and liver, as well as the kidney 
(563). In the RCTs, the subjects tended to be in the middle stages of the disease, whereas 
many of the citations on Fei zhang and other COPD-related disorders found in the classical 
books appeared to belong to the later phases of the disease. 
8.1.1.5 Syndrome differentiation in modern TCM and the RCTs 
In Chinese medicine practice, disease assessment involves diagnosis (of the disease), 
syndrome identification (of the pattern) and assessing the symptoms and signs (the 
presentation), followed by a treatment plan. In the classical literature, however, only the 
symptoms and signs were described in the majority of citations. Few of these combined 
differentiation of the syndrome with the description of the presenting symptoms and signs. By 
comparison, the modern TCM literature usually includes the following: diagnosis, syndrome 
identification and symptoms and signs, followed by the herbal formula with or without 
modifications.  
A study by Fu et al [15] investigated CM syndromes in patients with stable COPD or ECOPD 
using a large sample size (99 cases). This study showed that the incidence rates of excess 
syndromes in stable COPD were (in decreasing order): blood stasis; phlegm heat 
accumulation in the lung; followed by phlegm dampness retention in the lung. By comparison, 
the incidence rates of deficiency syndromes in stable COPD were (in decreasing order): 
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deficiency of lung qi; deficiency of spleen qi; followed by deficiency of kidney yang.  
Another study collected information from six hospitals for patients with COPD at the stable 
stage (774 cases) and analyzed the syndrome elements in a database using the latent structure 
method (564). These results identified syndromes of the lung, spleen, kidney, stomach and 
heart, which had the features of yin deficiency, yang deficiency, qi deficiency, phlegm 
(dampness), blood stasis, qi stagnation and heat. The authors concluded that these were 
similar to the syndromes identified in clinical settings (565).  
Shang et al. (2004) analysed correlations between CM syndromes and the four stages of 
COPD severity. Their results indicated that lung deficiency and spleen qi were the main types 
of deficiency syndrome at all COPD stages, deficiency of kidney yang was mostly present in 
severe and very severe conditions, blood stasis also appeared in both severe and very severe 
conditions with a few cases at the moderate stage, and there were a few cases of phlegm 
retention at all stages (566). Therefore, both qi deficiency and phlegm appeared at all stages, 
whereas blood stasis was more evident at the more severe stages. 
The 101 RCTs distinguished numerous syndromes in the following descending order: 1. lung 
and kidney qi deficiency; 2. lung and spleen qi deficiency; 3. lung, spleen and kidney qi 
deficiency; 4. lung qi deficiency; 5. qi deficiency and blood stasis; and 6. spleen and kidney 
deficiency with phlegm, and lung and spleen with phlegm stagnation. These syndromes were 
similar to those reported in the studies cited above, although syndrome differentiation was not 
mentioned in more than half of the included RCT studies. Thus, we could not make 
comparisons between studies based on syndrome differentiation and the severity of the COPD. 
Also, there are still no standard COPD syndromes in modern TCM. 
8.1.2. Main findings from the clinical trials 
The main findings from the analysis of the clinical trials were reported in the results of three systematic 
reviews: 1. oral ginseng formulae for stable COPD, which were included in 12 randomized control trials 
(RCTs); 2. oral CHM for improving the quality of life of patients with stable COPD, which was included in 
27 RCTs; and 3. oral CHM for stable COPD with physiological and symptomatic outcome measures, which 
was included in 101 RCTs.  
8.1.2.1 Oral ginseng formulae for stable COPD 
Twelve ginseng formulae from 12 RCTs that met the inclusion and exclusion criteria were 
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included (see chapter 6.1). It was found that ginseng formulae had possible effects for 
improving lung function, quality of life, alleviating symptoms and reducing COPD 
exacerbation rates (84). However, most of the included studies had a high or an unclear risk of 
bias as assessed by the Cochrane risk of bias and had low methodological quality as assessed 
by Jadad’s scale. 
8.1.2.2 CHM for improving Quality of Life 
As one of the outcome measures used in clinical trials, a quality of life questionnaire was used 
in 27 RCTs that matched the selection criteria. A meta-analysis found that oral CHMformulae 
may be beneficial for improving the QoL of patients with stable COPD (85). However, the 
weak methodological quality of these trials limits the strength of this conclusion.  
8.1.2.3 CHM for physiological and symptomatic outcome measures 
A total of 101 RCTs that studied patients with stable COPD were included in this review. All 
were parallel group studies that involved oral administration of CHM formulae or extracts of 
a single herb. Twelve RCTs compared CHM with placebo, 15 RCTs compared CHM with RP, 
46 RCTs compared CHM plus RP with RP, 16 RCTs compared CHM with no treatment and 
12 RCTs compared CHM with other CHM. The outcomes included spirometric parameters, 
symptom scores, exacerbation frequency or rate, BODE index, BMI, 6MWD, blood gas 
analysis and biomarkers. 
Assessments of risk of bias for all the included studies were judged using the six Cochrane 
domains for risk of bias. Of 101 studies, no study was judged as having a low risk of bias for 
all six domains, and only two studies (79, 461) provided adequate descriptions for both 
randomization and blinding. Zhang et al (2003) conducted a trial that compared two CHMs 
and Gross et al (2002) found that a ginseng extract significantly improved lung function after 
three months when compared with placebo.  
When the methodological quality was assessed by Jadad’s scale, only 26 studies received a 
score of 3 and could be regarded as having higher methodological quality, while the 
remaining studies were assessed as having low or weak methodological quality.  
A meta-analysis of these reviews found that oral CHMs (including ginseng formulae) may 
have promising effects for improving lung function, improving QoL, reducing exacerbation 
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rates or frequencies, alleviating symptoms and improving exercise tolerance as determined by 
the 6 minute walk distance test when CHM was compared with the control groups, 
particularly when CHM plus RP was compared with RP. No serious adverse events were 
found in any of these studies.  
8.2 Comparisons of the formulae used in classical books and in RCTs 
8.2.1. Frequently occurring herbs in classical books and RCTs 
The most frequent formulae in the total classical data set, after the general exclusions (898 
formulae) and excluding 187 unnamed formulae, were Xiao Qing Long Tang, Xiao Ban Xia 
Tang, Yue Bi Jia Ban Xia Tang, Xiao Qing Long Jia Shi Gao Tang, Xiao Ban Xia Jia Fu Ling 
Tang, Mu Fang Ji Tang, Wu Ling San, Zao Jiao Jian Wan and Ma Huang Gan Cao Jia Xing 
Ren Sheng Jiang Tang (see Table 5.22). Six of the high frequency formulae were also found to 
appear at step 2 (dyspnoea plus cough) of the step-wise hierarchical combinations (Table 5.26) 
and in the list of formulae identified using the global scoring system (Table 5.33).  
Ma Huang San, Zi Wan Tang and Ting Li Da Zao Tang became relatively more frequent when 
the global scoring system was used, while Xiao Ban Xia Jia Fu Ling Tang, Wu Ling San and 
Ma Huang Gan Cao Jia Xing Ren Sheng Jiang Tang became less frequent.  
The overall lists of formulae were strikingly similar. However, of the top frequency formulae, 
only Zao Jiao Jian Wan remained among the 21 formulae included at step 7. Thus, when the 
four symptoms were combined together, only a small number of formulae remained and these 
tended to differ from the formulae in the more general lists.  
One reason for these differences is the large number of different formula names in the total 
data set. This meant that many formulae had similar compositions. However, due to the 
different names, they only appeared at low frequencies in the data set. Consequently, the 
‘individual herb’ was considered a more appropriate level of analysis for comparisons. 
The main functions of the above formulae are dispersing the lung and suppressing wheezing, 
dispersing the lung and resolving phlegm as well as suppressing wheezing and stopping 
cough. They mainly target the acute stages of respiratory conditions. 
The following nine formulae were used frequently in the 101 RCTs: Liu Jun Zi Tang; Bu Fei 
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Tang; Shen Ge Tang; Bu Zhong Yi Qi Tang; Jian Pi Yi Fei granule; Zhou Fei Tang; Li Jin 
granule; Man Zhi Ke Chuan Ning liquid; and Fei Kong Tang. These formulae mainly tonify 
the lung and/or fortify the spleen and/or tonify the kidney, with the addition of herbs to 
activate blood or relieve cough or dyspnoea. 
8.2.2. Reasons for the use of different formulae in the RCTs and classical books 
None of the top ten frequently appearing formulae was the same when comparing the classical 
and modern reviews. 
For treating COPD, the contemporary formulae found in the RCTs tended to focus on 
tonifying the lung and fortifying the spleen. Typical formulae included Liu Jun Zi Tang, Bu 
Fei Tang, Zhou Fei Tang and others. These formulae all originated from the classical literature, 
but they did not appear among the high frequency formulae in the classical literature data. The 
main reason was that the RCTs focused on stable COPD patients with particular emphasis on 
the stable phase without any exacerbations or complications, such as heart or kidney disorders. 
Consequently, the symptoms of cough and dyspnoea may be relatively mild in these patients 
and may be partially managed with pharmaceutical medicines. Therefore, the focus of the 
CHMs used in the RCTs was not on symptom management but on strengthening the body.  
In contrast, the principal focus of the formulae identified in the classical literature was on the 
management of cough and dyspnoea and the resolution of phlegm, with strengthening of the 
lung and spleen as secondary aims. In the modern context, the high frequency formulae found 
in the classical literature were considered to be more applicable to the acute exacerbation 
stage of a chronic lung disorder than to the stable stage. This difference in focus might partly 
explain the different usages of formulae.  
8.3 Comparisons of herbs occurring at high frequencies in the RCT and 
classical data sets 
8.3.1 Herbs occurring at high frequency in classical books  
The included COPD-related classical citations provided a total data set of 5,858 herbs, which 
were included in 898 formulae. The herb with the highest frequency was Gan cao, which was 
included in 372 formulae. Other commonly used herbs mentioned in formulae in decreasing 
order (with the frequency in parentheses) were: Ban xia (266); Xing ren (249); Ren shen (217); 
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Fu ling (209); Wu wei zi (181); Chen pi (170); Sang bai pi (142); Sheng jiang (127); Kuan 
dong hua (124); Ma huang (117); Zi wan (114); Rou gui (113); Bei mu (102); Jie geng (99); 
Gan jiang (92); Mai men dong (87); Zhi shi (87); Bai zhu (82); and Da zao (78) (see Tables 
5.23 & 8.1).  
A series of step-wise hierarchical combinations of the principal symptoms of COPD, cough, 
dyspnoea, sputum production and chest tightness were used to select groups of citations that 
satisfied these criteria. At step 2, all of the herbs were included in formulae for dyspnoea plus 
cough; at step 5, all formulae were for dyspnoea plus cough and sputum; while at step 7, all 
were for dyspnoea plus cough, sputum and chest tightness (see Table 5.43). Also, citations 
were classified according to the three main global score categories of ‘most likely COPD’, 
‘possible complication of COPD’ and ‘possible COPD’ (see Table 5.43).  
The herbs that appeared in the top ten most frequent herbs at steps 2, 5 and 7 and in citations 
scored as ‘most likely COPD’ were: Gan cao; Ban xia; Xing ren; Ren shen; Fu ling; Wu wei 
zi; Chen pi; Sang bai pi; and Kuan dong hua. The remaining herbs in the lists of the top 20 
most frequent herbs showed variations in their relative frequencies based on the inclusion 
criteria.  
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Table 8. 1 Comparisons of high frequency herbs: RCT and Classical data sets 
Rank 
Total of  
101 RCTs 
The total 
data set 
Step 2.1 Step 5.1 Step 7 
Global 
score 4 
Global score 
3 
1 Huang qi  Gan cao Gan cao Gan cao Gan cao Gan cao Gan cao 
2 Bai zhu Ban xia Ban xia Ban xia Ban xia Ren shen Xing ren 
3 Fu ling Xing ren Xing ren Renshen Ren shen Ban xia Ren shen 
4 Dang shen Ren shen Ren shen Wu wei zi Xing ren Wu wei zi Ban xia 
5 Wu wei zi Fu ling Wu wei zi Xing ren Wu wei zi Xing ren Zi wan 
6 Gan cao Wu wei zi Fu ling Fu ling Fu ling Chen pi Ma huang 
7 Chen pi Chen pi Ma huang Chen pi Sheng jiang 
Kuan dong 
hua 
Wu wei zi 
8 Di huang 
Sang gen 
bai pi 
Chen pi 
Kuan dong 
hua 
Sang bai pi Fu ling 
Kuan dong 
hua 
9 Ban xia Sheng jiang Sang bai pi Sang bai pi Ying su ke Sang bai pi Sang bai pi 
10 
Mai men 
dong 
Kuan dong 
hua 
Kuan dong 
hua 
Bei mu Chen pi Bei mu Rou gui 
11 Dan shen Ma huang Zi wan Rou gui E jiao Ying su ke Fu ling 
12 Ge jie Zi wan Rou gui Zhi mu 
Kuan dong 
hua 
Zi wan Sheng jiang 
13 
Dang gui Rou gui Sheng jiang Ma huang Rou gui 
Mai men 
dong 
Chen pi 
14 
Ren shen Bei mu Xi xin 
Mai men 
dong 
Jie geng 
Rou gui Bei mu 
15 Shan yao Jie geng Bei mu E jiao Zi wan Zhi mu Xi xin 
16 Shan zhu yu Gan jiang Jie geng Xi xin Bei mu Sheng jiang Shi gao 
17 
Xing ren 
Mai men 
dong 
Gan jiang Ying su ke Xi xin 
Jie geng Gan jiang 
18 
Su zi Zhi shi 
Mai men 
dong 
Zi wan Zao jiao 
E jiao Jie geng 
19 Bei mu Bai zhu Zhi mu Shan yao Bai fan Xi xin Da zao 
20 
Kuan dong 
hua 
Da zao Zao jia   Ma huang Fang ji 
21 Bu gu zhi, 
Di long, 
Sang bai pi, 
Tao ren 
Xi xin Ying su ke   
  
Herbs appearing in both the RCT and classical data sets are in bold.  
Total data set: Total classical data set (after general exclusions); Step 2.1: dyspnoea + cough;  
Step 5.1: dyspnoea + cough+sputum; Step 7: dyspnoea + cough+sputum+chest tightness;  
Global score 4: ‘likely COPD’; Global score 3: ‘complication of COPD’ 
 
At step 7 of the step-wise hierarchical combinations, there were five herbs that were different 
when compared to the total data set. Ying su ke, Xi xin, E jiao, Ban fan and Zao jiao were 
included, while Ma huang, Gan jiang, Zhi shi, Da zao and Mai men dong did not appear. 
There were only three different herbs when the global score category of ‘most likely COPD’ 
was compared with the total data set. Ying su ke, Xi xin and E jiao were included, while Gan 
jiang, Zhi shi, Da zao were not in the high frequency list.  
Consequently, using the step-wise hierarchical combinations and the global score category 
‘most likely COPD’ produced very similar lists of high frequency herbs. These did not differ 
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greatly from the total list of herbs based on the combinations of search terms. Although 
greater consistency in the results had been expected for the herbs compared with the formulae, 
it appeared that many of the formulae located under the search terms tended to use similar 
herbs.  
Even though many of the herb entries were eliminated by the step-wise procedures, 
consistency remained in the list. One likely reason was that, due to the brevity of the symptom 
descriptions in the classical literature, formulae intended for persistent conditions that 
combined the main symptoms did not necessarily include complete descriptions and were 
consequently eliminated at early steps, while similar formulae were retained due to the greater 
level of detail provided in the citations.  
8.3.2 Frequently occurring herbs in the RCTs 
The top 20 frequently occurring herbs in the RCTs were ranked as follows: Huang qi (used in 
55 RCTs); Bai zhu (54); Fu ling (45); Dang shen (40); Gan cao (35); Wu wei zi (34); Chen pi 
(32); Di huang (Gan/Sheng/Shu) (30); Banxia (Fabanxia/Zhibanxia) (25); Dan shen (24); Mai 
dong (24); Ge jie (23); Dang gui (21); Ren shen (20, including Hong shen in 3, Sheng shai 
shen in 1, Gao li shen in 1, Xi yang shen in 3); Shan yao (19); Shan zhu yu (19); Xing ren 
(17); Su zi (15); Kuan dong hua (14); Bei mu (Zhebeimu/Chuanbeimu) (14); Bu gu zhi (13); 
Di long (13); Sang bai pi (13); and Tao ren (13). 
Huang qi, Dang shen and Ren shen are the major herbs used to tonify qi and Shan yao, Fu 
ling, Chen pi, Bai zhu, Mai men dong, Shan zhu yu, Wu wei zi, Ge jie and Di huang are the 
major herbs used to fortify the spleen and tonify the kidney. Also, Dan shen and Dang gui are 
often used to activate blood, while Gao cao, mostly Zhi gan cao, is commonly used for 
regulating the spleen and stomach. Five other frequently used herbs are the expectorants, 
antitussives and anti-asthmatics Xing ren, Ban xia, Su zi, Kuan dong hua and Bei mu. 
Therefore, in contrast to the results from the classical books, tonifying herbs were 
predominantly used in modern clinical trials to treat stable COPD. 
8.3.3 Comparisons of the herbs in the RCT and classical data sets 
Among the top 20 or so high frequency herbs, 11 were common to both the classical and RCT 
data sets. These included Gan cao, Xing ren, Ban xia, Ren shen, Fu ling, Wu wei zi, Chen pi, 
Kuan dong hua, Mai men dong, Bei mu and Bai zhu (see Appendix 20).  
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Ren shen, Bai zhu and Mai men dong are tonic herbs. Fu ling induces diuresis and excretes 
dampness, Wu wei zi is an astringent and Chen pi regulates qi. The herbs, Xing ren, Ban xia, 
Kuan dong hua and Bei mu are expectorants, antitussives and anti-asthmatics. Gan cao has 
diverse uses, including tonic effects, regulating the spleen and stomach and is also frequently 
included in formulae to harmonise the effects of other herbs; therefore, it is likely to be 
frequently included in formulae for a wide range of diseases and symptoms. 
 The analyses of the classical books showed that the following nine herbs were among the 
higher frequency herbs that were not common in the RCTs: Sheng jiang; Ma huang; Zi wan; 
Rou gui; Jie geng; Gan jiang; Zhi shi; Da zao; and Xi xin. Ma huang and Xi xin focus on 
relieving dyspnoea and Zi wan and Jie geng focus on cough (see Appendix 21). There were 
only four tonifying herbs among the higher frequency herbs in the classical data: Ren shen; 
Bai zhu; Wu wei zi and Rou gui. However, three of these were also frequently found in the 
RCT data set.  
In the RCT formulae there were numerous herbs for qi deficiency (Huang qi, Dang shen, Ren 
shen and Ge jie), herbs to resolve phlegm (Chen pi, Ban xi, Bei mu and Su zi) and to stop 
cough (Xing ren, Kuan dong hua). Similarly, the formulae in the classical literature included 
herbs for qi deficiency (Ren shen, Bai zhu, Shan Yao), for resolving phlegm (Ban xia, Chen pi, 
Bei mu) and for clearing the lung and stopping cough (Xing ren, Kuan dong hua, Zi wan). 
There were also more herbs for activating blood and removing stasis (Dan shen, Dang gui and 
Di huang) (see Appendix 22). 
Overall, the focus of the classical formulae was more on resolving phlegm and stopping 
cough, whereas for the RCT formulae the focus was more towards strengthening qi. Dang 
shen and Huang qi tend to have replaced Ren shen in modern formulae, but this is likely to be 
largely due to the high cost of Ren shen. Another difference was the greater focus on blood 
stasis in the RCTs. However, as mentioned earlier, addressing blood stasis was not entirely 
absent in the classical literature.  
Although the emphases for treating COPD are different between the classical and modern 
approaches, they both recognize the essential nature of the disease involving a deficiency at 
the root and an excess at the branch. 
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8.4 Mechanisms of the formulae and herbs used for treating COPD 
8.4.1 Pharmaceutical activities of formulae  
This section will explore the pharmaceutical properties of the high frequency formulae found 
in the modern RCTs. 
8.4.1.1 Bu Fei Tang 
Bu Fei Tang was used in three RCTs (375, 437, 447). It was derived from the book entitled 
Yong Lei Ling Fang (永类铃方) compiled by Li Zhongnan and the book entitled Yi Fang Kao 
(医方考) compiled by Wu Kun during the Ming dynasty. Bu Fei Tang consists of Huang qi, 
Ren shen, Shu di huang, Wu wei zi, Sang bai pi and Zi wan.  
A number of formulae with the name Bu Fei Tang appeared in the classical data set, but these 
were different from those in the RCTs, and Huang qi did not appear among the top frequency 
herbs in the classical data set. However, Bu Fei Tang and Huang qi were commonly used in 
modern clinical trials. Bu Fei Tang was also commonly used for treating qi deficiency cough 
in the classical books, as discussed earlier. In the experimental literature, Bu Fei Tang was 
found to enhance superoxide dismutase (SOD) activity and reduce malondialdehyde (MDA) 
levels in the blood plasma in a rat model of lung deficiency COPD. Thus, Bu Fei Tang might 
have protective effects for the airway mucosa and reduce lung injury, and may also clear free 
radicals and have anti-lipidperoxidation effects (567). 
In Chapter 2, (MMPs were also indicated as having an important role in the pathogenesis of 
COPD. MMP-9 is the largest and most structurally complex member of the MMP family. 
Both MMP-9 and the tissue inhibitor of matrix metalloproteinases (TIMP)-1, play important 
roles in airway inflammation and remodelling (568). In addition, when MMP-9 was used as a 
biomarker, the levels of MMP-9 in serum were related to declines in FEV1 (569). MMPs have 
also been therapeutic targets. An oral MMP-9 and MMP-12 inhibitor was used in a clinical 
trial for treating patients with moderate and severe COPD, although it did not produce any 
significant effects during a six week trial (570).  
Among the 101 RCTs, none measured the serum levels of MMP-9. However, an experimental 
study showed that Bu Fei Tang may have downregulated NF-κB activity and the protein 
expressions of MMP-9 and TIMP-1 and attenuated the airway remodelling in COPD in a rat 
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model with lung-Qi deficiency syndrome (571). This provided evidence that this CHM had 
effects on MMP-9 and TIMP-1. Also, Bu Fei Tang was found to significantly reduce the 
levels of TNF-α and IL-8 in BALF in a COPD rat model in study by Zhang et al. (2008). This 
suggested that Bu Fei Tang may relieve airway inflammation and may have beneficial effects 
on COPD with lung qi deficiency (572). Another study found that Bu Fei Tang may have 
inhibited airway remodelling and prevented the decline in lung function in COPD rats with 
lung qi deficiency (573). These results were consistent with those of two RCTs (375, 447).  
8.4.1.2 Bu Zhong Yi Qi Tang 
Bu Zhong Yi Qi Tang was used in three RCTs (65, 398, 402), but only appeared once in the 
classical data set for Ke chuan. Bu Zhong Yi Qi Tang consists of Huang qi, Ren shen, Bai zhu, 
Dang gui, Chai hu, Sheng ma, Gan cao and Chen pi. It was created by physician Li Dongyuan 
and recorded in the Pi Wei Lun (脾胃论处)(1249).  
No experimental studies of Bu Zhong Yi Qi Tang for COPD could be found, although Bu 
Zhong Yi Qi Tang has been shown to have the pharmaceutical actions of enhancing immunity 
and have anti-tumour anti-inflammatory effects. It can ameliorate the side effects of cancer 
drugs and is an effective biological response regulator (574). Bu Zhong Yi Qi Tang has also 
been found to increase T-lymphocytes division and increase the amounts of IL-2 in mice with 
spleen deficiency. Thus, it could positively increase lymphoid immune function in these mice 
(575). Similar results were found in two RCTs that showed that Bu Zhong Yi Qi Tang may 
have regulated the levels of IL-6 in serum (398, 463). 
Liu Jun Zi Tang 
Liu Jun Zi Tang was used in seven RCTs (73, 365, 408, 417, 419, 421, 440) and variations on 
this formula appeared in the classical data set. It consists of Ren shen (or Dang shen), Fu ling, 
Bai zhu, Gan cao, Chen pi and Ban xia. Its source was the book Shi Yi De Xiao Fang (世医得
效方) written over a period of 10 years by Wei Yilin and published during the Yuan dynasty 
(1345).  
An experimental study found that Liu Jun Zi Tang reduced the levels of IL-8, TNF-α and IL-4 
in a COPD rat model, so Liu Jun Zi Tang may relieve inflammation and improve 
immunological function (576). However, relevant biomarkers were not measured in the RCTs 
that used Liu Jun Zi Tang. 
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8.4.1.3 Shen Ge San 
Shen Ge San (also called Ren Shen Ge Jie San) was used in five RCTs (80, 342, 344, 422, 
427), but only appeared twice in the classical data set. Ren Shen Ge Jie San was found in the 
text Pu Ji Fang (普济方) complied by Zhu Li in 1406. The original formula included Ren 
shen, Ge jie, Fu ling, Xing ren, Bei mu, Sang bai pi and Zhi mu.  
Shen Ge San was found to reduce the serum levels of IL-8 and TNF-α in a rat COPD model, 
which indicated that it suppressed inflammation (577). It was also observed to reduce IL-8 
and TNF-α levels in one RCT (80).  
8.4.1.4 Li Jin Fang  
Li Jin Fang was used in two RCTs (423, 444). It was found to reduce IL-8, TNF-α and LTB4 
levels in the blood and BALF; thus, it appeared to inhibit airway inflammation, which may be 
its mechanism of action for treating COPD (578, 579). IL-8 and TNF-α were not measured in 
RCTs that used Li Jin Fang for stable COPD patients. 
8.4.1.5 Xiao Qing Long Tang 
Xiao Qing Long Tang was not used in any of the 101 RCTs; however, it was the most frequent 
formula in the classical data set. It has been found to reduce the levels of IL-8 and TNF-α and 
increase the IFN-γ/IL-4 ratio, so it may inhibit inflammation and regulate immune function 
(580). Xiao Qing Long Tang did not appear in the RCTs for stable COPD patients, but it was 
used in RCTs for ECOPD patients and might have relieved symptoms and had effects on 
airway inflammation and remodelling (581, 582).  
Using a rat model of COPD, an experimental study used different formulae, including Xiao 
Qing Long Tang, Ma Xing Shi Gan Tang, Yu Ping Feng San, Liu Jun Zi Tang and Shen Ge 
San, based on the syndrome differentiation for rats with the syndromes of cold phlegm 
retention in the lung, heat phlegm accumulation in the lung, lung qi deficiency, spleen qi 
deficiency and kidney deficiency to explore the effects of these formulae on the levels of NF-
κB expression in the airways and in inflammatory cells. It was found that these formulae 
might regulate the balance between oxidants and antioxidants (583). 
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8.4.2 Pharmaceutical actions of key herbs  
This section will explore the pharmaceutical actions of the main herbs used in the classical 
books and in modern RCTs. In the analysis of the classical literature, Ren shen was the most 
frequently used (257 times) tonifying qi herb in the formulae. Ginseng was not ranked at the 
top position, yet all of the high frequency formulae contained Ginseng. Thus, Ginseng played 
an important role in the classical formulae. Also, Ginseng, a key herb used for tonifying qi, is 
still used for treating chronic diseases, including COPD (584-586). Therefore, to evaluate the 
effectiveness of Ginseng formulae for treating stable COPD, a systematic review of oral 
Ginseng formulae for stable COPD was conducted at the first stage of the analysis of the 
modern RCTs.  
Unlike Ren shen, Dang shen was used in only 11 formulae in the classical books. However, it 
was one of the most frequently used herbs in the formulae in modern RCTs. The modern trend 
is to employ Dang shen to replace Ren shen for treating stable COPD. For example, in Liu 
Jun Zi Tang, Ren shen was one of ingredients in the classical formula, whereas Dang shen 
was used instead in the Liu Jun Zi Tang found in six RCTs (73, 365, 417, 419, 421, 440). 
There were two reasons for replacing Ren shen with Dang shen: 1. Ren shen is much more 
expensive than Dang shen; and 2. Ren shen is warmer than Dang shen and may induce 
phlegm-dampness retention in the lung, which can then change to phlegm heat, more readily 
than can Dang shen.  
While Ren shen was widely used, Dang shen was hardly mentioned in ancient Chinese 
materia medica texts. It appeared as another name for Ren shen in the Ming dynasty materia 
medica, but the earliest mentions of Dang shen as a separate herb appear to be in medical 
books from the Qing dynasty, such as Ben Cao Zheng Yi (本草正义) (587) and Shen Xian Ji 
Shi Liang Fang (神仙济世良方) (588). However, Dang shen rather than Ren shen is now 
more widely used. Due to their differences in chemical compositions and pharmaceutical 
actions, Dang shen cannot simply be regarded as a replacement for Ren shen. Whether Dang 
shen is superior to or should be used to replace Ren shen deserves further investigation. 
8.4.2.1 Ren shen 
In the classical literature, Ren shen played a very important role in treating COPD-related 
diseases as well as other lung diseases that were excluded from data analysis, such as Fei wei 
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and Fei lao. The book entitled Zhong Guo Ren Shen Fang Ji (中国人参方集) written by Song 
Chenji (2006) includes 3,521 Ren shen formulae. This book comprehensively classifies Ren 
shen prescriptions into 17 categories. Of these, one was under the heading of Expelling 
Sputum (Qu Tan Prescriptions), which contains 175 COPD-relevant formulae. The large 
number of classical formulae containing Ren shen attests to the importance of this herb in the 
development of Chinese medicine.  
Its earliest use appeared in the Treatise of Febrile Diseases written by Zhang Zhongjing and 
these classical Ren shen formulae are still being used clinically for treating various chronic 
conditions. Furthermore, Ren shen extracts are also used singly and Ren shen is not only 
widely used in China, but also all over the world. There has been extensive research on the 
properties of the active ingredients of Ren shen, which provides the scientific basis for using 
Ren shen for treating COPD.  
The majority of components of Ren shen are ginsenosides and ginseng polysaccharides, the 
pharmacological actions of which have been widely investigated worldwide. Ginseng has 
been found to have effects on multiple physiological systems. Therefore, Ren shen has been 
widely used for a variety of diseases, such as diabetes, lung cancer (589) and others. Also, 
compounds extracted from Ginseng have been extensively investigated in experimental and 
human studies (590). In mice, an extract was found to ameliorate airway inflammation (591) 
and a different extraxct was found to improve the oxidative stress status in aged rats (592). A 
recent study of a polysaccharide extract of Red Ginseng found that its immunostimulatory 
effects were via the molecular activation of macrophages (593) and a ginseng polysaccharide 
extract was found to to have anti-fibrotic actions in mouse cell-line (594). Clinical trials have 
shown that Ginseng extracts may be effective for preventing respiratory symptoms in 
community dwelling adults (595) and upper respiratory infections (596), as well as improving 
lung function in patients with moderate COPD (79).  
8.4.2.2 Huang qi 
In the classical data set, only 30 formulae included the combination of Huang qi and Ren shen. 
However, in modern RCTs, Huang qi combined with Ren shen and Huang qi combined with 
Dang shen are among the top pairs of herbs used in clinical treatments. 
Experimental studies on extracts of Huang qi found that airway hyper-responsiveness and 
remodelling in mice were inhibited by astragaloside IV (387) and an aqueous extract of 
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Huang qi (injection) decreased inflammatory infiltration and mucus secretion in lung tissues, 
which suggested that Astragalus membranaceus may have had an effect on preventing airway 
hyperreactivity in mice related to Th2 response inhibition (388). Astragalus was also found to 
modify responses of lipopolysaccharide-stimulated macrophages and had an effect of 
reducing the production of TNF-α, IL-6, IL-10 and IL-12 in a dose-dependent manner. This 
suggested that Astragalus may regulate macrophage-associated immune responses and reduce 
pro-inflammatory responses (597). Furthermore, an extract of Astragalus was shown to have 
potent activity as an immunological adjuvant when administered in a mouse cancer model 
(598). 
8.4.2.3 Dang shen 
There is experimental evidence in humans to suggest that Dang shen can improve respiratory 
symptoms in acute altitude sickness (389). An extract of Dang shen (Codonopsis lanceolata) 
was found to suppress the release of NO and TNF-α, which indicated that it had anti-
inflammatory actions (599). Dang shen was also found to have an immunological adjuvant 
effect on the immune responses to ovalbumin in mice (600). 
8.4.2.4 Bai zhu 
Extracts of Bai zhu were found to have anti-inflammatory effects on TNF-α and NO 
production by peritoneal macrophages in acute and chronic animal models (390) and in a rat 
lung cell membrane chromatography model (391). Lactone I, a component of Bai zhu, has 
also been found to reduce serum IL-1 and TNF- levels and improve the appetite of cachectic 
cancer patients (601).  
8.4.2.5 Fu ling 
Fu ling was shown to have anti-inflammatory effects on experimentally induced irritant 
contact dermatitis (ICD) in a repeated sodium lauryl sulphate (SLS) irritation model (393) and 
in an inflammation model in mice (602). A protein isolated from Poria cocos, PCP, was found 
to have immunomodulatory activities by activating the NF-κB signalling pathway to activate 
murine macrophages through a Toll-like receptor 4 (TLR4)-dependent mechanism (392).  
8.4.2.6 Wu wei zi 
Wu wei zi is considered an ‘adaptogen’ with stress protective effects (395). Schisandrin, a 
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compound isolated from the fruit of Schisandra chinensis, has been shown to have anti-
inflammatory activity by inhibiting the production of NO and the release of PGE2 in mice 
(396). Furthermore, Schisandrin B appears to exert anti-inflammatory actions by 
downregulating the production of pro-inflammatory mediators, including NO, TNF-α, PGE2, 
IL-1β and IL-6. It also inhibited the production of ROS (603). 
8.4.2.7 Ge jie 
A Gecko peptide extract may have improved immune functions in a mouse model of immune 
suppression (604). Gecko was shown to have anti-tumour effects in both in vitro and in vivo 
experiments by inducing tumour cell apoptosis and downregulating the protein expressions of 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) (605). 
8.4.2.8 Mai men dong 
Although Mai men dong (Radix Ophiopogon) was mentioned for moistening the lung and 
relieving cough in Chinese medicine, these antitussive and expectorant effects have not 
manifested in studies of its pharmacological actions. However, Mai men dong was shown to 
contribute to improving airway mucociliary clearance, which may be attributed to 
ameliorating airway mucus secretion in a quail model (606). In addition, an extract of the 
polysaccharides from Mai men dong had an antagonistic effect on acetylcholine and 
histamine induced bronchial smooth muscle contraction in a guinea pig model (607).  
8.4.2.9 Dan shen 
Dan shen was found to reduce IL-8 levels and the white blood cell and neutrophil counts in 
BALF in a rat COPD model and significantly suppressed airway inflammation (608). This 
was consistent with the results of RCTs. Dan shen injection significantly improved FEV1 and 
reduced the levels of IL-6 and TNF-α in sputum and increased the levels of IgG and CD3 T 
cells, CD4 T cells and the CD4/CD8 T cell ratios in the blood of patients with stable COPD. 
This indicated that Dan shen might relieve airway inflammation and improve pulmonary and 
immunological functions (609). Dan shen injection was also found to maintain the balance 
between MMP-9 and TIMP-1 in the sera of patients at the acute stage of COPD, which 
suggested that Dan shen might inhibit MMP production, have a protective effect on the 
bronchial membrane and have a role in treating COPD patients (610).  
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8.4.2.10 Tao ren 
Tao ren was found to reduce TNF-α and IL-2 levels and stimulate humoral immune responses 
in mice (611). Another study showed that the total protein of Tao ren (Prunus persica) had an 
immuno-modulatory effect by regulating the ratio of CD4/CD8 T cells and promoting 
apoptosis in S180 mouse cells (612).  
Overall, experimental studies have found immunomodulatory or immunostimulatory effects 
for Ren shen, Huang qi, Dang shen, Fu ling, Ge jie and Tao ren. A number of herbs have also 
demonstrated anti-inflammatory actions, including Huang qi, Ren shen, Dang shen, Bai zhu, 
Fu ling, Wu wei zi, Dan shen and Mai men dong, based on their effects on modulating 
cytokine expressions in vitro and/or in animal studies (613). However, these herbs warrant 
further investigation to determine their specific activities in COPD. 
8.4.3 Mechanisms of action of herbs and formulae for treating COPD 
Experimental and clinical research on the mechanisms of action of single herb extracts and 
CHM formulae provide evidence that CHMs, as adjunct therapies, may be promising for 
treating COPD patients and for preventing or slowing the progression of this disease.  
Biomarkers that were measured in the RCTs and in experimental studies on formulae and 
herbs included cytokines (e.g., IL-6, IL-8 and TNF-α), immunoglobulins and SOD activity, as 
well as T lymphocyte subsets (CD3, CD4), B lymphocytes (LTB4) and inflammatory cell 
types. 
The results of these studies suggest several mechanisms of action for the CHMs used for 
treating COPD: 1. effects on cytokine levels and suppressing airway inflammation; 2. 
improving immune functions; 3. maintaining the oxidant-antioxidant balance; and 4. 
regulating an imbalance between proteases and anti-proteases. All of these are very important 
factors in the pathogenesis of COPD. 
In conclusion, by building on the knowledge in the ancient literature, modern Chinese 
medicine has increased our understanding of and improved treatment methods for COPD. In 
modern Chinese medicine, research on COPD is multi-faceted. It systematically investigates 
the aetiology, pathogenesis, syndrome differentiation and principles for treating COPD, as 
well as the clinical effects and the pharmacological mechanisms of herbs. To date, some 
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Chinese medicines have been shown to be effective and additional research is being done to 
establish a definitive system for syndrome differentiation and treatment methods for COPD 
(614). 
8.5 Strengths of this project 
This project is the first of its kind to combine a systematic analysis of modern literature 
(including Chinese medicine and Western medicine) with analyses of RCTs and classical 
literature with the aim of evaluating CHM for treating COPD. The SRsof the RCTs and 
analyses of the CHMs used in these studies indicated that, as an adjunct therapy to 
pharmacotherapy, CHM is well-tolerated and has potential benefits for patients with stable 
COPD. Furthermore, these SRs are more comprehensive and analytical than earlier reviews of 
CHM RCTs for COPD. In a review by Guo et al (2006) (536), only 14 RCT studies were 
included that used CHM for treating COPD. CHM was either administered orally or by 
intravenous injection for stable COPD, acute COPD exacerbations and chronic bronchitis.  
In contrast, the SRsin this project focused solely on subjects with stable COPD, and excluded 
RCTs that studied patients with acute COPD exacerbations. This made the comparisons 
between studies more meaningful and valid. In the future, it would be appropriate to conduct a 
separate review on COPD cases that involve exacerbations. In addition, the analyses of 101 
RCTs identified the main herbs and formulae used for COPD, all of which warrant further 
experimental and clinical investigation. 
As is well known, COPD can follow two courses: stable and with exacerbations. The 
management strategies for these are completely different. The essential goals for managing 
stable COPD are to reduce the incidence of exacerbations and prevent the progressive 
development of COPD. The analyses of the RCTs showed that certain CHMs appeared to 
have benefits for reducing the acute exacerbation rate during the treatment period and, in 
some RCTs, over the entire follow-up period. The results of the RCTs and experimental 
studies also suggested that CHMs may have effects on inflammatory cytokines, which 
provides evidence for exploring the pharmacological actions of CHMs further for treating 
COPD.  
Much research attention has been given to COPD and clinical investigations have been 
conducted in China during the last ten years that have resulted in a large amount of clinical 
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evidence for treating COPD with CHM. However, the level of interest has been lower in other 
countries, including Western countries. More scientific research, especially on the 
pharmacological and biochemical properties of CHMs, is needed to eluncidate the 
mechanisms of CHMs’ actions in COPD treatment. Therefore, the findings of these reviews 
may provide an evidentiary basis for the roles of CHM for treating patients with stable COPD 
and stimulate additional studies to better understand the mechanisms of CHMs’ actions for 
treating this disease.  
This analysis of classical literature is also the first to use an electronic database that included 
1,000 classical Chinese medical books and extract the references that contained information 
relevant to the treatment of COPD. These results summarized the extensive ancient 
experiences on the use of herbs and formulae for treating lung diseases that manifested the 
symptoms and signs that are now associated with COPD.  
Combining the experiences of the classical and modern approaches may provide for a better 
understanding of this disease and also aid in identifying the appropriate herbs and formulae 
for treating patients with COPD in clinical practice.  
8.6 Limitations 
During the searches for the systematic reviews, languages were restricted to English and 
Chinese. Other languages, such as German, Japanese and Korean, were excluded because of a 
lack of accessibility to databases and a lack of language proficiency by the author. In effect, 
most of the included studies were conducted in China. Only 3 of the 101 studies were done in 
other countries. Therefore, a potential language of publication bias may affect the results of 
this study and may affect the generality of the conclusions. Other limitations for the methods 
used for analysing the clinical trials for COPD were discussed in Chapter 7. 
In the analysis of the classical literature, because there were no exact disease names in ancient 
Chinese medicine that matched the contemporary term COPD, search terms that were 
considered to be the most appropriate and relevant to COPD were determined and were used 
based on examination of the symptoms and signs of classical diseases. This may have resulted 
in incomplete data collection. Thus, the search terms used is a matter for further discussion.  
In addition, 187 unnamed formulae were excluded from the analysis of the formulae, although 
these were included in the herb-level analyses. Also, due to limitations in terms of human 
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resources and time, a great deal of content relevant to the symptoms of COPD in the classical 
Chinese medical books may be not have been explored. The use of frequencies and 
combinations of symptoms and signs is only one option for analyzing the large data set 
derived from the classical books. Furthermore, there were no criteria for evaluating the 
effectiveness of formulae in classical Chinese medical books. Specific information on this 
aspect is generally lacking; an assumption was made that the authors believed that their 
recommendations were effective unless they specifically stated otherwise. Because there is no 
plausible method for retrospectively evaluating the methods used in classical books, the herbs 
and formulae identified require further experimental and/or clinical evaluation. 
8.7 Implications for further study on CHMs for COPD  
Based on the findings of the analyses of the RCTs, more rigorous, higher methodological 
quality clinical trials on CHM for stable COPD are needed. The following are 
recommendations for addressing certain issues. 
8.7.1 RCT design  
8.7.1.1 Methodologies 
The methodological reporting quality of the majority of included studies in the SRs was weak 
largely with respect to the procedures used for blinding, randomization sequence generation 
and allocation concealment.  
The paucity of reporting of methodology, herbal quality and other details required by the 
CONSORT statment in clinical trials of CHMs has been a point of criticism (329). In 2006, a 
published review indicated that the overall methodological quality of RCTs on CHM 
treatments for COPD were poor based on the author’s assessments of clinical trial designs and 
RCT methodologies in CHM research; this author recommended that RCT design should be 
improved in future studies (536). Poor methodological quality of RCTs on CHM used for 
treating diseases other than COPD was also reported by most SRs (615).  
The major weaknesses in methodology are the lack of attention paid to specific details for 
randomization and blinding for allocation concealment. This can lead to ineffective blinding 
and increase biases during observations (616, 617). Double blinding means that neither the 
patients nor the treating physicians know which intervention will be given to each participant 
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(618). In addition, randomization methods and allocation concealment are considered to be 
necessary interrelated processes for successfully achieving a properly blinded RCT (619). 
These three domains were found to be weak in the risk of bias assessments. Adequate 
methodology and proper reporting should be addressed in future RCTs that investigate CHM.  
8.7.1.2 Control groups  
The types of controls used were quite varied, including placebo, RP, no treatment and other 
CHM. Aside from the concerns of ethics and limiting bias, how to choose a reasonable control 
group for RCTs has been discussed by Bian at el (2006)(620). In the investigations of CHM 
for COPD, the types of RP used in the RCTs varied. This lack of standardized RP usage may 
result in differences in determining effectiveness. Therefore, for future RCTs that investigate 
COPD, this concern should be addressed and a standardized pharmacotherapy for stable 
COPD should be decided upon based on the GOLD guidelines.  
Additionally, comparing one CHM with another CHM is not suggested as a suitable design 
for a RCT. RCTs for CHM are a recent development in China and a placebo is not easily 
accepted by local people, which leads to the problems of participant compliance and invalid 
results. To overcome the unwillingness of participants to accept a placebo, Chinese 
researchers have decided to compare a test CHM formula with another CHM used as control, 
in which the test CHM was based on syndrome differentiation and appropriate herbal 
prescription, whereas the control CHM formula was not. The control formula was difficult for 
the participants to recognize as being a placebo. Although this approach may overcome the 
participant compliance problem, it may compromise the findings of any significant 
differences between the two CHM formulae because it would not be entirely clear what effect 
the control CHM formula had on the disease condition.  
8.7.1.3 Outcome measure selection 
Lung function testing (LFT; spirometry) was performed in the majority of the RCTs. However, 
this is not currently perceived to be the most suitable predictor of COPD severity and 
mortality. Therefore, the choice of LFT as the outcome measure for the majority of RCTs was 
rather inappropriate. BODE has replaced LFT as the main outcome measure for COPD used 
in RCTs; however, this was measured in only two of the studies in the SRs. QoLQ and 
exacerbation rates were more commonly used in RCTs that investigated the effectiveness of 
CHM intervention for COPD, which was in line with international practices (621).  
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Although there are currently no surrogate outcome measures that can be definitively used for 
COPD, a number of biomarkers have potential as surrogate measures for the diagnosis of 
COPD, as outcome measures in clinical trials and in drug development pharmacogenomics. 
Chemokine and cytokine levels, such as for IL-8, IL-4 and TNF-α, were determined in both 
serum and sputum samples in some studies in the SRs. Yet, CRP, a remarkable inflammatory 
endpoint in COPD (622), was not measured in any of the RCTs. Thus, these more appropriate 
outcome measures should be adopted in future clinical trials for investigating the effects of 
CHMs on COPD (623).  
Safety of CHM is also an important aspect in CHM RCTs. Therefore, adverse events should 
be observed and reported in CHM RCTs. 
8.7.1.4 Identifying participants 
Selection criteria, both inclusion criteria and exclusion criteria, are necessary for recruiting 
participants. These criteria should be adequately described in CHM RCTs. None of the RCTs 
in the SRs made mention of or described adherence to the standardized procedures of the 
GOLD guidelines with regard to measuring FEV1. Similarly, there was no mention of 
standard procedures for making spirometric measurements. A lack of standardization when 
using these procedures may result in inaccurate applications of the inclusion and exclusion 
criteria.  
In most of the RCTs, patients were recruited who had varying stages of COPD. Because the 
different stages of COPD require different treatment principles and CHMs, these study 
designs could compromise the true effects of the intervention. Therefore, for future trials, it is 
advisable that recruiting COPD patients should be based on stricter inclusion and exclusion 
criteria such that only patients who have the same COPD stage will be included in the RCT. 
Because COPD is a rather complex disease and treatment principles can differ according to 
the different syndromes involved, future RCTs should include syndrome differentiation in 
their selection criteria. The patients should also be informed of their COPD severity in terms 
of its stage of development.  
8.7.1.5 Data analysis 
Missing data were not accounted for properly in the studies in which participants dropped out. 
Intention to treat (ITT) is broadly applied to data analysis for dealing with missing data. 
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Explaining the reasons for withdrawals and using ITT can reduce the bias in trials and their 
impacts on the results.  
8.7.1.6 Sample size calculations  
There was a large amount of variation in the numbers of participants across the studies. The 
methods used for calculating sample sizes were not provided in any of the RCTs and no 
rationales were given for the sample size choices. A small sample size can result in a study 
that is underpowered to detect a real effect. Without any sample size calculations, it is difficult 
to determine which studies were likely to have been underpowered and which had adequate 
power with regard to the outcome measures. 
8.7.1.7 Limitations of the RCT approach 
The SRs of the RCTs were guided by the Cochrane airway group and meta-analyses were 
performed for specific outcome measures when suitable data were provided by the authors. 
The included studies were all identified as randomized and controlled trials (RCTs), which 
belong to the classification level 2 of Cochrane reviews. Because the RCT is widely 
considered to be the gold standard design for determining the efficacy of an intervention in a 
clinical study, it is widely used in clinical trials, including investigations of CHMs. RCT 
results reflect the mean response of a population to an intervention rather than the responses 
of individuals. Due to the difference between individuals, an individual’s reaction to the same 
treatment for a chronic disease may be different. Thus, effectiveness may also vary.  
One characteristic of treatments used in Chinese medicine are that herbal formulae are 
designed to suit the individual. Among the included RCTs, some had made syndrome 
differentiations. However, this could not completely reflect the essence of Chinese medicine 
treatments. Thus, there is the issue of the degree to which an RCT can provide a reasonable 
evaluation of the efficacy of a CHM formula for treating patients with stable COPD. 
8.7.2 Research on CM syndromes of COPD relevant to COPD severity  
There are various CM syndromes of COPD, whereas Western medicine classifies COPD into 
four stages based on severity or disease progression. There is a need to clearly determine the 
correlations between Chinese medicine syndromes and the stages of COPD defined in 
Western medicine. Zhang, et al (2004) examined 318 COPD patients at varying stages of the 
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disease, performed a CM analysis of the differentiation of syndromes and graded them 
according to one of the four stages of COPD (i.e., early stage I, moderate stage II, severe 
stage III and late stage VI). They did a correspondence analysis using multivariate statistical 
methods. These results indicated that both early stage I and early stage IIa of COPD 
corresponded strongly to the syndromes of Lung qi deficiency and Spleen qi deficiency.  
According to CM principles, the spleen is the source of phlegm and the lung is the receptacle 
for phlegm. After a prolonged deficiency in lung and spleen qi, COPD progresses to severe 
stage III and the syndrome becomes predominantly one of phlegm turbidity. When the 
condition further develops to late stage III, yin and yang are usually damaged and leads to 
blood stasis with the resulting syndromes of either kidney yin or kidney yang deficiency, or 
even syndromes of blood stasis. This multivariate statistical method provided an analysis of 
the correlations between CM syndromes and the COPD grades, which could possibly provide 
a more objective basis for a CM diagnosis and treatment principles. The use of such objective 
approaches should be considered when selecting participants for inclusion in future RCTs.  
Among the published Chinese medicine clinical trials, only a few specifically included COPD 
patients at stages I and II. Most trials recruited COPD patients with varying degrees of 
severity that ranged from mild to moderate to severe. These inclusion criteria are 
inappropriate because different degrees of severity require different treatment plans. In 
addition, according to the Chinese medicine principles of aetiology and pathogenesis, COPD 
at different stages affects different visceral organs (zang organs) and, consequently, the 
selection of herbs is also different. Therefore, in future clinical trials, the study designs should 
consider separating their cohorts based on different degrees of severity and also use 
appropriate treatments based on an objective method of syndrome differentiation. This should 
minimize variations due to differences in COPD stages and syndromes.  
By aligning the severity of the symptoms and signs (i.e., classification) with the syndromes 
during selection, or using stratification based on these factors at baseline, it may be possible 
to maximize the selection of the appropriate herbs and, thereby, obtain optimal, clinically 
relevant results. Nevertheless, all sources of variation may be difficult to control for in this 
complex disease. Thus, large sample sizes may be needed to detect treatment effects, 
especially when CHM plus RP is compared to RP plus placebo.  
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8.7.3 Experimental research 
There is a need to investigate the pharmacological and biochemical roles of Chinese herbal 
medicines used for treating COPD from different aspects. For example, Dang shen and Huang 
qi used as a pair for treating stable COPD should be further investigated in terms of their 
pharmacological mechanisms. By comparison, the effectiveness of Ren shen has already been 
widely confirmed. Nevertheless, the comparative functions and effectiveness of Ren shen, 
Dang shen and Huang qi need to be further investigated to provide a scientific basis for their 
clinical use for COPD. 
8.7.4 Further clinical practice 
These analyses of the modern and classical literature provide data and discussions on the 
pathogenesis of COPD, syndrome differentiation in COPD and the mechanisms of CHMs 
used for treating COPD. In addition, these analyses explored which herbs and formulae were 
frequently used to treat COPD in classical and modern CM. It is hoped that these data and the 
associated discussions may aid practitioners to apply more evidence-based and more effective 
approaches for the use of herbs and formulae for treating patients with COPD. 
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10 APPENDICES 
Appendix 1 Table: Levels of Evidence 
 
Level Therapy/prevention, Aetiology/harm  
Level 1a Systematic reviews (SRs) with homogeneity of randomised clinical trials (RCTs) 
Level 1b Refers to individual RCTs with narrow confidence intervals 
Level 2a Denotes homogeneous SRs of cohort studies 
Level 2b Includes individual cohort studies and ‘low-quality’ RCTs (e.g. with <80% follow-up) 
Level 3a Refers to systematic homogeneous reviews of case-control studies 
Level 3b Principally represented by individual case-control studies 
Level 4 Denotes case series with poor-quality cohort-based and case-control studies 
Level 5 ‘Expert opinion’ without explicit critical appraisal or first-hand generation of data 
Ref: Oxford Centre for Evidence-Based Medicine Levels of Evidence 
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Appendix 2 Table: Summary of differential diagnosis of COPD and other lung diseases 
Disease Onset Age Symptoms Signs History 
Chest x-ray  
or CT 
Spirometry 
Other 
tests 
COPD Middle age 
chronic cough, sputum, 
shortness of breath, 
dyspnoea 
 
Smoking 
history 
X-ray or 
HRCT 
Spirometry  
Asthma 
Early life 
(childhood) 
Wheezing  Family history  Spirometry  
Bronchiectasis 
Severe infection 
in childhood 
Cough with large 
volumes of purulent 
sputum, haemoptysis 
Crackles and 
wheezes  
 
Rhinosinusitis HRCT   
Tuberculosis (TB) All ages (infants) Fever, haemoptysis   X-ray  
TST, 
Sputum 
exam 
Obliterative 
bronchiolitis 
Onset in younger 
age 
Shortness of breath, 
 cough 
Early inspiratory 
crackles or 
‘squeaks’ 
History of 
rheumatoid 
arthritis 
or fume 
exposure 
HRCT scan   
Diffuse 
panbronchiolitis 
(DPB) 
   
Chronic 
sinusitis 
   
Congestive heart 
failure (CHF) 
 
Dyspnoea, ankle or 
pulmonary oedema, 
fatigue, heart palpitations 
 
Fine basilar 
crackles 
 
 
Chest X-ray:  
DH, PE 
 
Volume 
restriction, 
not airflow 
limitation 
 
COPD, chronic obstructive pulmonary disease; CT, computed tomography; HRCT, high-resolution computed tomography; PE, pulmonary oedema;  
DH, dilated heart; TST, tuberculin skin test. 
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Appendix 3 Table: Syndromes and treatment of Cough, Dyspnoea, Feizhang, Zhiyin and Xiaozheng 
Terms Syndromes Treatment principles Formulae and ingredients 
Ke sou  
(internal impairment) 
Stagnation of phlegm-dampness 
in the lung 
Invigorate the spleen & 
eliminate dampness 
Er Chen Tang or San Zi Yang Qin Tang 
Ban xia, Chen pi, Fu ling Gan cao (Zhi) or Su zi, Bai jie zi, Lai fu zi 
Accumulation of phlegm and heat 
in the lung 
Remove heat to resolve 
phlegm 
Qing Jin Hua Tan Tang 
Huang qin, Shan zhi, Jie geng, Mai dong, Sang bai pi, Bei mu, Zhi mu, Gua lou 
ren, Ju hong, Fu ling, Gan cao 
Invasion of the lung by live-fire 
Remove the liver-fire and 
clear the lung 
Dai Ge San & Xie Bai San 
Qing dai, Hai ge qiao, Gan cao, Sang bai pi, Di gu pi, Jing mi 
Lung qi deficiency Tonify lung qi 
Bu Fei Tang 
Ren shen, Huang qi, Zi wan, Di huang (Shu), Wu wei zi, Sang bai pi 
Lung yin deficiency 
Nourish yin and moisten the 
lung 
Sha Shen Mai Dong Tang 
Shashen, Maidong, Yuzhu, Sangye, Gancao, Tianhuafeng, Biandou,  
Chuan zheng 
(deficiency) 
Deficiency of the lung Invigorate the lung  
Shenmai San & Bufei Tang 
Renshen, Maidong, Wuwei 
Plus Ren shen, Huang qi, Di huang (Shu),  Wu wei zi, Zi wan, Sang bai pi 
Deficiency of the kidney Tonify the kidney 
Qi Wei Dou Qi Wan 
Di huang, Shan zhu yu, Shan yao, Fu ling, Dan pi, Ze xie, Wu wei zi 
 
Fei zhang 
Deficiency of the lung and kidney Tonify the lung and kidney 
Ren Shen Ge Jie San modified 
Ren shen, Ge jie 
Yang deficiency of the spleen and 
kidney 
Fortify the spleen and tonify 
the kidney to warm yang and 
promote qi absorption 
Jin Gui Shen Qi Wan 
Rou gui, Fu zi, Di huang (Shu), Shan yao, Shan zhu yu, Fu ling, Dan pi, Ze xie 
Zhi yin 
Cold-fluid in the lung 
Warm the lung to remove fluid 
retention 
Xiao Qing Long Tang 
Ma huang, Gui zhi, Shao yao, Gan cao, Gan jiang, Xi xin, Ban xia, Wu wei zi 
Yang deficiency of the spleen and 
kidney 
Warm and invigorate the 
spleen and kidney to remove 
fluid retention 
Jin Gui Shen Qi Wan 
Rou gui, Fu zi, Di huang (Shu), Shan yao, Shan zhu yu, Fu ling, Dan pi, Ze xie 
Xiao zheng 
(Deficiency)  
Deficiency of the lung Tonify lung qi 
Yu Ping Feng San 
Huang qi, Bai zhu, Fang feng 
Deficiency of the spleen 
Strengthen the spleen to 
resolve phlegm 
Liu Jun Zi Tang 
Ren shen, Fu ling, Bai zhu, Chen pi, Ban xia (Zhi), Gan cao (Zhi) 
Deficiency of the kidney 
Tonify the kidney to promote 
qi absorption 
Jin Gui Shen Qi Wan or Qi Wei Dou Qi Wan 
Rou gui, Fu zi, Di huang (Shu), Shan yao, Shan zhu yu, Fu ling, Dan pi, Ze xie 
Or  
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Di huang, Shan zhu yu, Shan yao, Fu ling, Dan pi, Ze xie, Wu wei zi 
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Appendix 4 Table: Traditional disease names related to COPD found in books on TCM internal medicine 
and respiratory diseases 
First Author, 
date 
Book name in English 
Book name in 
Chinese 
Disease names relevant to 
COPD 
CACM, 2008 
Guidelines for the Diagnosis and Treatment of 
Common Internal Medicine Diseases in 
Chinese Medicine 
中医内科常见病诊
疗指南 
(西医疾病部分) 
Ke sou, Chuan zheng, Fei 
zhang 
Chao, 2011 Contemporary Chinese Internal Medicine 今日中医内科 
Ke sou, Chuan zheng, Fei 
zhang 
 
Fan, 2008 
Manual of Diagnosis and Treatment of Internal 
Medicine Diseases by Integrative Chinese and 
Western Medicine 
中西医结合内科疾
病诊疗手册 
Fei zhang 
Feng, 2000 
The Clinical Diagnosis and Treatment of 
Respiratory Diseases in TCM 
呼吸科专病中医临
床诊治 
Ke sou, Fei zhang 
Han, 2005 
Contemporary Respiratory Medicine in 
Traditional Chinese Medicine 
现代中医呼吸病学 
Ke sou, Chuan zheng, Fei 
zhang,  
Tan yin 
Hong, 1995 The Practice of Chinese Respiratory Medicine 实用中医呼吸病学 
Ke sou, Chuan zheng, Fei 
zhang 
Li, 2009 
Respiratory Diseases :Essentials of Clinical 
Treatment in TCM 
呼吸病-中医临床精
要 
Chuan zheng, Fei zhang 
Ouyang, 
1997 
Chinese Respiratory Medicine 中医呼吸病学 Ke sou, Chuan zheng 
Pan, 1997 
Compendium of the Treatment of Internal 
Medicine Diseases in Chinese Medicine 
中医内科治疗大成 
Ke sou, Chuan zheng, Fei 
zhang 
Wang, 1999 Chinese Internal Medicine 中医内科学 
Ke sou, Chuan zheng, Fei 
zhang 
Wang, 2009 The Practice of Chinese Internal Medicine 实用中医内科学 
Ke sou, Chuan zheng, Fei 
zhang,  
Tan ke, Tan sou 
Wu, 2001 
Chinese Internal Medicine Diagnosis and 
Therapy 
中医内科诊断治疗
学 
Jiu ke, Fei zhang, Zhi yin 
Zhu, 2011 
Diagnosis and Treatment of Diseases in 
Chinese Internal Medicine (National Standard 
Application) 
中医内科疾病诊疗
常规 
(国家标准应用) 
Jiu ke, Fei zhang 
CACM: China Association of Chinese Medicine 
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Appendix 5 SGRQ 
 
 
ST. GEORGE'S RESPIRATORY QUESTIONNAIRE (SGRQ) 
 
 
 
This questionnaire is designed to help us learn much more about how your  
breathing is troubling you and affecting your life. We want to find out  
which aspects of your illness cause you most problems, rather than what the  
doctors and nurses think your problems are. 
 
Please read the instructions carefully and ask if you do not understand anything.  
Do not spend too long deciding about your answers. 
 
 
 
 
 
 
Before completing the rest of the questionnaire: 
 
Please tick one box which best describes your present 
health: 
 
 
 
Very good 
 
 
 
Good 
 
 
 
Fair 
 
 
 
Poor 
 
 
 
Very poor 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright reserved 
P.W. Jones,  PhD  FRCP  
Professor of Respiratory Medicine,  
St. George’s University of London, 
Jenner Wing, 
Cranmer Terrace,  Tel.  +44 (0) 20 8725 5371 
London SW17 ORE, UK.  Fax  +44 (0) 20 8725 5955 
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St. George’s Respiratory Questionnaire 
PART 1 
 
These questions are about how much chest trouble you have had over the last 4 weeks. 
 
Please tick () one box for each question: 
 
 most 
days  
a week 
several 
days  
a week 
a few 
days  
a month 
only with 
chest 
infections 
not  
at  
all 
1. Over the last 4 weeks, I have coughed:      
 
2. Over the last 4 weeks, I have brought up  
phlegm (sputum):      
 
3. Over the last 4 weeks, I have had shortness 
of breath:       
 
4. Over the last 4 weeks, I have had attacks  
of wheezing:       
 
5. During the last 4 weeks, how many severe or very  
unpleasant attacks of chest trouble have you had? 
Please tick () one: 
     more than 3 attacks  
3 attacks  
2 attacks  
1 attack  
no attacks  
 
6. How long did the worst attack of chest trouble last? 
(Go to question 7 if you had no severe attacks) 
Please tick () one: 
       a week or more  
3 or more days  
1 or 2 days  
less than a day  
 
7. Over the last 4 weeks, in an average week, how many good days 
(with little chest trouble) have you had? 
Please tick () one: 
       No good days  
1 or 2 good days  
3 or 4 good days  
nearly every day is good  
every day is good  
 
8. If you have a wheeze, is it worse in the morning? 
Please tick () one: 
 No  
Yes  
 368 
 
 
 
St. George’s Respiratory Questionnaire 
PART 2 
 
Section 1 
 
How would you describe your chest condition? 
Please tick () one: 
          The most important problem I have  
Causes me quite a lot of problems  
Causes me a few problems  
Causes no problem  
 
If you have ever had paid employment. 
Please tick () one: 
 My chest trouble made me stop work altogether  
My chest trouble interferes with my work or made me change my work  
My chest trouble does not affect my work  
 
Section 2 
 
These questions are about what activities usually make you feel breathless these days. 
 
For each activity, please tick () 
one box as it applies to you these days: 
       True   False 
Sitting or lying still    
Getting washed or dressed   
Walking around the home   
Walking outside on level ground   
Walking up one flight of stairs   
Walking up hills     
Playing sports or active games   
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St. George’s Respiratory Questionnaire 
PART 2 
 
Section 3 
 
Some more questions about your cough and breathlessness these days. 
 
For each situation, please tick () 
one box as it applies to you these days: 
           True False 
                                                                          My cough hurts      
                                              My cough makes me tired         
                                             I am breathless when I talk       
                        I am breathless when I bend over   
 My cough or breathing disturbs my sleep       
                                                                                                      I get exhausted easily                                    
 
Section 4 
 
These are questions about other effects that your chest trouble may have on you these days. 
 
For each situation, please tick () 
one box as it applies to you these days: 
 True False 
 My cough or breathing is embarrassing in public   
                        My chest trouble is a bother to my family, friends or neighbours   
 I get afraid or panic when I cannot get my breath   
 I feel that I am not in control of my chest problem   
                    I do not expect my chest to get any better   
                                                    I have become frail or an invalid because of my chest   
                                                              Exercise is not safe for me   
                          Everything seems too much of an effort   
 
Section 5 
 
These are questions about your medication. If you are receiving no medication go straight 
to  
 
For each situation please tick () 
one box as it applies to you these days: 
 True False 
              My medication does not help me very much   
 I get embarrassed using my medication in public   
 I have unpleasant side effects from my medication       
                       My medication interferes with my life a lot   
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St. George’s Respiratory Questionnaire 
PART 2 
 
Section 6 
 
These are questions about how your activities might be affected by your breathing. 
 
For each situation, please tick () 
the correct box that applies to you 
because of your breathing: 
 True False 
 I take a long time to get washed or dressed   
 I cannot take a bath or shower, or I take a long time   
 I walk slower than other people, or I stop for rests   
Jobs such as housework take a long time, or I have to stop for rests   
 If I walk up one flight of stairs, I have to go slowly or stop   
 If I hurry or walk fast, I have to stop or slow down   
My breathing makes it difficult to do things such as walk up hills, carry things  
up stairs, light gardening (e.g. weeding), dance, play bowls or play golf   
My breathing makes it difficult to do things such as carry heavy loads, dig the 
 garden, jog or walk fast (8 km/hr), play tennis or swim laps   
My breathing makes it difficult to do things such as very heavy manual work, 
 run, cycle, swim fast or play competitive sports   
 
 
 
Section 7 
 
We would like to know how your chest trouble usually affects your daily life. 
 
For each situation, please tick () 
the correct box that applies to you 
because of your chest trouble: 
 True False 
 I cannot play sports or active games   
 I cannot go out for entertainment or recreation   
 I cannot go out of the house to do the shopping   
 I cannot do housework       
 I cannot move far from my bed or chair   
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St. George’s Respiratory Questionnaire 
 
 
Here is a list of other activities that your chest trouble may prevent you doing. (You do not have 
to tick these, they are just to remind you of ways in which your breathlessness may affect you): 
 
Going for walks or walking the dog 
Doing things at home or in the garden 
Sexual intercourse 
Going out to church or place of entertainment 
Going out in bad weather or into smoky rooms 
Visiting family or friends or playing with children 
 
 
Please write in any other important activities that your chest trouble may stop you doing: 
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
  
 
Now, would you tick the box (one only) which you think best describes how your chest 
trouble affects you: 
It does not stop me doing anything I would like to do           
It stops me doing one or two things I would like to do     
It stops me doing most of the things I would like to do    
It stops me doing everything I would like to do                
 
Thank you for filling in this questionnaire. Before you finish would you please check to see that 
you have answered all the questions. 
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Appendix 6 Dyspnea scale 
Dyspnea was assessed by the MMRC Scale that consists of five levels of dyspnoea as follows: 
 Grade 0: I only get breathless with strenuous exercise;  
 Grade 1: I get short of breath when hurrying on level ground or walking up a slight hill;  
 Grade 2: on level ground, I walk slower than people of the same age because of breathlessness, or have 
to stop for a breath when walking at my own pace;  
 Grade 3: I stop for a breath after walking about 100 yards or after a few minutes on level ground;  
 Grade 4: I am too breathless to leave the house or I am breathless when dressing.  
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Appendix 7 Search terms of RCTs 
The search terms for PubMed were done using the following steps: 
1. Pulmonary disease, chronic obstructive [MeSH] 
2. Bronchitis, chronic [MeSH]  
3. Emphysema [MeSH] 
4. (Chronic obstructive pulmonary disease [Text word] OR Chronic obstructive airway disease [Text word] 
OR Chronic obstructive lung disease [Text word] OR Chronic obstructive bronchitis disease [Text word])  
5. Chronic Airflow Limitation* [Text word] 
6. Chronic Airflow Obstruction* [Text word] 
7. Chronic Airways Obstruction* [Text word] 
8. (COPD [Text word] OR COAD [Text word] OR COBD [Text word])  
9. Chronic bronchitis [Text word] 
10. Chronic obstructive bronchitis [Text word] 
11. Emphysema [Text word] 
12. #I OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11  
13. Clinical trials [MeSH] 
14. Clinical trial [pt] 
15. Controlled clinical trial [pt] 
16. Randomized controlled trials [MeSH] 
17. Randomized controlled trial [pt]  
18. Random allocation [MeSH] 
19. Double-blind method [MeSH] 
20. Single-blind method [MeSH] 
21. Placebos [MeSH] 
22. Clin* trial* [TIAB] 
23. (Randomized clinical trial* [TIAB] OR Randomised clinical trial* [TIAB])  
24. Placebo [TIAB] 
25. (singl* blind* [TIAB] OR doubl* blind* [TIAB] OR tripl* blind* [TIAB] OR trebl*        blind* [TIAB])  
26. (singl* Mask* [TIAB] OR doubl* Mask* [TIAB] OR tripl* Mask* [TIAB] OR trebl* Mask* [TIAB])  
27. #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR 
#25 OR #26  
28. Animal/ NOT (human/ and animal/) 
29. #27 NOT #28 
30. Complementary Therapies [MeSH] 
31. Plants, Medicinal [MeSH] 
32. Medicine, Chinese traditional [MeSH] 
33. Medicine, traditional [MeSH] 
34. Plant extracts [MeSH] 
35. Phytotherapy [MeSH]  
36. Drugs, Chinese herbal [MeSH] 
37. Drugs, Non-Prescription [MeSH] 
38. Acupuncture [MeSH] 
39. Massage [MeSH] 
40. (Complementary Therap* [TIAB] OR Complementary medicine [TIAB] OR Alternative therap* [TIAB] 
OR Alternative medicine [TIAB] OR Traditional medicine [TIAB])  
41. (Plant extract* [TIAB] OR Herb* [TIAB] OR Phytotherap* [TIAB])  
42. (Chinese medicine [TIAB] OR Acupuncture [TIAB] OR Acupressure [TIAB] OR Moxibustion [TIAB] 
OR Moxa [TIAB] OR Massage [TIAB])  
43. #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR# 41 OR #42 
44. #12 AND #29 AND #43 
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Appendix 8 Table: Ten most frequent formulae in total data set following general exclusions* 
Formula code & name Freq. Terms Action Ingredients Book name Year 
Unnamed 187 various various various various various 
61 Xiao Qing Long Tang 10 Zhi yin 
Warm lung to dispel cold, resolve 
phlegm to stop wheezing 
Ma huang, Gan cao, Gui zhi, Shao yao, 
Gan Jiang, Ban xia, Xi xin, Wu wei zi 
Bing Yin Mai Zhi 1706 
59 Xiao Ban Xia Tang 9 Zhi yin 
Invigorate the spleen and eliminate 
fluid retention 
Ban xia, Sheng Jiang Pu Ji Fang 1406 
3 Yue Bi Jia Ban Xia Tang Fang 7 Fei zhang 
Clear heat and resolve phlegm to stop 
wheezing 
Ban xia, Ma huang,  
Shi gao, Gan cao 
Shen Ji Zong Lu 1117 
5 Xiao Qing Long Jia Shi Gao 
Tang 
6 Fei zhang 
Warm lung to dispel cold, resolve 
phlegm to stop wheezing, clear interior 
heat 
Shi gao, Ma huang, Shao yao, Gui,  
Xi Xin, Gan cao, Gan Jiang 
Shen Ji Zong Lu 1117 
57 Xiao Ban Xia Jia Fu Ling 
Tang 
6 Zhi yin 
Invigorate the spleen and eliminate 
fluid retention 
Ban xia, Sheng jiang, 
Fu ling 
Pu Ji Fang 1406 
54 Mu Fang Ji Tang 5 Zhi yin 
Promote the circulation of fluid, 
restore qi and remove heat 
Fang ji, Gui zhi, Ren shen,  
Shi gao 
Pu Ji Fang 1406 
63 Wu Ling San 5 Zhi yin Move qi to drain water 
Ze xie, Zhu ling, Fu ling, Bai zhu, 
 Rou gui 
Bing Yin Mai Zhi 1706 
144 Zao Jiao Jian Wan 5 
Tanyin 
kesou 
Tonify qi and resolve phlegm to calm 
dyspnea 
Zao jiao, Ren shen Ye Shi Lu Yan Fang 1186 
162 Ma Huang Gan Cao Jia 
Xing Ren, Sheng Jiang Tang  
5 
Tanyin 
kesou  
Warm lung to dispel cold, resolve 
phlegm to suppress cough 
Ma huang, Gan cao,  
Xing ren, Sheng jiang 
Zheng Zhi Zhai Yao 1862 
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Appendix 9 Table: Twenty formulae rated as used for ‘possible’, ‘most likely’ or ‘possible complication’ of COPD 
Formula code &name Terms Actions Ingredients Book name Year 
1 no name various  various various  
3 Yue Bi Jia Ban Xia Tang Fang Fei zhang 
Warm lung to dispel cold, 
resolve phlegm to stop wheezing 
Ban xia, Ma huang, Shi gao, Gan cao Shen Ji Zong Lu 1117 
5 Xiao Qing Long Jia Shi Gao Tang Fei zhang 
Warm lung to dispel cold, 
resolve phlegm to stop 
wheezing, clear interior heat 
Shi gao, Ma huang, Chi yao, Gui,  
Xi Xin, Gan cao, Gan Jiang 
Shen Ji Zong Lu 1117 
59 Xiao Ban Xia Tang Zhi yin 
Invigorate the spleen and 
eliminate fluid retention 
Ban xia, Sheng Jiang Pu Ji Fang 1406 
54 Mu Fang Ji Tang Zhi yin 
Promote the circulation of fluid, 
restore qi and remove heat 
Fang ji, Gui zhi, Ren shen, Shi gao Pu Ji Fang 1406 
61 Xiao Qing Long Tang Zhi yin 
Warm lung to dispel cold, 
resolve phlegm to stop wheezing 
Ma huang, Gan cao, Gui zhi, Ban xia, 
Shao yao, Gan Jiang, Xi xin, Wu wei zi 
Bing Yin Mai Zhi 1706 
144 Zao Jiao Jian Wan Tanyin kesou 
Tonify qi and resolve phlegm to 
calm dyspnea 
Zao jiao, Ren shen Ye Shi Lu Yan Fang 1186 
4 Ma Huang Tang Fei zhang 
Diffuse the lung to suppress 
cough and calm dyspnea 
Ma huang, Xi xin, Shao yao, Gui, 
Ban xia, Wu wei zi, Shi gao 
Sheng Ji Zong Lu 1117 
8 Zi Wan Tang Fei zhang Resolve phlegm and regulate qi 
Zi wan, Gan cao, Bing lang, Fu ling, 
Ting li zi 
Pu Ji Fang 1406 
60 Ting Li Da Zao Tang Zhi yin 
Purge the lung to resolve phlegm 
and calm dyspnea 
Ting li zi, Da zao Bing Yin Mai Zhi 1706 
162 Ma Huang Gan Cao Jia Xing Ren 
Sheng Jiang Tang 
Tanyin kesou 
Warm lung to dispel cold, 
resolve phlegm to suppress 
cough 
Ma huang, Gan cao, Xing ren,  
Sheng jiang 
Zheng Zhi Zhai Yao 1862 
337 Su Zi Jiang Qi Tang Chuan Zheng 
Direct qi downward to calm 
dyspnea, dispel phlegm to 
suppress cough 
Su zi, Ban xia, Chen pi, Hou po,  
Qian hu, Dang gui, Rou gui, Gan cao 
Ming Yi Zhi Zhang 1624 
21 Zi Wan San Jia Jian Fei zhang 
Moisten the lung to suppress 
cough 
Zi wan, Ren shen, Mai men dong,  
Jie geng, Bei mu, Wu wei zi, 
Fu ling, E jiao, Gan cao, Dan pi, 
Sheng jiang, Da zao 
Zhang Shi Yi Tong 1695 
55 Shi Zao Tang Zhi yin 
Purge the lung to resolve fluid 
retention 
Da zao, Da ji, Gan sui, Yuan hua Pu Ji Fang 1406 
57 Xiao Ban Xia Jia Fu ling Tang Zhi yin Invigorate the spleen and Ban xia, Sheng jiang, Fu ling Pu Ji Fang 1406 
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eliminate fluid retention 
58 Ze Xie Tang Zhi yin Eliminate fluid retention Ze xie, Bai zhu Pu Ji Fang 1406 
66 Mu Fang Ji Tang Jia Jian Zhi yin 
Promote the circulation of fluid, 
restore qi and remove 
Fang ji, Rou gui, Ren shen, Fu ling, 
Mang xiao 
Wai Tai Mi Yao 752 
127 Jiu Xian San 
Tanyin 
kesou 
Constrain the lung to suppress 
cough 
Ren shen, Jie geng, E jiao, Wu mei 
Kuan dong hua, Sang bai pi,  
Wu wei zi, Bei mu, Ying su ke 
Tai Ping Hui Min 
He Ji Ju Fang 
1078 
226 Ren Shen Kuan Dong Hua San Chuan sou Fortify spleen to resolve phlegm 
Ren shen, Zhi mu, Kuan dong hua, 
Bei Mu, Ying su ke, Ban xia 
Pu Ji Fang 1406 
477 Jiu Sou Wan Zi Jiu ke sou 
Diffuse the lung to resolve 
phlegm and suppress cough 
Hai ge fen, Dan xing, Xing ren, He zi, 
Qing dai, Zao jiao 
Yi Xue Gang Mu 1565 
Ref: Peng (2003) Zhong Guo Ming Yi Fang Ji Da Quan (中国名医方剂大全). 
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Appendix 10 Table: Formulae occurring in the data set at step 7 and also ranked as ‘most likely COPD’ 
 
Formula name Terms Actions* Ingredients Book name Year 
6 Ban Xia Yin Fang Fei zhang 
Diffuse the lung to resolve 
phlegm and suppress cough  
Ban xia, Mai men dong, Sheng ma, Qian hu, Bing lang, 
Chen pi, Zhu ye, Sheng di huang, Da huang 
Shen Ji Zong Lu 1117 
21 Zi Wan San Jia Jian Fei zhang 
Moisten the lung to suppress 
cough 
Zi wan, Ren shen, Jie geng, Mai men dong, 
Fu ling, E jiao, Bei mu, Wu wei zi, Gan cao, 
 Dan pi, Sheng jiang, Da zao 
Zhang Shi Yi 
Tong 
1695 
92 Run Fei Wan Tanyin kesou 
Diffuse the lung to resolve 
phlegm and suppress cough 
Ren shen, Kuan dong hua, Xi xin, Xing ren,  
Gan cao, Zhi mu, Rou gui, Jie geng 
Tai ping hui min 
he ji ju fang 
1078 
96 Kuan Dong Hua San Tanyin kesou 
Diffuse the lung to resolve 
phlegm and suppress cough 
Kuan dong hua, Zhi mu, Sang ye, Ban xia, 
Gan cao, Ma huang, E jiao, Xing ren, Bei mu 
Tai ping hui min 
he ji ju fang 
1078 
97 Xi Xin Wu Wei Zi Tang Tanyin kesou 
Diffuse the lung to resolve 
phlegm and suppress cough 
Xi xin, Ban xia, Gan cao, Wu mei, Wu wei zi,  
Ying su ke, Sang bai pi 
Tai ping hui min 
he ji ju fang 
1078 
98 Yang Zhong Tang Tanyin kesou 
Diffuse the lung to resolve 
phlegm and suppress cough 
Ban xia, Gan cao, Rou gui,  
Ying su ke, Sheng Jiang 
Tai ping hui min 
he ji ju fang 
1078 
112 Wen Fei Wan Tanyin kesou 
Warm the lung resolve 
phlegm and suppress cough 
Xi Xin, Rou gui, Ban xia, Fu zi, Kuan dong hua, 
Zi wan, Gan jiang, Xing ren, Chen pi, Gan cao, Ren shen  
Tai ping hui min 
he ji ju fang 
1078 
213 Shen Su Ban Xia Tang Chuan sou 
Diffuse the lung to resolve 
phlegm 
Ren shen, Rou gui, Gan cao, Mu xiang, Wu wei zi, Sang bai 
pi, Chen pi, Bai zhu, Zi su, Ban xia 
Pu Ji Fang 1406 
220 Shen Ying Dan Chuan sou 
Diffuse the lung to resolve 
phlegm and calm dyspnea 
Bo he, Gan cao, Ba dou, Wu ling zhi, Pen xiao,  
Qing fen, Dou chi 
Pu Ji Fang 1406 
258 Ren Shen Ding Chuan 
Tang 
Chuan sou 
Diffuse the lung to suppress 
cough and calm dyspnea, 
tonify lung qi 
Ren shen, Ma huang, Gan cao, E jiao, Ban xia, 
Sang bai pi, Wu wei zi, Ying su ke 
Pu Ji Fang 1406 
259 Chen Sha Li Ge Wan Chuan sou 
Resolve phlegm to move 
phlegm-fluid retention 
Tian nan xing, Fu ling, Gan sheng jiang, Sheng xi (生犀), 
Ban xia, Bai Fan, Shan yao, Zao jiao 
Pu Ji Fang 1406 
273 Dao Tan Wan Chuan sou 
Resolve phlegm to move 
phlegm-fluid retention 
Tian nan xing, Ban xia, Bai fan, Zao jiao,  
Sheng jiang 
Pu Ji Fang 1406 
454 Jin Bu Huan San Jiu kesou 
Warm the lung and stomach 
to dispel cold and resolve 
phlegm 
Ying su ke, Xing ren, Gan cao, Zhi ke Pu Ji Fang 1406 
484 Qing Jin Tang Jiu kesou 
Fortify spleen to resolve 
phlegm and suppress cough 
Ying su ke, Ren shen, Gan cao, Chen pi, Fu ling, Xing ren, E 
jiao, Wu wei zi, Sang bai pi, Yi yi ren, 
Zi su, Bai he, Bei mu, Ban xia, Kuan dong hua 
Pu Ji Fang 1584 
Ref: Peng (2003) Zhong Guo Ming Yi Fang Ji Da Quan (中国名医方剂大全). 
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Appendix 11 Table: Frequency of formulae occurring in the data set at step 7: ‘possible complications of COPD’ 
Formula name Terms Actions Ingredients Book name Year 
No name Fei zhang various 
Ke zi, Hai fen, Huang qin,  
Qing dai, Xing ren, Wu wei zi 
Ji Yang Gang Mu 1626 
8 Zi Wan Tang Fang Fei zhang Resolve phlegm and regulate qi 
Zi wan, Gan cao, Bing lang,  
Fu ling, Ting li zi 
Pu Ji Fang 1406 
33 Jia Wei Si Wu Tang Fei zhang 
Regulate qi and resolve phlegm and 
activate blood stasis 
Dang gui, Chuan xiong, Shao yao, 
Di huang, Ke zi, Tao ren, Qing pi 
Ji Yang Gang Mu 1626 
83 Ban Xia Wan Tanyin kesou 
Invigorate the spleen and eliminate 
fluid retention 
Ban xia, Bai fan, Sheng jiang 
Tai Ping Hui Min He 
Ji Ju Fang 
1078 
108 Ren Shen Yang Fei 
Wan 
Tanyin kesou 
Tonify qi and fortify spleen to 
resolve phlegm and suppress cough 
Huang qi, Ren shen, Fu ling, Gua lou,  
Xing ren, Ban xia, Zi su, Sang bai pi 
Tai Ping Hui Min He 
Ji Ju Fang 
1078 
278 Ting Li San Chuan Sou 
Diffuse the lung to resolve phlegm 
and calm dyspnea, 
tonify qi 
Ting li zi, Ge jie, Sang bai pi, Zhi zi,  
Ren shen, Jing jie, Bo he, Fu ling, Jie 
geng, Xing ren, Gan Cao 
Pu Ji Fang 1406 
144 Zao Jiao Jian Wan Tanyin kesou 
Tonify qi and resolve phlegm to 
calm dyspnea 
Zao jiao Ye Shi Lu Yan Fang 1186 
Ref: Peng (2003) Zhong Guo Ming Yi Fang Ji Da Quan (中国名医方剂大全) (336)
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Appendix 12 Table: The characteristics of the 101 studies included in review of Chinese herbal medicine for stable COPD with physical and symptomatic 
outcome measures 
No. of 
studies 
First 
author, 
date 
Location, Design 
[duration / 
follow up] 
Out /in 
patients 
No. subjects 
(R/A) 
M/F 
Age 
Mean SD 
(years) 
Severity of COPD:  
No. subjects 
CM Syndrome 
Differentiation 
COPD history 
(years) 
1 
Ao, 
2007 
Luzhou, Sichuan 
RCT [3 mths / NS] 
Both 
T: 32/32 
C: 28/28 
T: 20/12 
C: 19/9 
T: 57± NS 
C: 56± NS 
NS Liver Qi stasis 
T: 14± NS 
C: 15± NS 
2 
Che, 
2005 
Shenyang, 
Liaoning 
RCT [6 weeks / 
NS] 
NS 
T: 25/23 
C: 25/23 
T: 18/7 
C: 16/9 
T: 65.6± NS 
C: 64.5± NS 
T: IIA: 11, IIB: 10, 
III: 4 
C: IIA: 10, IIB: 12, 
III: 3 
NS 
T: 14±8 
C: 15±7.6 
3 
Chen, 
2004 
Fujian, China  
RCT [2 mths / NS] 
In patients 
T: 30/30 
C: 30/30 
35/25 65.00±NA 
Mild 15, Moderate 
26, Severe 19 
NS 21±NS 
4 
Chen, 
2006 
Nanning, Guangxi 
RCT [2 mths / NS] 
Both 
T: 35/35 
C: 35/35 
T: 23/12 
C: 22/13 
T: 60.5± NS 
C: 61± NS 
Mild & Moderate 
Lung Qi 
deficiency 
T: 16± NS 
C: 17± NS 
5 
Chen 
(1), 
2007 
Chengdu, China 
RCT [90 days / two 
seasons of winter 
and spring] 
Out patients 
T: 59/59 
C: 58/58 
T: 45/14 
C:42/16 
T:59.03±6.70 
C: 58.59±6.29 
T: I: 13, IIA: 20, IIB: 
18, III: 8 
C: I: 16, IIA: 19, 
IIB: 17, III: 6 
Lung & Kidney 
deficiency 
NS 
6 
Chen 
(2), 
2007 
Nanning, Guangxi 
RCT [4weeks / NS] 
Out patients 
T: 40/40 
C: 40/40 
T: 24/16 
C: 22/18 
T: 58.6 ± 6.1 
C: 57.1±5.6 
NS 
Lung Qi 
deficiency  
T: 13.4±6.8 
C: 14.4±6.1 
7 
Chen, 
2008 
Kaiyan, Liaoning 
RCT 
[3mths/9mths] 
Out patients 
T: 57/57 
C: 30/30 
T: 24/33 
C: 14/16 
T: >30  
C: >30  
NS NS 
T: 3-30 
C: 3-38 
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No. of 
studies 
First 
author, 
date 
Location, Design 
[duration / 
follow up] 
Out /in 
patients 
No. subjects 
(R/A) 
M/F 
Age 
Mean SD 
(years) 
Severity of COPD:  
No. subjects 
CM Syndrome 
Differentiation 
COPD history 
(years) 
8 
Chen 
(1), 
2009 
Fujian, China 
RCT [3 mths/NS] 
Out patients 
T: 30/30 
C: 30/30 
29/31 70.1± NS III & IV: NS NS NS 
9 
Chen 
(2), 
2009 
Mianyang, Sichuan 
RCT [2mths / NS] 
NS 
T: 27/27 
C: 27/27 
33/21 
47-78 
(58.26±6.91) 
NS 
Lung & spleen 
deficiency 
NS 
10 
Cui, 
2008 
Tangshan, Hebei 
RCT [1month /NS] 
Both  
T: 60/60 
C: 60/60 
T: 38/22 
C: 42/18 
T: 50-75 
C: 50-75 
NS NS 
T: 3-20 
C: 3-20 
11 
Du, 
2006  
Shiyan, Hubei 
RCT [8 weeks / 
NS] 
Out patients 
T: 18/18 
C: 18/18 
T: 16/2 
C: 15/3 
T: 58.61 ± 
10.69 
C: 58.44±9.54 
T: IIA: 7, IIB: 6, III: 
2 
C: IIA: 6, IIB: 7, III: 
1 
NS NS 
12 
Fang, 
2008 
Guangdong, China 
RCT [6 mths /NS] 
NS 
T: 35/30 
C: 35/26 
T: 26/4 
C: 23/3 
T: 68.0 ± 5.70 
C: 68.0±4.96 
T: I 8, II 22 
C: I 6, II 20 
NS NS 
13 
Feng, 
2005 
Beijing, China 
RCT [3 mths / NS] 
Out patients 
T: 35/35 
C: 37/37 
T: 16/19 
C: 18/19 
T: 60.59±8.99 
C: 56.57±8.81 
T: 0 8, I 9, IIA 9, IIB 
9 
C: 0 8, I 12, IIA 9, IIB 
8 
Qi deficiency & 
blood stasis 
NS 
14 
Feng, 
2006 
Shiyan, Hubei  
RCT [8 weeks / 
NS] 
Out patients 
T: 36/36 
C: 33/33 
NS 48-73 NS 
Lung & Spleen 
deficiency or / and 
Lung & Kidney 
deficiency 
5-23 
15 
Feng, 
2007 
Beijing, China 
RCT [3 mths / NS] 
Out patients 
T: 46/46 
C: 30/30 
T: 25/21 
C: 14/16 
T: 63.37±8.99 
C: 62.26±8.72 
T: IIA 24, IIB 22 
C: IIA 16, IIB 14 
Qi deficiency & 
blood stasis 
T: 6.15±1.71 
C: 6.23± 1.59 
16 Feng, Hebei, China NS T: 60/60 NS 63.0 ± 5.0 NS Multi syndromes 14.0±5.0 
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No. of 
studies 
First 
author, 
date 
Location, Design 
[duration / 
follow up] 
Out /in 
patients 
No. subjects 
(R/A) 
M/F 
Age 
Mean SD 
(years) 
Severity of COPD:  
No. subjects 
CM Syndrome 
Differentiation 
COPD history 
(years) 
2008 RCT [6mths/NS] C: 60/60 
17 
Gao, 
2008 
Xianyang, Shanxi 
RCT [3 mths /NS] 
Out patients 
T: 54/54 
C: 46/46 
T: 34/20 
C: 30/16 
T: 58± NS 
C: 56± NS 
T: I:15, IIA: 26, IIB: 
13 
C: I:13, IIA: 22, 
IIB:11 
Deficiency of 
Lung & Kidney 
T: 10.6± NS 
C: 9.4± NS 
18 
Gross, 
2002 
Tel Aviv, Israel 
RCT [6mths / NS] 
NS 
T&C: 
100/91 
T: 51; C: 41 
T: 30/21 
C: 25/16 
T: 59.0±12.6 
C: 62.0±10.5 
FEV1: 50-65% of 
predicted 
NS NS 
19 
Guo, 
2008 
Tangshan, China 
RCT [28 days/NS] 
Out patients 
T: 50/50 
C: 50/50 
T: 36/14 
C:34/16 
T: 56.00±NS 
C: 55.00±NS 
T: mild 8, moderate 
33, severe 9 
C: mild 7, moderate 
35, severe 8 
NS 
T: 16.00±NS 
C: 14.00±NS 
20 
Guo, 
2010 
Shanghai, China 
RCT [6mths/NS] 
Out patients 
T: 30/30 
C: 30/30 
T: 17/13 
C: 15/15 
T: 
68.27±12.35 
C: 
70.38±11.67 
NS 
Lung & Kidney 
deficiency 
T: 7.1±0.4 
C: 6.8±0.3 
21 
Hao, 
2008 
Guangzhou, China 
RCT [3 mths / NS] 
Both 
T: 41/41 
C: 41/41 
T: 30/11 
C: 28/13 
T: 63.12±3.75 
C: 60.28±2.87 
T: I 26, II 15 
C: I 29, II 12 
NS 
T: 18.21±3.02 
C: 16.27±2.73 
22 
He, 
2010 
Zhejiang, China  
RCT [6 mths/NS] 
Both  
T: 49/49 
C: 49/49 
86/12 75±5.8 I & II 
Lung & Spleen Qi 
deficiency 
11.25±5.86 
23 
Hong, 
2005 
Fujian, China  
RCT [6 
mths/6mths] 
NS 
T: 18/18 
C:18/18 
T: 16/2 
C: 15/3 
T: 67.56±5.19 
C: 66.00±6.40 
T: II 3, III 15 
C: II 3, III 15 
Lung & Spleen & 
Kidney deficiency 
T: 15.22±5.12 
C: 14.17±6.15 
24 Hu, Jiangxi, China Both T: 32/32 T: 21/11 50-69 (57) NS NS T: 5-30 
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2005 RCT [24 weeks 
/NS] 
C: 32/32 C: 20/12 > 70 (7) C: 3-35 
25 
Hu, 
2009 
Lanzhou, Gansu 
RCT [2 mths /NS 
In patients 
T: 35/35 
C: 32/32 
T: 20/15 
C: 14/18 
T: 64.7±7.5 
C: 63.2±5.4 
NS 
Yin deficiency of 
Lung & Kidney 
NS 
26 
Huang, 
2002 
Jiangshu, China 
RCI [1 month/NS] 
In patients & 
out patients 
T: 300/300 
C: 300/300 
T: 
185/115 
C: 
202/98 
T: 52.50±4.40 
C: 
57.20±10.40 
Mild to moderate 
Lung & Kidney 
deficiency 
T: 7.20±4.40 
C: 8.50±3.60 
27 
Huang, 
2005 
Guangdong, China 
RCT [3 mths/NS] 
Out patients 
T: 32/32 
C: 31/31 
T: 21/11 
C: 23/8 
T: 69.5±11.8 
C: 68.8±10.6 
T: II 17, III 15 
C: II 18, III 13 
NS 
T: 8.5±3.2 
C: 8.3±3.5 
28 
Huang,  
2009 
Nanning, Guangxi  
RCT [3 mths /NS] 
Out patients 
T: 30/30 
C: 30/30 
T: 17/13 
C: 19/11 
T: 59.03±6.70 
C: 58.59±6.29 
T: I:7, IIA: 8, IIB: 
12, III:3 
C: I:6, IIA: 6, 
IIB:11, III:4 
NS NS 
29 Ji, 2010 
Jiangsu, China 
RCT [3 mths /NS] 
Out patients  
T: 32/32 
C: 32/32 
T: 20/12 
C: 18/14 
T: 62.23±3.64 
C: 63.16±3.13 
T: I 25, II 7 
C: I 23, II 9 
NS 
T: 18.21±3.02 
C: 18.79±2.43 
30 
Jia, 
2007 
Jiangsu, China 
RCT [6 mths /NS] 
NS 
T: 30/30 
C: 25/25 
T: 23/7 
C: 17/8 
T: 61.6±6.1 
C: 63.2±5.3 
T: I 5, II 18, III 7 
C: I 3, II 17 III 5 
NS NS 
31 
Jian, 
2008 
Guangdong, China 
RCT [6 mths/NS] 
Both 
T: 23/23 
C: 22/22 
T: 18/5 
C: 16/6 
T: 71±9.6 
C: 69±8.9 
T: I 7, II 16 
C: I 7, II 15 
Lung & Kidney 
deficiency 
NS 
32 
Jin, 
2008 
Changsha, Hunan 
RCT [12 mths / 
NS] 
Out patients 
T: 23/23 
C: 23/23 
T: 16/7 
C: 15/8 
T: 45-75 
C: 43-75 
NS NS 
T: 16.2± NS 
C: 15.8± NS 
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33 
Lang, 
2010 
Shanghai, China 
RCT [6 
mths/6mths] 
NS 
T: 30/30 
C: 30/30 
NS NS NS NS NS 
34 
Lei, 
2006 
Zhangjiajie, Hunan 
RCT 
[2mths/10mths] 
 
NS 
T: 30/30 
C: 30/30 
T: 25/5 
C: 26/4 
T: 64.5±7.0 
C: 65.8±6.8 
NS 
Lung & spleen 
deficiency 
T: 8.74±2.35 
C: 9.01±3.21 
35 
Li (1), 
2006 
Zhengzhou, China  
RCT [2 mths /NS] 
NS 
T: 31/31 
C: 31/31 
T: 22/9 
C: 23/8 
T: 72.00±5.00 
C: 71.00±7.00 
T: mild 5,moderate 
21, severe 6 
C: mild 4, moderate 
21, severe 5 
Lung & Kidney 
deficiency 
T: 18.40±1.10 
C:19.50±6.60 
36 
Li (2), 
2006 
Tongzhou, Beijing 
RCT [8 weeks / 
NS] 
Both 
T: 85/85 
C: 40/40 
T: 53/32 
C: 28/12 
T: 53± NS 
C: 49± NS 
NS NS 
T: 22± NS 
C: 25± NS 
37 
Li, 
2007 
Xianyang, Shanxi 
RCT [3 mths / NS] 
Out patients 
T: 20/20 
C:18/16 
T: 14/6 
C: 15/3 
T: 60.25±4.67 
C: 57.22±4.39 
T: I:8, IIA: 12 
C: I:6, IIA: 12 
NS 
T: 14.58±4.72 
C:12.76±2.26 
38 
Liang, 
2005 
Fushan, 
Guangdong 
RCT [12 mths /NS] 
Out patients 
T: 32/32 
C: 31/31 
T: 18/14 
C: 16/15 
T: 62.8± NS 
C: 60.5± NS 
NS NS 
T: 15± NS 
C: 18± NS 
39 
Liang, 
2009 
Guangxi, China 
RCT [6 mths/NS] 
Out patients 
T: 32/32 
C: 33/33 
T: 20/12 
C: 22/11 
T: 69.73±NS 
C:70.69±NS 
T: II 13, III 12, IV 7 
C: II 15, III 12, IV 6 
NS 
T: 17.32±NS 
C: 17.02±NS 
40 
Lin, 
2003 
Guangzhou, China 
RCT [2 mths / NS] 
In patients & 
out patients 
T: 30/30 
C: 30/30 
T: 20/10 
C: 22/8 
T: 62.00±NS 
C: 60.50±NS 
NS Spleen deficiency 
T: 16.00±NS 
C: 15.40±NS 
41 Lin, Xianyang, Shanxi Out patients T: 31/31 T: 24/7 T: 68.0±5.7 T: I:6, IIA: 25 NS NS 
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2008 RCT [60 days / 
NS] 
C:31/31 C: 26/5 C: 68.0±4. 96 C: I:7, IIA: 24 
42 
Liu , 
2002 
Guangdong, China 
RCT [4 weeks /NS] 
Both 
T: 30/30 
C: 28/28 
T: 23/7 
C: 20/8 
T: 65± NS 
C: 67± NS 
NS NS NS 
43 
Liu, 
2005 
Guangdong, China 
RCT [6 mths / NS] 
NS 
T: 30/26 
C: 30/25 
T: 22/4 
C: 23/2 
T: 68.0 ± 5.70 
C: 68.0±4.96 
T: I 4, II 22 
C: I 5, II 20 
NS NS 
44 
Liu (1), 
2006 
Guangdong, China 
RCT [6 mths/NS] 
Out/ 
In patients 
T: 30/30 
C: 30/30 
T: 25/5 
C: 23/7 
T: 67.37±6.03 
C: 67.27±5.75 
T: I 4, II 26 
C: I 5, II 25 
NS 
T: 3.62±2.07 
C: 3.62±2.07 
45 
Liu (2), 
2006 
Chengdu, Sichuan 
RCT [2 mths /NS] 
Out patients 
T: 120/112 
C: 60/55 
T: 68/44 
C: 36/19 
T: 
66.76±10.28 
C: 
65.82±10.24 
T: mild 40, moderate 
52, severe 20  
C: mild 16, moderate 
26, severe 10 
NS 
T:16.58 ± 8.42 
C: 16.28± 8.24 
46 
Liu, 
2007 
Youxi,Fujian 
RCT [3 mths /NS] 
Both 
T: 32/32 
C: 30/30 
T: 18/12 
C: 14/6 
T: 62.25± NS 
C: 53.25± NS 
T: I 5, II15, III 12;                                           
C: I 6, II 12, III 12  
NS 
T: 16.55± NS 
C: 16.85± NS 
47 
Liu, 
2008 
Yulin,Shanxi 
RCT [10 days /NS] 
Out patients 
T: 62/62 
C: 62/62 
T: 40/22 
C: 42/20 
T: 62 ± 5.5 
C: 61.5 ± 7.3 
NS NS 
T: 20 ± 8.5 
C: 19.6± 7.3 
48 
Liu, 
2010 
Shanghai, China 
RCT [6 mths/NS] 
Out patients 
T: 30/30 
C: 30/30 
T: 18/12 
C: 16/14 
T: 65.12±5.36 
C: 64.12±7.36 
T: 0 5, I 9, II 16 
C: 0 6, I 10, II 14 
Qi deficiency and 
phlegm stasis  
T: 17.32±2.36 
C: 16.12±2.06 
49 
Luo, 
2002 
Hangzhou, 
Zhejiang 
RCT [3mths / NS] 
Out patients 
T: 36/36 
C: 20/20 
T: 25/11 
C: 14/6 
T: 
63.86±12.56 
C: 
63.90±12.56 
NS NS 
T:20.36 ± 
11.21 
C: 19.70± 
10.00 
50 Ma, Xianyang, Shanxi Out patients T: 33/33 T: 23/10 T: 39-74 T: I 12, II 15, III 6;                                           Lung qi deficiency T: 3-39 
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2009 RCT [2mths / NS] C: 32/32 C: 24/8 C: 36-71 C: I 9, II 19, III 4 C: 2-40 
51 
Mai, 
2009 
Guangdong, China 
RCT [2 mths/NS] 
Out patients 
T: 40/40 
C: 40/40 
T: 22/18 
C: 24/16 
T: 67.70±6.80 
C: 66.89±5.87 
T: II 12, III 28 
C: II 10 III 30 
NS 
T: 13.05±6.84 
C: 14.53±6.05 
52 
Ni, 
2008 
Shanghai, China 
RCT [2 
mths/4mths ] 
Out patients 
T: 34/34 
C: 34/34 
T: 19/15 
C: 20/14 
T: 64.35±6.77 
C: 64.62±7.05 
NS Kidney deficiency 
T: 11.24±5.02 
C: 10.50±4.56 
53 
Peng, 
2010 
Sichuan, China 
RCT [28 days 
/NS ] 
Both 
T: 62/62 
C: 60/60 
T: 39/23 
C: 38/22 
T: 59 ±NS 
C: 57 ±NS 
T: mild 12, moderate 
39, severe 11;  
C: mild 12, moderate 
38, severe 10 
NS 
T: 16± NS 
C: 14± NS 
54 
Pu, 
2010 
Jiangsu, China 
RCT [6 mths/NS] 
Out patients 
T: 30/30 
C: 30/30 
T: 17/13 
C: 18/12 
T: 64.5±8.5 
C: 63.5±9.0 
II & III NS 
T: 9.8±4.2 
C: 10±3.5 
55 
Qiu, 
2009 
Guangzhou, China 
RCT [2 mths / NS] 
Both 
T: 30/30 
C: 30/30 
43/17 69.65 NS NS 13.7±7.53 
56 
Shan, 
2007 
Guangdong, China 
RCT [6 mths/NS] 
Both 
T: 28/28 
C: 27/27 
T: 24/4 
C: 24/3 
T: 66.75±5.95 
C: 66.89±6.18 
T: I 5, II 23 
C: I 6, II 21 
NS 
T: 17.32±7.23 
C: 16.15±6.18 
57 
Shao, 
2006 
Xiamen, Fujian 
RCT [12 mths / 
NS] 
NS 
T: 36/36 
C: 38/38 
T: 25/11 
C: 28/10 
T: 73.6± NS 
C: 72.9± NS 
T: II 27, III 9 
C: II 30 III 8 
NS 
1-10 (38) 
>10 (36) 
58 
Shi (1), 
2008 
Shanghai, China 
RCT [2 mths/NS ] 
Out patients 
T: 100/94 
C: 30/30 
T: 44/56 
C: 14/16 
T: 
66.33±12.18 
C: 
70.83±12.61 
NS 
Kidney Yin 
deficiency 
T: 
15.64±10.51 
C: 18.55± 
12.38 
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59 
Shi (2), 
2008 
Tianjing, China 
RCT [6 mths/12 
mths] 
In patients 
T: 45/45 
C:45/45 
T: 31/14 
C: 29/16 
T: 69± NS 
C: 68.5± NS 
I-III Sanyin Xuhan NS 
60 
Shi, 
2009 
Chuangchun, Jilin 
RCT [6 mths/6 
mths] 
NS 
T: 90/90 
C: 90/90 
103/87 63.0±5.0 NS Multi syndroms 14.0±5.0 
61 
Shinoz
uka, 
2007 
Japan 
RCT [6 mths/NS] 
NS 
T: 1718 
C:17/18 
NS 73.0±1.0 
T: 40.7±5.0% 
C: 45.4±2.3% 
NS NS 
62 
Su, 
2005 
Beijing 
RCT [3mths / NS] 
NS 
T: 35/35 
C: 37/37 
T: 16/19 
C: 18/17 
T: 60.6±8.9 
C: 56.6±8.8 
NS 
Qi deficiency & 
blood stasis 
NS 
63 
Sun (1), 
2007 
Jiangsu, China 
RCT [6 mths/NS] 
NS 
T: 30 
C: 25 
45/10 70.3±6.8 Moderate  
Lung Qi & Kidney  
Qi deficiency 
NS 
64 
Sun (2), 
2007 
Nanjing, Jiangsu 
RCT [2 mths / NS] 
Both 
T: 19/19 
C:19/19 
T: 11/8 
C: 12/7 
T: 60.97±8.97 
C: 
59.54±10.87 
T: mild 3, moderate 
12, severe 4 C: mild 
4, moderate 11, 
severe 4 
Lung & Spleen & 
Kidney deficiency 
T: 11.24±5.02 
C: 10.50±4.56 
65 
Sun (1), 
2009 
Tianjing, China 
RCT [1 mth/NS] 
Out patients 
T: 30/30 
C: 30/30 
T: 21/9 
C: 22/8 
T: 60.97±8.97 
C: 
59.54±10.87 
II & III: NS NS NS 
66 
Sun (2), 
2009 
Nanjing,Jiangsu 
RCT [3 mths /NS] 
Out patients 
T: 30/30 
C: 30/30 
T: 24/6 
C: 24/6 
T: 64.67±8.54 
C: 68.30±7.68 
T: I 1, II 6, III 23 
C: I 1, II 13 III 15 
Lung & Spleen & 
Kidney deficiency 
T: 9.37±5.99 
C: 9.48±6.92 
67 
Tang, 
2009 
Guangdong, China 
RCT [2 mths/NS] 
Out /  
In patients 
T: 30/30 
C: 30/30 
T: 27/3 
C: 26/4 
T: 63.2± NS 
C: 65.5± NS 
NS 
Lung Qi & Kidney  
Qi deficiency 
T: 7.2±NS 
C: 7.5±NS 
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68 
Tang, 
2010 
Shanghai, China 
RCT [3 mths/NS] 
Out patients 
T: 34/34 
C: 35/35 
T: 23/11 
C: 26/9 
T: 72.18± 
10.78 
C: 71.00± 
10.53 
T: I-II 8, III-IV 26 
C: I-II 8,  III-IV 27 
Lung & Spleen & 
Kidney deficiency 
T: 14.53±9.15 
C: 
15.46±10.89 
69 
Tatsumi
, 2009 
Japan 
RCT [6 mths / NS] 
NS 
T: 34/37 
C: 34/37 
NS NS Moderate-severe NS NS 
70 
Tian, 
2005 
Chengdu, Sichuan 
RCT [90 days / 
NS] 
Out patients 
T: 50/50 
C: 49/49 
T: 32/18 
C: 29/20 
T: 60.17± 6.87 
C: 61.12± 6.85 
NS NS 
T: 10.7±0.51 
C: 10.59±0.52 
71 
Wang, 
2003 
Hangzhou, 
Zhejiang RCT [3 
mths / NS] 
Out patients 
T: 29/29 
C: 25/25 
T: 20/9 
C: 18/7 
T: 61.3± NS 
C: 61.3± NS 
NS NS 
T: 10.3-21 
C: 9.5-20.4 
72 
Wang, 
2005 
Hefei, Anhui 
RCT [2 mths / NS] 
NS 
T: 20/20 
C: 20/20 
T: 18/2 
C: 19/1 
T: 59.4± 7.5 
C: 60.9± 7.9 
T: IIA 8, IIB 9 III 3;                                       
C: IIA 9, IIB 9, III 2 
Qi deficiency of
lung & spleen 
T: 11.2±4.1 
C: 11.8±4.5 
73 
Wang, 
2006 
Hefei, Anhui  
RCT [28 days /NS] 
In patients 
T: 30/30 
C: 30/30 
T: 19/11 
C: 20/10 
T: 49.38± NS 
C: 47.62± NS 
NS NS NS 
74 
Wang, 
2009 
Zhejiang, China 
RCT [2 mths/NS] 
In patients 
T: 30/30 
C:32/32 
T: 24/6 
C: 25/7 
T: 70.5± NS 
C: 69.8± NS 
NS 
Lung Qi & Spleen 
Qi deficiency 
T: 7.3±NS 
C: 6.8±NS 
75 
Wu (1), 
2006 
Xinxiang, China 
RCT [2 mths / NS 
In patients & 
out patients 
T: 100/100 
C: 100/100 
T: 68 /32 
C: 72/28 
T: 71.87±4.37 
C: 69.33±5.71 
T: mild 21, moderate 
48, severe 31 C: 
mild 23, moderate 
51, severe 26 
Lung & Kidney   
deficiency 
T: 18.70±3.72 
C: 17.81±4.57 
76 
Wu (2), 
2006 
Dongyang, 
Zhejiang 
In patients 
T: 32/32 
C: 30/30 
T: 19/13 
C: 21/9 
T: 63-89 
C: 62-88 
NS NS NS 
 388 
 
No. of 
studies 
First 
author, 
date 
Location, Design 
[duration / 
follow up] 
Out /in 
patients 
No. subjects 
(R/A) 
M/F 
Age 
Mean SD 
(years) 
Severity of COPD:  
No. subjects 
CM Syndrome 
Differentiation 
COPD history 
(years) 
RCT [6 weeks 
/2mths] 
77 
Wu, 
2007 
Guangdong, China 
RCT [4 mths/NS] 
NS 
T: 71/63 
C: 62/59 
T: 49/14 
C: 43/16 
T: 61.5±NS 
C: 61.9±NS 
T: I 15, II 29, III 19 
C: I 14, II 27, III 18 
NS NS 
78 
Wu (1), 
2009 
Guiyang, Guizhou 
RCT [1 month / 
NS] 
Out patients 60 38/22 64± NS 
T: I 4, II 12, III 
10,IV 4 
C: I 4, II 13, III 9 IV 
2 
Spleen & stomach 
deficiency 
21± NS 
79 
Wu (2), 
2009 
Beijing 
RCT [12 weeks / 9 
mths] 
Out patients 
T: 30/30 
C: 26/26 
T: 19/11 
C: 19/7 
T: 67.10± 6.58 
C: 65.96± 9.66 
T: II 19, III 11 
C: II 15, III 11 
NS 
T: 13.4±6.35 
C: 15.31±6.95 
80 
Xiao, 
2000 
Zhanjiang, 
Guangdong 
RCT [2mths / NS] 
Both 
T: 54/54 
C: 54/54 
T: 30/24 
C: 29/25 
T: 68.3 ± NS 
C: 67.1 ± NS 
NS NS 
T: 13.36±NS 
C: 13.13±NS 
81 
Xin, 
2010 
Beijing, China 
RCT [28 days / 
NS] 
Out patients  
T: 30/30 
C: 28/28 
T: 16/14 
C: 14/14 
T: 58.5± NS 
C: 57.7±NS 
II & III NS 
T: 10.00±NS 
C: 10.00±NS 
82 
Xiong, 
2008 
Shenzhen, China 
RCT [6 mnths /NS] 
Both 
T: 30/30; 
C: 30/30 
T: 20/10 
C: 21/9 
T&C: 
72.00±NS 
Average of  FEV1  
T: 52.3%; C: 56.8% 
Lung & Kidney 
deficiency 
NS 
83 
Xiong, 
2010 
Shenzhen, China 
RCT [6 mnths /NS] 
NS 
T: 54/54 
C: 45/45 
T: 28/26 
C: 23/22 
T: 66.8 ± 3.4 
C: 65.9 ± 3.5 
NS NS NS 
84 
Xu, 
1996 
Luzhou, China 
RCT [30 days / 
NS] 
Both 
T: 72/72 
C: 30/30 
T: 52/20 
C: 21/9 
T: 63.50±NS; 
C: 60.80±NS 
T: mild 23, moderate 
31, severe 18;  
C: :mild 11 moderate 
Qi deficiency 
T: 9.50±NS 
C: 9.00±NS 
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No. of 
studies 
First 
author, 
date 
Location, Design 
[duration / 
follow up] 
Out /in 
patients 
No. subjects 
(R/A) 
M/F 
Age 
Mean SD 
(years) 
Severity of COPD:  
No. subjects 
CM Syndrome 
Differentiation 
COPD history 
(years) 
12, severe 7 
85 
Xu, 
2008 
Guangdong, China 
RCT [1 month / 
NS] 
Both  
T: 30/30 
C: 30/30 
42/18 
T&C: 66.34 ± 
10.28 
NS NS 
T&C: 10.4 ± 
NS 
86 
Xu, 
2009 
Guangdong, China 
RCT [3 weeks / 
NS] 
NS 
T: 33/33 
C: 33/33 
T: 22/11 
C: 23/10 
T: 69.8 ± NS 
C: 70.2 ± NS 
NS NS 
T: 8.6±NS 
C: 9.0 ±NS 
87 
Yang, 
2010 
Sichuan, China 
RCT [3 weeks / 
NS] 
Out patients  
T: 25/25 
C: 25/25 
28/22 68±NS NS NS 16 ±NS 
88 
You, 
2008 
Hunan, China 
RCT [2 mths/1 
year] 
Out patients 
T: 32/30 
C: 32/30 
T: NS 
C: NS 
T: 59.43±11.56 
C: 
56.23±10.69 
I & II:NS NS 
T: 6.15±1.71 
C: 6.23± 1.59 
89 
Zhai, 
2009 
Kaifeng, Henan 
RCT [6 mths / NS] 
Both  
T: 32/30; 
C: 32/30 
T: 20/12 
C: 19/11 
T: 60 ± NS 
C: 58 ± NS 
NS 
Qi deficiency of 
spleen & Kidney 
& phlegm 
NS 
90 
Zhang, 
2003 
Beijing 
RCT [3 mths /NS] 
Both 
T: 30/30; 
C: 30/30 
T: 18/12 
C: 19/11 
T&C: 50.1 ± 
NS 
NS NS 
T: 11.5±NS 
C: 9.6 ±NS 
91 
Zhang, 
2006 
Guangdong, China 
RCT [6 mths/NS] 
NS 
T: 24/24 
C: 22/22 
T: 18/6 
C: 17/5 
T: 66.70±6.60 
C: 67.89±4.57 
T: II 5, III 14 
C: II 4, III 18 
NS 
T: 14.05±6.54 
C: 15.33±5.0 
92 
Zhang, 
2007 
Jiangmen, 
Guangdong 
RCT [30 days / 
NS] 
Out patients 
T1: 20/20 
T2 20/20 
C: 20/20 
T1: 17/3 
T2 16/4 
C: 16/4 
T1: 70.2 ± NS 
T2: 70 ± NS 
C: 69.5 ± NS 
NS NS 
T1: 6.8 ± NS 
T2 7.3 ± NS 
C: 6.9 ± N 
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No. of 
studies 
First 
author, 
date 
Location, Design 
[duration / 
follow up] 
Out /in 
patients 
No. subjects 
(R/A) 
M/F 
Age 
Mean SD 
(years) 
Severity of COPD:  
No. subjects 
CM Syndrome 
Differentiation 
COPD history 
(years) 
93 
Zhang, 
2008 
Chengdu, Sichuan 
RCT [3 mths/NS] 
Out patients 
T: 38/37 
C: 35/31 
T: 28/10 
C: 25/10 
T: 63.5± 10.08 
C: 63.55± 
10.42 
I-III NS NS 
94 
Zhang 
(1), 
2009 
Guangdong, China 
RCT [6 mths/NS] 
Out patients 
T: 60/56 
C: 60/48 
NS 68.4±NS NS NS NS 
95 
Zhang 
(2), 
2009 
Tacheng, Xinjiang 
RCT [12 
weeks/NS] 
Out patients 
T: 30/30 
C: 30/30 
T: 21/9 
C: 18/12 
T: 58.8± NS 
C: 60.2± NS 
NS NS 
T: 22.6±NS 
C: 23.1±NS 
96 
Zhang, 
2010 
Hebei, China 
RCT [6 mths/1 
year] 
Both 
T: 60/60 
C: 60/60 
T: 38/22 
C: 40/20 
T: 56±NS 
C: 55 ±NS 
NS 
Lung & Kidney 
deficiency 
T: 16±NS 
C: 14±NS 
97 
Zhao, 
2009 
Jiangmen, 
Guangdong 
RCT [12 weeks 
/1year 
in patients 
T: 45/45 
C: 30/30 
50/25 
T&C: 
67.3±5.2 
NS 
Qi deficiency of 
Kidney & 
stagnation phlegm 
in lung 
T&C: 8± NS 
98 
Zhou, 
2007 
Caiwu, Shangdong 
RCT [1 month 
/NS] 
Both 
T: 30/30 
C: 30/30 
T: 22/8 
C: 21/9 
T: 63.63± 7.77 
C: 64.83± 7.37 
Mild & Moderate 
Qi deficiency of 
Lung & Spleen 
plus retention 
phlegm and blood 
stasis in lung  
NS 
99 
Zhu,  
2007 
Guangdong, China 
RCT [6 mths/NS] 
Both 
T: 35/35 
C: 32/32 
T: 16/19 
C: 15/17 
T: 72.0±10.3 
C: 71.7±9.5 
T: I 22, IIA 13 
C: I 20, IIA 12 
NS NS 
100 
Zhu, 
2010 
Jiangsu, China 
RCT [8 weeks/NS] 
Out patients  
58/53 
T: 27 C: 26 
38/20 50-75  
Moderate & severe: 
NS 
Qi & Yin 
deficiency or Ling 
& Kidney 
NS 
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No. of 
studies 
First 
author, 
date 
Location, Design 
[duration / 
follow up] 
Out /in 
patients 
No. subjects 
(R/A) 
M/F 
Age 
Mean SD 
(years) 
Severity of COPD:  
No. subjects 
CM Syndrome 
Differentiation 
COPD history 
(years) 
deficiency 
101 
Zhuan, 
2006 
Chengdu, Sichuan 
RCT [3mths / NS] 
Out patients 
T: 30/30 
C: 30/30 
36/24 
45-70 
(59.3±8.7) 
IIA 
Lung & spleen 
deficiency 
NS 
     T: treatment group; C: control group; NS: not specified
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Appendix 13 Table: Methodological quality of the 101 studies assessed by Jadad’s scale in review of Chinese herbal medicine for stable COPD with physical 
and symptomatic outcome measures 
First author, 
date 
Randomisatin 
Double 
blinding 
Description of 
withdrawals 
Adequate 
description of 
randomization 
Blinding adequately 
carried out 
Total scores 
Ao, 2007 1 NS 1 NS NS 2 
Che, 2005 1 NS 1 (reasons) NS NS 2 
Chen, 2004 1 NS 1 NS NS 2 
Chen, 2006 1 NS 1 1 NS 3 
Chen (1), 2007 1 NS 1 1 NS 3 
Chen (2), 2007 1 NS 1 1 NS 3 
Chen, 2008 1 NS 1 NS NS 2 
Chen (1), 2009 1 NS NS NS NS 1 
Chen (2), 2009 1 NS 1 NS NS 2 
Cui, 2008 1 NS 1 NS NS 2 
Du, 2006  1 NS 1 1 NS 3 
Fang, 2008 1 NS 0 (no reason) NS NS 1 
Feng, 2005 1 NS 1 1 NS 3 
Feng, 2006 1 NS 1 NS NS 2 
Feng, 2007 1 NS 1 1 NS 3 
Feng, 2008 1 NS 1 NS NS 2 
Gao, 2008 1 NS 1 NS NS 2 
Gross, 2002 1 1 0 (no reason) 1 0 3 
Guo, 2008 1 NS 1 NS NS 2 
Guo 2010 1 NS 1 NS NS 2 
Hao, 2008 1 NS 1 NS NS 2 
He, 2010 1 NS 1 1 NS 3 
Hong, 2005 1 NS 1 1 NS 3 
Hu, 2005 1 NS 1 NS NS 2 
Hu, 2009 1 NS 1 NS NS 2 
Huang, 2002 1 NS NS NS NS 1 
Huang, 2005 1 NS 1 NS NS 2 
Huang, 2009 1 NS 1 NS NS 2 
Ji, 2010 1 NS 1 NS NS 2 
 393 
 
First author, 
date 
Randomisatin 
Double 
blinding 
Description of 
withdrawals 
Adequate 
description of 
randomization 
Blinding adequately 
carried out 
Total scores 
Jia, 2007 1 NS 1 NS NS 2 
Jian, 2008 1 NS 1 1 NS 3 
Jin, 2008 1 NS 1 1 NS 3 
Lang, 2010 1 NS 1 NS NS 2 
Lei, 2006 1 NS 1 NS NS 2 
Li (1), 2006 1 NS NS 1 NS 2 
Li (2), 2006 1 NS 1 NS NS 2 
Li, 2007 1 NS 0 (no reason) NS NS 1 
Liang, 2005 1 NS 1 1 NS 3 
Liang, 2009 1 NS 1 NS NS 2 
Lin, 2003 1 NS 1 NS NS 2 
Lin, 2008 1 NS 1 NS NS 2 
Liu, 2002 1 NS 1 1 NS 3 
Liu, 2005 1 NS 0 (no reason) 1 NS 2 
Liu (1), 2006 1 NS 1 1 NS 3 
Liu (2), 2006 1 NS 0 (no reason) NS NS 1 
Liu, 2007 1 NS NS NS NS 1 
Liu, 2008 1 NS 1 NS NS 2 
Liu, 2010 1 NS 1 NS NS 2 
Luo, 2002 1 NS 1 NS NS 2 
Ma, 2009 1 NS 1 1 NS 3 
Mai, 2009 1 NS 1 NS NS 2 
Ni, 2008 1 NS 1 NS NS 2 
Peng, 2010 1 NS NS NS NS 1 
Pu, 2010 1 NS NS NS NS 1 
Qiu, 2009 1 NS 1 1 NS 3 
Shan, 2007 1 NS 1 1 NS 3 
Shao, 2006 1 NS 1 NS NS 2 
Shi (1), 2008 1 NS 1(reason) 1 NS 3 
Shi (2), 2008 1 NS 1 NS NS 2 
Shi, 2009 1 NS 1 NS NS 2 
Shinozuka, 2007 1 NS NS NS NS 1 
Su, 2005 1 NS 1 NS NS 2 
Sun (1), 2007 1 NS NS NS NS 1 
Sun (2), 2007 1 NS NS NS NS 1 
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First author, 
date 
Randomisatin 
Double 
blinding 
Description of 
withdrawals 
Adequate 
description of 
randomization 
Blinding adequately 
carried out 
Total scores 
Sun (1), 2009 1 NS 1 NS NS 2 
Sun (2), 2009 1 NS 1 -1 NS 1 
Tang, 2009 1 0 1 NS NS 2 
Tang, 2010 1 NS 1 1 NS 3 
Tatsumi, 2009 1 NS NS NS NS 1 
Tian, 2005 1 NS 1 NS NS 2 
Wang, 2003 1 NS 1 NS NS 2 
Wang, 2005 1 NS 1 1 NS 3 
Wang, 2006 1 NS 1 NS NS 2 
Wang, 2009 1 NS 1 (reason) NS NS 2 
Wu (1), 2006 1 NS 1 NS NS 2 
Wu (2), 2006 1 NS 1 NS NS 2 
Wu, 2007 1 NS 0 (no reason) NS NS 1 
Wu (1), 2009 1 NS NS NS NS 1 
Wu (2), 2009 1 NS 1 1 NS 3 
Xiao, 2000 1 NS 1 NS NS 2 
Xin, 2010 1 NS 1 NS NS 2 
Xiong, 2008 1 NS 1 NS NS 2 
Xiong, 2010 1 NS 1 NS NS 2 
Xu, 1996 1 NS NS NS NS 1 
Xu, 2008 1 NS NS NS NS 1 
Xu, 2009 1 NS 1 NS NS 2 
Yang, 2010 1 NS NS NS NS 1 
You, 2008 1 NS 1 (reason) 1 NS 3 
Zhai, 2009 1 NS 1 NS NS 2 
Zhang, 2003 1 1 1 1 0 4 
Zhang, 2006 1 NS 1 NS NS 2 
Zhang, 2007 1 NS NS NS NS 1 
Zhang, 2008 1 NS 1 (reason) NS NS 2 
Zhang (1), 2009 1 NS 1 NS NS 2 
Zhang (2), 2009 1 NS 1 NS NS 2 
Zhang, 2010 1 NS 1 NS NS 2 
Zhao, 2008 1 NS 1 NS NS 2 
Zhou, 2007 1 NS 1 1 NS 3 
Zhu, 2007 1 NS 1 1 NS 3 
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First author, 
date 
Randomisatin 
Double 
blinding 
Description of 
withdrawals 
Adequate 
description of 
randomization 
Blinding adequately 
carried out 
Total scores 
Zhu, 2010 1 1 1 (reason) NS NS 3 
Zhuan, 2006 1 NS NS 1 NS 2 
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Appendix 14 Table: Comparison of CHM (formulae and ingredients) and placebo control groups in review of Chinese herbal medicine for stable COPD with 
physical and symptomatic outcome measures 
First 
author, date 
Intervention 
Control Adverse event 
Formula name (form): Dose / Ingredients Plus RP 
Du, 2006 
Yinxingye extract tablet: 2 tablets, Tid 
Ginkgo biloba extract. 
No Placebo NO 
Gross, 2002 
Ginseng extract capsule: 100 mg Bid  
Renshen 
Bronchodilator (not specified) 
Placebo+ Bronchodilator (not 
specified) 
NO 
He, 2010  
Buzhong Yiqi Tang /granule: 6g Bid 
Huangqi, Dangshen, Baizhu, Shashen, Banxia, Chenpi, 
Sangbaipi, Yuzhu 
Theophylline Sustained-release 
Tablets 0.2g Bid  
Placebo + Theophylline Sustained-
release Tablets 0.2g Bid 
NO 
Huang, 2002 
Bufei Guben granule:10g Tid 
Renshen, Gejie, Yinyanghuo, Hutaorou, Buguzhi, Wuweizi, 
etc. 
No Placebo NS 
Li (1), 2006 
Bufei Yishen granule:10g Tid 
Renshen, Huangqi, Baizhu, Fangfeng, Maidong, Buguzhi, 
Wuweizi, Gejie, Shanyurou, Dongcongxiacao, Zhebeimu, 
Chenxiang, Weijin, Quanchong, Xingren, Chuanxiong. 
No Placebo NS 
Lin, 2003 
Jiapi Yifei granule: 10g Tid 
Rehshen, Baizhu, Fuling, Maidong, Sangbaipi, Huangqi. 
No Placebo NS 
Ni, 2008 Bushen Naqi granule: 10g Tid 
Theophylline,Inhaler of 
Salbutamol Placebo (Shanzha granule) + 
NS 
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First 
author, date 
Intervention 
Control Adverse event 
Formula name (form): Dose / Ingredients Plus RP 
Buguzhi, Yinyanghuo, Fupenzi, Wuweizi. Theophylline, Inhaler of Salbutamol 
Sun (1),  
2009 
Bufei granule: 16g Bid 
Dangshen, Shudihuang, Danggui, Shanzhuyu, Mahuang, 
Sangbaipi, Chenpi, Ziyuan. 
No Placebo NO 
Wu (1), 
2006 
Shenge granule: 1 bag Tid 
Renshen, Gejie, Xingren, Zhigancao, Fuling, Chuanbeimu, 
Sangbaipi, Dongcongxiacao, Baizhu, Huangqi, Chuanxiong, 
Dilong, 
No Placebo NS 
Xu, 2008 
Jianpi Yifei granule: 10g, Tid 
Hongshen, Baizhu, Fuling, Maidong, Sangbaipi, Huangqi. 
No Placebo NS 
Zhang, 2007 
Sanzi Yangqin Decoction: 200ml Bid 
Dangshen, Baizhu, Yunling, Suzi, Baijiezi, Laifuzi, Juhong, 
Fabanxia. 
No Placebo NS 
Zhuan, 2006 
Liujunzi Tang/Decoction: one packet once daily,300ml,Bid 
Dangshen, Chaobaizhu, Fuling, Chenpi, Zhibanxia, Gancao. 
No Placebo NS 
RP: routine pharmacotherapy 
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Appendix 15 Table: Comparison of CHM (formulae and ingredients) and RP groups in review of Chinese herbal medicine for stable COPD with physical 
and symptomatic outcome measures 
First author, 
date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Chen, 2006 
Lijin granule/decoction: one packet once daily, 100ml, Bid 
Dangshen, Huangqi, Maidong, Wuweizi, Ziyuan, Chuanbaimu, 
Gejie, Baizhu, Fangfeng, Fuling, Chenpi, Gancao. 
No Theophylline Tablets: 0.1g Tid NS 
Chen (2), 
2007 
Lijin granule/decoction:one packet once daily, 150ml, Bid 
Dangshen, Huangqi, Maidong, Wuweizi, Ziyuan, Chuanbaimu, 
Gejie, Baizhu, Fangfeng, Fuling, Chenpi, Gancao. 
No Theophylline Tablets: 0.1g Tid NS 
Hu, 2005 
Buzhong Yiqi Decoction: NS 
Huangqi, Dangshen, Baizhu, Zhigancao, Danggui, Chenpi, 
Shengma, Chaihu. 
No 
Ipratropium Bromide Aerosol, Pulmicort Aerosol, 
Theophylline 
NS 
Jin, 2008 
Jinpi Bufei Decoction: NS 
Renshen, Fuling, Baizhu, Danshen, Fabanxia, Zhuru, Gualoupi, 
Houpo, Zhiqiao, etc. 
No Bronchodilator NS 
Ma, 2009 
Yupingfeng pill: 6g, Bid 
Huangqi Baizhu Fangfeng 
No Mannatide tablets: 5mg Tid NO 
Shi (1) 2008 
Bushen Yifei capsule: 6 Tid 
Gandihuang, Shanyurou, Wuweizi, Yinyanghuo, Tusizi, 
Nvzhenzi, Huainiuxi, Gejie 
No Nucleotide and Casein Oral Solution: 10ml Tid NS 
Shi (2), 
2008 
Yougui Yin/Decoction 
Shenqi pill: 1 Bid; Xuesaitong tablet: 2# Tid Yongchongcaojun 
capsule: 3 Tid 
Shudihuang, Shanyao, Shanzhuyu, Gouji, Zhigancao, Duzhong, 
Rougui, Zhifuzi 
No 
Stage I: Salmeterol 100-200 μg; 
Stage II-III: Salmeterol Xinafoate/Fluticasone 
Propionate: 50 μg, Bid; 
OR 
Compound Aminophylline Tablets: 1# p.r.n 
NS 
Wang, 2003 
Xiazhi Number I granule: 15g Tid 
Huangqi, Ezhu, Tusizi, Zishiying, Qiyeyizhihua, etc. 
No 
Theophylline Controlled Release Capsules: 
0.2g Bid 
NS 
Wu (2), 
2006 
Liujuzi Tang/Decoction:one packet once daily, 150ml, Bid 
Dangshen, Fuling, Zhigancao, Chenpi, Jiangbanxia, Ziyuan, 
Kuandonghua, Taoren, Honghua, Danggui,etc. 
No Diastase Pancreatin and Pepsin Tablet: 4# Tid NS 
Wu (1), 
2009 
Liujunzi granule: 15g,Tid 
Dangshen, Baizhu, Fuling, Zhibanxia, Chenpi, Zhigancao. 
No Diastase Pancreatin and Pepsin Tablet: 2# Tid NO 
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First author, 
date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Xiao, 2000 
Manzhi Kechuanning oral liguid: 10ml Bid 
Renshen, Huangqi, Baizhu, Fuling, Shanyao, Hongzao 
No 
0.9% saline 30ml +Dexamethasone 3mg + 
Theophylline 0.125g: as Ultrasonic atomizing 
inhalation  Bid; 
Theophylline Controlled Release Tablets: 0.1g p.r.n 
NS 
Xin, 2010 
Yiqi Xiaotan Huayu formula/decoction: one packet once daily 
(400ml, Bid) 
Huangqi, Dangshen, Fuling, Baizhu, Gancao, Chenpi, Banxia, 
Gualou, Xingren, Zhiqiao, Chaihu, Taoren, Honghua, Huangqin, 
Danshen 
NO 
Theophylline Sustained-release Tablets: 0.2g Bid; 
Ambroxol Hydrochloride: 30mg Bid 
NO 
Xiong, 2008 
Shenge granule: 5g Bid 
Gaolishen, Gejie 
No 
Salmeterol Xinafoate/Fluticasone Propionate: 
1 puff Bid 
NS 
Zhai, 2009 
Bufei Nashen Tang/Decoction:one packet once daily 
Huangqi, Gejie, Baizhu, Fuling, Shudihuang, Shanzhuyu, 
Danggui, Wuweizi, Chenpi, Chenxiang, Rougui, Dilong, 
Danshen, Zhigancao, etc. 
No 
Theophylline, Salbutamol and ipratropium bromide: 
p.r.n 
NS 
Zhu, 2007 
Tianlong Kechuanling capsule: 4 capsules, Tid 
Qingtiankui, Kuandonghua, Fabanxia, Shufuzi, Wuweizi. 
No 
Compound Ipratropium Bromide Aerosor: 2 puffs, 
Qid 
NS 
RP: routine pharmacotherapy; I, II, III (severity of COPD): Stage I, Stage II, Stage III 
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Appendix 16 Table: Comparison of CHM (formulae and ingredients) plus RP and RP groups in review of Chinese herbal medicine for stable COPD with 
physical and symptomatic outcome measures 
First 
author, date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Ao, 2007 
Xiaoyaosan /decoction: one packet once daily, 150ml, Tid 
Danggui, Baishao, Chaihu, Fuling, Baizhu, Bohe, 
Huangqin, Gualou, Qianhu, Shegan, Pipaye. 
Theophylline Tablets: 0.1g Tid Theophylline Tablets: 0.1g Tid NS 
Che, 2005 
Zhike Qingfei oral liquid: 2 ml, Tid (QC ) 
Jinyinhua, Huangqin, Lianqiao, Banlangen, Kuandonghua, 
Ziyuan, Yuxingcao, Jiegeng, Mahuang, Pipaye, Huangqi, 
Gancao. 
RP RP Yes 
Chen, 2004 
Yiqi pill:2 pills Tid 
Renshen, Gejie Buguzhi 
RP RP NS 
Chen (1), 
2009 
Qiwei Duqi Tang (decoction): 250 ml Bid 
Shanzhuyu, Shanyao, Shudihuang, Mudanpi, Zexie, Fuling, 
Wuweizi, Huangqi, Dangshen, Baizhu. 
Salmeterol 50μg & Fluticasone 
500μg inhaled Bid 
Salmeterol 50 μg & Fluticasone 500 
μg inhaled Bid 
No 
Chen (2), 
2009 
Liujunzi Tang /Decoction:one packet once daily 
Dangshen, Chaobaizhu, Fuling, Chenpi, Zhibanxia, Gancao. 
Ipratropine 40 μg inhaled Tid; 
Theophylline Tablets: 0.1g Bid 
Ipratropine 40 μg inhaled Tid; 
 Theophylline Tablets: 0.1g Bid 
NS 
Feng, 2005 
Yiqihuoxuehuatang (decoction): one packet once daily 
Huangqi, Shuizhi, Beimu, Guangdilong etc. 
Plus Bailing capsule: 4 capsules, Tid 
Or 
Feikang granule: 10g once daily  
Huangqi, Shuizhi, Huangjing, Danggui, Chenpi etc. 
Stage 0: no treatment 
I: short-acting bronchodilator 
II: one or multi bronchodilators or 
inhaled glucocorticosteriod 
Stage 0: no treatment 
I: short-acting bronchodilator 
II: one or multi bronchodilators or 
inhaled glucocorticosteriod 
NS 
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First 
author, date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Plus Bailing capsule: 4 capsules, Tid 
Feng, 2006 
Jianpi Bufei Tang/decoction: 150 ml, Bid  
Taizishen, Huangqi, Gejie, Baizhu, Shengma, Chaihu, 
Danggui, Kuandonghua, Tusizi, Shuizhi. 
Doxofylline Tablets: 400mg Bid Doxofylline Tablets: 400mg Bid NS 
Feng, 2007 
Yiqihuoxuehuatang (decoction): one packet once daily 
Huangqi, Shuizhi, Beimu, Guangdilong etc. 
Plus Bailing capsule: 4 capsules, Tid 
Or 
Feikang granule: 10g once daily  
Huangqi, Shuizhi, Huangjing, Danggui, Chenpi etc. 
Plus Bailing capsule: 4 capsules, Tid 
RP RP NS 
Feng, 2008 
Bufei Tang (decoction): one packet once daily 
Dangshen, Huangqi, Baizhu, Shanyao, Wuweizi, Maidong, 
Yuzhu, Zhimu, Jiegeng, Chenpi, Zhibaibu, Zhigancao. 
Or  
Qiweiduqiwan & Shengmaisan (decoction): one packet 
once daily 
Shudihuang, Shanzhuyu, Shengshanyao, Fuling, Danpi, 
Gouji, Wuweizi, Taizishen, Maidong, Nvzhenzi, 
Huanliancao. 
Or 
Jinguishenqiwan (decoction): one packet once daily 
Shudihuang, Shanzhuyu, Shengshanyao, Fuling, Shufuzi, 
Rougui, Lujiaojiao, Tusizi, Dangshen, Baizhu, Danshen, 
Huainiuxi, Yiyiren. 
Or 
Suzijiangqi Tang (decoction): one packet once daily 
Zisuzi, Banxia, Qianhu, Houpo, Danggui, Chenpi, Rougui, 
Gancao. 
RP RP NS 
Guo, 2008 
Jianfei capsule: 2-3 capsules Tid 
Renshen, Gejie, Jinqiaomaigen, Dilong, Chuanbeimu, 
Xingren, etc. 
Theophylline Tablets & Mucosolva 
& inhaled long-acting β2-agonists 
Theophylline Tablets & Mucosolva & 
inhaled long-acting β2-agonists 
NS 
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First 
author, date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Hao, 2008 
Pingchuanfang/Decoction:one packet once daily 
Shufuzi, Danshen, Fuling, Buguzhi, Yinyanghuo, Dilong, 
Wuweizi, Zhigancao, Chenpi, Xixin. 
Theophylline Sustained-release 
Tablets 
Theophylline Sustained-release Tablets NS 
Hu, 2009 
Bufei Tang/Decoction:one packet once daily 
Dangshen, Huangqi, Xuanshen, Maidong, Buguzhi, 
Bajitian, Tusizi, Baibu, Sangbaipi, Chenpi, Jiegeng, 
Danshen.  
Ambroxol hydrochloride: 30mg 
Tid, 
 Salbutamol sulfate Aerosol:  
200 μg, Tid,  
TheophyllineSustained-release 
Tablets: 0.2g Bid 
Ambroxol hydrochloride: 30mg Tid, 
 Salbutamol sulfate Aerosol:  
200 μg, Tid,  
TheophyllineSustained-release 
Tablets: 0.2g Bid 
NS 
Huang, 2005 
Yupingfeng granule:5g Tid  
Huangqi, Baizhu, Fangfeng. 
Plus Jianpiyifei granule: 10g Tid 
Renshen, Baizhu, Fuling, Maidong, Sangbaipi, Huangqi. 
Plus Bailing capsule: 5 capsules Tid 
RP RP Yes 
Ji, 2010 
Yuchuan Zhisheng Syrup: one spoon Bid 
Dangshen, Zhihuangqi, Shanyao, Chaobaizhu, Hutaorou, 
Shudihuang, Huangjing, Danggui, Nanshashen, Fuling, 
Ziwan, Kuandonghua, Baibu, Suzi, Fabanxia, Baijiezi, 
Beimu, Taoren, Xingren, Ganjiang, Chenpi, Zhimahuang, 
Wuweizi, Baiguo, Chenxiang, Zhigancao, Ziheche, Gejie. 
Theophylline Tablets:  
0.1g, Bid 
Theophylline Tablets:  
0.1g, Bid 
NS 
Jia, 2007 
Yiqihuoxue formula (decoction): one packet once daily 
Huangqi, Dilong, Xuanshen, Danshen, Taizishen, Danggui, 
etc. 
Ipratropium bromide:  
40 μg Tid (inhaled) 
Ipratropium bromide:  
40 μg Tid (inhaled) 
NS 
Jian,  
2008 
Pingchuan capsule: 4 capsules Tid 
Renshen, Gejie, Tianqi etc.  
Ipratropium Bromide: 2 puffs, Bid Ipratropium Bromide: 2 puffs, Bid NS 
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author, date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Lang, 2010 
Baibu Yangfei Paste: NS 
Baibu 
RP RP NO 
Li (2), 2006 
Decoction:one packet once daily,200ml, Bid 
Huangqi. Baizhu. Shanyao. Taoren. Danshen. Sanqi. 
Chishao. Honghua. Chenpi. Xingren. Maidong 
Theophylline or Albuterol Theophylline or Albuterol NS 
Liang, 2005 
Jianpi Yifei Capsule & Bushen Peiyuan capsule: 3 
capsules/per Bid 
Dangshen. Baizhu. Wuweizi. Lingzhi. Maidong. 
Dongcongxiacao. Yucongrong. Shudihuang. Hetao 
Theophylline Sustained-release 
Tablets: 0.1g, Bid  
Plus Bromhexine Hydrochloride 
Tablets:16mg, Tid 
Theophylline Sustained-release 
Tablets: 0.1g, Bid  
Plus Bromhexine Hydrochloride 
Tablets:16mg, Tid 
NS 
Liang, 2009 
Dongping Tang (powder in decoction): one packet once 
daily 
Dongchongxiacao, Huangqi, Baizhu, Fangfeng. 
Stage 1: Salmeterol inhaler, 200μg 
up to Tid 
Stage 2: Theophylline tablets: 0.1-
0.2g Tid OR terbutaline sulfate 
tablets 2.5mg Bid OR salmeterol 
inhaler, 200μg up to Qid (if 
dyspnoea severe) 
Stage 3: Theophylline tablets: 0.1-
0.2g Tid OR terbutaline sulfate 
tablets 2.5mg Tid OR salmeterol 
inhaler, 200μg up to 6 times/day (if 
dyspnoea severe) 
Stage 1: Salmeterol inhaler, 200μg up 
to Tid 
Stage 2: Theophylline tablets: 0.1-0.2g 
Tid OR terbutaline sulfate tablets 
2.5mg Bid OR salmeterol inhaler, 
200μg up to Qid (if dyspnoea severe) 
Stage 3: Theophylline tablets: 0.1-0.2g 
Tid OR terbutaline sulfate tablets 
2.5mg Tid OR salmeterol inhaler, 
200μg up to 6 times/day (if dyspnoea 
severe) 
NS 
Liu (1), 
2006 
Huoxuehuayu formula (decoction): one packet once daily 
Chenpi, Fabanxia, Laifuzi, Zisuzi, Zhebeimu, Xingren, 
Taoren, Fuling, Maodongqing, Baijiezi, Gancao. 
Theophylline Sustained-release 
Tablets: 0.2g Bid 
Theophylline Sustained-release 
Tablets: 0.2g Bid 
NS 
Liu, 2007 Pingchuan III/Decoction:one packet once daily Combivent: 80μg, Bid Combivent: 80μg, Bid NS 
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Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
 Shufuzi, Ziheche, Gejie, Chuanshanlong, Sangshen, 
Danshen, Chishao, Dilong, Huangqi, Chenpi, Wuweizi. 
Bambuterol Hydrochloride: 10mg 
once daily 
Theophylline Sustained-release 
Tablets: 0.4g p.r.n 
Bambuterol Hydrochloride: 10mg 
once daily 
Theophylline Sustained-release 
Tablets: 0.4g p.r.n 
Liu, 2008 
Fuzheng Guben Tang/Decoction:one packet once daily 
Hongshen. Huangqi. Maidong. Wuweizi. Danshen. 
Buguzhi. Ziheche. Chuanxiong. Chenpi. Jiegeng. Sangbaipi 
Carbocisteine Tablets: 0.5g Tid 
Theophylline Sustained-release 
Tablets: 0.2g Bid 
Salbutamol inhaler: 200μg Tid 
Carbocisteine Tablets: 0.5g Tid 
Theophylline Sustained-release 
Tablets: 0.2g Bid 
Salbutamol inhaler: 200μg Tid 
NS 
Liu, 2010 
Yiqi Huatan Huoxue Tongluo formula/decoction: one packet 
once daily 100ml Bid 
Huangqi, Dangshen, Fuling, Baizhu, Chuanbeimu, Dilong, 
Danshen, Xixin, Baijiezi, Zishiying, Hongjingtian 
Salmeterol xinafoate/Fluticasone 
propionate: once daily or Bid 
Montelukast Sodium Tablets: 
10mg once daily 
Salmeterol xinafoate/Fluticasone 
propionate: once daily or Bid 
Montelukast Sodium Tablets: 10mg 
once daily 
NS 
Luo, 2002 
Baofei dingchuan granule: 15g/bag, 2 bag, Bid 
Dangshen, Huangqi, Danshen, Danggui, Shengdihuang, 
Maidong, Jiegeng, Gancao, Dilong, Yinyanghuo, etc. 
Theophylline Controlled Release 
Tablets: 0.2g Bid 
Carbocisteine Tablets: 0.5g Tid 
Theophylline Controlled Release 
Tablets: 0.2g Bid 
Carbocisteine Tablets: 0.5g Tid 
NS 
Mai, 2009 
Bufei Tang + Renshen Gejie Tang (decoction): 200ml once 
daily 
Dangshen, Huangqi, Shudihuang, Wuweizi, Ziyuan, 
Sangbaipi, Gejie. 
Antibiotics & Expectorants & 
Bronchodilators 
Antibiotics & Expectorants & 
Bronchodilators  
NS 
Peng, 2010 
Jinshui Liujun decoction: one packet once daily (Tid) 
Dangshen, Danshen, Yinyanghuo, Maidong, Shichangpu, 
Wuweizi, Danggui, Shudihuang, Baizhu, Fuling, Chenpi, 
Fabanxia, Tinglizi, Gancao. 
Theophylline Tablets+β2 agonist 
inhaler+Glucorticosteroid  inhaler  
Theophylline Tablets+β2 agonist 
inhaler+Glucorticosteroid  inhaler 
NS 
Pu, 2010 Shenge capsule: 4 capsules Tid Salmeterol xinafoate/ Fluticasone Salmeterol xinafoate/ Fluticasone NS 
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First 
author, date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Xiyangshen, Gejie, Congcaojunsi, Ziheche, Chuanbeimu, 
Shengsanqi. 
propionate: 50/250μg Bid propionate: 50/250μg Bid 
Qiu, 2009 
Guben Shengjin decoction: 200ml Bid 
Dangshen, Yunling, Baizhu, Shudihuang, etc. 
RP RP NS 
Shan, 2007 
Peitu Shengjin Tang (decoction): one packet once daily 
Dangshen, Wuzhualong, Fuling, Baizhu, Shanyao, 
Wuweizi, Kuandonghua, Xingren, Taoren, Suzi, Jineijin. 
Theophylline Sustained-release 
Tablets: 0.2g Bid 
Theophylline Sustained-release 
Tablets: 0.2g Bid 
NS 
Shi, 2009* 
Bufei Tang (decoction): one packet once daily 
Huangqi, Dangshen, Baizhu, Jiegeng, Chenpi, Zhigancao, 
Chaoshanyao, Zhimu, Wuweizi, Maidong, Yuzhu, Zhibaibu 
OR Qiweiduqiwan + Shengmaisan (decoction): as above 
Shudi, Shanyurou, Shengshanyao, Gouji, Maidong, 
Nvzhenzi, Hanliancao, Fuling, Danpi, Wuweizi, Taizishen   
OR Jinguishenqiwan (decoction): as above 
Shudi, Danshen, Yiyiren, Shanyurou, Chaoshanyao, Fuling, 
Dangshen, Baizhu, Huainiuxi, Shufuzi, Tusizi, Rougui, 
Lujiaojiao   
OR Suzijiangqitang (decoction): as above 
Zisuzi, Banxia, Qianhu, Houpo, Chenpi, Danggui, Rougui, 
Gancao.  
RP RP NS 
Shinozuka, 
2007 
Buzhong Yiqi extraction: 2.5g Tid 
Huangqi, Dangshen, Baizhu, Chenpi, Shengma, Danggui, 
Chaihu, Zhigancao。 
Bronchodilators  Bronchodilators NS 
Tang, 2010 Jianpi Yishen formula/decoction: one packet once daily 
Bronchodilators &  
Glucocorticosteroid inhaler 
Bronchodilators & Glucocorticosteroid 
inhaler 
NS 
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author, date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Huangqi, Dangshen, Baizhu, Shashen (Nan), Shashen (Bei), 
Buguzhi, Bajitian, Danggui 
Tatsumi, 
2009 
Buzhong Yiqi extraction: 2.5g Tid 
Huangqi, Dangshen, Baizhu, Chenpi, Shengma, Danggui, 
Chaihu, Zhigancao. 
Bronchodilators  Bronchodilators NS 
Tian, 2005 
Yifei Tang/Decoction:one packet once daily, 200ml, Tid 
Dangshen, Baizhu, Fuling, Huangqi, Shudihuang, 
Yinyanghuo, Ziyuan, Kuandonghua, Fabanxia, Ziheche, 
Baijiezi, Laifuzi, Suzi, Taoren, Gancao, etc. 
Theophylline Sustained-release 
Tablets or Terbutaline Sulfate 
Tablet 
Theophylline Sustained-releaseTablets 
or Terbutaline Sulfate Tablet 
NS 
Wang, 2005 
Yifei Jianpi/Decoction:one packet once daily 
Huangqi, Dangshen, Baizhu, Fuling, Fangfeng, Banxia, 
Chenpi, Dilong, Kuandonghua, Gancao. 
Salbutamol inhaler: p.r.n 
Ambroxol Hydrochloride Tablets: 
16mg Tid 
Salbutamol inhaler: p.r.n 
Ambroxol Hydrochloride Tablets: 
16mg Tid 
NS 
Wang, 2006 
Huatang Jiangqi capsule: 2g, Tid 
Baijiezi, Zisuzi, Baiqian, Jinfeicao, etc. 
Theophylline Tablets: 0.1g, Bid Theophylline Tablets: 0.1g, Bid NS 
Wang, 2009 
Sanshen Jianpi Tang (decoction): one packet once daily 
Taizishen, Danshen, Shashen, Fuling, Baizhu, Honghua, 
Danggui, Taoren, Jiegeng, Chishao, Tianhuafen, Zhibanxia, 
Shenggancao, Sharen, Xiangfu, Juhong. 
Salbutamol inhaler  
or Theophylline Tablets 
Salbutamol inhaler  
or Theophylline Tablets 
NS 
Wu (2), 
2006 
Liujuzi Tang/Decoction:one packet once daily, 150ml, Bid 
Dangshen, Fuling, Zhigancao, Chenpi, Jiangbanxia, Ziyuan, 
Kuandonghua, Taoren, Honghua, Danggui,etc. 
Diastase Pancreatin and Pepsin 
Tablet: 4# Tid 
Diastase Pancreatin and Pepsin Tablet: 
4# Tid 
NS 
Wu (2), 
2009 
Bufei Huoxue Huayu Tang/Decoction:one packet once daily 
Dangshen, Chuanxiong, Dilong, Wuweizi, 
Dongcongxiacao, etc. 
Ipratropium Bromide Aerosol:  
40 μg, Tid 
Ipratropium Bromide Aerosol:  
40 μg, Tid 
NO 
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author, date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Xu, 2009 
Jianpi Yifei granule: 10g, Tid 
Renshen, Fuling, Baizhu, Maidong, Sangbaipi, Huangqi, 
RP RP NS 
Yang, 2010 
Maxuan Zhike Liquid (Mixture): 20ml Tid 
Mahuang, Shigao, Xingren, Gancao, Shanyinhua, 
Xuanshen, Maidong, Jiegeng, Baiqian, Yuxingcao 
RP RP NS 
You, 2008 
Yifei Mixture: 100ml Bid 
Yinyanghuo, Xianmao, Renshen, Fuling, Baizhu, Danshen, 
Fabanxia, Zhuru, Gualoupi, Houpo, Zhiqiao, Gancao 
Salbutamol or becotide inhaler & 
Theophylline Tablets 
Salbutamol or becotide inhaler & 
Theophylline Tablets 
NS 
Zhang, 2010 
Bailing capsule: 5 capsules Tid 
Dongchongxiacao 
Ipratropium Bromide Aerosol:  
2 puffs, Tid 
Ipratropium Bromide Aerosol:  
2 puffs, Tid 
NS 
Zhao, 2009 
Dingchuan Tang & Yupingfeng Tang/Decoction: one packet 
once daily 
Baiguo, Mahuang, Zisuzi, Zhigancao, Kuandonghua, 
Xingren, Sangbaipi, Huangqin, Fabanxia, Huangqi, 
Fangfeng, Baizhu. 
Expectorant Expectorant NS 
Zhou, 2007 
Feisaitong Mixture/liguid: 100 ml,Tid 
Huangqi, Danshen, Jiegeng, Laifuzi, Zisuzi, Chantui, 
Dilong, Jinyinhua, Beishashen, Yiyiren, Shenggancao. 
Salbutamol Sulfate Tablets: 2.4mg, 
Tid 
Salbutamol Sulfate Tablets: 2.4mg, Tid NS 
Zhu, 2010 
Shengmai Yin or ZhenwuTang: NS 
Nanshashen, Maidong, Wuweizi, Yuzhu, Shengdihuang, 
Tianhuafen, Huangqi etc. 
OR  
Hongshen, Fuzi, Rougui, Baizhu, Ganjiang, Fuling, 
Chenxiang, Shudihuang etc. 
Salmeterol xinafoate 50ug/ 
Fluticasone propionate 500 ug:  
1 puff Bid 
Salmeterol xinafoate 50ug/ 
Fluticasone propionate 500 ug:  
1 puff Bid 
NO 
RP: Routine Pharmacotherapy; 0, I, II, III (severity of COPD): Stage 0, Stage I, Stage II, Stage III 
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Appendix 17 Table: Comparison of CHM (formulae and ingredients) with no treatment groups in review of Chinese herbal medicine for stable COPD with 
physical and symptomatic outcome measures 
First author, 
date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Cui, 2008 
Yiqi Huayu recipe/Decoction: one packet once daily,100ml,Bid 
Huangqi, Shengma, Jiegeng, Zhimu, Jiaogulan, Ezhu, Taoren, Wuzhualong. 
No No treatment NS 
Fang, 2008 
Zoufei granule:10g Tid 
Dangshen, Guizhi, Ziyuan, Kuandonghua, Wuweizi, Xingren, Taoren, Chenxiang, 
Zishiying, Goat lung. 
No No treatment NS 
Hong, 2005 
Yufeining pill: 6g Bid 
Renshen, Huangqi, Baizhu, Fangfeng, Ziheche, Hetaorou, Tusizi, Shanzhuyu, 
Wuweizi, Xingren, Gualou, Danshen, Taoren. 
No No treatment No 
Li, 2007 
Pingchuan Guben Tang/Decoction:one packet once daily 
Dangshen, Wuweizi, Dongcongxiacao, Hutaorou, Chenxiang, Lingcishi, Kanqi, Suzi, 
Kuandonghua, Fabanxia, Juhong. 
No No treatment NS 
Lin, 2008 
Manzhi Kechuanling (oral liquid): 10ml Bid 
Renshen, Huangqi, Baizhu, Fuling, Shanyao, Buguzhi, Lujiaojiao, Ziheche, Ejiao, 
Hetaoren, Gejie, Zisuzi, Chuanbeimu, Fabanxia, Yimucao, Taoren, Gancao 
No No treatment NS 
Liu, 
2005 
Zoufei Tang (decoction): 200ml Bid 
Dangshen, Gejie, Wuweizi, Xingren, Guizhi, Ziyuan, Kuandonghua, Hutaoren, Taoren, 
Chenxiang, Goat lung. 
No No treatment NS 
Liu (2), 
2006 
Gushen Dingchuan pill: 2g Tid 
Shudihuang, Fuzi, Buguzhi, Niuxi, Cheqianzi, Rougui, Jinyingzi, Yizhi, Fuling. 
No No treatment NS 
Shao, 2006 
Tongxinluo capsule: 2-4 capsules, Tid 
Quanxie, Shuizhi, Wugong, Tubiechong, Chuantui. 
No No treatment Yes 
Su, 2005 
Feikang granule: 10g, Tid 
Huangqi, Shuizhi, Haigeqiao, etc. 
No No treatment NS 
Tang, 2009 
Bailing capsule: 3 capsules Tid 
Dongchongxiacao. 
No No treatment NS 
Wu, 2007 
Liujunzi Tang (decoction):100ml Bid 
Dangshen, Baishu, Fuling, Chenpi, Zhibanxia, Gancao. 
No No treatment NS 
Xiong, 2010 
Bufei Yishen granule: 10g Tid 
Shengdi, Shanyurou, Nvzhenzi, Niuxi, Yinyanghuo, Tusizi 
No No treatment NS 
Zhang, 2006 Jiapi Yifei Bushen formula (decoction): one packet once daily No No treatment NS 
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date 
Intervention 
Control 
Adverse 
event 
Formula name (form): Dose / Ingredients Plus RP 
Huangqi, Dangshi, Baizhu, Fuling, Maidong, Shashen, Buguzhi, Tusizi, Nvzhenzi, 
Gejie, Xingren, Gualou, Beimu, Danshen, Chuanxiong, 
Zhang, 2008 
Liujunzi Pill: 9g,Bid 
Renshen, Baizhu, Fuling, Zhigancao, Chenpi, Banxia, Dazao, Shengjiang. 
No No treatment NS 
Zhang (1), 
2009 
Yifei Yangyin Tang (decoction): 300ml Bid 
Baihe, Shengdihuang, Shudihuang, Chuanbei, Jiegeng, Zhiqiao, Maidong, Baishao, 
Danggui, Shashen, Weishanyao, Fuling, Huangqi, Shenggancao. 
No No treatment NS 
Zhang (2), 
2009 
Wenshen Bufei Tang/Decoction: one packet once daily, 100ml, Bid 
Dangshen, Wuweizi, Fuling, Huangqi, Ziyuan, Sangbaipi, Shudihuang, Shanzhuyu, 
Huaishanyao, Zexie, Danpi, Buguzhi, Rougui. 
No treatment NS 
RP: routine pharmacotherapy 
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Appendix 18 Table: Comparison of test CHM (formulae and ingredients) with other CHM (formulae and ingredients) groups in review of Chinese herbal 
medicine for stable COPD with physical and symptomatic outcome measures 
First author, 
date 
Intervention 
Control 
Adverse 
event Formula name (form): Dose / Ingredients Plus RP 
Chen (1), 
2007 
Feikangning capsule: 3 capsules, Tid 
Renshen, Buguzhi, Dongcongxiacaojunsi, Danshen, etc. 
No 
Jinshuibao capsule 
Extract of Dongcongxiacao 
NO 
Chen 2008 
Guben Pingchuan pill:6g, Tid 
Huangqi, Renshen, Ziheche, Lujiaojiao, Guibanjiao, Bajitian, 
Shudihuang, Shanzhuyu, Huaishanyao, Tusizi, Maidong, Wuweizi, 
Suzi, Xingren, Chenpi, Danshen, Gejie. 
No 
Zhenqi Fuzheng capsule: 2 capsules, Bid 
Nuzhenzi, Huangqi 
NS 
Gao, 2008 
Zoufei Pingchuan capsule: 4 capsules, Tid 
Shudihuang, Huangqi, Kuandonghua, Wuweizi, Xuanfuhua, 
Dongcongxiacao, Shuizhi. 
No 
Jinshuibao capsule: 3 capsules, Tid 
Extract of Dongcongxiacao 
NS 
Guo, 2010 
Chuankangning Decoction: 150ml, Bid 
Shengshashen, Shudihuang, Danggui, Zhibanxia, Chenpi, Fuling, 
Lujiaopian, Zhimahuang, Xingren, Baijiezi, Chuanxiong, Ezhu, 
Wuweizi, Zhigancao. 
No 
Guben Kechuan tablet: 5 tablets Tid 
Dangshen, Baizhu, Fuling, Maidong, 
Zhigancao, Wuweizi, Buguzhi. 
NS 
Huang, 2009 
Bufei tablet: 3
#
 Tid 
Huangqi, Danshen, Fangfeng, Baizhu, Jiaogulan, Gejie, Jiegeng, 
Wuweizi etc. 
No 
Jinshuibao capsule: 3 capsules, Tid 
Extract of Dongcongxiacao 
NS 
Lei, 2006 
Shenqi Feibao: NS 
Huangqi, Dangshen, Buguzhi, Danshen, Baibu, Sangbaipi. 
No Zhike Huatan Pingchuan CHM NS 
Liu, 2002 
Feikang II granule: 8g, Tid 
Renshen, Baizhu, Zhigancao, Shudihuang, Shanzhuyu, Shanyao, 
Maodongqing, Quangualou, Danpi, Zexie, Fuling, Maidong, Tinglizi, 
Wuweizi. 
No Feikang I granule: 8g,Tid NO 
Sun (1), 
2007 
Shenge Yifei capsule: 4 Tid 
Xiyangshen, Gejie, Congcaojunsi, Ziheche, Chuanbaimu, Shensanqi. 
No 
Jinshuibao capsule: 3 capsules, Tid 
Extract of Dongcongxiacao 
NS 
Sun (2), 
2007 
Yishen Guben Tang:NS 
Ziheche, Kanqi, Gejie, Zishiying, Danggui, Dangshen, Shudihuang, 
Maidong, Danshen, Yujin, Suzi, Kuandonghua, Wuweizi, etc. 
No Guben Kechuan tablet:4 tablets, Tid NS 
Sun (2), 
2009 
Guben Kechuan granule: 1 bag, Bid (QC) 
Dangshen, Fuling, Baizhu, Shashen, Zhihuangqi, Guizhi, Baishao, 
Fangfeng, Baibu, Suzi, Shudihuang, Shanyurou, Goujizi, Kanqi, 
No Gu Ben Ke Chuan tablet:4#, Tid NS 
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date 
Intervention 
Control 
Adverse 
event Formula name (form): Dose / Ingredients Plus RP 
Ganjiang, Wuweizi. 
Xu, 1996 
Yiqi Mianyi granule: 20g Tid 
Renshen, Fuling, Baizhu, Ciwujia, Shanzhuyu. 
No Zhen Qi Fu Zheng granule: 15g Bid NS 
Zhang, 2003 
Tiaobu Feishen capsule: 4 capsules, Tid 
Xiyangshen, Dongcongxiacao, Shanyurou, Danshen, Fuling, etc. 
No Guben Kechuan tablet: 3 tablets, Tid NO 
RP: routine pharmacotherapy 
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Appendix 19 Table: Herbs included in the flormulae used in the 101 RCTs by functional category 
No. Categories of Materia Medica Name of herbs total 
1 
Release the 
Exterior 
Warm and acrid herbs Ma huang, Gui zhi, Fang feng, Sheng jiang, Su ye, Xi xin 6 
Cool and acrid herbs Chai hu, Chan tui, Bo he, Sheng ma 4 
2 Clear the Heat 
drain fire, Shi gao, Tian hua fen, Wei jin, Zhi mu, Zhi zi 5 
cool the blood Chi shao, Dan pi, Sheng di huang, Xuan shen 4 
clear heat and dry dampness Huang lian, Huang qin 2 
clear heat and relieve toxicity 
Ban lan gen, She gan, Jin qiao mai gen, Lian qiao, Jin yin hua, Qi ye yi zhi hua, 
Jin qiao mai, Qing tian kui, Yu xing cao 
9 
3 Drain dampness 
Dry dampness Cang zhu, Hou po, Sha ren 3 
Transform dampens Fu ling, Che qian zi, Yi yi re, Ze xie 4 
4 Activate the blood 
Activate blood 
Chuan xiong, Dans hen, E zhu, Niu xi, Hong hua, Mao dong qing, Shui zhi, 
Su mu, Tao ren, Yu jin, Yi mu cao 
11 
Stop bleeding San qi 1 
5 Tonify 
Tonify qi 
Bai zhu, Ci wu jia, Da zao, Dang shen, Gan cao, Gao li shen, Hong jing tian, Xi yang 
shen, Hutaoren, Jiao gu lan, Hong shen, Ren shen, Tai zi shen, 
Ling zhi, Huang qi, Shan yao, Sheng shai shen, Yang fei (Goat lung) 
18 
Replenish blood Bai shao, Dang gui, E jiao, Zi he che, Di huang, 5 
Tonify yang 
Ba ji tian, Dong chong xia cao, Kan qi, Bu gu zhi, He tao ren, Lu jiao jiao, Du zhong, 
Dong chong xia cao jun si, Ron cong rong, Sang shen, Xian mao, Shan zhu yu, Tu si zi, 
13 
Replenish yin Huang jing, Huan lian cao, Gou ji, Gui ban jiao, Mai dong, Sha shen, Nu zhen zi, Yuzhu 8 
6 
Resolve Phlegm 
and suppress cough 
Resolve phlegm 
Banxia, Bai jie zi, Gualou, Gua lou pi, Chuan bei mu, Hai ge qiao, Zhu ru, Xuan fu hua, 
Zhe bei mu 
9 
Suppress cough 
Bai bu, Bai guo, Kuan dong hua, Jie geng, Pi pa ye, Qian hu, 
Sang bai pi, Su zi, Ting li zi, Xing ren, Zi wan 
11 
7 Warm the Interior and Expel Cold Fu zhi, Gan jiang, Rou gui 3 
8 Regulate the Qi Chen pi, Chen xiang, Ju hong, Xiang fu, Xie bai, Zhi qiao 6 
9 Tranquilizers Ling ci shi, Zi shi ying 2 
10 Astringents Fu pen zi, Jin ying zi, Wu wei zi, Yi zhi ren 4 
11 Removing food stagnation Ji nei jin, Lai fu zi 2 
12 Dispelling Wind-Dampness Wu xiao she, Chuan shan long, Xu chang qing 3 
13 Extinguishing Wind and Stopping Tremors Di long, Quan xie, Wu gong, Wu zha long, Tu bie chong 5 
14 Opening orifices Shi chang pu 1 
over
all 
  139 
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Appendix 20 Table: Comparisons of high frequency herbs common to classical literature and modern clinical trials 
Herb name Botanical name Properties Channels entered Effects Indications 
Gan cao 
Glycyrrhiza uralensis 
Fisch 
Neutral & sweet 
Heart, lung, spleen 
& stomach 
Invigorates spleen & replenishes qi or 
eliminates phlegm & arrests cough 
Deficiency of spleen qi & stomach 
qi or cough & dyspnoea 
Ban xia 
Pinelliae ternate 
(Thunb.) Breit  
Warm, acrid & toxic 
Lung, spleen & 
stomach 
Eliminates dampness & resolves phlegm 
Profuse sputum, cough, adverse 
upward flow of qi 
Xing ren Prunus armeniaca L. 
Slightly warm, bitter 
& slightly toxic 
Lung & large 
intestine 
Relieves cough & asthma 
Multiple kinds of cough and 
dyspnoea 
Ren shen 
Panax ginseng C.A. 
Mey. 
Neutral, sweet & 
slight bitter 
Spleen, lung & 
heart 
Replenishes primordial qi & tonifies spleen 
& lung 
Prostration syndromes due to 
deficient qi, chronic illness & 
shortness of breath 
Fu ling 
Poria cocos (Schw.) 
Wolf 
Neutral, sweet & 
tasteless 
Heart, spleen & 
kidney 
Induces diuresis, excretes dampness, 
invigorates spleen & replenishes middle-
Jiao 
Phlegm retention & deficiency of 
spleen 
Wu wei zi 
Schisandra chinensis 
(Turcz.) Baill 
Warm, sour & sweet 
Lung, kidney & 
heart 
Astringes lung & nourishes kidney 
Chronic cough and asthma due to 
by deficiency 
Chen pi 
Citrus tangerine 
Hort. et Tanaka 
Warm & pungent Spleen & lung 
Regulates qi, normalizes the function of 
middle-Jiao, eliminates dampness & 
resolves phlegm 
Cough, profuse sputum & full and 
oppressed feeling in chest due to 
accumulation of phlegm-dampness 
in the lung 
Kuan dong hua Tussilago farfara L. Acrid & warm Lung  Directs qi downward and suppresses cough  
Coughing due to different types of 
cold in lung 
Bei mu 
Fritillaria cirrhosa 
D.Don 
Bitter, sweet & 
slightly cold 
Heart & lung Clears heat and transforms phlegm 
Cough, chiefly chronic cough, with 
signs of fire due to yin deficiency 
Mai men dong 
Ophiopogon 
japonicus Ker-Gawl  
Slightly cold, sweet 
& slightly bitter 
Lung, heart & 
stomach 
Moistens lung & nourishes yin Dry cough with sticky sputum 
Ba zhu 
Atractylodis 
Macrocephala Koidz 
Warm, bitter & sweet Spleen & stomach 
Replenishes qi, reinforces the spleen, 
eliminates dampness & induces diuresis  
Phlegm retention due to deficiency 
of spleen 
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Appendix 21 Table: The characteristics of herbs used frequently in the classical literature 
Herb name Botanical name Properties Channels entered Effects Indications 
Sang bai pi Morus alba L. Sweet & cold Lung & spleen 
Suppresses cough and calms panting, 
clears and resolves heat-phlegm 
Coughing and wheezing due to lung heat 
Sheng jiang 
Zingiber officinale 
(Willd.) Rosc. 
Acrid & warm 
Lung, spleen & 
stomach 
Disperses cold and suppresses cough 
Exterior cold patterns or cough due to 
both acute wind-cold cough patterns and 
chronic disorders with phlegm  
Ma huang 
Ephedra sinica Stapf., 
E. equisetina Bunge. 
Warm, pungent & 
bitter  
Lung & bladder Promotes the flow of lung qi 
Cough with dyspnoea due to dispersion of 
lung qi 
Zi wan Aster tartaricus L.f. 
Bitter & slightly 
warm 
Lung Suppresses cough and expels phlegm 
For chronic cough, especially cold-
induced cough with copious sputum 
Rou gui 
Cinnamomum cassia 
Presl 
Hot, acrid & sweet 
Kidney, spleen, heart 
& liver 
Supplements fire & strengthens yang Syndromes of yang deficiency 
Jie geng 
Platycodon 
grandiflorum (Jacq.) 
A. DC. 
Neutral, pungent & 
sweet 
Lung Ventilates lung & resolves phlegm 
Cough due to wind-heat or wind -cold 
exopathogens 
Gan jiang 
Zingiber officinale 
Rosc 
Hot & pungent  
Spleen, stomach, 
heart & lung 
Warms lung and resolves phlegm 
retention 
Cough & dyspnoea due to retention of 
cold phlegm in the lung 
Zhi shi Citus aurantium L. 
Slightly cold, bitter 
& pungent 
Spleen, stomach & 
large intestine 
Relieves stagnation of qi & resolves 
phlegm 
Stiffness & fullness in the chest due to 
obstruction of flow qi by phlegm 
Da zao Ziziphus jujuba Mill. Sweet & neutral Spleen & stomach 
Fortifies spleen and replenishes qi; 
Nourishes the blood and calms the 
spirit 
Weakness, shortness of breath, lassitude, 
reduced appetite and loose stools due to 
spleen and stomach deficiency 
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Appendix 22 Table: The characteristics of herbs used frequently in the RCTs 
Herb 
name 
Botanical name Properties 
Channels 
entered 
Effects Indications 
Huang 
qi 
Astragalus 
membranaceus 
Sweet & 
slightly 
warm 
Lung & 
spleen  
Fortifies spleen & 
replenishes qi;  
Increases yang qi of 
the spleen and 
stomach; tonifies qi 
and blood 
Lack of appetite, fatigue and 
diarrhoea due to spleen deficiency; 
prolapse disorders; post partum 
fever due to qi and blood 
deficiency 
Dang 
shen 
Codonopsis 
pilosula(Franch.) 
Nannf. 
Sweet & 
neutral 
Lung & 
spleen  
Tonifies middle qi 
and lung; 
strengthens qi and 
nourishes fluids 
Chronic illness, such as lack of 
appetite, fatigue and diarrhoea due 
to spleen deficiency; or chronic 
cough and shortness of breath, or 
copious sputum. 
Di 
huang 
Rehmannia 
glutinosa 
Libosch (dried 
root) 
Sweet & 
slightly 
warm 
Heart, 
kidney & 
liver 
Tonifies blood, 
nourishes yin, 
nourishes the blood 
and tonifies essence 
Blood deficiency (irregular 
menstruation), kidney yin 
deficiency (night sweats, wasting 
and thirsting) and low back pain. 
Dan 
shen 
Salvia 
miltiorrhiza Bge 
Bitter & 
slightly 
cold  
Heart, 
pericardium 
& liver 
Invigorates the blood 
and breaks up blood 
stasis  
Lower abdomen, such as 
dysmenorrhoeal, & chest or 
epigastric pain 
Ge jie 
Gekko gecko 
Linnaeus 
Salty & 
neutral 
Lung & 
kidney 
Tonifies the kidney 
and the lung,  
assists kidney yang 
and augments the 
essence and blood 
Wheezing, consumptive cough or 
with streaked sputum, urinary 
frequency due to kidney yang 
deficiency 
Dang 
gui 
Angelica sinensis 
(Oliv.) Diels 
Sweet, 
acrid, 
bitter & 
warm 
Heart, liver 
& spleen 
Tonifies the blood 
and regulates 
menses, invigorates 
and harmonises the 
blood and disperses 
cold ect. 
Blood deficiency,  
stop pains due to blood stasis 
Shan 
yao 
Dioscorea 
opposita Thunb. 
Sweet & 
neutral 
Kidney, 
lung & 
spleen 
Tonifies and 
augments the spleen 
and stomach, tonifies 
lung qi and 
replenishes lung yin, 
tonifies kidney, etc. 
Lack of appetite, fatigue and 
diarrhoea due to deficiency of 
spleen or stomach; chronic cough 
and wheezing due to lung 
deficiency; frequent urination, 
vaginal discharge 
Shan 
zhu yu 
Cornus 
officinalis Sieb. 
& Zucc. 
Sour & 
slightly 
warm 
Kidney & 
liver 
Tonifies kidney yang 
and stabilises the 
kidney and retains 
the essences, 
stops excessive 
sweating 
Tonifies and 
augments the kidney 
and liver. 
Leakage of fluids due to weak 
essence (excessive urination); 
excessive sweating; light-
headedness, dizziness, Sore and 
weak lower back and knees due to 
liver and kidney deficiency; 
excessive uterine bleeding and 
prolonged menstruation due to 
deficiency pattern. 
Su zi 
Perilla frutescens 
(L.) Britt. 
Acrid & 
warm 
Large 
intestine & 
lung 
Suppresses cough 
and calms panting, 
directs downward qi 
and resolves phlegm 
Coughing and wheezing with 
copious phlegm; constipation due 
to intestine 
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Appendix 23 Table: The Pharmacological activities of herbs used frequently in the classical literature 
Herb name 
Pharmaceutical 
name 
Chemical 
Constituents 
Pharmacological activities 
Clinical 
application  
Gancao 
Radix 
Glycyrrhizae 
Uralensis  
Glycyrrhizin 
Glycyrrhizic acide 
Liquiritigenin 
Mineralocorticoid effect; 
Glucocorticoid effect; 
Anti-inflammatory effect 
Anti-allergic effect 
Chronic bronchial 
asthma 
Use in 
gastroenterology 
Banxia 
Rhizoma Pinelliae 
Ternatae 
Beta-sitosterol, 
coniine, 
protoanemonin, 
homogentisic acid,  
aspartic acid 
Essential oils 
Polysaccharide 
Amylose 
Antitussive effect 
Antiemetic effect 
Respiratory 
disorder 
Xingren 
Semen 
pruniArmeniacae  
Amygdalin, 
amygdalase, 
prunase,  
Emulsin, fatty acid 
N/A 
Pulmonary 
diseases 
Renshen Radix ginseng  
 
Panaxosides, 
Saponins, 
Polysaccharide etc. 
Central nervous system effect,  
Peripheral nervous system effect, 
Cardiovascular effect, 
Metabolic effect, 
Endocrine effect,  
Immunological effect, 
gastrointestinal effect etc. 
N/A 
Fuling 
Sclerotium poriae 
cocos 
β-pachyman, 
Triterpenoid, 
Pachymic-acid, 
fats, glucose, 
protein, etc. 
Urinary effect,  
Central nervous system effect, 
Effect on smooth muscle, 
Endocrine effect.  
 
 
N/A 
Wuweizi 
Fructus 
schisandrae 
chinensis 
Sesquicarene, 
lignans, 
Schisandrin 
Gomisin A, etc. 
Central nervous system effect, 
 Respiratory effect, 
Peripheral nervous system effect, 
Cardiovascular effect 
 
Anicteric 
infectious hepatitis, 
neurasthenia. 
Chen pi 
Pericarpium Citri 
Reticulatae 
Limonene, 
Hesperdin, 
isopropenyltoluene, 
elemene, etc.  
Effect on smooth muscle, 
Cardiovascular effect, anti-
inflammatory effect 
Infectious disease 
Sangbaipi 
Cortex Mori Albae 
Radicis 
Mulberrin, 
Scopoletine 
mulberrochromene, 
morusin, 
cyclomulberrin, 
etc. 
Diuretic effect,  
Effect on blood pressure, 
Central nervous system effect. 
 
Shengjiang 
Rhizoma 
Zingiberis 
Officinalis Recens 
Naphtha, Gingerol, 
diphenylheptanes, 
Zingiberol, 
zingiberene, etc. 
Effect on the gastrointestinal 
system, etc. 
Bacillary dysentery 
Kuandonghua 
Flos Tussilaginis 
Farfarae 
Faradiol, Butin, 
triterpenoid 
saponins etc. 
Respiratory effect, 
Cardiovascular effect 
Pulmonary 
diseases; 
Rise in blood 
pressure 
Mahuang Herma Ephedrae 
L-ephedrine, D-
pseudoephedrine, 
1-N-
Diaphoretic effect,  
Bronchodilation effect,  
Antiviral etc. 
Pulmonary 
diseases; 
influenza 
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methylephedrine 
Ziwan 
Radix Asteris 
Tatarici 
Astersaponin, 
Shionone, 
quercetin, etc.  
Respiratory effect, 
Antimicrobial effect. 
Pulmonary 
diseases; 
Rougui 
Cotex Cinnamomi 
cassiae 
Cinnamaldehyde, 
Cinnamyl acetate,  
Phenylpropyl 
acetate. 
Central nervous system effect,  
Cardiovascular effect, 
Effect on temperature regulation, 
Antibiotic effect 
Asthma 
Beimu 
Bulbus, fritillariae 
cirrhosae 
Sipeimine, 
fritimine, 
chinpeimine 
Effect on smooth muscle N/A 
Jiegeng 
Radix Platycodi 
Grandiflori 
Plpatycodigenin, 
polygalain-acid, 
Platycodonin, etc. 
Strong expectorant effect, 
Antufungal effect, 
Endocrine effect. 
Pulmonary 
diseases; lowered 
plasma glucose 
levels. 
Ganjiang 
Rhizoma 
Zingiberis 
officinalis 
α-zingiberene, 6-
gingesulfonicacid, 
gingeralycolipid,  
phellandrene, etc. 
Central nervous system effect N/A 
Maimendong 
Tuber 
Ophiopogonis 
Japonici 
Ophiopogonin, 
ruscogenin, Beta-
sitosterol, 
stigmasterol. 
Endocrine effect N/A 
Zhishi 
Fructus 
immaturus citri 
aurantii  
Hesperidin, 
Neohespeidin, 
Naringenin-7-ruti-
noside, α-pinene, 
etc. 
Effect on uterus,  
Effect on intestines,  
Cardiovascular effect. Etc. 
N/A 
Baizhu 
Rhizoma 
Atractylodis 
Macrocephalae 
Atractylon, 
Butenolide A, 
Butenolide B, 
Acetoxyatracty-
lon, 
hydroxyatractylon,  
vitamin A. 
Urinary effect, 
Endocrine effect, 
Hematologic effect etc. 
N/A 
Dazao 
Fructus Zizyphi 
Jujubae 
Ziziphussaponin 
I,II,III, Jujuboside 
B, cAMP, cGMp, 
vitamin A, vitamin 
B2, vitamin C, 
calcium, 
phosphorous, iron. 
N/A N/A 
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Appendix 24 Table: The Pharmacological activities of herbs used frequently in the RCTs 
Herb 
name 
Pharmaceutical 
name 
Chemical Constituents Pharmacological activities 
Clinical 
application  
Huangqi 
Radix Astragali 
Membranaceus 
Astragalosides, 6-
dimethoxyisoflavane, 
calycosin 
Vasodilatory effect; 
Prolonged diuretic effect; 
Effect on endurance, 
Endocrine effect 
Reduction of 
blood pressure 
Dangshen 
Radix 
Codonopsitis 
pilosulae 
Ternatae 
Saponins, alkaloids, 
taraxerylacetate, 
glucose, friedelin etc. 
Hematologic effect, 
Endocrine effect, 
Vasodilatory effect, 
Immunologic effect. 
N/A 
Dihuang 
Radix Rehmannia 
glutinosae 
conquitae 
Beta-sitosterol, 
Mannitol, stigmasterol, 
campesterol etc.  
 hypertension 
Danshen 
Radix Salviae 
Miltiorrhizae 
Tanshinone, 
cryptotanshinone, 
salbiol, isotanshinone 
Vasodilatory effect 
Reduction of 
blood pressure 
Gejie Gecko 
Carnoside, carnitine, 
guanine, albumen. 
Hormonal effect prostate 
Danggui 
Radix angelicae 
sinensis 
Butylidene phthalide, 
ligustilide,sequiterpenes, 
Beta-sitosterol etc. 
Cardiovvascular effect, 
Antibiotic effect, 
Effect on smooth muscle. 
Effect of lower 
blood pressure, 
pain 
Shanyao 
Radix dioscorea 
oppositae 
Saponins, choline, ɖ -
abscisin 
vitamin C, mannan, 
phytic acid, allantoin 
N/A N/A 
Shanzhuyu 
Fructus corni 
officinalis 
Verbenalin, saponins, 
morroniside, loganin, 
cornusiin A and B, 
ursolic acid, tannin, 
vitamin A. 
Antibiotic effect, general effect 
( diuretic effect, lowered blood 
pressure, little effect on serum 
glucose)  
Inhibitory 
effect against 
bacteria; 
Lowered blood 
pressure 
Suzi 
Fructus Perillae 
Frutescentis 
N/A N/A N/A   
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Appendix 25: Names of Chinese medicinal substances 
Pinyin name Chinese  Botanical/Scientific name 
An xi xiang 安息香 Styrax tonkinensis 
Ba dou 巴豆 Croton tiglium L 
Bai bian dou 白扁豆 Dolichos lablab L. 
Bai bu 百部 Stemona sessilifolia 
Bai dou kou 白豆蔻 Amomum krervanh Pierre ex Gagnep.  
Bai fan 白矾 Alumen  
Bai fu zi 白附子 Typhonium giganteum Engl. 
Bai he 百合 Lilium lancifolium Thunb. 
Bai ji 白芨 Bletilla striata (Thunb.) Reichb. 
Bai ji li 白蒺藜 Tribulus terrestris L.  
Bai jiao xiang  白胶香 Liquidambar taiwaniana Hance  
Bai jie zi 白芥子 Brassica juncea (L.) Czern. & Coss. 
Bai shao 白芍 Paeonia lactiflora Pall. 
Bai shi ying 白石英 White quartz 
Bai zhi 白芷 Angelica dahurica (Fisch.ex Hoffm.) Benth. 
Bai zhu 白术 Atractylodes macrocephala Koidz.  
Bai zi ren 柏子仁 Platycladus orientalis (L.) Franco 
Ban xia (zhi) 半夏 Pinellia ternata (Thunb.) Breit. 
Bei mu 贝母 Fritillaria cirrhosa D.Don 
Bi qi  荸荠 Eleocharis dulcis (Burm.f.)Trin.ex Henschel 
Bi xie 萆薢 Dioscorea collettii Hook.f.var.hypoglauca Palibin 
Bie jia 鳖甲 Trionyx sinensis Wiegmann 
Bing lang 槟榔 Areca catechu L. 
Bo he 薄荷 Mentha haplocalyx Briq. 
Bu gu zhi 补骨脂 Psoralea corylifolia L.  
Cang zhu 苍术 Atractylodes lancea (Thunb.)DC  
Cha ye 茶叶 Camellia sinensis O.Ktze (leaf) 
Chai hu 柴胡 Bupleurum chinense DC.  
Chan tui  蝉蜕 Cyptotympana pustulata Fabricius. 
Che qian zi 车前子 Plantago asiatica L. 
Chen pi 陈皮 Citrus reticulata Blanco 
Chen xiang 沉香 Aquilaria sinensis (Lour.) Gilg. 
Chi shi zhi 赤石脂 Halloysitum rubrum 
Chi xiao dou 赤小豆 Phaseolus calcaratus Roxb. 
Chu shi zi 楮实子 Broussonetia papyrifera (L.)Vent． 
Chuan jiao 川椒 Zanthoxylum bungeanum Maxim.  
Chuan lian zi 川楝子 Melia toosendan Sieb. & Zucc.  
Chuan wu  川乌 Aconitum carmichaeli Debx.  
Chuan xiong,  川芎 Ligusticum chuanxiong Hort. 
Ci huang 雌黄 Realgar 
Ci shi 磁石 Magnetite 
Cong bai   葱白 Allium fistulosum L． 
Da dou huang juan 大豆黄卷 Glycine max (L.) Merr. 
Da fu pi 大腹皮 Areca catechu L. 
Da huang 大黄 Rheum palmatum L. 
Da ji 大戟 Euphorbia pekinensis Rupr. 
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Da qing yan  大青盐 Halite 
Da zao 大枣 Ziziphus jujuba Mill. 
Dan dou chi 淡豆豉 Glycine max (L.) Merr.  
Dan nan xing 胆南星 Arisaema heterophyllum Bl.  
Dan shen 丹参 Salvia miltiorrhiza 
Dan zhu ye 淡竹叶 Lophatherum gracile Brongn. 
Dang gui 当归 Angelica sinensis (Oliv.) Diels  
Dang shen 党参 Codonopsis pilosula (Franch.) Nannf.  
Di gu pi 地骨皮 Lycium barbarum L. 
Di huang 地黄 Rehmannia glutinosa Libosch (dried root)  
Di yu 地榆 Sanguisorba officinalis L. 
Ding xiang 丁香 Eugenia caryophyllata Thunb. 
Du zhong 杜仲 Eucommia ulmoides Oliv.  
E jiao 阿胶 Asini Corii Colla  
E zhu  莪术 Curcuma phaeocaulis Valeton 
Fang feng 防风 Saposhnikovia divaricata (Turcz.) Schischk. 
Fang ji 防己 Stephania tetrandra S.Moore 
Feng mi 蜂蜜 Honey 
Fu ling 茯苓 Poria cocos (Schw.) Wolf 
Fu pen zi 复盆子 Rubus chingii Hu  
Fu xiao mai 浮小麦 Triticum aestivum L. 
Fu zi (zhi) 附子 Aconitum carmichaeli Debx. 
Gan cao 甘草 Glycyrrhiza uralensis Fisch.  
Gan jiang 干姜 Zingiber officinale (Willd.) Rosc. 
Gan sui 甘遂 Euphorbia kansui Liou 
Gao ben 藁本 Ligusticum sinense Oliv. 
Ge fen  蛤粉 Meretrix meretrix L./Cyclina sinensis Gmelin 
Ge gen 葛根 Pueraria lobata (Willd.) Ohwi 
Ge jie 蛤蚧 Gekko gecko L. 
Gou qi zi 枸杞子 Lycium barbarum L. 
Gou teng 钩藤 Uncaria rhynchophylla (Miq.) Jacks. 
Gua di 瓜蒂 Cucumis melo L. 
Gua lou pi 瓜蒌皮 Tirchosanthes kirilowii Maxim. 
Gui ban jiao 龟板胶 Plastron of Chinemys reevesii (Gray)  
Gui zhi 桂枝 Cinnamomum cassia Presl 
Hai fen 海粉 Notarchus leachii freeri (Griffin)  
Hai fu shi  海浮石 Pumice 
Hai ge ke 海蛤壳 Meretrix meretrix L. 
Hai she 海蛇 Sea snake 
Han shui shi 寒水石 Calcite  
He zi 诃子 Terminalia chebula Retz． 
Hou po 厚朴 Magnolia officinalis Rehd. & Wils.  
Hu jiao 胡椒 Piper nigrum L. 
Hu tao ren 胡桃肉 Juglans regia L. 
Hua shi 滑石 Talc 
Huai hua 槐花 Sophora japonica L.  
Huai jiao 槐角 Sophora japonica L. 
Huang bai 黄柏 Phellodendron chinense Schneid. 
Huang la 黄蜡 beeswax 
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Huang lian 黄连 Coptis chinensis Franch. 
Huang qi 黄芪 Astragalus membranaceus Fisch. 
Huo ma ren, 火麻仁 Cannabis sativa L. 
Huo xiang 藿香 Pogostemon cablin (Blanco) Benth. 
Jiang can 僵蚕 Bombyx mori L. 
Jiang huang 姜黄 Curcuma longa L. 
Jie geng 桔梗 Platycodon grandiflorus (Jacq.) A.DC. 
Jin bo 金箔 Gold leaf 
Jing jie 荆芥 Schizonepeta tenuifolia Briq. 
Jing mi 粳米 Oryza sativa L.  
Ju hong 橘红 Citrus reticulata Blanco 
Ku lian 苦楝 Melia spp. 
Kuan dong hua 款冬花 Tussilago farfara L. 
Lai fu zi 莱菔子 Raphanus sativus L. 
Lei wan 雷丸 Polyporus mylittae Cook.et Mass. 
Li lu  藜芦 Veratrum spp. 
Lian qiao 连翘 Forsythia suspense (Thunb.)Vahl 
Lian xu 莲须 Nelumbo nucifera Gaertn. (stamen) 
Lian zi 莲子 Nelumbo nucifera Gaertn. (dried seed) 
Lian zi xin 莲子心 Nelumbo nucifera Gaertn. 
Liang Jiang 良姜 Alpinia officinarum Hance 
Ling yang jiao 羚羊角 Saiga tatarica L.  
Liu huang 硫黄 Sulfur 
Long dan cao 龙胆草 Gentiana scabra Bge. 
Long gu 龙骨 Fossilia ossis mastodi 
Long nao 龙脑 Dryobalanops aromatica Gaertn.  
Lu feng fang 露蜂房 Vespae nidus 
Lu jiao jiao 鹿角胶 Cervus nippon Temminck  
Lv dou 绿豆 Phaseolus radiatus L. 
Ma dou ling 马兜铃 Aristolochia debilis Sieb.et Zucc. 
Ma huang 麻黄 Ephedra sinica Stapf 
Ma ya xiao 马牙消 Mirabalite (with long crystals) 
Mai men dong 麦门冬 Ophiopogon japonicus (Thunb.) Ker-Gawl.  
Man jing zi 蔓荆子 Vitis trifolia L. var. simplicifolia Cham. 
Mang xiao 芒硝 Natrii sulfas 
Mao gen 茅根 Imperata cylindrica Beauv.var.major(Nees)C.E.Hubb 
Meng shi 礞石 Chlorite-schist 
Mi tuo seng 密陀僧 Lithargyrum  
Mo yao 没药 Commiphora myrrha Engl. 
Mu dan pi, Dan pi 牡丹皮 Paeonia suffruticosa Andr. 
Mu gua 木瓜 Chaenomeles speciosa (Sweet)Nakai 
Mu li 牡蛎 Ostrea gigas Thunb.  
Mu tong 木通 Akebia quinata (Thunb.) Decne. 
Mu xiang 木香 Aucklandia lappa Decne. 
Nan mu xiang 南木香 Aristolochia yunnanensis Franch.  
Niu ru 牛乳 Cow’s milk 
Niu xi 牛膝 Achyranthes bidentata Blume 
Nuo mi 糯米 Oryza sativa L.  
Peng sha 硼砂 Borax 
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Pi pa ye 枇杷叶 Eriobotrya japonica (Thunb.)Lindl. 
Pu huang 蒲黄 Typha angustifolia L. 
Qian cao 茜草 Rubia cordifolia L. 
Qian dan 铅丹 Lead oxide 
Qian hu 前胡 Peucedanum praeruptorum Dunn. 
Qian niu zi 牵牛子 Pharbitis nil (L.)Choisy  
Qian shi 芡实 Euryale ferox Salisb. 
Qiang huo 羌活 Notopterygium incisum Ting ex H.T.Chang 
Qin jiao 秦艽 Gentiana macrophylla Pall. 
Qing dai 青黛 Isatis indigotica Fort. 
qing fen 轻粉 Calomelas  
Qing pi 青皮 Citrus reticulata Blanco 
Quan xie 全蝎 Buthus Martensii Karsch  
Ren ru zhi 人乳汁 Human milk 
Ren shen 人参 Panax ginseng C.A. Mey. 
Rou cong rong 肉苁蓉 Cistanche deserticola Y.C. Ma  
Rou gui 肉桂 Cinnamomum cassia Presl. 
Ru xiang 乳香 Boswellia carterii Birdw. 
Sang bai pi 桑白皮 Morus alba L. 
Sang ye 桑叶 Morus alba L. 
Sha ren 砂仁 Amomum villosum Lour. 
Sha shen 沙参 Adenophora tetraphylla (Thunb.)Fisch 
Sha yuan zi  沙苑子 Astragalus complanatus R. Br. 
Shan yao 山药 Dioscorea opposita Thunb. 
Shan zha 山楂 Crataegus pinnatifida Bge. 
Shan zhu yu 山茱萸 Cornus officinalis Sieb. & Zucc.  
Shang lu 商路 Phytolacca acinosa Roxb.  
She gan 射干 Belamcanda chinensis (L.)DC. 
She xiang 麝香 Moschus moschiferus L. 
Shen qu 神曲 Massa medicata fermentica 
Sheng di huang 生地黄 Rehmannia glutinosa Libosch 
Sheng jiang 生姜 Zingiber officinale (Willd.) Rosc.  
Sheng ma 升麻 Cimicifuga foetida L. 
Shi chang pu 石菖蒲 Acorus tatarinowii Schott.  
Shi gao 石膏 Crystalline gypsum 
Shi hu 石斛 Dendrobium loddigesii Rolfe.  
Shi jue ming 石决明 Haliotis diversicolor Reeve 
Shi zhong ru 石钟乳 Stalactitum tubuliform 
Shu di huang 熟地黄 Rehmannia glutinosa Libosch.  
Su geng  苏梗 Perilla frutescens (L.) Britt. 
Su he xiang 苏合香 Liquidambar orientalis Mill. 
Su mu  苏木 Caesalpinia sappan L.  
Tan xiang 檀香 Santalum album L. 
Tao ren 桃仁 Prunus persica (L.) Batsch  
Tian hua fen 天花粉 Tirchosanthes kirilowii Maxim. 
Tian ma 天麻 Gastrodia elata Bl. 
Tian men dong 天门冬 Asparagus cochinchinensis (Lour.) Merr. 
Tian nan xing 天南星 Arisaema erubescens (Wall.) Schott. 
Tian ting li zi 甜葶苈子 Descurainia sophia (L.)Webb.ex Prantl 
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Tian xiong 天雄 Aconitum carmichaeli Debx.  
Tian zhu huang 天竺黄 Bambusa textilis McClure  
Ting li zi 葶苈子 Lepidium apetalum Willd. 
Tong cao 通草 Tetrapanax papyferus (Hook.)K.Koch 
Tu si zi 菟丝子 Cuscuta chinensis Lam.  
Wei rui  葳蕤 Prinsepia uniflora Batal. 
Wu bei zi 五倍子 Rhus chinensis Mill.(=Rhus semialata Murray) 
Wu jia pi  五加皮 Acanthopanax gracilistylus W.W.Smith 
Wu ling zhi 五灵脂 Trogopterus xanthipes Milne-Edwards 
Wu mei 乌梅 Prunus mume (Sieb.)Sieb. & Zucc. 
Wu wei zi 五味子 Schisandra chinensis (Turcz.) Baill. 
Wu yao  乌药 Lindera aggregate (Sims.)Kosterm. 
Wu zhu yu 吴茱萸 Evodia rutaecarpa (Juss.)Benth. 
Xi jiao 犀角 Cornus rhinocerii 
Xi xin 细辛 Asarum sieboldii Miq. var. seoulense Nakai 
Xi yang shen 西洋参 Panax quinquefolium L. 
Xiang fu (zi) 香附(子) Cyperus rotundus L. 
Xiao huang mi  小黄米 Panicum miliaceum L. 
Xiao hui xiang  小茴香 Foeniculum vulgare Mill. 
Xing ren 杏仁 Prunus armeniaca L. 
Xiong huang 雄黄 Realgar 
Xuan fu hua 旋复花 Inula japonica Thunb. 
Xuan shen 玄参 Scrophularia ningpoensis Hemsl. 
Yan hu suo 延胡索 Corydalis yanhusuo W.T.Wang  
Yi tang 饴糖 Maltosum 
Yi yi ren 薏苡仁 Coix lacryma-jobi L. var. ma-yuen (Roman.) Stapf 
Yi zhi Ren 益智仁 Alpinia oxyphylla Miq.  
Yin bo 银箔 Silver leaf 
Ying su ke 罌粟壳 Papaver somniferum L. 
Yu jin 郁金 Curcuma wenyujin Y.H. Chen & C. Ling 
Yu li ren 郁李仁 Prunus japonica BGE. 
Yuan hua 芫花 Daphne genkwa Sieb.et Zucc. 
Zao jia 皂荚 Gleditsia sinensis Lam. 
Ze xie 泽泻 Alisma orientalis (Sam.) Juzep. 
Zhen su 真酥 butter 
Zhi mu 知母 Anemarrhena aspheloides Bge. 
Zhi shi 枳实 Citrus aurantium L. 
Zhi zi 栀子 Gardenia jasminoides Ellis  
Zhu li 竹沥 Phyllostachys nigra（Lodd.）Munro var. henonis（Mitf.）Stapf ex Rendle 
Zhu ling 猪苓 Polyporus umbellatus (Pers.)Fries 
Zhu sha 朱砂 Cinnabar 
zhu shen 猪肾 Pig kidney 
Zhu ye 竹叶 Phyllostachys nigra (Lodd.) Munro var.henonis(Mitf.) Stapf ex Rendle 
Zi shi ying 紫石英 Fluoritum 
Zi su ye 苏叶 Perilla frutescens (L.) Britt. 
Zi su zi  紫苏子 Perilla frutescens (L.) Britt. 
Zi tan  紫檀 Pterocarpus indicus Willd. 
Zi yan 紫菀 Aster tartaricus L.f. 
 
